Professional Documents
Culture Documents
Coronary Artery Disease: Therapeutics and Drug Discovery: Miao Wang Editor
Coronary Artery Disease: Therapeutics and Drug Discovery: Miao Wang Editor
Coronary
Artery Disease:
Therapeutics and
Drug Discovery
Advances in Experimental Medicine and Biology
Volume 1177
Series Editors
Wim E. Crusio, CNRS and University of Bordeaux UMR 5287, Institut de
Neurosciences Cognitives et Intégratives d’Aquitaine, Pessac Cedex, France
John D. Lambris, University of Pennsylvania, Philadelphia, PA, USA
Heinfried H. Radeke, Clinic of the Goethe University Frankfurt Main,
Institute of Pharmacology & Toxicology, Frankfurt am Main, Germany
Nima Rezaei, Research Center for Immunodeficiencies, Children’s Medical Center,
Tehran University of Medical Sciences, Tehran, Iran
Advances in Experimental Medicine and Biology provides a platform for scientific
contributions in the main disciplines of the biomedicine and the life sciences. This
series publishes thematic volumes on contemporary research in the areas of
microbiology, immunology, neurosciences, biochemistry, biomedical engineering,
genetics, physiology, and cancer research. Covering emerging topics and
techniques in basic and clinical science, it brings together clinicians and researchers
from various fields.
Advances in Experimental Medicine and Biology has been publishing excep-
tional works in the field for over 40 years, and is indexed in SCOPUS, Medline
(PubMed), Journal Citation Reports/Science Edition, Science Citation Index
Expanded (SciSearch, Web of Science), EMBASE, BIOSIS, Reaxys,
EMBiology, the Chemical Abstracts Service (CAS), and Pathway Studio.
2018 Impact Factor: 2.126.
123
Editor
Miao Wang
Fuwai Hospital
National Center for Cardiovascular
Diseases, Chinese Academy of Medical
Sciences and Peking Union Medical College
Beijing, China
This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721,
Singapore
Contents
v
Contributors
vii
viii Contributors
1.1 Epidemiology
In most developed countries, coronary artery disease (CAD) is one of the primary
causes leading death. The primary cause of CAD is the atherosclerosis of coronary
arteries. The word “atherosclerosis” is the combination of two Greek words, “athero”
and “sclerosis”, which mean “gruel” and “hardening”, respectively. Though during
the last 40 years, a decrease in the global coronary heart disease (CHD) mortality has
been seen. From 1990s to 2000s, mortality caused by acute MI declined up to 50%.
Of all the cardiovascular disease (CVD) cases, nearly one-third to 50% were caused
by CHD (Rosamond et al. 2008; LloydJones et al. 2010; Nichols et al. 2014). Each
year, more than four million people die of CHD in the 49 countries of Europe and
Northern Asia. Also, about 1.5 million Americans suffer from heart attack or stroke
yearly, which results in around 250,000 deaths.
1.1.1 Prevalence
From the report on The 2010 Heart Disease and Stroke Statistics update of the
American Heart Association (LloydJones et al. 2010), despite the significant increase
in CVD deaths since 1990, age-standardized death rate of the same period fell by
22% instead, which was mainly contributed by shifting age demographics and causes
of death worldwide.
In a 2009 report, which made use of the NHANES data, MI prevalence of middle-
aged individuals (35–54 years) was compared by sex from 1988 to 1994 and 1999 to
2004 (Towfighi et al. 2009). In this report, it showed a greater MI prevalence in both
time periods (2.5 versus 0.7 and 2.2 versus 1.0, respectively) in men than women.
Prevalence of anatomic CHD of both general population and military personnel has
been documented to decrease over time according to autopsy data.
Based on the comparison of autopsy data between the periods 1979 to 1983 and
1990 to 1994, the prevalence of significant anatomic CHD fell in both male and
female aged 20–59 subjects, 42%–32% and 29%–16%, respectively (Roger et al.
2001). Yet the prevalence showed no difference for those over 60.
An autopsy analysis including 3832 United States military personnel, who died
of combat or unintentional injuries between October 2001 and August 2011, and
of whom 98% were male, with a mean age of 26, showed a 8.5% prevalence of
CHD (Webber et al. 2001). Compared with the autopsy-documented CHD prevalence
1 Coronary Artery Disease: From Mechanism to Clinical Practice 3
shown during the Korean War in the 1950s (77%) and the Vietnam War in the 1960s
(45%), a significant decrease would be seen.
The original Framingham Study cohort with 44 years’ follow-up displayed that the
lifetime risk of developing CHD was 49% and 32% for 40 years old men and women,
respectively, For CHD free people who were at age 70, the nontrivial lifetime risk of
developing CHD was 35% and 24% for men and women, respectively.
Both the longevity and age-specific mortality from CVD, CHD, and stroke have
been improved since 1975. Yet still, high prevalence and treatment cost are the
principal features of CVD and its related complications. One cohort study, which
included over 1.9 million people, who were 30 or above, free of known baseline
CVD, suggested that neither myocardial infarction nor stroke were the majority of
initial CVD presentations (Kannel 1987). Angina, heart failure, peripheral arterial
disease, transient ischemic attack, and abdominal aortic aneurysm, along with some
less common manifestations, represented 66 percent of the initial CVD presentations
based on a median of six years’ follow-up.
Though for both genders, the incidence increases greatly with age, women appar-
ently lag behind men, 10 years for total coronary events and 20 years when it comes
to more serious manifestations of coronary disease, such as MI and sudden death, yet
as people grow older, the incidence of sex ratio narrows progressively (LloydJones
et al. 2010). The incidence of women aged 65–94 tripled compared to ages 35–64,
and it doubled in men. For women who are menopausal, the rates of incidence and
severity of coronary disease tripled of those the same age.
In developed countries, the incidence of CHD has declined with time. An epidemi-
ologic follow-up study of 10,869 patients from 1971 to 1982 and the other one that
consisted of 9774 patients from 1982 to 1992 were included in NHANES I (Ergin
et al. 2004), according to which the CHD incidence descended to 1.14% cases from
1.33%.
The decline of heart disease mortality that has been seen in America and regions
with relatively advanced economies and health care systems does not apply to the
whole world. Despite their counties’ income level, the number one cause of death
4 C. Shao et al.
of patients is ischemic heart disease. And between 1990 and 2020, nearly 29% and
48% increase in coronary heart disease mortality, respectively, for women and men
from developed countries could be expected according to the report. For women and
men in developing countries, the corresponding estimated rises were 120 and 137%
(Yusuf et al. 2001).
Together with the mortality associated with initial CVD event improvement is
the rapidly increased prevalence of CVD in developing countries. Also along with
the growth of population worldwide, the global burden of CHD was estimated to
rise by 29% due to the increases in therapy and longevity (Goyal and Yusuf 2006).
Furthermore, markedly regional variation was showed in CHD mortality; according
to the 2010 data, while South Asia possess the largest number of CHD death, Eastern
Europe and Central Asia have the highest rate of CHD mortality.
In China, what comes along with economic development is an epidemiological
transition. Every year more than 1 million people die of ischemic heart disease (IHD),
which means the mortality caused by IHD has risen more than double during the past
two decades (Yang et al. 2013; Omran 1971). Number of individuals with myocar-
dial infarction will rise to 23 million by 2030 based on the estimation of World Bank
(The World Bank 2013), with the trend to accelerate. Improvements of implement-
ing policies have been executed with financial barriers reduced, numbers of hospi-
tals and physicians increased to develop the Chinese medical care system, while the
epidemiology’s changing (Chen 2009; Ministry of Health of People’s Republic of
China 2012). Yet during the last ten years, no definition of clinical profiles, manage-
ment, and outcome of patients with this disorder found in any national representative
studies, even though acute myocardial infarction being such crucial in China, par-
ticularly ST-segment elevation myocardial infarction (STEMI) accounting for 80%
of such events in the country. A retrospective analysis of hospital records named
China PEACE-Retrospective AMI Study and lasted from 2006 to 2011 assessed the
trends in STEMI management and outcomes in China during the past decade. For
both 30-day acute MI hospital mortality and readmission rate of Medicare bene-
ficiaries 65 years of age, important regional differences was found existing. Thus,
performance may be improved with the reasons of such differences understood.
Over the past decade, incidence rate of STEMI has dropped whereas the rate of
non-ST-elevation ACS ascended in the United States Community. MI presentations
contribute approximately 25–40% STEMI so far. The non-ST elevation MI compared
with ST elevation MI relatively increased over time (Furman et al. 1975; Rogers
et al. 1990; Roger et al. 2010). A report including 2.5 million MIs from 1990–
2006 from The National Registry of Myocardial Infarction (Rogers et al. 1990)
showed that the proportion of NESTEMI, accounted for 59% of MIs, and that was
19% in 1994. And this variation was related to the incidence of STEMI’s certain
decline and rate of NSTEMI’s increase or remain unchanged (Roger et al. 2010). The
1 Coronary Artery Disease: From Mechanism to Clinical Practice 5
mortality rates from STEMI, in-hospital (nearly 5–6%) and 1-year (nearly 7–18%),
have declined remarkably in association with a significant raise in the frequency of
care, which consist of guideline directed medical therapy (GDMT) and interventions
(“defect-free” care).
Risk factors of CHD exist among many individuals of the general population; for indi-
viduals with one or more risk factors, over 90% of CHD events would eventually hap-
pen (Yusuf et al. 2004; Vasan et al. 2005; Stamler et al. 1999). According to the report
from three observational studies, systolic blood pressure ≥140 mmHg/diastolic blood
pressure ≥90 mmHg, total cholesterol ≥240 mg/dL (≥6.22 mmol/L), diabetes, obe-
sity, and smoking were defined as the five major CHD risk factors, which caused
approximately an over 50% of cardiovascular mortality (Patel et al. 2015) 0.87% (men
aged 40–59 in the MRFIT trial) to 100% (women aged 18–39 in the Framingham
Heart Study) subjects dying of CHD exposed to at least one risk factor.
Meanwhile, a much lower incident rate of CHD can be predicted among people
without major risk factors. In Framingham Heart Study and the Third National Health
and Nutrition Examination Survey (NHANES III), the frequency and predictive value
of the five major risk factors were evaluated. The percentage of patients having one
to two elevated risk factors is nearly 60% for men and 50% for women, and for
those with at least one borderline risk factor (defined as low density lipoprotein
cholesterol (LDL-C) 100–159 mg/dL [2.6–4.1 mmol/L], high density lipoprotein
cholesterol (HDL-C) 40–59 mg/dL [1.0–1.5 mmol/L], blood pressure 120–139/80–
89 mmHg, smoking history and impaired fasting glucose without overt diabetes), is
26% and 41%, respectively. Apart from women aged 35–40 (8.9%) or 45–54 (3.7%),
only 0–0.4% had none of elevated or borderline risk factor. This cohort also evaluates
the frequency of “borderline” risk factors (Vasan et al. 2005). The incidence of CHD
events is nearly 8% for patients with multiple borderline risk factors, while it rarely
happens to patients with none.
Studies of both Western and Asian population display a rise in the risk when mul-
tiple risk factors exist (Vasan et al. 2005; Jackson et al. 2005; Lowe et al. 1998; Asia
Pacific Cohort Studies Collaboration 2005). Take the general principles in ESTAB-
LISHED RISK FACTORS FOR ATHEROSCLEROTIC CVD as example. Almost
all cases of CHD are caused by atherosclerosis, which processes as follows: fatty
streaks in adolescence, plaques in early adulthood, thrombotic occlusions, and coro-
nary events in middle age and after. For coronary arteries and other arterial beds,
when various factors take concerted actions, the risk of atherosclerotic plaques rises
(Wilson 1994). Adult patients with dyslipidemia, hypertension, and diabetes can use
risk factor assessment as therapy guidance, while risk of coronary disease events
can be helpfully estimated by using multivariate formulations (Wilson et al. 1998;
Ridker 1999).
6 C. Shao et al.
It has been a long time that in emerging nations, the prevalence of risk factors
remains strange and/or neglected in the literature. A national representative cohort
of Chinese showed a low overall prevalence of CVD (1.8% and 1.1% in males and
females, respectively) (Yang et al. 2012). Traditional CVD risk factors showed a
much higher prevalence; followings are the prevalence of risk factors for male and
female, respectively: overweight or obese—36.7 and 29.8%, hypertension—30.1 and
24.8%, dyslipidemia—64 and 67.4%, and hyperglycemia—26.7 and 23.6%. With the
presentation of risk factors, the odds of CVD increased (odds ratio 2.4, 4.2, 4.9, and
7.2 for 1, 2, 3, and 4 or more risk factors, respectively, compared with no risk factors)
(Yang et al. 2012). The result indicated that without medical intervention and effective
lifestyle, the incidence and prevalence of CVD in China may rise significantly.
Despite the abstruseness of CVD risk factors prevalence, as the improvement of
awareness and diet and lifestyle, prevalence of established risk factors has changed.
Reports from NHANES show that from 1960 to 2000, the prevalence of obesity (body
mass index ≥ 30 kg/m2 ) rises to 30% from 15%. Meanwhile, the diagnosed diabetes
increased to 5% from 1.8%, especially obvious in obese population. On the contrary,
there are other cardiovascular risk factors declined significantly, with smoking 39–
26%, hypertension (blood pressure ≥140/≥90 mmHg) 31–15%, and serum total
cholesterol ≥240 mg/dL (6.2 mmol/L) drop from 34 to 17%. These changes were
associated with the improved usage of lipid-lowering drugs and antihypertensive
medications, occurring among all weight groups. Also, seven ideal cardiovascular
health metrics have been promoted by AHA, which includes physical activeness, no
smoking, normal blood pressure, normal blood glucose level, normal total cholesterol
level, normal weight, and healthy diet.
Among participations in NHANES (1988–1994), all seven metrics were achieved
by only 2%. Compared to those achieving none or one metric, people with six or
seven metrics had lower cardiovascular mortality (adjusted harzard ratio [HR] 0.24,
95% confidence interval [CI] 0.13–0.47) and overall mortality (adjusted HR 0.49,
95% CI 0.33–0.74). In NHANES (1999–2002), people with five or more metrics had
lower cardiovascular mortality (adjusted HR 0.12, 95% CI 0.03–0.57) compared to
people with none.
1.2.2 Hypertension
Lipids (mainly cholesterol and triglycerides) are compounds that involve in water.
They need apolipoproteins or apoproteins to transport in blood. Also in the INTER-
HEART, 49% of the population-attributable risk of a first MI was contributed by dys-
lipidemia,which was defined as a raised apo B to apo A-1 ratio) (Yusuf et al. 2004).
Lipoprotein metabolism Disturbances are usually familial, with Lp (a) excess (alone
or with other dyslipidemia), combined hyperlipidemia, and hypertriglyceridemia
with hypoalphalipoproteinemia being the most common ones. With the given of pri-
mary and secondary prevention, coronary events and mortality can be reduced as the
total and LDL-cholesterol levels decrease (mainly all with statins) based on random-
ized trials (Shepherd et al. 1995; Downs et al. 1998; Sacks et al. 1996). Statins therapy
contributes to LDL-cholesterol lowering may as well as other factors improvement.
Mild to moderate renal dysfunction are now proved to be associated with substantial
increase in CHD risk as well as end-stage renal disease (Gansevoort et al. 2013).
According to the ACC/AHA 2004 practice guidelines, chronic kidney disease was
a CHD risk equivalent (National Kidney Foundation 2002; Antman et al. 2006a).
The annual cardiac death rate of patients with no chronic kidney disease (CKD) and
ischemia was 4.5, 11% for those who had both.
8 C. Shao et al.
The contributions of CVD development appear to include age, and each additional
decade of life was associated with an approximate doubling of the risk of vascular
disease: 51–60 years 3.5%, 61–70 years 7.15, 71–80 years 13%, 81–90 years 22.3%,
and 91–100 years 32.5%.
Male gender alone may contribute to the risk of CHD, although the potential
mechanisms for such risk are not well understood. Several population studies have
identified male gender as a risk factor for higher rates of CHD and CHD-related
mortality. from the ONTARGET and TRANSCEND study populations, females had
approximately 20% lower risk than males for all major cardiovascular endpoints
including cardiovascular death, myocardial infarction (MI) and a combined endpoint
of death, MI, stroke, and heart failure hospitalization (adjusted relative risk [RR] 0.81,
95% CI 0.76–0.87) (Kappert et al. 2012).
Family history alone also could contribute to CHD, especially for the young who have
the family history of premature disease (Sesso et al. 2001; Andresdottir et al. 2002;
Roncaglioni et al. 1992; Lloyd-Jones et al. 2004; Murabito et al. 2005; Sivapalarat-
nam et al. 2010; Otaki et al. 2013). It is generally agreed that first-degree relative
such as parent or sibling suffering from atherosclerotic CVD or dead from CVD
indicates a remarkable family history, even prior to age 55 (males) or 65 (females)
(Patel et al. 2018). For people who have two or more first-degree relatives die of
premature cardiovascular disease, the incidence of CVD increased 3 times before
50. The Framingham Offspring Study started an analysis to explore the reliability of
self-reported family history of CHD and risk factors for CHD (Sivapalaratnam et al.
2010), and the findings were noted as follows: For family histories of hypertension,
diabetes, and hypercholesterolemia, the positive statement’s value for prediction was
over 75%, while for cardiac death, it was 66% and 47%, respectively, for fathers and
mothers. When it came to a negative statement, for family history of cardiac death or
diabetes, the predictive value was over 90%, yet for family history of hypertension
or hypercholesterolemia, less than 60%.
Cardiovascular risk factors in childhood can be recognized and used to predict the
subsequent development of CHD (Li et al. 2003; Raitakari et al. 2003; Davis et al.
2001).
1 Coronary Artery Disease: From Mechanism to Clinical Practice 9
Cigarette smoking is an important and reversible risk factor for CHD. Compared with
nonsmokers, subjects who smoke no less than 20 cigarettes every day have a higher
incidence of myocardial infarction, six times increased for women while 3 times for
men (Njølstad et al. 1996; Prescott et al. 1998). Of the population-attributable risk
of a first MI, 36% was led by smoking in the INTERHEART (Yusuf et al. 2004).
On the other hand, a study of smokers who had MI showed that the risk of recurrent
infarction decreased by 50% for those with one year’s smoking cessation; for those
with two years, the risk was normalized to that of nonsmokers (Wilhelmsson et al.
1975). Patients benefit from smoking cessation no matter how long or how much
they smoked previously.
1.2.10 Diet
The risk of CHD may also be contributed by high glycemic index (GI) or glycemic
load (GL) diets. Increasing evidence points out that the risk of CHD and stroke
and the consumption of fruit and vegetable have an inverse correlation. According
to the meta-analysis of seven prospective cohorts, every additional daily portion
of fruit could decrease the risk of stroke by 11%; yet no similar effect found in
vegetable (Dauchet et al. 2005). While according to the INTERHEART study, 14%
of population-attributed risk of first MI was caused by lacking of daily fruit and
vegetables consumption (Yusuf et al. 2004). Significant controversy exists regarding
the types of dietary fat and the associated risks of CHD (Chowdhury et al. 2014; de
Souza et al. 2015). In a 2014 meta-analysis, no significant association was identified
between types of dietary fat (i.e., saturated, monounsaturated, or polyunsaturated)
and risk of CHD (Chowdhury et al. 2014). Higher risks of CHD have been associated
with higher red meat and high-fat dairy products’ consumption. Compared to low
fiber consumption, the reduced risk of CHD and stroke is associated with high intake
of fiber. The reduction in risk for MI was associated to an additional 10 g fiber intake
per day (relative risk 0.81, 95% CI 0.66–0.99) (Rimm et al. 1996; Wolk et al. 1999).
A neutral effect on the development of CVD was found in both caffeinated and non-
caffeinated coffee intake (Floegel et al. 2012). Both risk of acute coronary events
and CHD mortality have an inverse correlation with high serum concentrations of
enterolactone and high diet putative biomarker of fiber and vegetables.
1.2.11 Obesity
It is reported that obesity is the risk factor for atherosclerosis, CHD, hypertension,
insulin resistance and glucose intolerance, hypertriglyceridemia, and lower levels of
10 C. Shao et al.
HDL-C (Eckel et al. 2004; Calle et al. 1999; Wolk et al. 2007; Tirosh et al. 2011).
After adjusting for traditional risk factors, the occurrence of CHD and cerebrovas-
cular disease can be predicted by obesity (measured by body mass index [BMI])
significantly and independently (Wilson et al. 2008). In addition to that, the risk of
CVD increases along with the BMI linearly (Jensen et al. 2014; Twig et al. 2016). All
atherogenic risk factors can be intensified or worsened by obesity, while only some
can be aggravated by physical inactivity. Yet both obesity and physical inactivity
would make patients of all ages more vulnerable to CHD events.
1.2.12 Exercise
Exercise was suggested that coronary heart disease and all-cause mortality can be
effectively protected by exercise, even it is moderate degree (Yusuf et al. 2004). Exer-
cise benefits variously–serum HDL-cholesterol elevated, blood pressure reduced,
insulin resistance decreased, and weight loss. Besides the exercise amount, the
decrease of coronary heart disease risk and overall cardiovascular mortality is also
related to the degree of cardiovascular fitness, which is a measure of physical activity
and determined by the exercise duration and the Maximal Oxygen Consumption on
treadmill (Barlow et al. 2012; Mandsager et al. 2018). The INTERHEART study
also found that 12% of the population-attributable risk of a first MI was contributed
by lacking of regular physical activity (Yusuf et al. 2004).
All of sudden cardiac death, acute precipitation of MI and the early development
of atherosclerosis may be promoted by psychosocial factors, including depres-
sion, anger, stress, and other factors, and all the above have a relationship with
cardiovascular outcomes.
It has been reported that the increased risk of CVD is related to various numerous
inflammatory markers (Emerging Risk Factors Collaboration et al. 2010), such as
C-reactive protein (CRP), interleukin-6, myeloperoxidase, and other inflammatory
markers. What else has been reported to be the markers of increased CHD risk are
elevated levels of white blood cells, erythrocyte sedimentation rates, interleukin-
18, tumor necrosis factor alpha, transforming growth factor beta, soluble inter-
cellular adhesion molecule-1, P-selectin, cathepsin S, and lipoprotein-associated
phospholipase A2.
1 Coronary Artery Disease: From Mechanism to Clinical Practice 11
So far, a widely accepted angina pectoris severity grading system was proposed by
CCS (Canadian Cardiovascular Society) (Kaul et al. 2009). And this system, which
was modified by NYHA (New York Heart Association) functional classification,
makes a more specific classification of patients possible. In addition to the above,
there is also an angina score and a specific scale of activity, developed by Califf and
Goldman with their associates, respectively.
Yet all these grading system would be limited without precise observation of
patients or their diverse symptoms’ tolerance. The reproducibility shown on the
CCS was only 73%, and no positive correlation was found between that and objec-
tive measures of exercise performance. The indicator in the Goldman scale is the
metabolic cost of particular activity, and it seems to be effective for both physicians
and nonphysicians. While in the anginal score of Califf and coworkers, both ST and T
wave changes on the ECG and clinical manifestations are combined, which becomes
an independent prognostic factor except LV function, age, coronary angiographic
anatomy, and gender.
Anxiety and major distress are common clinical features of STEMI patients, who
usually have anguished facial expression, with fist clenched and held against their
sternums during description. While any activity was believed to aggravate their dis-
comfort for severe angina pectoris patients, whose preferences are sitting, lying or
standing still.
Clinical manifestations of typical LV failure and sympathetic patients include
chest discomfort and suffocation. Their sputum is usually pink, frothy or blood-
streaked. Thus sitting or propped up in bed are their typical position. And skin pallor
and cold perspiration also may be obvious.
Features of cardiogenic shock are as follows: listless lying, pallor face, cold and
humid skin, few or no autonomous movements, bluey or mottled extremities, and
cyanosed nail beds and lips. Both normal conversation or confusion and disorientation
could happen for patients in shock based on their cerebral perfusion level.
Different degrees of LV failure and underlying rhythm make heart rate various,
including bradycardia, rapid regular or irregular tachycardia. Premature ventricular
beats are also ordinary. Rapid and regular pulse in these patients usually means sinus
tachycardia at 100–110 beats/min. Relief of anxiety and pain would slow down the
heartbeat.
1 Coronary Artery Disease: From Mechanism to Clinical Practice 13
Though the systolic and pulse pressure decreased and diastolic pressure elevated
for tachycardia accompanied stroke volume reduction, the blood pressure for most
patients with noncomplex STEMI is normal. For patients whose previous blood
pressure is normal, probably due to the release of adrenergic, which is secondary
to agitation, pain, and anxiety, occasional hypertension would be observed in the
first few hours, and arterial pressure over 160/90 mmHg. Although 3–6 months
postinfarction, elevated blood pressure would be recovered for many of those who
have a history of hypertension, without post-STEMI therapy, the blood pressure of
some often get normalized.
For patients with massive infarction, LV dysfunction and venous pooling resulted
from morphine and/or nitrates administration would cause acute fall in arterial
pressure, which inclines to back to preinfarction levels once they recover.
According to the definition of cardiogenic shock, the systolic pressure should be
lower than 90 mmHg with proved end-organ hypoperfusion. Since for some infe-
rior infarction patients who have activated Bezold–Jarisch reflex, a transient under
90 mmHg systolic pressure is also possible, hypotension is not a independent indi-
cator for cardiogenic shock. For patients with slight hypotension, cardiogenic shock
results from infarction extension and ischemia increasing. Their blood pressure may
decline gradually and cardiac output reduce progressively in hours or days.
Hypertension, tachycardia, or both occur in half of both inferior and ante-
rior STEMI patients, with excess parasympathetic stimulation occurring in former,
sympathetic excess in the latter.
Within 24–48 h starting from onset, fever and nonspecific response to necrosis occur
in most extensive STEMI patients. Following the development of STEMI may be
mildly increased respiratory rate. Based on the fact that with therapy for physical and
psychological discomfort, respiratory rate of non-HF patients was back to normal,
its elevation was brought on by pain and anxiety, while respiratory rate in LV failure
patients has correlation with the serious degree of failure. And the respiratory rate in
pulmonary edema patients may over 40/min.
1.3.3.4 Chest
For STEMI patients who also have LV failure and/or LV reduction, moist rales are
audible. For severe LV failure patients, diffuse wheezing exists. The occurrence of
hemoptysis can also indicate pulmonary embolism with infarction. In 1967, based on
STEMI patients’ presence and severity of rales, a prognostic classification plan was
suggested by Killip and Kimball (Barter et al. 2007). No rales or third heart sound
was detected in Class I patients. A mild to medium rales (<50% of lung fields) and
14 C. Shao et al.
a possible S3 in Class II patients. Rales in over 50% of each lung field and continual
pulmonary edema in Class III patients, while cardiogenic shock occurs in Class IV
patients.
Auscultation
Murmurs
For patients with mitral valve regurgitation or tricuspid regurgitation or interventric-
ular septum rupture, systolic murmurs usually are audible.
Friction Rubs
Pericardial friction rubs, most of which would be noticed in two or three days since
infarction onset, are usually audible either along the border of left sternal or just
inside the apical impulse for STEMI patients.
Laboratory Findings
Electrocardiography
Serial electrocardiographic changes occur in most of STEMI patients. Yet ECG has
been limited with age of the infarct, presence of conduction defects, changes in elec-
trolyte concentrations, extent of myocardial injury, its location, presence of previous
infarcts or acute pericarditis, and administration of cardioactive drugs in the diag-
nosis and location of MI. ST segment and T wave changes, which are nonspecific,
may be caused in the following cases: stable and unstable angina pectoris, acute
and chronic pericarditis, early repolarization, shock, following the administration of
digitalis, ventricular hypertrophy, myocarditis, electrolyte imbalance, and metabolic
disorders; all the cases above could be differentiated from STEMI with the help of
Serial ECG. With shock, persistent metabolic disorders and administration of digi-
talis eliminated, persistent changes prove infarction while transient changes support
electrolyte disturbances or angina.
The electrocardiographic leads suggest that the infarction location, all of QRS
duration and the extent of ST-segment elevation are related to poor prognosis. For
most STEMI patients, electrocardiographic changes occur from the onset of infarc-
tion and last lifelong especially when they develop into Q waves. While for substantial
minority, after several years, Q waves and even ECG are back to normal.
The Q wave patterns that may mimic MI in the following conditions: ventricular
hypertrophy, preexcitation, pneumothorax, amyloid heart disease, traumatic heart
disease, hyperkalemia, early repolarization, myocardial disease, conduction disor-
ders, pulmonary embolus, heart tumors, pericarditis, intracranial hemorrhage, and
cardiac sarcoidosis.
A fairly sensitive and specific evidence of infarction in right ventricular is the ST-
segment elevation in the right precordial leads (V1, V3R to V6R) (Bhatt et al. 2007;
Bangalore et al. 2007). Anterior ST-segment elevation caused by right ventricular
injury usually would be inhibited by concurrent inferior wall injury. Likewise, the
anterior ST-segment depression seems to be wakened by right ventricular infarction.
1.3.5 Imaging
Echocardiography
The fairly portable facility provides an ideal evaluation solution for coronary care
unit (CCU) or even emergency patients with MI. Echocardiography, which favors
myocardial ischemia, can also help with the diagnosis for MI patients with chest
pain and nondiagnostic ECG based on the distinct area of disordered contraction.
Similarly, it also help with the diagnosis of aortic dissection.
16 C. Shao et al.
Computed Tomography
Despite its relative inconvenience, compared to echocardiography, computed tomog-
raphy is more sensitive in thrombus detection. Various applications of computed
tomography include detection of LV aneurysms, assessment of cavity dimensions,
and wall thickness and intracardiac thrombi in STEMI patients. Except that, MI
patients’ cross-sectional information can also be obtained.
Cardiac Magnetic Resonance Imaging
Compared to its narrow usage in acute phase, cardiac magnetic resonance imaging
is widely used in subacute and chronic phases of MI, such as to localize and size the
infarction area, to recognize early MI, and to assess the ischemic insult. Other than
the above, it provides the assessments of infarcted and noninfarcted tissue perfu-
sion, myocardium reperfusion, ventricular segmental wall motion and chamber size,
also the identification of harmed but not infarcted myocardium, myocardial fibrosis,
edema, hypertrophy, wall thinning, and the temporal transition between ischemia
and infarction (Al-Mallah et al. 2006).
Electrocardiography
With the recognition that the infarcted myocardium volume implicate prognosis,
interest has been concentrated on the accurate measurement of MI. However, the
mortality rate is related to the number of electrocardiographic leads that display
ST-segment elevation; for anterior MI patients, quantity of ST-segment elevations
obtained from multiple precordial leads has a relationship with the myocardial injury
extent. Compared to patients with only 2 or 3 leads with ST-segment elevation, the
mortality rate of those with 8 or 9 are 2–3 times higher. A relationship also exists
between the ischemia duration, which could be estimated by monitoring ST-segment
1 Coronary Artery Disease: From Mechanism to Clinical Practice 17
continuously, and IS (infarcted size), IS/AAR (area at risk) ratio, and subsequent
abnormality in partial wall motion extent (Bonaa et al. 2006).
Serum Cardiac Markers
With its release ratio, volume of distribution, and amount of lost marker, the infarcted
size can be estimated with the usage of serum cardiac markers. The measurement of
MI size can use the help of serial calculations of proteins discharged from necrotic
myocardium. Besides that, it can be estimated approximately with the crest value
of CK or CK-MB, which has wide prognostic applications. Yet the washout kinet-
ics of CK and other markers could be remarkably altered by the coronary artery
reperfusion, which leads to overstated and premature peak levels and less the use-
ful of the curves. Infarcted size may be responsibly determined with post-STEMI
cardiac-specific troponin level test even after a successful reperfusion (Levonen et al.
2008).
Noninvasive Imaging Techniques
The infarct size can be assessed both experimentally and clinically with the help of the
imaging modalities above. For patients whose arteries are occluded persistently, par-
tial heterogeneity of infarction patterns can be displayed clearly in contrast-enhanced
cardiac magnetic resonance.
Post-MI angina; new-onset (de novo) angina (class II or III of the Canadian Cardio-
vascular Society classification); prolonged (0.20 min) angina at rest; or previous sta-
ble angina become unstable in recent with at least Canadian Cardiovascular Society
Class III angina characteristics (crescendo angina).
80 and 20% patients are found to have prolonged and de novo/crescendo angina,
respectively. The elderly, female and patients with diabetes, chronic renal disease or
dementia found are more likely to get anginal pain. One of the characters of typical
chest pain refers to the retrosternal sensation of pressure or heaviness radiating to
the left arm, sometimes to both arms or to the right arm, neck or jaw. A typical
chest pain usually lasts for several minutes or persistent. What else possibly come
along are sweating, nausea, abdominal pain, dyspnoea, and syncope. Epigastric pain,
indigestion-like symptoms, and isolated dyspnoea are all included in the typical
presentations. Intense physical activity and its relief afterword would aggravate the
symptoms, which possibly lead to a higher the chance of myocardial ischaemia.
Nitrites can relieve the symptoms, which according to a report of acute chest pain’s
other causes is not specific for angina.
There is very limited performance of chest pain characteristics to diagnose MI.
The incidence of NSTE-ACS is possibly to be increased by many factors, including
male gender, older age, diabetes, hypertension, hyperlipidaemia, renal insufficiency,
and family history of CAD, previous manifestation of CAD as well as carotid artery
18 C. Shao et al.
involves a significant proportion of the left ventricle or in those with antecedent left
ventricular dysfunction. The presence of congestion confers an adverse prognosis.
Transthoracic echocardiography (UCG) should be routinely available in emer-
gency rooms, which is performed/interpreted by trained physicians in all patients
during hospitalization for NSTE-ACS. It is useful to identify abnormalities sugges-
tive of myocardial ischaemia or necrosis. Besides, UCG is helpful in other which is
related with chest pain, such as aortic valve stenosis, pericardial effusion, acute aortic
dissection, hypertrophic cardiomyopathy or acute pulmonary embolism. Moreover,
UCG is the diagnostic tool for patients with hemodynamics instability of suspected
cardiac origin. Evaluation of left ventricular (LV) systolic function is important to
estimate prognosis.
Compared to male’s presentation time, it would generally be ten years later for female
to get coronary heart disease (CHD), and burden of risk factors for women are greater
20 C. Shao et al.
(Rutledge et al. 2009). Symptoms at the beginning would not be considered as the
presentation of heart disease by women, which results in not prompt medical advice;
they also will not be used in evaluating myocardial ischemia as early in women.
Women under 45 years also have CHD and the prognosis is worse compared to
men. CHD first presentation can be various, including sudden cardiac death (SCD),
myocardial infarction (MI), heart failure (HF) or chest pain. The Reynolds risk score
as alternative was developed for female patients since risk in women with early heart
disease family history was underestimated.
Hemopericardium and death from cardiac tamponade are often caused by rupture of
the free wall of the left ventricle (Antman et al. 2006b). There are mainly three types
of rupture, including the catastrophic (an acute tear leading to immediate death), the
subacute (nausea, hypotension), and the pericardial (discomfort) (Birnbaum et al.
2002a).
1 Coronary Artery Disease: From Mechanism to Clinical Practice 21
The 30-day mortality of patients who had acute myocardial infarction and subsequent
rupture of interventricular septum is high (Birnbaum et al. 2002b). The character
of a ruptured interventricular septum is a new harsh, loud holosystolic murmur,
which is usually together with a thrill and can be heard best at the lower left sternal
border (Antman et al. 2006b). It has been reported that for critical patients with acute
septal rupture after AMI, their conditions can be stabilized by catheter placing an
umbrella-shaped device within the ruptured septum.
It appears that for either during hospitalization or over the first year and non-sustained
runs of ventricular tachycardia has no relationship with increased mortality risk.
STEMI patients who have transmural infarction and left ventricular dysfunction
usually have late yet maybe sustained ventricular tachycardia, which often causes
significant hemodynamic deterioration and is related to both hospital and long-term
mortality rates.
It’s significant that the levels of serum potassium and magnesium be maintained
above 4.5 mEq/l and 2 mEq/l, respectively. And for STEMI patients, it is compulsive
to abolish the sustained ventricular tachycardia rapidly. An index episode of ven-
tricular tachycardia is usually followed with several days’ maintenance infusions of
antiarrhythmic drugs, which is a common clinical practice. Specialized methods like
surgery or antitachycardia devices implantation should be considered for recurrent
or refractory ventricular tachycardia.
1.4.6.5 Bradyarrhythmias
Sinus Bradycardia
Sinus bradycardia usually happens at the early stage of STEMI, especially for patients
who have inferior and posterior infarction (Antman et al. 2006b). For patients whose
extremely slow sinus rate (<40–50 beats/min) is in association with hypotension,
1 Coronary Artery Disease: From Mechanism to Clinical Practice 23
atropine can raise the heart rate effectively without the company of hypotension
or ventricular ectopy, sinus bradycardia alone should firstly be observed instead of
treatment.
Intraventricular Block
Blood of the right bundle branch and the left posterior division are supplied from both
anterior descending and right coronary arteries, whereas that of the left anterior divi-
sion is supplied only from septal perforators, whose origin is left anterior descending
coronary artery. Since nearly half of conduction blocks observed in STEMI patients
are already present on the first ECG, they can’t all be considered to be the complica-
tions of infarcts, and they may stand for the antecedent disease of conduction system
(Di Chiara 2006; Wong et al. 2006).
Right bundle branch block, which is usually new and related to anteroseptal infarc-
tion, alone can cause AV block. It appears that for anterior STEMI patients, with the
company of congestive heart failure, isolated right bundle branch block is related to
an elevated mortality risk, even without the occurrence of complete AV block.
24 C. Shao et al.
Atrial flutter, which commonly is transient and is the typical consequence of aug-
mented sympathetic stimulation of the atria in STEMI patients, usually occurs in
LV failure and pulmonary emboli patients, who has hemodynamic deterioration that
aggravated by arrhythmia, or atrial infarction (Kober et al. 2006).
Fibrillation is commonly transient and likely to happen in LV failure patients just
like atrial premature complexes. Yet patients who have pericarditis and atria ischemic
injury and right ventricular infarction can also have that. The treatments for atrial flut-
ter and fibrillation in STEMI patients and these conditions in other settings are sim-
ilar. Oral anticoagulants should be administered in patients with recurrent episodes
of atrial fibrillation. Beta-blocker should also be used in patients after STEMI if no
contraindications exist. And these agents can also help to decrease the ventricular
rate, should atrial fibrillation recurrence, except other several beneficial effects.
Both previous abnormalities on the ECG and patients’ blurry description of discom-
fort sometimes make the evaluation of postinfarction chest discomfort complicated.
Patients may either be too sensitive to transient discomfort or negative a potential
recrudescence of symptoms. Diagnostic strategies can be used are as follows: repeat
ECG reading, assessment of the response to sublingual nitroglycerin, 0.4 mg and
repeat physical examination.
With a repeat ST-segment elevation on ECG within the first 18–24 h after the pri-
mary infarction, and abnormal serum cardiac markers, recurrent infarction is worth
of serious consideration (Keeley et al. 2003). After 24 h, either re-elevated cardiac
markers or newly appeared Q wave on ECG can be used to diagnose recurrent infarc-
tion. Catheterization and percutaneous coronary intervention, or repeat fibrinolysis
if PCIs unavailable, should be considered for patients who have re-elevated ST seg-
ment. During the arrangement of other procedures, patients may be stabilized with an
intra-aortic balloon pump being inserted (Scirica et al. 2006; Antman et al. 2006c).
1 Coronary Artery Disease: From Mechanism to Clinical Practice 25
Effusions are usually detected with echocardiography. And the incidence changes
along with criteria, laboratory expertise, and technique. Patients with the presence
of congestive failure, larger infarcts, and anterior STEMI are more likely to have
effusions. Most post-STEMI pericardial effusions do not lead to hemodynamic com-
promise; and with the occurrence of tamponade, ventricular rupture or hemorrhagic
pericarditis often induces effusions (Hombach et al. 2005).
1.4.8.4 Pericarditis
Pain caused by pericarditis may start in the first day and last 6 weeks post-STEMI. A
higher dose of aspirin (650 mg orally every 4–6 h) is necessary to treat the pericar-
dial discomfort. And nonsteroidal antiinflammatory agents and steroids should be
prevented from using since their interference with the formation of myocardial scar
(Abildstrom et al. 2005; Birnbaum and Drew 2003).
The origin of mainly all peri-MI pulmonary emboli is thrombi in the veins of the
lower extremities; mural thrombi overlying an area of right ventricular infarction as
the origin is rather uncommon.
Left ventricular aneurysm, which is often termed as true aneurysm, usually means
discrete, dyskinetic area of the left ventricular wall with a broad neck. Compared
to true aneurysms after STEMI, it is more common to see dyskinetic or akinetic
areas of the left ventricle, which are known as regional wall motion abnormalities.
The wall of the true aneurysm, which generally consists of fibrous tissue, necrotic
muscle, and sometimes viable myocardium, is thinner compared to the rest wall of the
26 C. Shao et al.
left ventricle. In contrast to patients without aneurysms, the mortality of those who
have is six times higher. Ventricular reconstruction surgery is worth of consideration
(Cheitlin et al. 2003; Vargas et al. 1999).
During the acute phase of infarction, a thrombogenic surface inside the left ven-
tricle may be contributed by endocardial inflammation. Since the septum has been
transmural-infarcted extensively, infarcted myocardium of both ventricles may be
overlay with mural thrombi. When an embolic event has already occurred, or patient
has a large anterior infarction with or without echocardiographically visualized
thrombus, anticoagulation is recommended (intravenous heparin to increase the acti-
vated partial thromboplastin time to 1.5–2 times that of control, followed by at least
3–6 months of warfarin) (Rehan et al. 2006; Barbera and Hillis 1999).
1.5.3 Inflammation
accumulation of minimally oxidized LDL develop together in the arterial wall. Sev-
eral adhesion molecules are expressed in the endothelial cell, including P- and E-
selectins, intercellular adhesion molecule, and vascular cell adhesion molecule-1,
which bind to circulating leukocytes (Hansson 2001). Chemoattractants such as
monocyte chemotactic protein can mediate transmigration of leukocytes into the
arterial wall, which leads to accumulation of inflammatory macrophages and T-cells
within the arterial wall (Hansson 2001). Proteolytic enzymes and a variety of pep-
tide growth factors and cytokines which can degrade matrix proteins and stimulate
smooth muscle cells, endothelial cells, and macrophages are released by those acti-
vated leukocytes. Macrophage accumulation of oxidized LDL leads to foam cells
aggregation. Several inflammatory cells, including macrophages, B and T lympho-
cytes, endothelial cells, vascular smooth muscle cells, and fibroblasts express CD40
receptor and CD40 ligand (Schonbeck and Libby 2001).
Plaque disruption and thrombosis can also be led to by the inflammatory process.
A large lipid core, a thin fibrous cap, and inflammatory cells at the thinnest portion
of the cap surface are characters of vulnerable plaques (Davies et al. 1993). Matrix
metalloproteinases (MMPs) and other substances expressed by macrophages lead to
degradation of the cap, resulting in an unstable plaque that is susceptible to rupture,
which have been shown in several studies (Galis and Khatri 2002). Then, formation
of a thrombus can be led to by exposure of the underlying atheroma and tissue factor
to circulating platelets and thrombin. It is serum markers of inflammation such as
high-sensitivity C-reactive protein that are elevated in patients with acute coronary
syndromes and PAD, which independently predicts subsequent events (Ridker et al.
2001).
Excess generation of reactive oxygen species (ROS) has been proved to be a crit-
ical pathological process in atherogenesis. Each component of the atherosclerotic
blood vessel has been demonstrated to increase production of ROS, primarily super-
oxide anion (O2 ) (Maytin et al. 1999). Important sources of ROS are endothelial
cells, vascular smooth muscle cells fibroblasts, and infiltrating leukocytes (Zalba
et al. 2000). The importance of oxidation can be seen by the presence of oxidized
LDL in atherosclerotic lesions, although the mechanism of oxidative modification of
LDL remains unknown. As measured by autoantibody titers, the amount of oxidized
LDL is reflective of the atherosclerotic burden (Tsimikas et al. 2001). Oxidized LDL
induces a series of atherogenic processes, including production of matrix metallo-
proteinases, transcription of proatherogenic genes and antagonism of endothelial cell
production of NO, promotion of vascular smooth muscle cell apoptosis (Kita et al.
2001).
1 Coronary Artery Disease: From Mechanism to Clinical Practice 29
The vascular smooth muscle cell (SMC) plays a critical role in atherosclerosis. The
growth factor, the SMC undergoes a phenotypic change that leads to a migratory
and secretory cell that migrates into the neointima after being activated by injury,
(Rivard and Andres 2000). SMCs proliferate and secrete matrix proteins and enzymes
through growth factor and cytokine stimulation.
The atherosclerotic plaque contains cellular elements and extracellular matrix.
The constituents of the plaque’s extracellular matrix include proteoglycans, gly-
cosaminoglycans, collagen, elastin, fibronectin, vitronectin, laminin, and throm-
bospondin. Activated SMCs are closely related to the production of these matrix
proteins (Raines 2000). Collagen provides the structural support and scaffold for the
vessel wall, whose production and degradation are both increased in atherosclero-
sis (Rekhter 1999). Activated SMCs and macrophages secrete MMPs that degrade
collagen and elastin, whereas SMCs produce collagen (Benjamin 2001). The entire
vessel can enlarge or constrict in size during development of atherosclerosis. This is
often referred to as geometric remodeling, which plays a critical role in determining
luminal patency.
References
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events
(CAPRIE) (1996) CAPRIE Steering Committee. Lancet 348:1329–1339
Abidov A, Rozanski A, Hachamovitch R et al (2005) Prognostic significance of dyspnea in patients
referred for cardiac stress testing. N Engl J Med 353:1889
Abildstrom SZ, Ottesen MM, Rask-Madsen C, Andersen PK, Rosthoj S, Torp-Pedersen C, Kober
L (2005) Sudden cardiovascular death following myocardial infarction: the importance of left
ventricular systolic dysfunction and congestive heart failure. Int J Cardiol 104:184–189
Al-Delaimy WK, Merchant AT, Rimm EB et al (2004) Effect of type 2 diabetes and its duration on
the risk of peripheral arterial disease among men. Am J Med 116:236
Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA et al (2006) Angiotensin-converting enzyme inhibitors
in coronary artery disease and preserved left ventricular systolic function: A systematic review
and meta-analysis of randomized controlled trials. J Am Coll Cardiol 47:1576
30 C. Shao et al.
Almdal T, Scharling H, Jensen JS, Vestergaard H (2004) The independent effect of type 2 diabetes
mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men
and women with 20 years of follow-up. Arch Intern Med 164:1422
Andresdottir MB, Sigurdsson G, Sigvaldason H et al (2002) Fifteen percent of myocardial infarc-
tions and coronary revascularizations explained by family history unrelated to conventional risk
factors. The Reykjavik Cohort Study. Eur Heart J 23:1655
Antman EM, Anbe DT, Armstrong PW et al (2006a) ACC/AHA guidelines for the management
of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/
statements.htm. Accessed 24 Aug 2006
Antman EM, Anbe DT, Armstrong PW et al (2006b) ACC/AHA guidelines for the manage-
ment of patients with ST-elevation myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. Accessed 19 Apr
2006
Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon
JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E (2006c) Enoxaparin versus unfractionated
heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488
Asia Pacific Cohort Studies Collaboration (2005) Joint effects of systolic blood pressure and serum
cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 112:3384
Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS (2005) Trends in man-
agement and outcomes of patients with acute myocardial infarction complicated by cardiogenic
shock. JAMA 294:448–454
Bangalore S, Messerli FH, Kostis JB et al (2007) Cardiovascular protection using beta-blockers: a
critical review of the evidence. J Am Coll Cardiol 50:563
Barbera S, Hillis LD (1999) Echocardiographic recognition of left ventricular mural thrombus.
Echocardiography 16:289–295
Barlow CE, Defina LF, Radford NB et al (2012) Cardiorespiratory fitness and long-term survival
in “low-risk” adults. J Am Heart Assoc 1:e001354
Barter P, Gotto AM, LaRosa JC et al (2007) HDL cholesterol, very low levels of LDL cholesterol,
and cardiovascular events. N Engl J Med 357:1301
Benjamin IJ (2001) Matrix metalloproteinases: from biology to therapeutic strategies in cardiovas-
cular disease. J Investig Med 49:381–397
Berk BC, Abe JI, Min W et al (2001) Endothelial atheroprotective and anti-inflammatory
mechanisms. Ann N Y Acad Sci 947:93–109
Bhatt DL, Flather MD, Hacke W et al (2007) Patients with prior myocardial infarction, stroke, or
symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49:1982
Birnbaum Y, Drew BJ (2003) The electrocardiogram in ST elevation acute myocardial infarction:
correlation with coronary anatomy and prognosis. Postgrad Med J 79:490–504
Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ (2002a) Ventricular septal rupture after acute
myocardial infarction. N Engl J Med 347:1426–1432
Birnbaum Y, Chamoun AJ, Conti VR, Uretsky BF (2002b) Mitral regurgitation following acute
myocardial infarction. Coron Artery Dis 13:337–344
Bonaa KH, Njolstad I, Ueland PM et al (2006) Homocysteine lowering and cardiovascular events
after acute myocardial infarction. N Engl J Med 354:1578
Calle EE, Thun MJ, Petrelli JM et al (1999) Body-mass index and mortality in a prospective cohort
of U.S. adults. N Engl J Med 341:1097
Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis DL, Douglas PS,
Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H,
Thys DM (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocar-
diography: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the
Clinical Application of Echocardiography). Accessed 19 Apr 2006
Chen Z (2009) Launch of the health-care reform plan in China. Lancet 373:1322–1324
1 Coronary Artery Disease: From Mechanism to Clinical Practice 31
Jackson R, Lawes CM, Bennett DA et al (2005) Treatment with drugs to lower blood pressure and
blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 365:434
Jensen MD, Ryan DH, Apovian CM et al (2014) 2013 AHA/ACC/TOS guideline for the man-
agement of overweight and obesity in adults: a report of the American College of Cardiol-
ogy/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
Circulation 129:S102
Kannel WB, McGee DL (1979a) Diabetes and cardiovascular risk factors: the Framingham study.
Circulation 59:8
Kannel WB, McGee DL (1979b) Diabetes and glucose tolerance as risk factors for cardiovascular
disease: the Framingham study. Diabetes Care 2:120
Kannel WB (1987) Prevalence and clinical aspects of unrecognized myocardial infarction and
sudden unexpected death. Circulation 75:II4
Kappert K, Böhm M, Schmieder R et al (2012) Impact of sex on cardiovascular outcome in patients
at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-
Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan
Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation
126:934
Kaul P, Naylor CD, Armstrong PW et al (2009) Assessment of activity status and survival according
to the Canadian Cardiovascular Society angina classification. Can J Cardiol 25:e225
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic
therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet
361:13–20
Kita T, Kume N, Minami M et al (2001) Role of oxidized LDL in atherosclerosis. Ann N Y Acad
Sci 947:199–205
Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev
V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL,
Leimberger JD, Califf RM (2006) Previously known and newly diagnosed atrial fibrillation: a
major risk indicator after a myocardial infarction complicated by heart failure or left ventricular
dysfunction. Eur J Heart Fail
Lee DC, Johnson NP (2009) Quantification of absolute myocardial blood flow by magnetic
resonance perfusion imaging. JACC Cardiovasc Imaging 2:761
Levonen A-L, Vahakangas E, Koponen JK et al (2008) Antioxidant gene therapy for cardiovascular
disease: current status and future perspectives. Circulation 117:2142
Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure
to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective
studies. Lancet 360:1903
Li S, Chen W, Srinivasan SR et al (2003) Childhood cardiovascular risk factors and carotid vascular
changes in adulthood: the Bogalusa Heart Study. JAMA 290:2271
Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874
Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143
LloydJones D, Adams RJ, Brown TM et al (2010) Executive summary: heart disease and stroke
statistics 2010 update: a report from the American Heart Association. Circulation 121:948
Lloyd-Jones DM, Nam BH, D’Agostino RB Sr et al (2004) Parental cardiovasculardisease as a
risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and
offspring. JAMA 291:2204
Loscalzo J (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res
88:756–762
Lowe LP, Greenland P, Ruth KJ et al (1998) Impact of major cardiovascular disease risk factors,
particularly in combination, on 22-year mortality in women and men. Arch Intern Med 158:2007
Luft FC (2002) Proinflammatory effects of angiotensin II and endothelin: targets for progression
of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 11:59–66
Makin A, Silverman SH, Lip GY (2002) Peripheral vascular disease and Virchow’s triad for
thrombogenesis. QJM. 95:199–210
1 Coronary Artery Disease: From Mechanism to Clinical Practice 33
Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in
men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J
Med 333:1301
Singer DE, Nathan DM, Anderson KM et al (1992) Association of HbA1c with prevalent
cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41:202
Sipahi I, Tuzcu EM, Wolski KE et al (2007) Beta-blockers and progression of coronary
atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 147:10
Sivapalaratnam S, Boekholdt SM, Trip MD et al (2010) Family history of premature coronary heart
disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 96:1985
Stamler J, Stamler R, Neaton JD et al (1999) Low risk-factor profile and long-term cardiovascular
and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult
and middle-aged men and women. JAMA 282:2012
The World Bank (2013) Toward a healthy and harmonious life in China: stemming the rising tide
of non-communicable diseases. http://www.worldbank.org/content/dam/Worldbank/document/
NCD_report_en.pdf. Accessed 27 Nov 2013
Tirosh A, Shai I, Afek A et al (2011) Adolescent BMI trajectory and risk of diabetes versus coronary
disease. N Engl J Med 364:1315
Towfighi A, Zheng L, Ovbiagele B. Sexspecific trends in midlife coronary heart disease risk and
prevalence. Arch Intern Med 169:1762
Tsimikas S, Palinski W, Witztum JL (2001) Circulating autoantibodies to oxidized LDL corre-
late with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice.
Arterioscler Thromb Vasc Biol 21:95–100
Twig G, Yaniv G, Levine H et al (2016) Body-mass index in 2.3 million adolescents and
cardiovascular death in adulthood. N Engl J Med 374:2430
Udelson JE, Patten RD, Konstam MA (2003) New concepts in post-infarction ventricular
remodeling. Rev Cardiovasc Med 4(Suppl 3):S3–S12
Vallance P, Chan N (2001) Endothelial function and nitric oxide: clinical relevance. Heart. 85:342–
350
Vargas SO, Sampson BA, Schoen FJ (1999) Pathologic detection of early myocardial infarction: a
critical review of the evolution and usefulness of modern techniques. Mod Pathol 12:635–645
Vasan RS, Sullivan LM, Wilson PW et al (2005) Relative importance of borderline and elevated
levels of coronary heart disease risk factors. Ann Intern Med 142:393
Volpi A, Cavalli A, Santoro L, Negri E (1998) Incidence and prognosis of early primary ventricular
fibrillation in acute myocardial infarction—results of the Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico (GISSI-2) database. Am J Cardiol 82:265–271
Webber BJ, Seguin PG, Burnett DG et al (2012) Prevalence of and risk factors for autopsy determined
atherosclerosis among US service members, 2001-2011. JAMA 308:2577
White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J,
Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA (2005) Mortality
and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left
ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results
from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112:3391–3399
Wilhelmsson C, Vedin JA, Elmfeldt D et al (1975) Smoking and myocardial infarction. Lancet
1:415
Wilson PW (1994) Established risk factors and coronary artery disease: the Framingham Study.
Am J Hypertens 7:7S
Wilson PW, D’Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk
factor categories. Circulation 97:1837
Wilson PW, Bozeman SR, Burton TM et al (2008) Prediction of first events of coronary heart disease
and stroke with consideration of adiposity. Circulation 118:124
Wolk A, Manson JE, Stampfer MJ et al (1999) Long-term intake of dietary fiber and decreased risk
of coronary heart disease among women. JAMA 281:1998
36 C. Shao et al.
Wolk R, Berger P, Lennon RJ et al (2007) Association between plasma adiponectin levels and
unstable coronary syndromes. Eur Heart J 28:292
Wong CK, Stewart RA, Gao W, French JK, Raffel C, White HD (2006) Prognostic differences
between different types of bundle branch block during the early phase of acute myocardial infarc-
tion: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Eur Heart J
27:21–28
Yang ZJ, Liu J, Ge JP et al (2012) Prevalence of cardiovascular disease risk factor in the Chinese
population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J
33:213
Yang G, Wang Y, Zeng Y et al (2013) Rapid health transition in China, 1990–2010: findings from
the Global Burden of Disease Study 2010. Lancet 381:1987–2015
Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular diseases: part I:
general considerations, the epidemiologic transition, risk factors, and impact of urbanization.
Circulation 104:2746
Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated
with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet
364:937
Zalba G, Beaumont J, San Jose G et al (2000) Vascular oxidant stress: molecular mechanisms and
pathophysiological implications. J Physiol Biochem 56:57–64
Zavaroni I, Bonora E, Pagliara M et al (1989) Risk factors for coronary artery disease in healthy
persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:702
Chapter 2
Evidence in Guidelines for Treatment
of Coronary Artery Disease
Diet and lifestyle management should always be considered necessary for the thera-
peutic treatment of CAD. Unhealthy diet and lifestyle act as basic CAD risk factors
which not only initiate CAD process but also worsen the prognosis of CAD, as sup-
ported by various evidences. No matter how effective drugs and revascularization
techniques might be, an experienced cardiologist shall never ignore the importance
of diet and lifestyle management.
Diet management is one of the fundamental factors to CAD risk control. According to
AHA dietary guidelines, population goals are summarized as (see Table 2.1): forming
overall healthy eating pattern, maintaining appropriate body weight, and achieving
desirable cholesterol profile and blood pressure levels (Krauss et al. 2000).
As a general principle, the AHA guidelines supports the consumption of a variety
of foods from all food categories with special emphasis on fruits and vegetables,
including fat-free and low-fat dairy products; cereal and grain products; legumes and
nuts; and fish, poultry, and lean meats (Krauss et al. 2000). We did a comprehensive
search for new relevant evidences in databases including PubMed, Embase, and so
on. In the following part, evidences will be listed per general food categories.
could bring enormous public health benefit in preventing stroke and car-
diovascular diseases (Glover et al. 2011). However, despite the rarity, there
are contradictory evidences in animal model experiments. Chetboul et al.
(2014) carried out a 2-year prospective randomized, blinded, and controlled
study on cardiovascular effects of dietary salt intake in aged healthy cats, and
found chronic high dietary salt intake was not associated with an increased
risk of systemic arterial hypertension and myocardial dysfunction. Despite
the contradictory evidence, this kind of evidences are generally rare and of
little value of reference. To our current best knowledge, it is safe to stay to
guidelines recommendations.
iii. Limitation of Alcohol Intake
It is well known that excessive alcohol consumption leads to increased car-
diovascular risk. Excessive consumption of alcohol not only damages coro-
nary artery but also harms various parts of the cardiovascular system, causing
cardiomyopathy, arrhythmia, hypertension, and so on. Nevertheless, alcohol
limitation should never be taken to the extremes, as it is widely acknowl-
edged that moderate alcohol consumption, and wine consumption in partic-
ular, is associated with a significant reduction in cardiovascular morbidity
and mortality in epidemiological studies (Worm et al. 2013). The benefi-
cial effect of moderate alcohol consumption is probably due to benevolent
interactions between alcohols, beneficial lipid components, and coagulation
factors. Therefore, it is vital to maintain a balance optimal for human body.
It is suggested in the dietary guidelines that no more than 2 drinks per day
(men) and 1 drink per day (women) among those who drink (Krauss et al.
2000).
iv. About Supplementary Nutrients
Several supplementary nutrients are mentioned in the dietary guidelines,
including antioxidants, folic acid, vitamin B, soy protein and isoflavones,
fiber supplements, ω-3 fatty acid supplements, stenol/sterol ester-containing
foods, fat substitutes, and so on. (Krauss et al. 2000). It is unrealistic to
list all up-to-date evidences about these nutrients here, but most of these
supplementary nutrients are generally considered to have protective effect
against CAD. Given current knowledge, further research on these nutrients
is warranted.
e. Author’s Comments on Dietary Guidelines
This part unfolds mainly according to AHA Dietary Guidelines Recommenda-
tions, providing additional recent evidences for readers to refer to. Maintenance
of healthy diet and lifestyle is absolutely essential for CAD risk reduction.
It’s worth mentioning that in an era of big data and precision medicine, dietary
recommendations is getting more and more personalized with the accumulation
of new evidences. Advances in genomic, proteomic, and other “-omics” studies
are gradually enabling precise dietary intervention targeting each individual’s
unique genomic trait. There is no doubt that more genomic-scale researches are
widely needed for CAD dietary database to be established. It is predictable that in
42 S. Jia et al.
the near future, with advancing technologies bringing down related cost, precise
dietary intervention will be economically affordable to most population, making
CAD risk control cost-effective for general population.
Early clinical trials and meta-analyses have provided substantive and convincing
evidence on the preventive strengths of lifestyle adjustment. Even though some tips
have been amended so far, conclusion from a recent meta-analysis of 48 RCTs
(1999–2009) accorded with formal results. Lifestyle modification programs were
associated with reduced all-cause mortality (summary OR 1.34, 95% CI 1.10–1.64),
cardiac mortality (summary OR 1.48, 95% CI 1.17–1.88), and cardiac readmission
and non-fatal reinfarction (summary OR 1.35, 95% CI 1.17–1.55) (Janssen et al.
2012).
Analysis from a large RCT (the Organization to Assess Strategies in Acute
Ischemic Syndromes (OASIS) 5 trials) revealed that patients who change their behav-
ior (quit smoking, modify diet, and exercise) after ACS were at lower repeat CV
events in 6 months. The benefits from each behavior modification are additive as the
highest risk of a repeat CV event belonged to those who change none of them (OR,
3.77; 95% CI, 2.40–5.91; p < 0.0001) (Chow et al. 2010).
What should be emphasized is that changing the habits never too easy to achieve
and even sustain for a lifetime. Support and guidance from physicians and other
external factors, comprehensive, continuing, and individualized, is deemed to be of
great importance.
1. Exercise
The effectiveness of regular physical activity to reduce all-cause and CVD mortality
has a sound basis. For patients following either STEMI or NSE-ACS, exercise training
plays a major role in cardiac rehabilitation. Despite insufficient data from RCTs in
the population of stable coronary artery disease, it is well accepted that physical
activity contributes to meliorate ischemic symptoms and progression.
Several pathophysiological mechanisms are considered to explain its protec-
tive impact: (i) improvement of endothelial function; (ii) reduced progression of
atherosclerosis; (iii) reduced thrombotic risk; and (iv) improved formation of collat-
erals (Members et al. 2012). Furthermore, it has positive effects on many other risk
factors, including hypertension, dyslipidemia, obesity, diabetes mellitus, and major
depression.
Guidelines encourage CAD patients to acquire 30–60 min of moderate-intensity
aerobic activity, such as brisk walking, at least 5 days and preferably 7 days per week
(I, B), in line with recommendation in healthy population.
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 43
2. Cigarette cessation
Smoking is a strongly and independently evoking factor of CAD. From the last
century, several observational studies have established clear conclusion about the
increased risk of CV events in smokers. Moreover, passive smoking also has adverse
influence on the development and progression of CVD.
Thus, quitting smoking is definitely a desirable and powerful preventive measure
for patients with CAD, for example, result from the CASS Registry revealed higher
rate of six-year mortality among continuing smokers than among those who quit
smoking during the year before enrollment and abstained throughout the study (rel-
ative risk, 1.7; 95% CI 1.4–2.0). Furthermore, no difference was found in assorted
ages (Hermanson 1988). A meta-analysis of 20 studies further confirmed that quitting
smoking was associated with a substantial reduction in risk of all-cause mortality
among patients with CHD (crude relative risk, 0.64; 95% CI 0.58–0.71). This risk
reduction appears to be consistent regardless of any other characteristics like age,
sex, index cardiac event, and so on (Critchley and Capewell 2003).
Admittedly, cessation is a troubling task for a large number of smokers. Various
strategies and policies have been formed. Notwithstanding, evidence-based treatment
for smoking cessation was underused. Physicians should provide a specific plan for
smokers after thorough discussion with them.
The safety and effectiveness of adjuvant pharmacotherapy including nicotine
replacement, antidepressant drug bupropion, and varenicline is called for ques-
tion. No significant adverse functions on cardiovascular system have been reported,
though, the application must be rational with other strategies’ company.
An RCT assessed the safety and efficacy of 10-week aid of transdermal nicotine in
patients with cardiovascular disease and found that: (1) The primary endpoints were
comparable in the nicotine group as that in the placebo group (5.4 vs 7.9%; 95% CI
1.6–6.5%; P = 0.23). (2) Transdermal nicotine significantly lowered the cessation
rate after 14 weeks (p < 0.001) but this vantage eroded after 24 weeks. Some other
small RCTs also confirmed that NRT is safe for quitters with CAD (stable angina,
after myocardial infarction) regardless of its possible cardiovascular toxicity (Joseph
et al. 1996). In addition, it is of importance to ensure that dosing does not exceed
the manufacturer’s recommendation and to warn patients to stop using NRT if they
relapse to smoking (Mcrobbie and Hajek 2001).
2.1.2.2 Bupropion
(relative risk 1.21; 95% CI 1.02–1.45) but not continuous abstinence (RR, 1.19; 95%
CI 0.97–1.45). However, these effects didn’t last for 12 months (Grandi et al. 2013).
2.1.2.3 Varenicline
Varenicline is the latest drug approved by FDA for smoking cessation. An RCT
has been conducted in smokers with SCAD. After 12-week use, varenicline showed
higher continuous abstinence rate (CAR) than placebo during weeks 9 through 12
(47.0 vs 13.9%; OR 6.11; 95% CI 4.18–8.93) and weeks 9 through 52 (19.2 vs
7.2%; OR, 3.14; 95% CI 1.93–5.11), and no significant difference in cardiovascular
outcomes (Rigotti et al. 2010).
A large cohort study evaluated the safety of varenicline and bupropion and they
didn’t differ in either the primary or secondary endpoint of cardiovascular events
when applied to the elderly (Graham et al. 2014).
Acute coronary syndrome (ACS), according to the definition, consists of three cardiac
conditions: ST elevation myocardial infarction (STEMI), non-ST elevation myocar-
dial infarction (NSTEMI), and unstable angina (UA). The combination of NSTEMI
and UA is non-ST elevation acute coronary syndrome (NSTE-ACS). Contrary to
stable coronary artery disease, ACS is an urgent and sometimes a fatal condition
that requires immediate medical treatment. Complete management of ACS involves
multiple aspects, including pre-hospital care, in-hospital care in different settings,
post-hospitalization care, and so on. Limited by the length of this part, we will mainly
elaborate on in-hospital care in PCI-available hospitals.
The American Heart Association/American College of Cardiology (AHA/ACC)
and European Society of Cardiology have published various guidelines based on
clinical evidences. In this part, we will summarize parts of the recommendations
from these guidelines and try to update with new evidences.
Aspiration Thrombectomy
Aspiration thrombectomy is an interventional procedure in which the thrombus inside
a vessel is removed by suction through interventional catheterization techniques. It is
a rapid and an effective way of removing thrombi in thromboembolic occlusions of the
limb arteries below the inguinal ligament (Oguzkurt et al. 2010). The AHA guidelines
stated that manual aspiration thrombectomy is reasonable for patients undergoing
primary PCI (IIa, B). The ESC guidelines also stated routine thrombus aspiration
should be considered (IIa, B). Nevertheless, strong recent evidences suggest against
aspiration thrombectomy. A meta-analysis of 17 trials with 20,960 patients found
aspiration thrombectomy before primary PCI is not associated with any benefit on
clinical endpoints and might increase the risk of stroke (Elgendy et al. 2015). Jolly
et al. (2016) found in a 1-year follow-up of the largest randomized trial of thrombus
aspiration that routine thrombus aspiration during PCI for STEMI did not reduce
long-term clinical outcomes and might be associated with an increase in stroke. Based
on recent evidences, routine aspiration thrombectomy should not be recommended
as treatment strategy for STEMI patients.
Since the publication of the ESC and AHA guidelines on STEMI, there are a
number of new antiplatelet and anticoagulant agents approved for clinical use. Can-
grelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was
tested for PCI (Steg et al. 2013). In a pooled analysis of three large randomized tri-
als that included 24,910 patients, cangrelor was found to have significantly reduced
PCI periprocedural thrombotic complications, although at the expense of increased
bleeding (Lu et al. 2014). A recent evidence from a small-scale trial of 32 patients
showed cangrelor in combination with ticagrelor resulted in consistent and strong
P2Y12 inhibition during and after infusion, which also demonstrated cangrelor may
bridge the gap until oral P2Y12 inhibiters achieve effect in real-world STEMI patients
undergoing primary PCI (Mohammad et al. 2016).
Sarpogrelate, a specific 5HT2-receptor antagonist, is another novel antiplatelet
agent which blocks serotonin-induced platelet aggregation. Yet usage of sarpogrelate
in STEMI is rarely reported. Noh et al. (2016) carried out a retrospective cohort study,
including a total of 93,876 patients undergoing PCI, and found that sarpogrelate-
containing triple antiplatelet therapy demonstrated comparable rates of MACCE
prevention compared to the conventional dual antiplatelet therapy (DAPT) after PCI,
without significantly increasing bleeding risk during the two-year follow-up period.
Further large-scale studies are needed for the evaluation of sarpogrelate.
In contrast to AHA and ESC guidelines on STEMI, both AHA and ESC guidelines on
NSTE-ACS made more detailed recommendations on early management and phar-
macological treatment of NSTE-ACS patients with less emphasis on invasive PCI
recommendations. ACC/AHA guidelines on NSTE-ACS provided an algorithm for
management of patients with definite or likely NSTE-ACS (see Fig. 2.2) (Amsterdam
et al. 2014). As for whether to initiate invasive strategy or the timing of initiating
invasive strategy, ESC guidelines gave a clear recommendation using a flowchart
based on risk criteria grading (see Table 2.3 and Fig. 2.3) (Roffi et al. 2016).
Multivessel PCI
It is recommended in the AHA guidelines that a strategy of multivessel PCI, in
contrast to culprit lesion-only PCI, may be reasonable in patients undergoing coro-
nary revascularization as part of the treatment for NSTE-ACS (IIb, B). It is still
unclear whether multivessel PCI is beneficial to NSTE-ACS patients with multi-
vessel lesions. Jang et al. (2015) performed a meta-analysis of eight observational
studies with 8,425 patients, finding no significant differences in all-cause mortality
and myocardial infarction. However, it is found that multivessel PCI was associated
with a significantly lower rate of repeat revascularization (OR 0.75, 95% CI 0.56–
1.00). It is concluded that multivessel PCI reduced repeat revascularization without
significant benefits in terms of mortality or myocardial infarction at the long-term
follow-up in patients with NSTE-ACS and multivessel coronary disease. Since there
48 S. Jia et al.
Fig. 2.2 Selection of non-ST-elevation acute coronary syndrome (NSTE-ACS) treatment strategy
and timing according to initial risk stratification
Table 2.3 Primary PCI in STEMI (American College of Emergency et al. 2013)
Class of Recommendation Level of Evidence
Ischemic symptoms <12 h I A
Ischemic symptoms <12 h and I B
contraindications to fibrinolytic therapy
irrespective of time delay from FMC (First
Medical Contact)
Cardiogenic shock or acute severe heart I B
failure (HF) irrespective of time delay from
myocardial infarction (MI)
Evidence of ongoing ischemia 12–24 h after IIa B
symptom onset
PCI of a non-infarct artery at the time of III: Harm B
primary PCI in patients without
hemodynamic compromise
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 49
Fig. 2.3 Algorithm for management of patients with definite or likely NSTE-ACS (Worm et al.
2013) (In patients who have been treated with fondaparinux (as upfront therapy) who are under-
going PCI, an additional anticoagulant with anti-IIa activity should be administered at the time
of PCI because of the risk of catheter thrombosis. ASA indicates aspirin; CABG, coronary artery
bypass graft; cath, catheter; COR, Class of Recommendation; DAPT, dual antiplatelet therapy; GPI,
glycoprotein IIb/IIIa inhibitor; LOE, Level of Evidence; NSTE-ACS, non-ST-elevation acute coro-
nary syndrome; PCI, percutaneous coronary intervention; pts, patients; and UFH, unfractionated
heparin)
50 S. Jia et al.
Table 2.4 Primary PCI: indications and procedural aspects (Task Force Members Steg et al. 2012)
Recommendations Classa Levelb
Indications for primary PCI
Primary PCI is the recommended reperfusion therapy over fibrinolysis if I A
performed by an experienced team within 120 min of FMC
Primary PCI is indicated for patients with severe acute heart failure or I B
cardiogenic shock, unless the expected PCI related delay is excessive and the
patient presents early after symptom onset.
Procedural aspects of primary PCI
Stenting is recommended (over balloon angioplasty alone) for primary PCI I A
Primary PCI should be limited to the culprit vessel with the exception of IIa B
cardiogenic shock and persistent ischemia after PCI of the supposed culprit
lesion
If performed by an experienced radial operator, radial access should be IIa B
preferred over femoral access
If the patient has no contraindications to prolonged DAPT (indication for IIa A
oral anticoagulation, or estimated high long-term bleeding risk) and is likely
to be compliant, DES should be preferred over BMS
Routine thrombus aspiration should be considered IIa B
Routine use of distal protection devices is not recommended III C
Routine use of IABP (in patients without shock) is not recommended III A
BMS = bare-metal stent; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; IABP =
intra-aortic balloon pump; PCI = percutaneous coronary intervention
a Class of recommendation
b Level of evidence
is still little new evidence after the publication of both guidelines on NSTE-ACS,
future studies on the efficacy and safety issues remain warranted (Tables 2.4, 2.5).
the immediate post-event period and over the lifetimes of patients. With similar
efficacy and safety level plus better cost-effectiveness, fondaparinux seems to
be a wiser choice over enoxaparin. Nevertheless, according to AHA guidelines,
fondaparinux should not be used as the sole anticoagulant to support PCI in
patients with NSTE-ACS due to an increased risk of catheter thrombosis (III, B)
(Table 2.6).
b. Bivalirudin
Bivalirudin, a specific and reversible direct thrombin inhibitor (DTI), is recom-
mended in both AHA and ESC guidelines to be a useful anticoagulant. Recent
trials and meta-analysis are supportive of guideline recommendations. From the
ACUITY trial that included 13,819 patients of NSTE-ACS treated with an early
invasive strategy, Geisler et al. (2016) found that treatment with bivalirudin alone
significantly reduced major bleeding and improved net clinical outcomes dur-
ing the upstream medical management phase with comparable rates of MACE.
52 S. Jia et al.
Statins
Both guidelines made clear and strong recommendations on statins usage for NSTE-
ACS patients. Besides its lipid-lowering effects, statins have been discovered to have
anti-inflammation and antithrombotic properties as well, which is a possible cause
for its multiple beneficial effects. It is recommended in ESC guidelines to start high-
intensity statin therapy as early as possible, unless contraindicated, and maintain it
long term (I, A). Shehata et al. (2015) found in a small-scale study of 140 patients
that intensive atorvastatin therapy in NSTE-ACS patients is associated with lower
hs-CRP levels and with higher left ventricular ejection fraction after 6 months, with
no significant impact on adverse cardiac events. Based on current knowledge, it is
necessary to comply with the guidelines recommendations on statins.
54 S. Jia et al.
Vasospastic angina
In terms of vasospastic angina, the ESC guidelines recommended that calcium chan-
nel blockers and nitrates should be considered and beta-blockers must be avoided
(IIa, B) (Roffi et al. 2016). A review on pharmacotherapy of vasospastic angina con-
firmed this line of recommendation, saying that CCBs are recommended as first-line
agents for treatment and prevention of vasospastic angina, and that some evidence has
shown the benefit of combined non-DHP and DHP CCBs therapy (Harris et al. 2016).
Similar recommendations corresponding to the ESC guidelines are also made in the
review, with additional introduction of the effects of statins and alpha1-adrenergic
antagonists. Further evidences are needed for clinical application of these new agents.
Conclusion
Last but not the least, it’s always important to remember that management of both
STEMI and NSTE-ACS is an integrated body of multiple team works. Due to the
length of this part, we chose to only focus on the most effective and core parts of ACS
treatment, percutaneous coronary intervention, and protective medications. A com-
plete management of ACS involves timely and accurate diagnosis, making strategic
decisions based on risk assessment, pharmacological treatment or revascularization,
early and late hospital care, post-hospital discharge care, and so on. Failure of any
element above is detrimental to an ACS condition. Although PCI is widely available
around the world nowadays, there are still some medical centers where thrombolysis
using fibrinolytic agents is still favorable, and there are recommendations accord-
ingly in the guidelines. When it is contraindicated to perform PCI, thrombolysis is
once again essential for revascularization of occluded arteries.
The AHA and ESC guidelines on STEMI and NSTE-ACS provided in-depth
up-to-date recommendations to the whole procedure of ACS management, and also
pointed out evidence gaps that can be filled with later studies or new methods of
treatment worth developing in the near future. These guidelines are carefully written
and reviewed by experts worldwide, and are indeed worth referring to for most
medical practitioners.
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 55
with daily life silent ischemia due to CAD, atenolol reduced daily life ischemia
and was associated with reduced risk for adverse outcome at 1-year follow-up
(Shu et al. 2012).
2. A meta-analysis reviewed 26 trials up to 2010 and concluded that the therapy of
beta-blockers has significantly decreased all-cause mortality comparing with no
treatment (OR 0.40, 95% CI 0.20–0.79), but no statistical difference in all-cause
mortality when compared with neither placebo (OR 0.92, 95% CI 0.62–1.38) nor
calcium channel blocker (OR 0.84, 95% CI 0.49–1.44). Similar negative results
were reported with regard to fatal and non-fatal acute myocardial infarction,
revascularization, and quality of life (Ardissino et al. 1995).
In view of their multiple benefits (anti-ischemic, antihypertension, reinfarction
prevention), it is reasonable to consider beta-blockers over CCBs as the initial choice
in treating patients with SCAD. Nevertheless, it is reminded that the first-class rec-
ommendations in guidelines mostly came from trials performed in selective patients
with former myocardial infarction or heart failure. It still lacks clear-cut proof from
large randomized clinical trials concerning the efficacy in SCAD.
Calcium Antagonists
Long-Acting Nitrates
The effect of nitrates results from the vasodilator effect (both evident in systemic and
coronary vessels) on ventricular preload reduction, which in turn reduces myocardial
wall tension and O2 requirements. Furthermore, nitroglycerin causes redistribution
of blood flow from normally perfused segments to ischemic areas due to increasing
collateral blood flow and lowering of LV diastolic pressure. Comparing with BB or
CCB, there is no significant difference in the controlling of weekly angina onsets,
time to ST-segment depression, total exercise time, and the frequency of sublingual
nitroglycerin use.
There is no available evidence from RCTs about their influence on CAD outcomes.
So, guidelines recommend long-acting nitrates be used for controlling ischemic
occurrences when BB/CCB is contraindicated, intolerated or when it’s necessary
to add nitrates with them (Fihn et al. 2012).
Ranolazine
Ranolazine acts as an inhibitor of late inward sodium current, then prevents Ca2+ over-
load by inhibiting the sodium-dependent calcium channel, thus reducing ventricular
diastolic tension and O2 consumption.
(1) There is some evidence of its anti-ischemic work from original small-scale
RCTs. The ERICA trial identified its work on significantly reducing angina
episodes (2.88 ± 0.19 vs 3.31 ± 0.22, p = 0.028) and nitroglycerin consumption
(2.03 ± 0.20 vs 2.68 ± 0.22, p = 0.014) (Chaitman 2004). Dose-related increase
in improvement of exercise performance and time to ST-segment depression was
observed in the MARISA (Monotherapy Assessment of Ranolazine In Stable
58 S. Jia et al.
Angina) trial (Kosiborod et al. 2013). Besides, the TERISA trial found it espe-
cially significant for patients with high HbA1c to reduce the angina episodes
(Melloni and Newby 2008).
(2) The MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less
Ischemia in Non-ST Elevation Acute Coronary Syndromes-Thrombolysis in
Myocardial Infarction) trial designed to examine the long-term impact and
safety of ranolazine in treating post-MI patients, confirmed its noticeable bene-
fits of decreasing recurrent ischemia, but failed to find any difference in primary
and major secondary endpoint (cardiovascular death, MI, or severe recurrent
ischemia) in comparison with placebo (Vitale et al. 2012).
Trimetazidine
Ivabradine
This drug specifically inhibits sinus node If current, leading to lower heart rate and
then decreasing oxygen demand without any effect on other aspects like cardiac
function or blood pressure.
(1) Clinical trials have offered proof about the efficacy of ivabradine to attenuate
ischemic symptom, reduce nitroglycerine use, and improve exercise tolerance
during a stress test. In comparison with atenolol, ivabradine showed similar
potentials of improving exercise capacity and reducing angina episodes.
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 59
2.3.2 Revascularization
With great advances in technology and adjuvant medicine for periprocedural and
long-term use, more CAD patients with various lesions are eligible for revascular-
ization (PCI and CABG). Revascularization is conducted in patients for two simi-
lar purposes: symptom relief and events prevention. Albeit elaborate indications in
guidelines, practical management must take individual characteristics, preference
and compliance, and so on into consideration.
2.3.2.1 CABG
The merit of CABG in symptom attenuation has been revealed in several RCTs. The
superiority of CABG to medical therapy in the management of specific subsets of
CAD was firmly established in a meta-analysis of seven RCTs, which is still the
major foundation for contemporary CABG. It demonstrated a survival benefit of
CABG in patients with LM or three-vessel CAD, particularly when the proximal
LAD coronary artery was involved (Shaw et al. 2008).
2.3.2.2 PCI
Still, there remains lot of debates over the necessity, the feasibility, and the efficacy
of revascularization.
1. In the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggres-
sive Drug Evaluation), PCI was at vantage of more freedom from angina at
1-year follow-up but was equivalent by 5 years. In the substudy of this trial,
PCI manifested a greater reduction in myocardial ischemia (−2.7 vs −0.5%, P <
0.0001) than medical therapy, and more patients exhibited a relevant reduction in
ischemia (33 vs 19%, P = 0.0004), particularly among those with moderate-to-
severe ischemia (78 vs 52%, P = 0.007) (Hueb et al. 2004). In contrast, MASS
II reported that for patients with multivessel CAD, after one-year follow-up, PCI
was not superior to medical treatment owing to a higher rate of short-term events
and an increased need for additional revascularization (13.3 vs 8.3%) (Trikalinos
et al. 2009).
2. To date, few RCT or meta-analysis has proved survival improvement with appli-
cation of PCI in SCAD. In the COURAGE trial, among patients with significant
60 S. Jia et al.
one-, two-, and three-vessel CAD without left main stem (LMS) involved, there
was no significant difference in the composite endpoint of death, stroke, or non-
fatal MI between OMT and OMT plus PCI at a median follow-up of 4.6 years
(HR for the PCI group 1.05, 95% CI 0.87–1.27, P = 0.62). An overview of 61
RCTs enrolling over 25,000 patients tested PCI for the treatment of non-acute
CAD. While BMS and DES produced detectable reduction in the need for revas-
cularization, no avail has found in the hard outcomes of death or MI, compared
to medical therapy (De Bruyne et al. 2012). Notably, a recent RCT in patients
with SCAD and functionally significant stenosis (FFR <0.80) proposed the com-
petitive prognostic profit of FFR-guided PCI. A significant difference in primary
endpoint event (4.3% in the PCI group vs 12.7% in the medical therapy group,
hazard ratio 0.32; 95% CI 0.19–0.53; P < 0.001) was observed, driven by a lower
rate of urgent revascularization in the PCI group than in the medical therapy
group (1.6 vs 11.1%; hazard ratio 0.13; 95% CI 0.06–0.30; P < 0.001) (Cohen
et al. 2014).
Aspirin
The SAPAT (Swedish Angina Pectoris Aspirin Trial), initially prospectively exam-
ined low-dose aspirin in treating patients with stable angina, reported that, in contrast
with placebo, aspirin had a significant reduction in primary outcome events of MI
and sudden death (34, 95% CI 24–49%, p = 0.003) and secondary outcome events
(vascular events, vascular death, all-cause mortality, stroke) decreased ranging from
62 S. Jia et al.
22 to 32% (Berger et al. 2008). A meta-analysis assessed the efficacy and risk of
aspirin in treating stable CAD. It was found that low-dose aspirin was associated
with a 21% reduction in the risk of overall cardiovascular events (non-fatal MI, non-
fatal stroke, and cardiovascular death) (95% CI 0.72–0.88), and similar advantage
also worked in each single event, respectively, though with an increase in severe
bleeding (odds ratio 2.2, 95% CI, 1.4–3.4) (Lancet 1996).
P2Y12 Inhibitors
Formal data from the CAPRIE trial has showed the equivalence of clopidogrel and
aspirin in preventing CV events among patients at ischemic risks (Lemesle et al.
2016). A latest prospective registry study (the CONORO study) pointed out that
clopidogrel tended to be used in higher-risk patients with SCAD compared with
aspirin: composite of cardiovascular death, myocardial infarction or stroke at 5.8
versus 4.2% (p = 0.056). However, after propensity score matching, comparable
event rates were observed between the groups (5.9% in clopidogrel vs 4.4% in aspirin
respectively, p = 0.207) (Squizzato 2011).
To date, clinical trials testing prasugrel, or ticagrelor comparing with aspirin in
treatment of SCAD have not been conducted. Thus only clopidogrel is chosen as the
second-line therapy in patients with aspirin-intolerant patients or at high ischemic
risks.
A study aiming at atrial fibrillation patients with SCAD showed that the addition of
antiplatelet therapy to VKA therapy was not reducing the risk of recurrent CV events
or thromboembolism, but significantly adding more risk of bleeding (Yusuf 2000).
With little information on this topic, combination therapy of antiplatelet therapy and
oral VKA anticoagulation in certain risky patients calls for further investigation and
prudent reassessment.
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 63
2.3.3.2 ACEI/ARB
ACEI
ARB
The LIFE study compares losartan with atenolol in patients with hypertension and
LV hypertrophy. There was a significant reduction of stroke (5 vs 7%; RR 0.87; 95%
CI, 0.63–0.89) and composite primary endpoint of death, MI, or stroke in the losartan
group (11 vs 13%; RR 0.87; 95% CI, 0.77–0.98). Equivalent result was also found in
the subgroup of diabetic patients (Yusuf et al. 2008). In the VALUE study, there was
no difference between valsartan and amlodipine in the primary combined endpoint
of cardiovascular mortality and morbidity except for a 19% relative increase in MI
(p = 0.02) and a 15% increase in stroke (p = 0.08) in valsartan arm (Lemesle et al.
2017).
2. Mixed results of the comparison between ARB and ACEI have been presented.
The ONTARGET study enrolling patients with stable IHD and preserved LV function
provided evidence that ARBs are equal to ACE inhibitors in the prevention of clinical
endpoints (RR, 1.01; 95% CI, 0.94–1.09), like cardiovascular death, myocardial
infarction, stroke, or hospitalization for heart failure, but there was no additive benefit
of combination therapy (RR, 0.99; 95% CI, 0.92–1.07) (Baigent 2010).
However, by analyzing different trials and groups of patients, meta-analyses
showed controversial conclusions. Some stressed that ACEIs have favorable effects
on all-cause mortality, non-fatal MI, and stroke, while ARBs are only associated
with reduction of stroke. Others reputed that ARBs have the equivalent potential
for reducing the risk of all-cause death, new-onset HF, stroke, and IHD. The latest
result from a prospective registry on stable CAD (the CORONOR study) found that
a significant proportion of stable CAD patients are treated with ARB rather than with
ACEI in modern practice. ARB shows similar outcomes of the combined endpoint
64 S. Jia et al.
2.3.3.3 Beta-Blockers
Until now, there is no evidence from large RCTs, specifically in patients with SCAD,
examining the benefit of lifestyle modifications, including regular physical activity,
healthy diet, and weight loss, but overall results in other populations (like people
with no CVD or post-MI patients) show consistent results. So these strategies are
considered to be positive when applied to patients with SCAD.
2.3.4.2 Cigarette
Still, few large RCTs have been performed in SCAD, but formal results strongly
suggest that cigarette cessation is an effective strategy of secondary prevention.
2.3.4.3 Dyslipidemia
Patients with SCAD are supposed to take good administration of serum lipid level,
starting with both diet and lifestyle adjustment. Prognosis can be further improved
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 65
2.3.4.4 Hypertension
BP Goal
Of what impact BP reduction acts on the balance of O2 demand and supply is quite
intricate. And whether the lower BP goal is appropriate for the treatment of CAD is
still a heated debate.
The ACCORD trial compared two different BP goals in diabetic patients at high
CVD risks. Intensive therapy (targeting a systolic pressure of <120 mmHg) failed
to reduce the primary composite outcome (hazard ratio 0.88; 95% CI 0.73–1.06; P
= 0.20) and overall mortality (hazard ratio, 1.07; 95% CI, 0.85–1.35; P = 0.55), as
compared with standard therapy (targeting a systolic pressure of <140 mmHg), while
the serious adverse effect of medicine occurred significantly more in the intensive
treatment (p < 0.001) (Lima et al. 2013). Relevant committees reconsidered BP
control as secondary prevention of diabetes and recommended a systolic pressure of
<140 mmHg in replacement (Camafort 2011).
Based on considerable amount of the statistics from epidemiological stud-
ies, observational, or interventional trials, a commonly admitted BP goal is
<140/90 mmHg in general, <140/80 mmHg in patients with DM, and <130/80 mmHg
in those with CKD (Camafort 2011).
2.3.4.5 Diabetes
Adverse Effects
From the MASS II study, patients with stable multivessel CAD and preserved left
ventricular ejection fraction, all of the three therapeutic regimens (medical therapy,
CABG, and PCI) had higher rates of overall mortality (32.3 vs 23.2%, p = 0.024)
and cardiac-related deaths (19.4 vs 12.7%, p = 0.031) among diabetic than those in
non-diabetic patients (Frasuresmith and Lespérance 2008).
Glucose Goal
References
ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes
mellitus. N Engl J Med 362(17): 1575
American College of Emergency P, Society for Cardiovascular A, Interventions et al (2013)
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of
the American College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol 61(4): e78–140
American Heart Association Nutrition C, Lichtenstein AH, Appel LJ, et al (2006) Diet and lifestyle
recommendations revision 2006: a scientific statement from the American Heart Association
Nutrition Committee. Circulation 114(1): 82–96
68 S. Jia et al.
Amsterdam EA, Wenger NK, Brindis RG et al (2014) 2014 AHA/ACC guideline for the management
of patients with non-ST-elevation acute coronary syndromes: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol
64(24):e139–e228
Ardissino D et al (1995) Selection of medical treatment in stable angina pectoris: results of the
International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 25(7):1516–1521
Armaganijan LV, Alexander KP, Huang Z et al (2016) Effect of age on efficacy and safety of
vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from
the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome
(TRACER) trial. Am Heart J 178:176–184
Auffret V, Leurent G, Boulmier D et al (2016) Efficacy and safety of prehospital administration of
unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous
coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI
registry. Arch Cardiovasc Dis 109(12):696–707
Baigent C et al (2010) Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of
more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants
in 26 randomised trials. Lancet. 376(9753): 1670–1681
Bavishi C, Panwar S, Messerli FH, Bangalore S (2015) Meta-analysis of comparison of the newer
Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation
acute coronary syndrome. Am J Cardiol 116(5):809–817
Berger JS, Brown DL, Becker RC (2008) Low-dose aspirin in patients with stable cardiovascular
disease: a meta-analysis. Am J Med 121(1):43–49
Bhupathiraju SN, Wedick NM, Pan A et al (2013) Quantity and variety in fruit and vegetable intake
and risk of coronary heart disease. Am J Clin Nutr 98(6):1514–1523
Blumenthal JA et al (2003) Depression as a risk factor for mortality after coronary artery bypass
surgery. Lancet 55(2):604
Brener S et al (2006) Antihypertensive therapy and regression of coronary artery disease: insights
from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis
(CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular.
Am Heart J 152(6):1059–1063
Burg MM, Benedetto MC, Soufer R (2003) Depressive symptoms and mortality two years after
coronary artery bypass graft surgery (CABG) in men. Psychosom Med 65(4):508
Camafort M et al (2011) Glucose control and outcome in patients with stable diabetes and previous
coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA registry. Diabet
Med 28(1): 73–80
Chaitman BR et al (2004) Anti-ischemic effects and long-term survival during ranolazine
monotherapy in patients with chronic severe angina. J Am Coll Card 43(8): 1375–1382
Chazov EI et al (2005) Trimetazidine in Angina Combination Therapy–the TACT study: trimetazi-
dine versus conventional treatment in patients with stable angina pectoris in a randomized,
placebo-controlled, multicenter study. Am J Ther 12(1):35
Chen H et al (2013) Relationship of depression, stress and endothelial function in stable angina
patients. Physiol Behav 118(4):152–158
Chetboul V, Reynolds BS, Trehiou-Sechi E et al (2014) Cardiovascular effects of dietary salt intake
in aged healthy cats: a 2-year prospective randomized, blinded, and controlled study. PLoS ONE
9(6):e97862
Chow CK et al (2010) Association of diet, exercise, and smoking modification with risk of early
cardiovascular events after acute coronary syndromes. Circulation 121(6):750
Cohen DJ et al (2014) Cost-effectiveness of percutaneous coronary intervention with drug-eluting
stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final
results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac
Surgery (SYNTAX) trial. Circulation 130(14):1146–1157
Critchley JA, Capewell S (2003) Mortality risk reduction associated with smoking cessation in
patients with coronary heart disease: a systematic review. JAMA J Am Med Assoc 290(1):86–97
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 69
Dalmeijer GW, Struijk EA, van der Schouw YT et al (2013) Dairy intake and coronary heart disease
or stroke—a population-based cohort study. Int J Cardiol 167(3):925–929
De Bruyne B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable
coronary disease. N Engl J Med 367(11):991–1001
Diercks DB et al (2006) The obesity paradox in non-ST-segment elevation acute coronary syn-
dromes: results from the can rapid risk stratification of unstable angina patients suppress adverse
outcomes with early implementation of the American College of Cardiology/American Heart
Association guidelines quality improvement initiative. Am Heart J 152(1):140–148
Elgendy IY, Huo T, Bhatt DL, Bavry AA (2015) Is aspiration thrombectomy beneficial in patients
undergoing primary percutaneous coronary intervention? Meta-analysis of randomized trials.
Circ Cardiovasc Interv 8(7):e002258
Farag M, Gorog DA, Prasad A, Srinivasan M (2015) Bivalirudin versus unfractionated heparin:
a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary
syndromes. Open Heart 2(1):e000258
Farkouh ME et al (2012) Strategies for multivessel revascularization in patients with diabetes. N
Engl J Med 367(25):2375–2384
Fihn SD et al (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis
and Management of Patients With Stable Ischemic Heart Disease A Report of the American Col-
lege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,
and the A. Circulation 60(24):2564–2603
Fox KM et al (1996) The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol,
nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608
patients with stable angina. The TIBET Study Group. Eur Heart J 17(1): 96–103
Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with
stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial
(the EUROPA study). Lancet 362(9386):782–788
Fox K et al (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular
systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet
372(9641):807–816
Frasuresmith N, Lespérance F (2003) Depression and other psychological risks following
myocardial infarction. Arch Gen Psychiatry 60(6):627–636
Frasuresmith N, Lespérance F (2008) Depression and anxiety as predictors of 2-year cardiac events
in patients with stable coronary artery disease. Arch Gen Psychiatry 65(1):62
Frasuresmith N, Lespérance F, Talajic M (1993) Depression following myocardial infarction. Impact
on 6-month survival. JAMA J Am Med Assoc 270(15): 1819
Gan Y, Tong X, Li L et al (2015) Consumption of fruit and vegetable and risk of coronary heart
disease: a meta-analysis of prospective cohort studies. Int J Cardiol 183:129–137
Geisler T, Droppa M, Gawaz M et al (2016) Impact of anticoagulation regimen prior to revascu-
larization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY
trial. Catheter Cardiovasc Interv 88(2):174–181
Glover M, Zuber AM, O’Shaughnessy KM (2011) Hypertension, dietary salt intake, and the role
of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc Ther 29(1):68–76
Graham DJ et al (2014) Cardiovascular and mortality risks in older Medicare patients treated with
varenicline or bupropion for smoking cessation: an observational cohort study. Pharmacoepi-
demiol Drug Saf 23(11):1205–1212
Grandi SM, Shimony A, Eisenberg MJ (2013) Bupropion for smoking cessation in patients hospital-
ized with cardiovascular disease: a systematic review and meta-analysis of randomized controlled
trials. Can J Cardiol 29(12):1704–1711
Guarini G et al (2016) Pharmacological agents targeting myocardial metabolism for the management
of chronic stable angina: an update. Cardiovasc Drugs Ther 30(4):379–391
Gunton J, Hartshorne T, Langrish J, Chuang A, Chew D (2016) P2Y12 inhibitor pre-treatment in
non-ST-elevation acute coronary syndrome: a decision-analytic model. J Clin Med 5(8)
70 S. Jia et al.
Gurfinkel EP et al (2004) Flu vaccination in acute coronary syndromes and planned percutaneous
coronary interventions (FLUVACS) Study. Eur Heart J 25(1):25–31
Harris KA, Kris-Etherton PM (2010) Effects of whole grains on coronary heart disease risk. Curr
Atheroscler Rep 12(6):368–376
Harris JR, Hale GM, Dasari TW, Schwier NC (2016) Pharmacotherapy of vasospastic angina. J
Cardiovasc Pharmacol Ther 21(5):439–451
Hermanson B et al (1988) Beneficial six-year outcome of smoking cessation in older men and
women with coronary artery disease. Results from the CASS registry. N Engl J Med 319(21):
1365
Hueb W et al (2004) The medicine, angioplasty, or surgery study (MASS-II): a randomized, con-
trolled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year
results. J Am Coll Cardiol 43(10):1743–1751
Hueb W et al (2007) Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS
II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary
artery disease. Circulation 115(9):1082–1089
Hueb W et al (2010) Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study
(MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel
coronary artery disease. Circulation 122(10):949–957
Jang JS, Jin HY, Seo JS et al (2015) Meta-analysis of multivessel versus culprit-only percutaneous
coronary intervention in patients with non-ST-segment elevation acute coronary syndrome and
multivessel coronary disease. Am J Cardiol 115(8):1027–1032
Janssen V et al (2012) Lifestyle modification programmes for patients with coronary heart dis-
ease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol
20(4):620–640
Jolly SS, Cairns JA, Yusuf S et al (2016) Outcomes after thrombus aspiration for ST elevation
myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet
387(10014):127–135
Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland
M, Antonuccio DO, Hartman N, McGovern PG (1996) The safety of transdermal nicotine as an
aid to smoking cessation in patients with cardiac disease. NEJM N Engl J Med 335(24): 1792
Julius S et al (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with reg-
imens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363(9426):2022–
2031
Juul-Moller S et al (1992) Double-blind trial of aspirin in primary prevention of myocardial infarc-
tion in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial
(SAPAT) Group. Lancet 340(8833): 1421–1425
Kolh P et al (2014) ESC/EACTS guidelines on myocardial revascularization: The Task Force on
Myocardial Revascularization of the European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of.
Eur J Cardio-Thoracic Surg 72(4): 1253–1379
Kosiborod M et al (2013) Evaluation of ranolazine in patients with type 2 diabetes mellitus
and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Dia-
betes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol
61(20):2038–2045
Krauss RM, Eckel RH, Howard B et al (2000) AHA dietary guidelines: revision 2000: a statement
for healthcare professionals from the Nutrition Committee of the American Heart Association.
Stroke 31(11):2751–2766
Lamberts M et al (2014) Antiplatelet therapy for stable coronary artery disease in atrial fibrillation
patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129(15):1577–1585
Lancet T (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of
ischaemic events (CAPRIE). Lancet 348(9038):1329
Lavie CJ, Milani RV, Ventura HO (2009) Obesity and cardiovascular disease: risk factor, paradox,
and impact of weight loss. J Am Coll Cardiol 53(21):1925–1932
2 Evidence in Guidelines for Treatment of Coronary Artery Disease 71
Lemesle G et al (2016) Clopidogrel use as single antiplatelet therapy in outpatients with stable coro-
nary artery disease: prevalence, correlates and association with prognosis (from the CORONOR
Study). Cardiology 134(1):11–18
Lemesle G et al (2017) Angiotensin II receptor blockers versus angiotensin-converting enzyme
inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic
impact (from the CORONOR study). J Cardiol 69(3):542–547
Li F, Li Y, Wang L (2013) The impact of anxiety and depression on prognosis in patients with
coronary heart disease after percutaneous coronary intervention. China J Heal Psychol
Lima EG et al (2013) Impact of diabetes on 10-year outcomes of patients with multivessel coronary
artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial. Am Heart J
166(2):250–257
Lindholm LH et al (2002) Cardiovascular morbidity and mortality in patients with diabetes in the
Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial
against atenolol. Lancet 359(9311):1004–1010
Lu Y, Hajifathalian K et al. (2014) Metabolic mediators of the effects of body-mass index, over-
weight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective
cohorts with 1.8 million participants. Lancet 383(9921): 970–983. Global burden of metabolic
risk factors for chronic diseases C
McGuire S, U.S. Department of Agriculture and U.S. Department of Health and Human Ser-
vices, Dietary Guidelines for Americans (2010). 7th Edition, Washington, DC: U.S. Government
Printing Office, January 2011. Adv Nutr 2(3): 293–294 (2011)
Mcrobbie H, Hajek P (2001) Nicotine replacement therapy in patients with cardiovascular disease:
guidelines for health professionals. Addiction 96(11):1547–1551
Melloni C, Newby LK (2008) Metabolic efficiency with ranolazine for less ischemia in non-ST
elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther
6(1):9–16
Members ATF et al (2012) ESC Guidelines for the management of acute myocardial infarction in
patients presenting with ST-segment elevation. Eur Heart J 33(20):2569–2619
Mohammad MA, Andell P, Koul S et al (2016) Cangrelor in combination with ticagrelor pro-
vides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary
intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets:
1–3
Nagumo S, Wakabayashi K, Tsujiuchi M et al (2016) Clinical impact of undersized- versus
oversized-stenting approaches in ST-elevation myocardial infarction. Cardiovasc Revasculariza-
tion Med Incl Mol Interv 17(6):362–368
Noh Y, Lee J, Shin S et al (2016) Antiplatelet therapy of cilostazol or sarpogrelate with aspirin
and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using the
Korean National Health Insurance Claim Database. PLoS ONE 11(3):e0150475
Oguzkurt L, Ozkan U, Gumus B, Coskun I, Koca N, Gulcan O (2010) Percutaneous aspiration
thrombectomy in the treatment of lower extremity thromboembolic occlusions. Diagn Interv
Radiol 16(1):79–83
Peiyuan H, Jingang Y, Haiyan X et al (2016) The comparison of the outcomes between primary
PCI, fibrinolysis, and no reperfusion in patients >/= 75 years old with ST-segment elevation
myocardial infarction: results from the Chinese Acute Myocardial Infarction (CAMI) registry.
PLoS ONE 11(11):e0165672
Pepine CJ et al (1994) Effects of treatment on outcome in mildly symptomatic patients with ischemia
during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 90(2): 762–768
Pepine CJ et al (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment
strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study
(INVEST): a randomized controlled trial. JAMA J Am Med Assoc 13(2): 19–20
Pfisterer M (2004) Long-term outcome in elderly patients with chronic angina managed invasively
versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive
versus Medical therapy in Elderly patients (TIME). Circulation 110(10):1213–1218
72 S. Jia et al.
Worm N, Belz GG, Stein-Hammer C (2013) Moderate wine consumption and prevention of coronary
heart disease. Dtsch Med Wochenschr 138(51–52):2653–2657
Yusuf S et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovas-
cular events in high-risk patients. N Engl J Med 342(3): 145–153. The Heart Outcomes Prevention
Evaluation Study Investigators
Yusuf S et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N
Engl J Med 358(15):1547–1559
Zhao XM, Gao CY, Chu YJ et al (2015) Fondaparinux vs. enoxaparin in patients with non-ST ele-
vation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention
and tirofiban: an exploratory study in China. J Clin Pharm Ther
Zong G, Gao A, Hu FB, Sun Q (2016) Whole grain intake and mortality from all causes, car-
diovascular disease, and cancer: a meta-analysis of prospective cohort studies. Circulation
133(24):2370–2380
Chapter 3
Revascularization for Coronary Artery
Disease: Principle and Challenges
Since the pathophysiology of coronary artery disease (CAD) was first established
in the 1870s that impaired blood supply and caused the myocardial infarction
(Diodato and Chedrawy 2014), cardiologists had always been striving for approaches
for reconstructing coronary blood supply, which was later known as coronary
revascularization, to radically resolve the problem.
In 1964, the first coronary artery bypass grafting (CABG) was performed, and
13 years later, percutaneous coronary intervention (PCI) was first available for
myocardial revascularization. After decades of continuous advances, both proce-
dures have become conventional therapies for CAD, with over 310,000 CABGs and
1.4 million catheterizations were performed in the United States in 2001 (Riley et al.
2011). In this article, we will introduce the approaches for revascularization and
future challenges.
fibrinolysis. PCI was also recommended in patients with onset of symptom more
than 12 h and the presence of continuing ischemia, life-threatening arrhythmias,
pain, and electrocardiography changes. In patients with severe acute heart failure or
cardiogenic shock, PCI is indicated no matter time delay.
3.2 Fibrinolysis
Thrombus in coronary arteries occludes the vessel, arrests blood flow, causes
ischemic in myocardium, and provokes acute coronary syndrome. Targeting offend-
ing thrombus, thrombolytic therapy is an extensively used therapy for patient with
acute ST-elevation (Q wave) myocardial infarction (STEMI), especially for those
patients unavailable to PCI in 120 min.
Intravenous infusion of fibrinolytic drugs, commonly plasminogen activators, is
utilized to activate the blood fibrinolytic system (Chapin and Hajjar 2015). These
agents are highly specific to their substrate plasminogen, which was converted to
active enzyme plasmin (Collen and Lijnen 2005). Free plasmin in the blood is very
rapidly inactivated by α2 -antiplasmin, but plasmin generated at the fibrin surface is
partially protected from inactivation (Collen et al. 1538).
Patients with the following criteria are eligible for fibrinolytic therapy: (1) diagnosed
of new developed myocardial infarction with confirmed symptoms and evidences;
(2) cannot timely receive PCI for revascularization. Fibrinolytic therapy reduces the
risk of mortality in patients with acute STEMI by 15–30%, as compared with placebo
group and thus should be considered for all eligible patients, especially when PCI is
not timely available. Early fibrinolytic therapy is recommended, better in 3 h after
the outbreak of chest pain (Kolh and Windecker 2014).
Diseases with high risk of severe hemorrhage are absolute contraindications to
fibrinolytic therapy that include previous intracranial hemorrhage (ICH), known
structural cerebral vascular lesion, known malignant intracranial neoplasm, ischemic
stroke within three months, suspected aortic dissection, active bleeding or bleeding
diathesis, significant closed-head or facial trauma within three months, and major
trauma or surgery or prolonged cardiopulmonary (>10 min) in less than 2 weeks.
Important relative contraindications include: hypertension with systolic blood
pressure over 180 mmHg (Gore et al. 1995; Aylward et al. 1996); ischemic stroke in
more than three months previously (Tanne et al. 1998); internal bleeding in the last
2 weeks; noncompressible vascular puncture; anaphylactic reactions to fibrinolytic
78 D. Gu et al.
agents; prolonged cardiopulmonary (>10 min) in less than 3 weeks; pregnancy; active
peptic ulcer; and current use of anticoagulant.
After decades of development, the index list of fibrinolytic agents has increased
significantly and tends to reduce the risk of adverse events and increase the safety.
Streptokinase is the first generation of fibrinolytic agent. Randomized trials have
demonstrated that streptokinase reduced in-hospital and short-term mortality (Fran-
zosi et al. 1998; Baigent et al. 1998). However, this early used agent was found
to be associated with several adverse effects. Streptokinase is produced by beta-
hemolytic streptococcus (Anderson and Willerson 1993; Marder and Sherry 1988)
and is actually an antigenic that causes allergic reactions, especially under repeated
administrations. Other events include hypotension and bleeding at puncture site. Risk
of stroke is much lower but can cause catastrophic outcomes (GUSTO investigators
1993). Fibrinokinase is the other type of fibrinolytic agents (Astrup and Permin
1947), including tissue-type plasminogen activator (t-PA) (Rijken et al. 1979, 1980)
and single-chain urokinase-type plasminogen activator (scu-PA or pro-urokinase).
In the multisites randomized streptokinase-controlled GUSTO trial enrolling 41,021
patients with myocardial infarction, t-PA reduced 14% (95% confidence interval,
5.9–21.3%) of mortality (Investigators 1993). To date, t-PA is used worldwide in
about 300,000 AMI patients every year, and has become a lifesaving drug for the
treatment of evolving acute myocardial infarction and other thromboembolic diseases
(Collen et al. 1538). Scu-PA is another agent for thrombolysis, which contributed to
higher patency rate and reduced risk of complications (Meyer 1989; Spiecker et al.
1999; Bar et al. 1997; Tebbe et al. 1995; Zarich et al. 1995; del Zoppo et al. 1998;
Furlan and Abou-Chebl 2002).
The third-generation fibrinolytic agents include recombinant plasminogen acti-
vator (r-PA), which is a nonglycosylated deletion mutant of wild-type recombinant
tissue-type plasminogen activator (t-PA) (Wu et al. 1990). Early trials have demon-
strated that r-PA has a higher rate of TIMI grade III flow at 60 and 90 min compared
with t-PA. It was also associated with a reduced need for additional coronary inter-
ventions early after thrombolytic procedures. However, r-PA was not shown to get
more benefit in either 35-day mortality or the overall incidence of TIMI grade III
flow in these early trials (Bode et al. 1996; Smalling et al. 1995). Trials with much
higher statistics power were conducted to compare the safety and effect of r-PA with
other fibrinolytic agents.
GUSTO III trial compared r-PA with t-PA in 15,059 patients and showed no
significant difference between the two drugs in the rate of mortality and stroke. There
was no significant difference between r-PA and t-PA in mortality at one year (11.2 vs.
11.1%) (Topol et al. 2000). In INJECT trial, r-PA was compared with streptokinase in
the treatment of acute MI (Wilcox 1995), and was shown to be equivalent to standard
streptokinase in 35-day mortality, recurrent MI, in-hospital stroke rates, and major
3 Revascularization for Coronary Artery Disease … 79
bleeding events. T-PA was also associated with reduced risk of cardiogenic shock or
hypotension and heart failure.
3.2.3 Complications
Bleeding and hemorrhagic stroke are two primary complications of all fibrinolytic
agents, which raise concerns about risk of harm overwhelming benefits.
3.2.3.1 Bleeding
In GUSTO-I trial, 11.4% of the patients treated by streptokinase and t-PA had mod-
erate bleeding, defined by the need for transfusion without influencing hemody-
namic status or a need for interventions, while 1.8% had severe bleeding, defined
by substantial hemodynamic compromise that required intervention or treatment
(Berkowitz et al. 1997). Risk factors for bleeding include increased age, lighter
weight, female sex, African ancestry, and experiencing invasive procedures. Bleed-
ing also increases the risk of nonhemorrhagic adverse events, and accordingly is
associated with increased length of hospital stay and mortality (Berkowitz et al.
1997).
3.2.3.2 Stroke
Percutaneous coronary intervention (PCI) has become the most frequently performed
therapeutic procedure in medicine. Balloon angioplasty provided a nonsurgical revas-
cularization alternative to CABG, but was limited by acute arterial recoil, dissections,
and restenosis. Coronary stents were developed to prevent abrupt artery closure fol-
lowing balloon angioplasty. Bare metal stents (BMS) improved procedural safety and
80 D. Gu et al.
efficacy, however, was associated with arterial injury and elicited neointimal hyper-
plasia, leading to restenosis and adverse consequences. Drug-eluting stent (DES)
was designed to decrease neointimal hyperplasia and reduced the rate of restenosis.
In DES, metallic stent is coated with polymer and antiproliferative agents. The con-
trolled local release of agents has reduced the local proliferative healing response
and consistently reduced the risk of restenosis. Randomized trials and large registry
studies have reported that DES significantly reduced the risk of repeat revascular-
ization. In a meta-analysis involving 38 trials and 18,000 patients, early generation
of DES significantly decreased the rate of repeat revascularization. In a large ran-
domized trial, DES reduced the risk of stent thrombosis, repeat revascularization,
and myocardial infarction. As a result, stenting has become the standard of care for
PCIs, and DES is placed in most patients.
Currently DESs have the same general components, which include stent platform,
polymer, and antiproliferative agents. The difference mainly exists in the biologic
characteristics and antiproliferative effects of coating agents.
The first commercially available DESs include the sirolimus-eluting stent and
paclitaxel-eluting stent, and are now mostly replaced by second-generation DES
with advanced stent platforms and polymer biocompatibility.
The “second-generation” DES, including zotarolimus-eluting stent and the
everolimus-eluting stent, has undergone further modification. The stent platform is
made of cobalt- or platinum-chromium alloy and is thinner and more deliverable than
the first-generation DES. The new-generation DESs have polymer with better phar-
macokinetics and are more biocompatible, generating less inflammatory response
and more rapid vessel endothelialization, which may be associated with lower rates
of myocardial infarction and stent thrombosis. In a meta-analysis of four random-
ized trials, DES reduced the risk of all-cause death (RR = 0.8, 95% CI 0.59–1.07),
myocardial infarction (RR = 0.56, 95% CI 0.43–0.72), stent thrombosis (RR = 0.32,
95% CI 0.20–0.51), and repeat revascularization (RR = 0.57, 95% CI 0.46–0.71).
DESs provide effective and relatively safe alternatives to CABG for patients with
coronary artery disease. In FAME-2 trial, DESs significantly reduced the need for
urgent revascularization as compared with medical therapy in patients with stable
coronary artery disease (1.6% vs. 11.1%, P < 0.001). According to the 2014 guide-
lines of European Society of Cardiology for myocardial revascularization, use of
DES has a class IA recommendation for patients with stable coronary artery disease.
3 Revascularization for Coronary Artery Disease … 81
Use of DES in patients with multivessel disease, unprotected left main disease, and
diabetes is still a matter of debate.
Stent implantation has become standard reperfusion approach for patients with
acute myocardial infarction. Several trials have shown that DES reduced the risk of
repeat revascularization in patients with acute myocardial infarction as compared
with BMS, but was associated with very late stent thrombosis. In the EXAMINA-
TION study, everolimus-eluting stents reduced the risk of repeat revascularization
and stent thrombosis as well. Larger studies with long-term outcomes will provide
more detailed evidence on the use of DES for infarction. DES has a class IA recom-
mendation for patients with acute infarction and do not have contradictions for dual
antiplatelet therapy.
Improvements in devices, the use of stents, and aggressive antiplatelet therapy have
significantly reduced the incidence of major periprocedural complications of PCI
over the past 15–20 years. However, percutaneous and intracoronary procedure
also have potential risk of coronary artery complications. The use of guidewires,
catheters into the diseased artery, may lead to vessel injuries and consequent major
complications.
Coronary arterial dissection and acute closure were once mostly occurred after percu-
taneous transluminal coronary angioplasty, without intentional stenting. This com-
plication is commonly due to arterial dissection. Vigorous attempts by guidewire
and the following catheters, and the “controlled injury” induced by inflation of the
dilation catheter are the main cause of arterial dissection. Dissections occurred in up
to 50% of patients who received coronary angioplasty, but were much less frequent
since stents are generally used in most percutaneous coronary procedures.
Acute closure was mostly associated with large dissections (Huber et al. 1991;
Ellis et al. 1988) and occurs in 4–9% of angioplasty cases. Dissection with reduced
flow or total occlusion increases the risk mortality and nonfatal myocardial infarction
by 10 times. Most occlusion (90%) can be reversed by stent implantation, but some
patients still require bypass surgery to deal with persistent occlusion and ischemia.
the external elastic membrane. This complication occurs more commonly in coronary
angioplasty than in stenting.
3.3.3.3 Perforation
Perforation and rupture of coronary arteries are serious complications that result
from guidewire attempts, atherectomy devices, and balloons dilation. Coronary artery
perforations occur in 0.2–0.6% of patients undergoing angioplasty and are 0.84%
(Stankovic et al. 2004). After stent implantation. but are potentially catastrophic.
Significant adverse events occurred in 35% (29 of 84) patients with a perforation,
including 7 death (8.3%).
The risk of inability to deliver the stent to or expand it within the target lesion is higher
for lesions in the left circumflex artery and other longer and complex stenosis. In
patients with unsuccessful stent deployment, as much as 43% had major cardiac event
in 30 days, as compared with 4% in those with successful deployment (Schuhlen
et al. 1998). The risk of stent deployment is much lower for new generations of
stents, which ranged from 0.4 to 2% (Bolte et al. 2001).
Coronary artery bypass grafting (CABG) is the most commonly performed cardiac
surgery and most effective for the revascularization for stenotic coronary arteries. In
patients with coronary artery disease caused by partially or completely obstructed
atherosclerotic coronary arteries, CABG is used to relieve myocardial ischemia by
constructing grafts to bypass culprit lesions and complement blood supply to distal
coronary branches.
3 Revascularization for Coronary Artery Disease … 83
CABG is very effective in improving the patients prognosis after coronary artery
disease, and selecting the eligible patients is a critical precondition for good out-
comes. The evaluation of patients for CABG is based on the characteristics and
comorbidity of the patient, the coronary anatomy, and, extent of coronary artery dis-
ease. CABG is performed primarily for patients with complex stable CAD including
over 50% stenosis in left main disease with SYNTAX score over 33, and/or three-
vessel disease (≥50%) with SYNTAX score over 23. Patients with two-vessel CAD
involving LAD artery and a SYNTAX score ≥23 is also recommended to undergo
CABG. Patients with impaired left ventricular ejection fraction (≤45%), diabetes,
and ischemic mitral regurgitation are getting more survival benefit from CABG.
GEA could be considered for revascularization for inferior wall. However, the author
still emphasized that more evidence is needed.
The risk of perioperative myocardial infarction with new Q wave on ECG after
CABG ranges from 0 to 10% in different cardiac centers, and is higher in patients
with cardiomegaly, long time cardiopulmonary bypass, repeat CABG, and combined
cardiac surgery (Chaitman et al. 1983; Yokoyama et al. 2000; Stephan et al. 1996). A
new Q wave myocardial infarction indicates poor myocardial perfusion distal to grafts
anastomosis. The diagnosis of perioperative myocardial infarction, however, may be
difficult, for the CABG-induced postoperative myocardial injury and inflammation
also lead to ECG changes and cardiac enzyme elevation. The currently used diagnosis
for MI was according to Joint European Society of Cardiology/American College of
Cardiology Foundation/American Heart Association/World Health Federation Task
Force definition, which requires increases of biomarkers greater than five times the
99th percentile of the upper reference limit plus either new pathologic Q waves or new
left bundle branch block, angiographically documented new graft, native coronary
artery occlusion, or imaging evidence of new loss of viable myocardium (Thygesen
et al. 2007).
Perioperative myocardial infarction increases the risk of postoperative adverse
events. The Coronary Artery Surgery Study (CASS) reported a in-hospital mortality
of 9.7% in patients with perioperative new Q wave MI, as compared with 1.0% in
those without MI.
Graft occlusion within the first 30 days after surgery are generally due to suboptimal
anastomosis technique and injured graft during harvesting, and occurs in 5–10%
of saphenous vein grafts (Dauerman et al. 1996). Antiplatelet therapy, as important
secondary preventive strategy, would reduce the risk of postoperative occlusion,
and advanced surgical techniques like no-touch approach might also have potential
benefits.
Low cardiac output is a relative frequent early postoperative complication. The inci-
dence of low output syndrome is 6% in patients with preoperative left ventricular
ejection fraction >40, 12% in those with LVEF between 20–40, and 23% in those
3 Revascularization for Coronary Artery Disease … 85
with LVEF <20% (Yau et al. 1999). The incidence of low cardiac output can result
from perioperative factors including cardioplegic arrest and ischemic injury, reduced
preload, excessive afterload, and perioperative complications like arrhythmias and
MI (McKenney et al. 1994; Roberts et al. 1977), and often transient and response
to fluid therapy and/or inotropic support. However, persistent low cardiac output for
which pharmacologic therapy is ineffective, mechanical support is necessary.
3.4.2.4 Arrhythmias
Arrhythmias are common complications after CABG, and most often are tach-
yarrhythmias. Atrial fibrillation is one of the most important postoperative events,
occurs in 15–40% of CABG cases. Atrial fibrillation after CABG is usually self-
limited but is associated with increased risk of adverse outcomes including stroke, in-
hospital and long-term mortality (Villareal et al. 2004; Bramer et al. 2010; Mariscalco
et al. 2008). Perioperative beta blocker is considered the most effective therapy for the
prevention of postoperative atrial fibrillation, and the current guideline recommended
continued perioperative beta blocker therapy for patient without contradictions.
The concept of Heart Team was first introduced in 2000s through randomized trials
(Head et al. 2013). A Heart Team is made up of clinical or noninvasive cardiolo-
gists, cardiac surgeons and interventional cardiologists, provides a balanced, mul-
tidisciplinary decision-making process. The main job of Heart Team is to review
the patient’s medical condition and assess anatomy of coronary disease together, to
develop the best revascularization options that combines local therapeutic capabil-
ity and patient preferences. The 2011 ACCF/AHA Guideline for Coronary Artery
Bypass Graft Surgery give a Class I (Level of Evidence: C) recommendations for
Heart Team approach to revascularization in patients with unprotected left main or
complex CAD (Hillis et al. 2011). Correspondingly, a Class I recommendation was
made in 2014 ESC/EACTS Guidelines on myocardial revascularization (Kolh and
Windecker 2014).
However, Heart Team has not yet been widely implemented for the novelty of
concept, lack of experience and proven benefit, logistical issues, and doctors passive
opinions. Moreover, the absence of reliable criteria or guidelines for Heart Team
organization and involvement has made the formation and validation of Heart Team
more difficult. The process of multidisciplinary decision-making by Heart Team also
raised concerns on prolonged time delay before treatment and increasing expense.
Therefore, it is crucial to design appropriate organizations and logistics to enlarge the
86 D. Gu et al.
effect of Heart Team. A coordinator is helpful for acquiring all necessary information
for decision making during Heart Team discussion. Leadership, but not dominance,
is important for efficient team work, active participation, and innovation. Ad hoc
meetings after coronary angiogram may be the best opportunity for Heart Team to
collaborate and develop optimal strategy. The process of decision-making has three
key points: sufficient information transfer, among physicians, from physicians to
patients and patients to physicians; adequate discussion; and consensus.
We believe that a balanced multidisciplinary Heart Team has a promising future
for interpret the available diagnostics, implement guideline directed therapy, con-
sider local expertise and through shared decision-making take into account patient
preferences, to provide a more objective and uniform decision-making process (Head
et al. 2013). However, evidence on the benefit of Heart Team still requires updating.
As a paucity of observational and randomized data, further study is still needed to
provide insight to the Heart Team approach.
Significant left main coronary artery disease (LMCAD defined as a greater than
50% angiographic narrowing) is found in 4–6% of all patients who undergo coro-
nary arteriography (Ragosta et al. 2006) and is associated with high morbidity and
mortality owing to the large amount of myocardium at risk (at least 75% of the left
ventricle) (Serruys et al. 2009). The optimal management of patients with left main
coronary artery disease has been the subject of intense investigation for decades, both
CABG and PCI along with best selected preventive therapies was recommended in
the newest guidelines on myocardial revascularization for left main coronary artery
disease in selective patients, and coronary artery bypass graft surgery (CABG) with
best selected preventive therapies is recommended for all patients with significant
left main coronary artery disease due to significantly improved survival.
CABG has a long track record of safety and efficacy in patients with LMCAD and
is associated with significantly better cardiovascular outcomes, including mortality.
In the 1970s, Veterans Administration Cooperative Study compared a strategy of
initial CABG versus deferred CABG, substantial survival advantages were observed
in patients underwent initial CABG at 2 years and 11 years, and also greater benefit
was found in high-risk patients with more than 75% left main stenosis and/or left
ventricular dysfunction, compared with patients with 50–75% stenosis and normal
left ventricular function. The CASS Registry contained data from 1,484 patients with
more than 50% left main CAD initially treated surgically or nonsurgically, median
survival duration was 13.3 years in the surgical group, 6.6 years in the medical group
(Caracciolo et al. 1995). With the development of surgical technology, Thirty-day
mortality of CABG is now under 2% in some United States institutions, and in Fuwai
hospital, this rate is lower than 1%.
The LMCAD once was a forbidden territory for percutaneous coronary inter-
vention (PCI), however, the accumulation of experience, coupled with improved
3 Revascularization for Coronary Artery Disease … 87
technology and pharmacology, has led to this approach being rapidly evolved and
broadly adopted in stenosis (Park et al. 2015), and also for cautiously selected patients
with LMCAD. The NOBLE trial (Nordic-Baltic-British Left Main Revasculariza-
tion) and EXCEL trial (Evaluation of XIENCE vs. Coronary Artery Bypass Surgery
for Effectiveness of Left Main Revascularization) were the latest published stud-
ies focus on the comparison of CABG with PCI for left main CAD. The NOBLE
study, 1201 patients were randomly assigned, reported that CABG might provide a
better clinical outcome for treatment of left main coronary artery disease than PCI,
regard to the primary endpoint of major adverse cardiac and cerebrovascular events,
with 46% excess hazard with PCI over CABG at 5 years (P = 0.01). However, the
EXCEL trial, in which 1905 participants were enrolled, showed that the primary
composite endpoint event of death, stroke, or MI at 3 years occurred in 15.4% of the
patients in the PCI group and in 14.7% of the patients in the CABG group (P = 0.02
for noninferiority), leading to the conclusion that in patients with left main coronary
artery disease and low or intermediate SYNTAX scores, PCI with everolimus-eluting
stents was noninferior to CABG. In a 2016 meta-analysis examined the results of
PCI versus CABG for unprotected left main coronary artery stenosis, the pooled
data were numerically leveraged by EXCEL and varied in their definition of peripro-
cedural MI, leading to a neutral result for the primary endpoint of all-cause death,
MI, or stroke (odds ratio, 0.97; 95% confidence interval, 0.79–1.17; P = 0.73) (Ner-
lekar et al. 2016). Taken together, EXCEL and NOBLE confirmed that CABG is the
most robust and durable therapy for coronary revascularization in the presence of
LMCAD, and also, for the treatment of patients with left main coronary artery disease
and low or intermediate SYNTAX scores, PCI with everolimus-eluting stents can be
considered as another choice. Meanwhile, a professional Heart Team should also be
involved, helps to balance the risks and benefits associated with each procedure in
conjunction with the baseline risk profile and patient preferences, and finally make
the best choice of the optimum revascularization strategy for an individual patient.
cardiovascular events. While it has achieved some measure of popularity, HCR has
not been evaluated in reliable large-scale randomized trials comparing it with PCI or
CABG. The largest observational study to date, published on JACC in 2016, com-
pared 200 patients who underwent HCR and 98 patients who underwent multivessel
PCI, and reported that the rate of primary outcome of major adverse cardiac and
cerebrovascular events (i.e., death, stroke, MI, and repeat revascularization) within
12 months of the procedure was similar between the two groups after adjustment for
baseline risk (0.142 vs. 0.119%, respectively; hazard ratio 1.063; p = 0.80) (Puskas
et al. 2016). Until evidence from more well-designed randomized trials supporting
its use is available, we believe HCR is a reasonable choice at centers with expertise.
Heart failure (HF) is a common clinical syndrome resulting from any structural or
functional cardiac disorder that impairs the ability of the ventricle to fill with or eject
blood, and coronary artery disease or ischemic cardiomyopathy is a dominant cause
of HF in developed countries. Thus, revascularization with CABG or PCI is indicated
for symptomatic relief of angina pectoris in patients with heart failure. The Surgical
Treatment for Ischemic Heart Failure (STICH) study (Velazquez et al. 2016) was
designed to test the hypothesis that CABG plus guideline-directed medical therapy
for coronary artery disease, heart failure, and left ventricular dysfunction would
improve survival over that with medical therapy alone in a sample of 1212 patients
with CAD and LV dysfunction (EF ≤ 35%). After 10 years’ follow-up, the authors
reported that the primary outcome event (death from any cause) occurred in 359
patients (58.9%) in the CABG group and in 398 patients (66.1%) in the medical
therapy group (hazard ratio with CABG vs. medical therapy, 0.84; 95% confidence
interval (Tanne et al. 1998), 0.73–0.97; P = 0.02 by log-rank test), and the median
survival was 1.44 years longer in the CABG group (7.73 years among patients in the
CABG group and 6.29 years among patients in the medical therapy group). Based on
these results, the STICH supports a significant benefit of CABG plus medical therapy
over medical therapy alone with respect to the rate of death from any cause among
patients with ischemic cardiomyopathy. Meanwhile, since most studies refer to the
revascularization strategies for patients suffering from coronary artery disease and set
LV dysfunction as an exclusive criterion, the available data is insufficient to evaluate
the efficacy of PCI and compare PCI with CABG in patients with LV dysfunction.
A recent propensity score matching study compared PCI with everolimus-eluting
stents versus CABG and concluded that in patients with multivessel disease and
severe LV systolic dysfunction, PCI with an EES resulted in survival similar to that
of CABG (Bangalore et al. 2016). However, we highly recommend that the choice
between CABG and PCI should be made by the Heart Team after careful evaluation
of the patient’s clinical status and coronary anatomy, including SYNTAX score,
90 D. Gu et al.
3.5.4.2 Diabetes
Patients with diabetes comprise as many as 25–30% of those who undergo revascular-
ization, and the short- and long-term results of revascularization with percutaneous
coronary intervention or coronary artery bypass graft surgery are often worse in
diabetic patients (Malmberg et al. 2000), emphasized by a higher risk of cardiovas-
cular events and death than those without diabetes. The approach to revascularization
in diabetic patients with left main or lesser degrees of coronary disease is similar
to the broad population of patients; however, the optimal revascularization strat-
egy for patients with diabetes and multivessel coronary artery disease remains to be
deliberated.
BARI 2D trial (Group et al. 2009) (The Bypass Angioplasty Revascularization
Investigation 2 Diabetes) was designed to address the effects of therapy on the rate
of myocardial ischemia, a major cause of death in patients with diabetes, and of
insulin resistance, the fundamental mechanism underlying diabetes with profound
cardiovascular consequences. Overall, 2368 patients with type 2 diabetes mellitus
and stable ischemic heart disease were enrolled, at 5 years, the primary endpoints of
the rates of survival or freedom from major cardiovascular event death, myocardial
infarction (Wu et al. 1990, or stroke) did not differ significantly between the revas-
cularization group and the IMT alone group (88.3 vs. 87.8% and 77.2 vs. 75.9%,
respectively). However, in sub-group analysis, the rate of freedom from major car-
diovascular events was significantly higher in the CABG plus IMT stratum compared
to the corresponding IMT stratum (77.6 vs. 69.5%), predominantly attributable to a
reduction in nonfatal MI.
The FREEDOM trial (Farkouh et al. 2012) (Future Revascularization Evaluation
in Patients with Diabetes Mellitus) compares CABG against PCI with the use of early-
generation DES (94%) in diabetic patients undergoing elective revascularization for
multivessel disease without left main coronary stenosis. A total of 1900 patients were
enrolled at 140 international centers from 2005 through 2010 and were followed for a
minimum of 2 years (median among survivors, 3.8 years). A more frequent primary
outcome occurrence (a composite of death from any cause, nonfatal myocardial
infarction, and nonfatal stroke) was observed in the PCI group (P = 0.005), with
5-year rates of 26.6% in the PCI group and 18.7% in the CABG group, driven
by a borderline reduction of all-cause mortality (P = 0.049) and by a markedly
lower rate of myocardial infarction in the CABG group (P < 0.001), leading to the
authors’ conclusion that for patients with diabetes and advanced coronary artery
disease, CABG was superior to PCI in that it significantly reduced rates of death and
myocardial infarction.
In the CARDia trial (Kapur et al. 2010) (Coronary Artery Revascularization in
Diabetes), 510 diabetic patients with multivessel or complex single-vessel CAD at
24 sites were enrolled and randomly assigned to either CABG or PCI with the use of
3 Revascularization for Coronary Artery Disease … 91
either BMS or DES and routine use of abciximab. There were no differences between
CABG and PCI for the primary endpoint of 1-year composite of death, myocardial
infarction, or stroke (12.4% in the CABG and 11.6% in the PCI group), whereas
repeat revascularization was more common among patients assigned to PCI, and
also a higher rate of stroke in patients underwent CABG.
Hence, taking currently available evidence into consideration, for diabetic patients
with multivessel CAD, CABG is the best revascularization choice; however, among
diabetic patients with multivessel disease and low SYNTAX score, PCI can be
considered as a treatment alternative.
balloon angioplasty in the setting of primary PCI as it reduces the risk of abrupt clo-
sure, re-infarction, and repeat revascularization. Meanwhile, thrombus aspiration has
been proposed as an adjunct during primary PCI, to further improve epicardial and
myocardial reperfusion by prevention of distal embolization of thrombotic material
and plaque debris.
Early, routine, post-thrombolysis angiography with subsequent PCI (if required)
has been proven to reduce the rates of re-infarction and recurrent ischemia, which
is referred as secondary PCI, compared with a strategy of “watchful waiting” (in
this situation, angiography and revascularization were indicated only in patients
with spontaneous or induced severe ischemia or LV dysfunction). In cases of failed
fibrinolysis, or if there is evidence of re-occlusion or re-infarction with recurrence of
ST-segment elevation, the patient should undergo immediate coronary angiography
and rescue PCI (Gershlick et al. 2005).
CABG has a limited role in the acute phase of STEMI other than for cardiogenic
shock, but it may be indicated for failed PCI, for coronary anatomy not amenable to
PCI, and at the time of surgical repair of a mechanical defect, such as ventricular sep-
tal, papillary muscle, or free-wall rupture (O’Gara et al. 2013). The implementation
of standard operative approach, such as on-pump beating-heart surgery, off-pump
techniques, or adjunctive temporary mechanical circulatory support devices has led
to improved survival rates after CABG in the acute hospital phase, but the timing
of urgent CABG in patients with STEMI should be cautiously considered, and also
an alternative antiplatelet strategy in patients with STEMI who may require urgent
CABG during their index hospitalization (Hillis et al. 2011).
Patients with established cardiovascular disease (CVD) have a high risk of subse-
quent cardiovascular events, including myocardial infarction (MI), stroke, and death;
thus, we recommend that all patients with established coronary heart disease should
receive interventions to prevent a subsequent CVD event. These are termed sec-
ondary prevention, including therapeutic lifestyle changes (TLCs) and adjunctive
drug therapies, which can be briefly referred to as ABCDE plan; A for Aspirin and
Anti-angina therapy, B for Beta-blockers and Blood pressure control, C for Choles-
terol lowing and Cigarette quitting, D for Diet control and Diabetes treatment, E for
Exercise and Education. The reduction of mortality and improvement of life quality
due to effective secondary prevention has been determined by clinical studies and
recommended by clinical guidelines (Smith et al. 2006). For patients at high risk
(those with a prior CVD event as well as those whose 10-year risk is >10%), older
adults, accompanied with diabetes mellitus, chronic kidney disease, interventions to
prevent CVD events should be more emphasized and intensified.
3 Revascularization for Coronary Artery Disease … 95
3.6.2 Exercise
References
Anderson HV, Willerson JT (1993) Thrombolysis in acute myocardial infarction. N Engl J Med
329(10):703–709
Astrup T, Permin PM (1947) Fibrinolysis in the animal organism. Nature 159(4046):681
Aylward PE, Wilcox RG, Horgan JH et al (1996) Relation of increased arterial blood pressure to
mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial
infarction. a randomized trial. GUSTO-I investigators. Ann Intern Med 125(11):891–900
Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2: 10 year survival among
patients with suspected acute myocardial infarction in randomised comparison of intravenous
streptokinase, oral aspirin, both, or neither. the ISIS-2 (Second international study of infarct
survival) collaborative group. BMJ 316(7141):1337–43
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL (2016) Revascularization in
patients with multivessel coronary artery disease and severe left ventricular systolic dys-
function: everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation
133(22):2132–2140
Bar FW, Meyer J, Vermeer F et al (1997) Comparison of saruplase and alteplase in acute myocardial
infarction. SESAM study group. the study in Europe with saruplase and alteplase in myocardial
infarction. Am J Cardiol 79(6):727–732
Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT (2006) Benefit of early invasive therapy
in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am
Coll Cardiol 48(7):1319–1325
Ben-Gal Y, Moses JW, Mehran R et al (2010) Surgical versus percutaneous revascularization for
multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (acute
catheterization and urgent intervention triage strategy) trial. JACC Cardiovasc Interv 3(10):1059–
1067
Berkowitz SD, Granger CB, Pieper KS et al (1997) Incidence and predictors of bleeding after
contemporary thrombolytic therapy for myocardial infarction. the global utilization of streptok-
inase and tissue plasminogen activator for occluded coronary arteries (GUSTO) I investigators.
Circulation 95(11):2508–2516
Bode C, Smalling RW, Berg G et al (1996) Randomized comparison of coronary thrombolysis
achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded,
accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial
infarction. The RAPID II Investigators. Circulation 94(5):891–898
Bolte J, Neumann U, Pfafferott C et al (2001) Incidence, management, and outcome of stent loss
during intracoronary stenting. Am J Cardiol 88(5):565–567
Bramer S, van Straten AH, Soliman Hamad MA, Berreklouw E, Martens EJ, Maessen JG (2010)
The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass
grafting. Ann Thorac Surg 90(2):443–449
Caracciolo EA, Davis KB, Sopko G et al (1995) Comparison of surgical and medical group sur-
vival in patients with left main coronary artery disease. long-term CASS experience. Circulation
91(9):2325–2334
Chaitman BR, Alderman EL, Sheffield LT et al (1983) Use of survival analysis to determine the
clinical significance of new Q waves after coronary bypass surgery. Circulation 67(2):302–309
Chapin JC, Hajjar KA (2015) Fibrinolysis and the control of blood coagulation. Blood Rev 29(1):17–
24
Collen D, Lijnen HR (2005) Thrombolytic agents. Thromb Haemost 93(4):627–630
Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal
account (1538–7933 (Print))
Dauerman HL, Cutlip DE, Sellke FW (1996) Intracoronary thrombolysis in the treatment of graft
closure immediately after CABG. Ann Thorac Surg 62(1):280–283
del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M (1998) PROACT: a
phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle
3 Revascularization for Coronary Artery Disease … 97
cerebral artery stroke. PROACT investigators. prolyse in acute cerebral thromboembolism. Stroke
29(1):4–11
Desai ND, Cohen EA, Naylor CD, Fremes SE (2004) Radial artery patency study I. a random-
ized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med
351(22):2302–9
Diodato M, Chedrawy EG (2014) Coronary artery bypass graft surgery: the past, present, and future
of myocardial revascularisation. Surg Res Pract 2014:726158
Ellis SG, Roubin GS, King SB 3rd et al (1988) Angiographic and clinical predictors of acute closure
after native vessel coronary angioplasty. Circulation 77(2):372–379
Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in
patients with diabetes. N Engl J Med 367(25):2375–2384
Fletcher GF, Ades PA, Kligfield P et al (2013) Exercise standards for testing and training: a scientific
statement from the American heart association. Circulation 128(8):873–934
Franzosi MG, Santoro E, De Vita C et al (1998) Ten-year follow-up of the first megatrial testing
thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano
per lo Studio della Sopravvivenza nell’Infarto-1 study. GISSI Investig Circ 98(24):2659–2665
Furlan AJ, Abou-Chebl A (2002) The role of recombinant pro-urokinase (r-pro-UK) and intra-
arterial thrombolysis in acute ischaemic stroke: the PROACT trials. prolyse in acute cerebral
thromboembolism. Curr Med Res Opin 18 Suppl 2:s44–s47
Gershlick AH, Stephens-Lloyd A, Hughes S et al (2005) Rescue angioplasty after failed
thrombolytic therapy for acute myocardial infarction. N Engl J Med 353(26):2758–2768
Gore JM, Granger CB, Simoons ML et al (1995) Stroke after thrombolysis. mortality and functional
outcomes in the GUSTO-I trial. global use of strategies to open occluded coronary arteries.
Circulation 92(10):2811–8
Group BDS, Frye RL, August P et al (2009) A randomized trial of therapies for type 2 diabetes and
coronary artery disease. N Engl J Med 360(24):2503–2515
GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic
strategies for acute myocardial infarction. N Engl J Med 329(10):673–682
Head SJ, Kaul S, Mack MJ et al (2013) The rationale for heart team decision-making for patients
with stable, complex coronary artery disease. Eur Heart J 34(32):2510–2518
Hillis LD, Smith PK, Anderson JL et al (2011) ACCF/AHA guideline for coronary artery
bypass graft surgery: a report of the American college of cardiology foundation/American heart
association task force on practice guidelines. Circulation 124(23):e652–e735
Hlatky MA, Boothroyd DB, Bravata DM et al (2009) Coronary artery bypass surgery compared with
percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual
patient data from ten randomised trials. Lancet 373(9670):1190–1197
Huber MS, Mooney JF, Madison J, Mooney MR (1991) Use of a morphologic classification to predict
clinical outcome after dissection from coronary angioplasty. Am J Cardiol 68(5):467–471
Huynh T, Cox JL, Massel D et al (2004) Predictors of intracranial hemorrhage with fibrinolytic
therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J
148(1):86–91
Joner M, Finn AV, Farb A et al (2006) Pathology of drug-eluting stents in humans: delayed healing
and late thrombotic risk. J Am Coll Cardiol 48(1):193–202
Kapur A, Hall RJ, Malik IS et al (2010) Randomized comparison of percutaneous coronary inter-
vention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia
(Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55(5):432–440
Katritsis DG, Siontis GC, Kastrati A et al (2011) Optimal timing of coronary angiography and
potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J 32(1):32–40
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic
therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet
361(9351):13–20
Kolh P, Windecker S (2014) ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart
J 35(46):3235–3236
98 D. Gu et al.
Kulik A, Ruel M, Jneid H et al (2015) Secondary prevention after coronary artery bypass graft
surgery: a scientific statement from the American heart association. Circulation 131(10):927–964
Loop FD, Lytle BW, Cosgrove DM et al (1986) Influence of the internal-mammary-artery graft on
10-year survival and other cardiac events. N Engl J Med 314(1):1–6
Malmberg K, Yusuf S, Gerstein HC et al (2000) Impact of diabetes on long-term prognosis in patients
with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization
to assess strategies for ischemic syndromes) Registry. Circulation 102(9):1014–1019
Marder VJ, Sherry S (1988) Thrombolytic therapy: current status (1). N Engl J Med 318(23):1512–
1520
Mariscalco G, Klersy C, Zanobini M et al (2008) Atrial fibrillation after isolated coronary surgery
affects late survival. Circulation 118(16):1612–1618
McKenney PA, Apstein CS, Mendes LA et al (1994) Increased left ventricular diastolic chamber
stiffness immediately after coronary artery bypass surgery. J Am Coll Cardiol 24(5):1189–1194
Meyer J (1989) Randomised double-blind trial of recombinant pro-urokinase against streptokinase
in acute myocardial infarction. PRIMI trial study group. Lancet 1(8643):863–868
Mohr FW, Morice MC, Kappetein AP et al (2013) Coronary artery bypass graft surgery versus
percutaneous coronary intervention in patients with three-vessel disease and left main coronary
disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381(9867):629–638
Morrison DA, Sethi G, Sacks J et al (2001) Percutaneous coronary intervention versus coronary
artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk fac-
tors for adverse outcomes with bypass: a multicenter, randomized trial. investigators of the Depart-
ment of Veterans affairs cooperative study #385, the Angina with extremely serious operative
mortality evaluation (AWESOME). J Am Coll Cardiol 38(1):143–9
Navarese EP, Gurbel PA, Andreotti F et al (2013) Optimal timing of coronary invasive strategy
in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis.
Ann Intern Med 158(4):261–270
Nerlekar N, Ha FJ, Verma KP et al (2016) Percutaneous coronary intervention using drug-eluting
stents versus coronary artery bypass grafting for unprotected left main coronary artery stenosis:
a meta-analysis of randomized trials. Circ Cardiovasc Interv 9(12)
O’Donoghue M, Boden WE, Braunwald E et al (2008) Early invasive vs conservative treatment
strategies in women and men with unstable angina and non-ST-segment elevation myocardial
infarction: a meta-analysis. JAMA 300(1):71–80
O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the man-
agement of ST-elevation myocardial infarction: a report of the American college of cardi-
ology foundation/American heart association task force on practice guidelines. Circulation
127(4):e362–e425
Park SJ, Ahn JM, Kim YH et al (2015) Temporal trends in revascularization strategy and out-
comes in left main coronary artery stenosis: data from the ASAN medical center-left MAIN
revascularization registry. Circ Cardiovasc Interv 8(3):e001846
Puskas JD, Halkos ME, DeRose JJ et al (2016) Hybrid coronary revascularization for the treatment
of multivessel coronary artery disease: a multicenter observational study. J Am Coll Cardiol
68(4):356–365
Ragosta M, Dee S, Sarembock IJ, Lipson LC, Gimple LW, Powers ER (2006) Prevalence of unfa-
vorable angiographic characteristics for percutaneous intervention in patients with unprotected
left main coronary artery disease. Catheter Cardiovasc Interv 68(3):357–362
Rijken DC, Wijngaards G, Zaal-de Jong M, Welbergen J (1979) Purification and partial char-
acterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta
580(1):140–153
Rijken DC, Wijngaards G, Welbergen J (1980) Relationship between tissue plasminogen activator
and the activators in blood and vascular wall (0049–3848 (Print))
Riley RF, Don CW, Powell W, Maynard C, Dean LS (2011) Trends in coronary revascularization
in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention
volumes. Circ Cardiovasc Qual Outcomes 4(2):193–197
3 Revascularization for Coronary Artery Disease … 99
Roberts AJ, Niarchos AP, Subramanian VA et al (1977) Systemic hypertension associated with coro-
nary artery bypass surgery. Predisposing factors, hemodynamic characteristics, humoral profile,
and treatment. J Thorac Cardiovasc Surg 74(6):846–859
Rodriguez A, Bernardi V, Navia J et al (2001) Argentine randomized study: coronary angioplasty
with stenting versus Coronary Bypass surgery in patients with multiple-vessel disease (ERACI II):
30-day and one-year follow-up results. ERACI II investigators. J Am Coll Cardiol 37(1):51–58
Schuhlen H, Kastrati A, Dirschinger J et al (1998) Intracoronary stenting and risk for major adverse
cardiac events during the first month. Circulation 98(2):104–111
Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus
coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–
972
Smalling RW, Bode C, Kalbfleisch J et al (1995) More rapid, complete, and stable coronary
thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute
myocardial infarction. RAPID Investig Circ 91(11):2725–2732
Smith SC Jr, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for
patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the
National Heart, Lung, and blood institute. Circulation 113(19):2363–2372
Spiecker M, Windeler J, Vermeer F et al (1999) Thrombolysis with saruplase versus streptokinase in
acute myocardial infarction: five-year results of the PRIMI trial. Am Heart J 138(3 Pt 1):518–524
Stankovic G, Orlic D, Corvaja N et al (2004) Incidence, predictors, in-hospital, and late outcomes
of coronary artery perforations. Am J Cardiol 93(2):213–216
Stephan WJ, O’Keefe JH Jr, Piehler JM et al (1996) Coronary angioplasty versus repeat coronary
artery bypass grafting for patients with previous bypass surgery. J Am Coll Cardiol 28(5):1140–
1146
Suma H, Tanabe H, Takahashi A et al (2007) Twenty years experience with the gastroepiploic artery
graft for CABG. Circulation 116(11 Suppl):I188–I191
Tanne D, Gottlieb S, Caspi A et al (1998) Treatment and outcome of patients with acute myocardial
infarction and prior cerebrovascular events in the thrombolytic era: the Israeli Thrombolytic
National Survey. Arch Intern Med 158(6):601–606
Tebbe U, Windeler J, Boesl I et al (1995) Thrombolysis with recombinant unglycosylated single-
chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influ-
ence of heparin on early patency rate (LIMITS study). liquemin in myocardial infarction during
thrombolysis with saruplase. J Am Coll Cardiol 26(2):365–73
Thygesen K, Alpert JS, White HD (2007) Joint ESCAAHAWHFTFftRoMI. Universal definition
of myocardial infarction. Eur Heart J 28(20):2525–2538
Topol EJ, Ohman EM, Armstrong PW et al (2000) Survival outcomes 1 year after reperfusion therapy
with either alteplase or reteplase for acute myocardial infarction. Circulation 102:1761–1765
Trivax JE, Franklin BA, Goldstein JA et al (2010) Acute cardiac effects of marathon running. J
Appl Physiol (1985) 108(5):1148–53
Varghese T, Schultz WM, McCue AA et al (2016) Physical activity in the prevention of coronary
heart disease: implications for the clinician. Heart 102(12):904–909
Velazquez EJ, Lee KL, Deja MA et al (2011) Coronary-artery bypass surgery in patients with left
ventricular dysfunction. N Engl J Med 364(17):1607–1616
Velazquez EJ, Lee KL, Jones RH et al (2016) Coronary-artery bypass surgery in patients with
ischemic cardiomyopathy. N Engl J Med 374(16):1511–1520
Villareal RP, Hariharan R, Liu BC et al (2004) Postoperative atrial fibrillation and mortality after
coronary artery bypass surgery. J Am Coll Cardiol 43(5):742–748
Wilcox RG (1995) Randomised, double-blind comparison of reteplase double-bolus administration
with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence.
international joint efficacy comparison of thrombolytics. Lancet 346(8971):329–336
Wu Z, Van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D (1990) Pharmacokinetics and
coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking
100 D. Gu et al.
the finger-like, growth factor-like, and first kringle domains (amino acids 6–173) in a canine
model. J Cardiovasc Pharmacol 16(2):197–203
Yau TM, Fedak PW, Weisel RD, Teng C, Ivanov J (1999) Predictors of operative risk for coro-
nary bypass operations in patients with left ventricular dysfunction. J Thorac Cardiovasc Surg
118(6):1006–1013
Yokoyama Y, Chaitman BR, Hardison RM et al (2000) Association between new electrocardio-
graphic abnormalities after coronary revascularization and five-year cardiac mortality in BARI
randomized and registry patients. Am J Cardiol 86(8):819–824
Yusuf S, Zucker D, Peduzzi P et al (1994) Effect of coronary artery bypass graft surgery on survival:
overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery
Trialists Collaboration. Lancet 344(8922):563–570
Zarich SW, Kowalchuk GJ, Weaver WD et al (1995) Sequential combination thrombolytic ther-
apy for acute myocardial infarction: results of the Pro-Urokinase and t-PA enhancement of
thrombolysis (PATENT) trial. J Am Coll Cardiol 26(2):374–379
Chapter 4
Antithrombotic Drugs—Pharmacology
and Perspectives
Abstract Thrombosis, the localized clotting of blood that affects arterial or venous
circulation, is one of the leading causes of death worldwide. Arterial thrombosis is
commonly initiated by vascular endothelial injury, while venous thrombosis mainly
stems from blood stasis. Despite these differences, platelet adhesion, activation and
aggregation, and fibrin formation as a result of coagulation constitute the fundamental
processes of thrombus formation. Antithrombotic drugs permitted on the clinical
currently can dramatically reduce major adverse cardiovascular events; however,
they can also increase the bleeding risk. Discovery of antithrombotic drugs that can
effectively prevent thrombosis while sparing bleeding side effects remains unmet
medical need. In this chapter, we provide an overview on the pathophysiology of
thrombosis, followed by introduction of each class of antithrombotic drugs including
their pharmacology, clinical applications and limitations. Practical challenges and
future perspectives of antithrombotic drugs are discussed in the last part of this
chapter.
4.1.1 Platelet
Platelets play a critical role in hemostasis by forming the primary plug and providing a
surface that concentrates activated coagulation factors to enhance the rate of thrombin
generation. There are three steps of platelet plug formation:
4.1.2 Coagulation
Coagulation is the process by which blood changes from a liquid to a gel, which
takes place in three essential steps:
4 Antithrombotic Drugs-Pharmacology and Perspectives 103
• Antithrombin attenuates coagulation by inactivating factors IIa, IXa, Xa, XIa and
XIIa.
• Protein C system exerts anticoagulant effects by inactivating factors Va and VIIIa.
• Tissue factor pathway inhibitor (TFPI) specifically impedes extrinsic pathway by
inactivating factor Xa and FVIIa-TF complex.
4.1.3.1 Fibrinolysis
Fibrinolysis is the normal body breakdown of blood clots, which refers to the process
of fibrin degraded by the fibrin-specific protease, plasmin.
Plasminogen, an inactive precursor of plasmin, is enmeshed within the blood clot
when the clot is formed. After the clot has stopped bleeding (generally several days),
plasminogen is converted by plasminogen activators to plasmin, which digests fibrin,
limits the clot extension and removes the remaining unnecessary blood clot.
There are two endogenous plasminogen activators synthesized by endothelial cells
and released in response to injury: tissue plasminogen activator (t-PA) and urokinase
(u-PA); the former predominates under most conditions. Plasmin further stimulates
plasmin formation by producing more activated t-PA and u-PA.
Fibrinolysis is regulated to remove unwanted thrombi while preserving fibrin in
wounds to maintain hemostasis. t-PA and u-PA are inhibited by plasminogen activator
104 T. Li et al.
4.1.3.2 Thrombolysis
Wall shear rates increase gradually from 300 to 800 s−1 in large arteries to 500–
1600 s−1 in arterioles of the microcirculation. In pathologically stenotic vessels, the
wall shear rates can reach 10,000 s−1 or even higher. Such a high-flow and high-stress
arterial circulation is not suitable for coagulation factors to concentrate. In contrast,
platelets can adhere to blood vessels, be activated to generate procoagulant proper-
ties on their cell surfaces and provide places for interaction of coagulation factors.
Therefore, arterial thrombosis occurs mainly due to the formation of platelet plug.
Factors that impel platelet adhesion, activation and aggregation promote formation
of arterial thrombi.
Arterial thrombi, also known as white thrombi, tend to contain more platelets
as the core and relatively few fibrin and red cells, with recruited white blood cells.
Arterial thrombi are frequently occlusive in arterioles, and nonocclusive in large
arteries (such as the aorta and common carotid arteries).
Arterial thrombosis most commonly develops in the coronary, cerebral and
femoral arteries (in decreasing order of frequency), causing downstream ischemia of
organs or extremities. Occlusive arterial thrombi can result in serious diseases, such
as myocardial infarction (MI), stroke or critical limb ischemic necrosis.
4 Antithrombotic Drugs-Pharmacology and Perspectives 105
In the venous circulation, low shear forces are insufficient to directly activate platelets,
while slow blood flow is conducive to the increase of local coagulation factors con-
centration. The initiation of venous thrombosis is thought to be caused by tissue
factor, which leads to conversion of prothrombin to thrombin, followed by fibrin
deposition. Therefore, intrinsic activation of the coagulation cascade plays a piv-
otal role in venous thrombosis. Any factor that directly or indirectly raises local
coagulation factors concentration increases the risk of venous thrombosis.
• Stasis, referred to a condition of slow blood flow, is the most important risk factor
for venous thrombosis, mostly caused by prolonged immobilization as well as any
other mechanical factor that slows venous blood flow (e.g., atrial fibrillation (AF),
congestive heart failure).
• Hypercoagulability includes acquired hypercoagulability (e.g., certain forms of
cancer, use of oral contraceptives) and genetic hypercoagulability (e.g., fac-
torVLeiden, a mutation in factorV resulting in activated protein C resistance),
which also plays a role in venous thrombosis.
• Endothelial injury has little effect on venous thrombosis. The majority of venous
thrombi form without any injured endothelium.
Venous thrombi are described pathologically as red thrombi. Formed in the slug-
gish venous circulation, they are composed predominantly of fibrin and red blood
cells, with relatively few platelets which attach to downstream fibrin. Unlike arterial
thrombi, venous thrombi are almost invariably occlusive and may form long casts of
the vessels in which they arise.
Venous thrombosis often develops in deep veins, known as deep venous thrombo-
sis (DVT), most commonly in the lower extremities (90% of cases). The most fatal
consequence of DVT is pulmonary embolism (PE), which occurs when part or all of a
deep venous thrombus travels through the bloodstream as an embolus and obstructs a
pulmonary artery. DVT and PE are not separate disorders but a continuous syndrome
of venous thromboembolism (VTE).
Atrial fibrillation is associated with stasis of blood in the left atria, which promotes
the formation of mural thrombi and significantly increases the risk of cardiogenic
thromboembolic stroke.
106 T. Li et al.
Platelets play an important role in hemostasis and thrombosis. The properties that
make platelets useful in hemostasis also allow platelets to form pathological thrombi,
particularly in arterial circulation with high shear forces, and subsequently lead
to myocardial infarction, stroke and peripheral arterial thrombosis. Consequently,
antiplatelet therapy is a cornerstone of secondary prevention in patients with estab-
lished coronary, cerebrovascular or peripheral artery disease. It also has important
applications for treatment of acute arterial thrombosis (Holbrook et al. 2012).
Platelet function mainly depends on their membrane receptors and is modulated
by a variety of substances (Table 4.1).
Theoretically, all the receptors and substances above are potential targets for mod-
ulation of platelet function. Any agent that increases negative regulation or reduces
positive regulation can act as an antiplatelet drug. Several targets for antiplatelet
drugs that have been identified are as follows.
TxA2 is a potent platelet agonist that exerts its effects via interaction with throm-
boxane prostanoid receptors (TP), and it also induces platelet aggregation by increas-
ing expression of GPIIbIIIa on platelet surface. COX-1 inhibitors such as aspirin,
the most widely used antiplatelet drug, suppress the production of TxA2 , thereby
attenuating TxA2 -mediated platelet activation and aggregation.
ADP is a powerful platelet agonist that works through at least two receptors,
P2Y1 and P2Y12 . P2Y1 binding to ADP directly induces platelet activation and
aggregation, while P2Y12 binding to ADP inhibits adenylyl cyclase, decreasing intra-
cellular cAMP levels to weaken cAMP-dependent inhibition of platelet activation.
4 Antithrombotic Drugs-Pharmacology and Perspectives 107
Table 4.1 The functions of important platelet membrane receptors and their corresponding ligands
Platelet membrane receptor Ligands Functions
GPIb/IX/V vWF Adhesion (under high shear
forces)
GPIa/IIa Collagen Adhesion
GPVI Collagen Activation
TxA2 receptor TxA2 Activation, aggregation
P2Y12 ADP Activation, aggregation
P2Y1 ADP Activation, aggregation
– Ca2+a Activation, aggregation
5-HT2A receptor Serotonin Activation, aggregation
V1 -type receptor Vasopressin Activation, aggregation
PAR-1 Thrombin Activation
PAR-4 Thrombin Activation
GPIb Thrombin Activation
AT1 -type receptor Angiotensin II Activation
α2 -Adrenergic receptors Epinephrine Activation
GPIIbIIIa Fibrinogen, vWF Aggregation, adhesion
EP3 PGE2 (at low concentrations) aggregation
IP PGI2 (at low concentrations), Inhibits activation
PGE2 (at high concentrations)
EP4 /EP2 PGE2 (at high concentrations) Inhibits activation
– NOa Inhibits activation and
aggregation
– cAMPa Inhibit activation
– cGMPa Inhibits activation and
aggregation
a The substance acts within the platelet
and its derivatives accelerate the rate at which antithrombin inhibits coagulation
factors, thereby indirectly exerting anticoagulant effects.
Anticoagulant therapy is sometimes monitored using coagulation testing because
of (1) the narrow therapeutic window of some agents and (2) marked biologic
variation in effect with some agents.
110 T. Li et al.
Antiplatelet drugs inhibit platelet adhesion, activation and aggregation, which include
aspirin, ADP receptor antagonists, GPIIbIIIa receptor inhibitors, cilostazol and vora-
paxar (Mega and Simon 2015; Wiviott and Steg 2015). The characteristics of these
drugs are more or less different due to their discrete mechanisms of action, distinct
chemical structures and different pharmacokinetics. Antiplatelet drugs can produce
hemorrhage as their major side effect. Generally, they do not cause bleeding by them-
selves; instead, they exacerbate pre-existing bleeding or predispose to bleeding from
pathologic lesions, particularly in the gastrointestinal or central nervous system.
4.3.1 Aspirin
Mechanism of action
Cyclooxygenase (COX)-1 is an intracellular enzyme that converts arachidonic acid
released from membrane phospholipids to PGG2 , which is then converted to PGH2 by
a peroxidase. In activated platelets, PGH2 is converted to TxA2 which further activates
new platelets, whereas in endothelial cells, PGH2 is converted to prostacyclin (PGI2 ),
a potent inhibitor of platelet function by increasing intra-platelet cAMP.
4 Antithrombotic Drugs-Pharmacology and Perspectives 111
Clinical applications
Aspirin is widely used for secondary prevention of thrombotic events in patients
with established coronary artery disease, cerebrovascular artery disease or periph-
eral artery disease (PAD). It is also recommended for treatment of acute myocar-
dial infarction (AMI) or acute ischemic stroke. However, using aspirin for primary
prevention of cardiovascular events is controversial. Numerous clinical trials have
shown that aspirin for primary prevention is not supported by sufficient evidence but
it does increase bleeding risk. The results of two large trials published in 2018 (the
ASCEND trial and the ARRIVE trial) also support the conclusion (Bowman et al.
2018; Gaziano et al. 2018). Aspirin and other antiplatelet drugs have little effect on
prevention of cardiogenic embolic stroke in patients with AF.
Adverse effects
The main adverse effects of aspirin as antiplatelet doses are gastrointestinal intol-
erance, gastrointestinal ulceration and hemorrhage. Use of enteric-coated aspirin
instead of plain aspirin does not eliminate gastrointestinal side effects.
Hepatic and renal toxicity, asthma and rash rarely if ever occur at antiplatelet
doses.
Limitations
High on-aspirin platelet reactivity (HaPR), which is once known as aspirin resistance,
refers to a reduction in aspirin’s efficacy in protecting patients from ischemic events,
frequently associated with high on-clopidogrel platelet reactivity (HcPR). There is
no evidence that the resistance can be reversed by higher doses of aspirin (Guirgis
et al. 2017).
The dose of aspirin that inhibits TxA2 but not interferes in PGI2 production has
not been found.
4.3.2.1 Clopidogrel
Mechanism of action
Clopidogrel is a thienopyridine prodrug which irreversibly inhibits P2Y12 , thereby
blocking the ADP pathway of platelets. It requires metabolic activation in the liver
which leads to a relatively slow onset of action. Irreversible inhibition of P2Y12
means that platelets are affected for the remainder of their lifetime.
Clinical applications
Clopidogrel is indicated for the reduction of thrombotic events (MI and stroke) in
patients with ACS or recent stroke, or established PAD.
Contraindications
Adverse effects
The major adverse effect of clopidogrel is bleeding. Gastrointestinal upset has also
been observed. Thrombotic thrombocytopenic purpura can occur but is rare.
Limitations
HcPR can occur in a substantial percentage of patients. Because clopidogrel requires
activation via the cytochrome P450 enzyme isoform CYP2C19 in the liver, the effect
of clopidogrel on inhibition of platelets considerably varies among patients. Indi-
viduals with CYP2C19 polymorphisms may have poor metabolism of clopidogrel,
resulting in inadequate drug effect and ultimately leading to ischemic events. Ran-
domized clinical trials have failed to show that higher doses improve the outcome
in such patients. Other factors that affect the efficacy of clopidogrel include age and
basal platelet activity. Further research is required to clarify the value of personal-
ized antiplatelet therapy based on genetic detection and platelet function testing as a
preventive strategy for HcPR.
Clopidogrel has a slow onset of action (6–12 h) and a slow offset of action (3–
5 days), which could potentially limit the use of this drug in some clinical scenarios,
such as when the need for surgery is uncertain before use.
4.3.2.2 Prasugrel
Mechanism of action
Like clopidogrel, prasugrel irreversibly blocks P2Y12 . Unlike clopidogrel, prasugrel
is rapidly and completely absorbed and activated, and CYP2C19 polymorphisms do
not influence its metabolism. Consequently, prasugrel acts more rapidly and effective
than clopidogrel does.
4 Antithrombotic Drugs-Pharmacology and Perspectives 113
Clinical applications
Prasugrel is only indicated in patients with ACS who are to be managed with per-
cutaneous coronary intervention (PCI) to reduce thrombotic cardiovascular events
(including stent thrombosis).
Contraindications
Adverse effects
Prasugrel is associated with higher rates of life-threatening bleeding than clopidogrel.
Thrombotic thrombocytopenic purpura has been reported.
4.3.2.3 Ticagrelor
Mechanism of action
Ticagrelor produces reversible inhibition of P2Y12 , and does not require metabolic
activation. Thus, ticagrelor has a more rapid onset and offset of action than
clopidogrel does.
Clinical applications
Ticagrelor is indicated for the reduction of thrombotic events (including stent throm-
bosis) in patients with ACS who are managed with PCI or medication. Current
guidelines give preference to ticagrelor over clopidogrel for patients with ACS.
Contraindications
Adverse effects
Ticagrelor has a higher risk of intracranial bleeding than clopidogrel. Dyspnea is
reported in 14% of patients.
4.3.2.4 Cangrelor
Mechanism of action
Cangrelor is a parenteral reversible inhibitor of P2Y12 . It has an immediate onset of
action and an offset of action within an hour.
114 T. Li et al.
Clinical applications
Cangrelor is indicated as an adjunct to PCI for the prevention of periprocedural MI,
repeat coronary revascularization and stent thrombosis in patients undergoing PCI
without prior P2Y12 antagonist and GPIIbIIIa antagonist therapy.
Contraindications
• Ongoing bleeds.
• Hypersensitivity to cangrelor.
Adverse effects
The risk of bleeding with cangrelor is greater than that with clopidogrel during
coronary intervention.
Limitations
Co-administered clopidogrel, prasugrel or ticagrelor will have no antiplatelet effect.
Mechanism of action
Blockade of GPIIbIIIa can be achieved with monoclonal antibodies or with peptide
or nonpeptide inhibitors. Abciximab is a chimeric human-murine monoclonal anti-
body Fab fragment directed against the activated form of GPIIbIIIa. Eptifibatide is a
cyclic peptide blocking the fibrinogen binding site on GPIIbIIIa. Tirofiban is a non-
peptidic, reversible inhibitor of GPIIbIIIa. They inhibit the final common pathway of
platelet aggregation, providing the strongest antiplatelet effect. They act rapidly, and
abciximab bound to platelets for up to 2 weeks, whereas eptifibatide and tirofiban
have a short duration of action of a few seconds.
Clinical applications
Abciximab, eptifibatide and tirofiban are indicated as adjuncts to PCI for the pre-
vention of cardiac ischemic complications (death, MI or refractory ischemia/repeat
coronary revascularization) in patients undergoing PCI, particularly in those with
AMI. Moreover, tirofiban and eptifibatide are used in high-risk patients with unsta-
ble angina. All of these presently available GPIIbIIIa antagonists are administered
intravenously for short-term use.
Adverse effects
Bleeding is more likely to occur with GPIIbIIIa inhibitors than with oral antiplatelet
drugs, but is easily controlled in most cases due to the drugs’ short half-lives. In
addition, thrombocytopenia is the most serious complication.
4 Antithrombotic Drugs-Pharmacology and Perspectives 115
Limitations
Abciximab is immunogenic because of its mouse component and may induce anti-
mouse antibodies, preventing repeated use in patients.
4.3.4 Cilostazol
Mechanism of action
cAMP is formed from ATP with catalysis by adenylate cyclase and degraded by
cAMP phosphodiesterase (PDE). Therefore, drugs elevate intra-platelet cAMP levels
through stimulating adenylate cyclase activity to promote the synthesis of cAMP, or
through inhibiting PDE to suppress the degradation of cAMP.
Cilostazol selectively and reversibly inhibits PDE III activity in platelets and blood
vessels, leading to inhibition of platelet aggregation and vasodilation, respectively.
Clinical applications
Cilostazol is FDA-approved to treat intermittent claudication. As it has been shown to
reduce risk of stroke in Asian populations and the rate of stent thrombosis, cilostazol
is also indicated for prevention of stroke, and is an alternative to aspirin for patients
who require DAPT but cannot tolerate aspirin.
Contraindications
Adverse effects
Headache is the most common side effect, and others include diarrhea, abnormal
stools, peripheral edema, tachycardia, and so on.
Limitations
Cilostazol’s cardiovascular side effects limit its indications. Another PDE inhibitor
with vasodilator effects, dipyridamole, which also blocks the uptake of adenosine to
increase adenosine plasma levels, further promoting cAMP production, is no longer
recommended for patients with coronary vascular disease due to its severe car-
diovascular adverse effects such as cardiac death, MI, ventricular fibrillation and
hypotension.
116 T. Li et al.
4.3.5 Vorapaxar
Mechanism of action
Vorapaxar is a potent, long-acting, oral PAR-1 inhibitor. It selectively inhibits PAR-
1, the major thrombin receptor on human platelets. The drug has a rapid onset of
action, and its effect can persist for up to 4 weeks after the drug is stopped.
Clinical applications
Vorapaxar is indicated for the reduction of thrombotic vascular events in patients
with a history of MI or PAD.
Contraindications
Adverse effects
Vorapaxar increases the risk of bleeding.
Anticoagulants are drugs that prevent blood clotting process by inhibiting coagula-
tion factors, including parenteral and oral anticoagulants. Clinically, they are mainly
used in the prevention and treatment of thromboembolic diseases. Currently avail-
able parenteral anticoagulants mainly include heparin, LMWH, fondaparinux and
bivalirudin. Currently available oral anticoagulants mainly include dabigatran etexi-
late, an oral thrombin inhibitor; and rivaroxaban, apixaban, edoxaban and betrixaban,
the oral factor Xa inhibitors.
4.4.1.1 Heparin
Mechanism of action
Heparin inhibits coagulation, both in vivo and in vitro, by activating antithrombin III
and accelerating the rate at which it inhibits thrombin, factor Xa, XIa, XIIa and IXa.
Synthesized in the liver, antithrombin plays as a plasma cofactor for heparin and is
a member of the serine protease inhibitor superfamily. Once bound to antithrombin,
heparin induces a conformational change in the reactive center of antithrombin that
enhances the rate at which antithrombin inhibits its target clotting factors.
Clinical applications
Contraindications
Side effects
• Hemorrhage. Bleeding risk increases with higher heparin dose, as well as the
concomitant administration of drugs such as antiplatelet or fibrinolytic agents.
Protamine sulfate can be used to neutralize heparin in patient with serious bleeding.
• Thrombocytopenia and thrombosis. Heparin-induced thrombocytopenia
(Warkentin et al. 2005, 2010; Jaax and Greinacher 2012) is an antibody-
induced process triggered by antibodies against neoantigens on PF4 that are
exposed when heparin binds to this protein. PF4 is released by platelet 4 that binds
with both circulating heparin and heparan sulfate of vascular endothelial cells
forming complexes that trigger the antibody response predominantly through
immunoglobulin G. The Fc segments of IgG are able to interact with the Fc γ
118 T. Li et al.
Limitations
4.4.1.3 Bivalirudin
Bivalirudin is a synthetic 20-amino acid analogue of hirudin and it can inhibit throm-
bin reversibly and directly. It can bind with plasmin both in blood circulation and in
the form of combination. Bivalirudin interacts with the active site of thrombin with
the NH2 -terminal portion, and its COOH-terminal tail binds to the substrate bind-
ing domain on thrombin called exosite1. Clinically, bivalirudin is used in selected
patients undergoing percutaneous coronary interventions. It is contraindicated in
patients with active hemorrhage or allergy to bivalirudin. And it can cause some side
effects such as bleeding and hypersensitivity reactions.
4.4.1.4 Argatroban
4.4.1.5 Fondaparinux
4.4.2.1 Warfarin
Mechanism of action
All the vitamin K-dependent clotting factors possess glutamic acid residues at their N-
terminals. Warfarin interferes with the post-translational γ-carboxylation of glutamic
acid residues in clotting factors II, VII, IX and X by inhibiting vitamin K epoxide
reductase component 1. By blocking vitamin K epoxide reductase, warfarin inhibits
the conversion of oxidized vitamin K into its reduced form. This inhibits vitamin
K-dependent gamma-carboxylation of factors II, VII, IX and X because the reduced
vitamin K serves as a cofactor for a gamma-glutamylcarboxylase, which catalyzes
the gamma-carboxylation process, thereby converting prozymogens to zymogens
capable of binding calcium and interacting with anionic phospholipid surfaces.
Clinical applications
Contraindications
Side effects
• Bleeding. Bleeding complications mainly occur when the INR exceeds the thera-
peutic range, which can be mild such as hematuria or epistaxis, or more severe such
as gastrointestinal or retroperitoneal bleeding, even the life-threatening intracranial
bleeding.
4 Antithrombotic Drugs-Pharmacology and Perspectives 121
• Skin necrosis. Usually occurs at the beginning several days of therapy. Skin necro-
sis can form on the thighs, buttocks, breasts and the typical lesion has a progressive
necrotic in its center. The reason for the skin necrotic results from the congenital
or acquired deficiency of protein C or protein S.
• Pregnancy. Warfarin can cross the placenta and can cause fetal abnormalities or
bleeding, especially in the first trimester of pregnancy.
Limitations
Warfarin and other vitamin K antagonists require frequent blood tests to individualize
dose and are inconvenient as well as having a low margin of safety.
Mechanism of action
The new oral anticoagulants are small molecules which can bind to the active cen-
ter of the target enzyme reversibly. Dabigatran etexilate, with a hydrophobic tail, is
orally active direct thrombin inhibitor, and the pro-drug of dabigatran is a synthetic
serine protease inhibitor. Dabigatran etexilate can bind to the specific fibrin site of
antithrombin and block the dissociation of fibrinogen, thus blocking the key steps
of thrombin enzymatic reaction and consequent thrombosis to play an anticoagulant
role. Other kinds of NOACs, such as rivaroxaban, apixaban and edoxaban, are selec-
tive factor Xa inhibitors. They bind to the active site of the factor Xa and prevent the
interaction of factor Xa with its substrate, which can inhibit the activity of thrombin
and prolong the clotting time.
Clinical application
Contraindications
• Allergic reaction.
• Significant active hemorrhage.
• High risk of massive hemorrhage.
• Combined application of other anticoagulants.
• Hepatic dysfunction or liver diseases.
• Mechanical prosthetic valve.
Side effects
• Bleeding is the most common side effect of the new oral anticoagulants. The risk
for gastrointestinal bleeding is higher with dabigatran and rivaroxaban than with
warfarin.
• Nephrotoxicity. Rivaroxaban and apixaban is less harmful than dabigatran in
kidney injury.
• Dyspepsia. Mainly occurs in patients treated with dabigatran.
Limitations
• Currently, there is no efficacious antagonist for NOACs and this may increase the
risk of bleeding.
• Despite the wide therapeutic window, there is no specific laboratory index that
can be observed to estimate the therapeutic effect of NOACs. And this may be a
puzzled problem the doctors have to face with.
• Because of the short half-life, it will be dangerous if the patients forget to take
NOACs.
• The patients with dysfunction of liver or kidney should be careful to take the
NOACs.
• Limitation in the secondary prevention of acute coronary syndrome.
• The new oral anticoagulants are more expensive than warfarin, which may be a
big problem for poor patients, especially in developing countries.
4.5.1 Streptokinase
Mechanism of action
Streptokinase can bind with endogenous plasminogen in 1:1 ratio to form a complex,
thereby inducing a conformational change in plasminogen which exposes its active
site. This conformationally altered plasminogen converts additional plasminogen
molecule to plasmin. The streptokinase–plasminogen complex activates both free
and fibrin-bound plasminogen.
Clinical applications
Streptokinase is widely used in thrombotic diseases such as acute myocardial infarc-
tion, cerebral infarction, pulmonary embolism, deep vein thrombosis and acute or
subacute peripheral arterial thrombosis.
Contraindications
• Bleeding, surgery or trauma within two weeks.
• Ulcer diseases or esophageal varices.
• Uncontrolled hypertension.
• Coagulation dysfunction and hemorrhage diseases.
• Severe liver and kidney dysfunction.
• Gestation period.
• Allergic reaction.
Side effects
• Allergic reactions. They may be manifested as a rash, fever, chills or rigors.
• Transient hypotension. This may be result from the release of bradykinin induced
by plasmin.
Limitations
Streptokinase extracted from pathogenic hemolytic streptococcus may have
certain antigenicity and cause systemic fibrinolysis, increasing the risk of bleeding.
4.5.2 Urokinase
Urokinase is a two-chain serine protease derived from cultured fetal kidney cells. It
consists of two polypeptide chain with a molecular weight of 34,000.
124 T. Li et al.
Mechanism of action
Urokinase converts plasminogen to plasmin by specific cleavage of an Arg-Val bond
in plasminogen.
Clinical applications
Like streptokinase, urokinase is mainly used in the thrombolytic therapy for throm-
boembolism diseases including acute extensive pulmonary embolism, coronary
embolism and myocardial infarction occurs with 6–12 h, acute cerebrovascular
embolism, retinal artery and peripheral arterial embolism, prevention of thrombosis
after heart valve replacement surgeries.
Contraindications
Side effects
• Bleeding. Bleeding can occur in the superficial location such as skin, mucosa and
vascular puncture site, as well as the visceral bleeding such as gastrointestinal
bleeding, hemoptysis, hematuria, retroperitoneal bleeding, cerebral bleeding.
• Mild allergic reaction. Such as skin eruption, bronchial spasm and fever.
• Gastrointestinal reaction. Such as nausea, vomiting and inappetence.
Limitations
Like streptococcus, urokinase may activate fibrinolytic system and increase the risk
of bleeding.
t-PA is the physiological fibrinogen activator in the body and released by vascular
endothelial cells into the blood circulation. Now recombinant tissue-type plasmino-
gen activator such as alteplase has been prepared by method of genetic engineering
(Longstaff et al. 2008).
Mechanism of action
t-PA binds with fibrin through its lysine residues at the location approaching
fibrinogen-plasminogen binding site and converts the endogenous fibrinogen into
fibrin (Silva et al. 2012).
4 Antithrombotic Drugs-Pharmacology and Perspectives 125
Clinical applications
Contraindications
Side effects
Limitations
Because of the short half-life, alteplase requires continuous intravenous administra-
tion.
4.5.4 Anistreplase
Mechanism of action
After the anistreplase enters the blood, it diffuses to the surface of thrombus con-
taining fibrin, and binds to fibrin through the plasminogen lysine active center of the
126 T. Li et al.
complex. After slowly removing the acetyl group, the plasminogen on the surface of
fibrin is converted into plasmin and plays a role of thrombolysis.
Clinical applications
Side effects
Limitations
The high cost of anistreplase may be a problem for poor patients.
4.5.5 Tenecteplase
Mechanism of action
Through its lysine residue, tenecteplase binds to fibrin and activates plasminogen
binding to fibrin, which is consequently converted into plasmin. This effect is sig-
nificantly stronger than that of t-PA in the activation of plasminogen in the blood
circulation. Because tenecteplase is more fibrin specific than t-PA and selectively
activates plasminogen, it does not cause bleeding complications, which is common
in patients treated with streptokinase.
Clinical applications
• Hemorrhage diseases.
• Arteriovenous malformation or artery aneurysm.
• Acute ischemic stroke or subarachnoid hemorrhage.
Side effects
Limitations
When used in conjunction with other drugs that affect clotting function, it increases
the risk of bleeding significantly.
4.5.6 Reteplase
Mechanism of action
Reteplase converts inactive plasminogen into plasmin by hydrolyzing the peptide
bond between arginine at position 560 and valine at position 561 in the plasminogen
peptide chain.
Clinical applications
Acute myocardial infarction in adults is caused by coronary artery obstruction.
Contraindications
• Active hemorrhage.
• History of hemorrhage stroke and ischemic stroke within six months.
• History of recent surgery or trauma.
• Arteriovenous malformation or artery aneurysm.
• Uncontrolled hypertension.
128 T. Li et al.
Side effects
Limitations
The interaction of reteplase with other cardioactive drugs has not been studied. The
use of heparin, vitamin K antagonists and antiplatelet agents before and after r-PA
treatment may increase the risk of bleeding.
Although the dual antiplatelet therapy of aspirin and clopidogrel has been the cor-
nerstone of antithrombotic management for patients with acute coronary syndrome
or undergoing percutaneous coronary intervention, the atherosclerosis thrombosis
events still happen, which promotes the research of new antiplatelet. Currently, there
are some new drugs targeting the multiple molecules in the signaling pathway of
platelet aggregation that are on clinical trial, including P2Y12 receptor antagonists
such as MRS2179, MRS2500; oral GPIIb/IIIa receptor antagonists such as MNS,
RUC-1; platelet collagen antagonists such as GPVI antagonists kistomin, revacept
and GPIb antagonists 6B4-Fab monoclonal antibodies; nitric oxide donors LA846,
LA419; prostaglandin E receptor 3 antagonist DG-041; serotonin receptor antago-
nists, APD791; phosphatidylinositol 3-kinase inhibitor TGX-221, thrombin receptor
PAR-4 inhibitors. Thrombin receptor PAR-1 antagonists such as vorapaxar, atopaxar
can selectively interfere platelet activation induced by thrombin and inhibit patho-
logical thrombosis. Because the PAR-1 signaling pathway is not so critical in the
normal hemostatic process, it may not increase the risk of bleeding by inhibiting
PAR-1, which means that PAR-1 antagonists can be the ideal antiplatelet drugs the-
oretically. The combination of dual antiplatelet therapy and PAR-1 inhibitors may
thoroughly reduce the thrombosis induced by platelet.
With the gradual development of science and technology, we have a better under-
standing about the platelet functions and the factors or pathway associated with the
platelet adhesion, activation, aggregation, and it is predicted that more effective and
safer new antiplatelet drugs will come into being and bring more powerful help for
the clinical practices. The accumulated clinical evidences about the superiority and
limitations of antiplatelet drugs, as well as the emerging of new drugs and therapeutic
technologies, will markedly improve the patients’ antithrombotic therapies.
4 Antithrombotic Drugs-Pharmacology and Perspectives 129
4.6.2 Anticoagulants
The discovery of streptokinase and urokinase can degrade fibrins and allows them
to be used in thrombolytic therapy, but there is a systemic bleeding problem. The
second-generational plasminogen activators, such as anistreplase and t-PA, partially
alleviate bleeding problem. The third-generational thrombolytic drugs are mainly the
130 T. Li et al.
variants of t-PA, and have improved stability, security and efficacy. The ideal throm-
bolytic drugs have the following advantages: the specific selection of fibrin; good
revascularized effect; low incidence of vascular re-embolization and hemorrhage;
anti-PAI-1 effect, no antigenicity; reasonable price.
Although the thrombolytic drugs permitted on the clinical can dramatically reduce
the mortality after acute myocardial infarction and are used to treat a variety of
thromboembolic diseases, they have obvious shortages as well, including bleed-
ing tendency, limited specificity on fibrin, excessive dose of treatment, vascular
re-embolization. Some complementary drugs used with thrombolytic drugs also
have associated side effects The third-generational thrombolytic drugs created by
genetic engineering technology can not only improve the thrombolytic effects but
also enhance specificity on the fibrin, as well as the prolonged plasma half-life time
and resistance of PAI-1 inhibited effect, which contribute markedly to the security
of the drugs.
Up till now, thrombolytic drugs cannot reach the perfect effect that make the 100%
recovery of the coronary artery and totally avoid the systemic bleeding and vascu-
lar re-embolization. Therefore, it is necessary to create ideal thrombolytic drugs.
The target drug delivery of plasmin variant combined with liposome technique is a
developing direction in the future.
References
Graham DJ et al (2016) Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries
treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med
176(11):1662–1671
Guirgis M, Thompson P, Jansen S (2017) Review of aspirin and clopidogrel resistance in peripheral
arterial disease. J Vasc Surg 66(5):1576–1586
Holbrook A et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic
therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S–e184S
Huish S, Thelwell C, Longstaff C (2017) Activity regulation by fibrinogen and fibrin of streptokinase
from Streptococcus pyogenes. PloS one 12(1):e0170936.
Jaax ME, Greinacher A (2012) Management of heparin-induced thrombocytopenia. Expert Opin
Pharmacother 13(7)
Longstaff C, Williams S, Thelwell C (2008) Fibrin binding and the regulation of plasminogen
activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 6(3):212–223
Mega JL, Simon T (2015) Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet
and anticoagulant treatments. Lancet (Lond, Engl) 386(9990):281–291
Melandri G et al (2009) Review of tenecteplase (TNKase) in the treatment of acute myocardial
infarction. Vasc Health Risk Manag 5(1):249–256
Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular-weight heparin compared with
intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of
randomized, controlled trials. Ann Intern Med 140(3):175–183
Silva, MMCG et al. (2012) Regulation of fibrinolysis by C-terminal lysines operates through
plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost: JTH
10(11):2354–2360
Simpson D et al (2006) Reteplase: a review of its use in the management of thrombotic occlusive
disorders. Am J Cardiovasc Drugs: Drugs, Devices, Other Interv 6(4):265–285
Simpson D et al (2007) Spotlight on reteplase in thrombotic occlusive disorders. BioDrugs: Clin
Immunother, Biopharm Gene Ther 21(1):65–68
Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of
bleeding. N Engl J Med 368(14):1272–1274
Thelwell C, Longstaff C (2014) Biosimilars: the process is the product. The example of recombinant
streptokinase. J Thromb Haemost: JTH 12(8):1229–1233
Warkentin TE et al (2005) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients
receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106(12):3791–
3796
Warkentin TE et al (2010) Anti-PF4/heparin antibody formation postorthopedic surgery thrombo-
prophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of
immunization. J Thromb Haemost: JTH 8(3):504–512
Wiviott SD, Steg PG (2015) Clinical evidence for oral antiplatelet therapy in acute coronary
syndromes. Lancet (Lond, Engl) 386(9990):292–302
Chapter 5
Lipid-Modifying Drugs: Pharmacology
and Perspectives
Abstract Coronary artery disease (CAD) is one of the leading causes of death
worldwide. It is well known that dyslipidemia is a major pathogenic risk factor for
atherosclerosis and CAD, which results in cardiac ischemic injury and myocardial
infarction. Lipid-modifying drugs can effectively improve lipid abnormalities includ-
ing reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) or
increasing high-density lipoprotein cholesterol (HDL-C), and eventually decrease
the incidence of cardiovascular events. This chapter will review basic principles of
lipid metabolism and focus on the therapeutic strategies of lipids modifying drugs
(statins, proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, niacin,
polyunsaturated fatty acids, and so on) in patients with arteriosclerotic cardiovascu-
lar disease. Meanwhile, the challenges and perspectives of the lipid-lowering agents
currently in clinical practice as well as their limitations will be outlined.
Coronary artery disease (CAD) is the leading cause of death worldwide, and the treat-
ment and prevention of cardiovascular disease are facing severe challenges (Rosen-
son et al. 2014a). Lipid abnormalities usually persist in CAD patients. Low-density
lipoprotein (LDL) cholesterol (LDL-C) is an established risk associated with the
development of atherosclerosis and subsequent cardiovascular disease (CVD). High
triglycerides (TG) levels are associated with high cardiovascular risk, the presence of
CAD, and a higher mortality. Low high-density lipoprotein (HDL) cholesterol (HDL-
C) levels are also associated with CAD in patients submitted to coronary angiography
(Averna and Stroes 2017). The widespread availability, persuasive clinical database,
and relative safety of the lipid-modifying drugs have established pharmacologic con-
trol of blood lipids as an increasingly acceptable strategy. Strategies to reduce cardio-
vascular risk in primary and secondary prevention focus on optimization of LDL-C
levels. Primary prevention in patients without evident coronary disease remains a
highly desirable aim. Lifestyle interventions (diet, smoking cessation, and physi-
cal activity) are the first line of treatment and may achieve cholesterol reduction in
many patients. The national American campaign, promoting dietary management
and other lifestyle measures, has resulted in a reduction of mean blood cholesterol
levels and a fall in coronary heart disease (CHD) mortality rates. Clinical trials of
lipid-lowering drugs such as hydroxymethylglutaryl-CoA (HMG-CoA) reductase
inhibitors (statins) in the past decade have demonstrated safety and clinical event
reduction across the spectrum of cardiovascular risk (Nakamura et al. 2006). Still
debated, however, are the fiscal and ethical issues related to the cost-effectiveness
of lipid drug therapy in lower risk primary prevention (Taylor et al. 2011). Within
secondary prevention, the latest guidelines from the American Heart Association
(AHA) and American College of Cardiology (ACC) on secondary prevention sup-
port aggressive risk-reduction therapies for patients with established coronary and
other atherosclerotic vascular disease (Smith et al. 2011). For patients at very high
risk for future CHD, results from two clinical trials demonstrated the cardiovascular
benefit of lipid lowering to levels significantly less than those prescribed by ATP III
(LaRosa et al. 2005; Pedersen et al. 2005). Thus, the updated 2011 AHA-ACC guide-
lines support the recommended LDL-C goal of less than 100 mg/dL (2.6 mmol/L) for
all patients with CHD and other clinical forms of atherosclerotic disease, but allow
for an optional goal of less than 70 mg/dL (1.8 mmol/L) in such patients. These guide-
lines do not modify the ATP III recommendations for patients without atherosclerotic
disease who have diabetes or multiple risk factors and a 10-year risk level for CHD
greater than 20% (LDL-C: 100 mg/dL). Although drug-induced LDL-C reduction
remains an essential component of cardiovascular risk factor management, total risk
can also be modified through blood pressure control, dietary changes, increased
exercise, weight loss, and strictly no smoking.
Projected trends in elevated total cholesterol would lead to a 9.2 million increase in
annual cardiovascular disease events over 2010–2030 (Moran et al. 2010).
5.1.2 TG Metabolism
The data showed that the risk of coronary heart disease was increased in patients
with mild to moderate serum TG levels (Miller et al. 2011). Liver is the main organ
of triglyceride metabolism and plays an important role in the regulation of energy
metabolism (Tamura and Shimomura 2005). In the liver, absorption of fat from the
gut, lipolysis-induced liberation of fat from adipocytes, and synthesis of fatty acids
136 R.-X. Xu and Y.-J. Wu
from amino acids and carbohydrates are the three main sources of free fatty acids
(FFA). TG are then formed following the etherification of FFA with glycerol. The
liver cells secrete the TG in the form of very low-density lipoprotein (VLDL). Lipids
accumulate in the liver in the presence of excess FFA; this results from an imbalance
in the TG to VLDL ratio and is commonly a sequela of pregnancy, obesity, diabetes,
corticosteroid use, or total parenteral nutrition. When inadequate amounts of protein
are ingested or absorbed, the liver undergoes fatty alterations as the TG accumulate
due to limited protein availability for lipoprotein synthesis (Aarsland et al. 1996).
Elevated triglyceride and low HDL-C levels are believed to directly increase cardio-
vascular risk and should be treated initially with lifestyle modification, followed by
niacin, a fibrate, or intensification of LDL-C lowering therapy if necessary.
Lipoprotein is taking TC and cholesterol ester (CE) as the core, and the surface is
covered with polar phospholipids, cholesterol, and a small amount of protein. Plasma
lipoprotein can be divided into four categories by ultracentrifugation: chylomicrons
(CM), VLDL, LDL, and HDL, where LDL is the highest level of cholesterol-rich
lipoproteins (Gursky 2005).
Elevated plasma levels of LDL have been shown to be a common risk factor for
coronary artery disease and other atherosclerotic diseases (Krauss 1995). Intervention
trial data over the past two or three decades have demonstrated that cholesterol
modification, especially reduction in LDL-C levels, is associated with favorable
effects on reduction in CAD events. Clearance of LDL is mediated mainly by the LDL
receptor (LDLR) mediated endocytosis of the liver, and the dysfunction of the LDLR
is one of the major causes of coronary artery disease. The LDLR mediates the removal
of LDL particles by binding to apo B100 and apo E (Brown and Goldstein 1979). In
this process, if the ligand or receptor is abnormal, it will lead to the disorder of plasma
cholesterol levels, resulting in atherosclerosis and other cardiovascular diseases. The
most important site of LDLR expression is the liver, where its regulation is controlled
by sterol regulatory element-binding proteins (SREBPs). In addition, the expression
level of LDLR was also negatively regulated by oxidized LDL (ox-LDL), resulting in
significantly increased LDL levels in the blood. And it can cause the accumulation of
LDL in the blood vessel wall and promote the occurrence of coronary artery disease. A
prospective meta-analysis of data from 90,056 individuals in 14 randomized trials of
statins has shown that decreasing LDL-C level can significantly reduce the incidence
and mortality risk of ASCVD (Baigent et al. 2005).
HDL is a highly heterogeneous lipoprotein in plasma, and it is mainly synthesized
in liver and small intestine. HDL-C is a key factor in predicting cardiovascular disease
risk. Clinical data show that a 1% increase in serum concentrations of HDL-C can
decrease cardiovascular risk by 2–3% (Gotto and Brinton 2004). Although epidemi-
ological studies have shown a significant negative correlation between HDL-C levels
and cardiovascular risk (Expert Panel on Detection 2001), there is no cardiovascular
5 Lipid-Modifying Drugs: Pharmacology and Perspectives 137
benefit in clinical trials with elevated HDL-C alone. Therefore, the researchers also
proposed the HDL function hypothesis, that is, the HDL function and the existence
of a causal relationship between the protection of atherosclerosis, and HDL function
may not be assessed by the HDL-C level. HDL contributes to the elimination of
cholesterol in foam cells during arterial disease, either by returning cholesteryl ester
directly to the liver through the SR-BI receptor or through transfer to the apolipopro-
tein B (apo B)–containing lipoproteins in exchange for triglycerides. HDL also exerts
anti-inflammatory and antioxidant effects (Rohrer et al. 2004). In addition, HDL
also has the role of anti-thrombosis, endothelial repair, vascular regeneration, anti-
diabetes, and anti-microbial infection. These are the main research directions of the
HDL function hypothesis, in order to provide evidence for the correlation between
HDL function and coronary artery disease.
After the failure of HDL-C test, some researchers began to shift their attention to
the correlation between TG concentration and cardiovascular disease. Epidemiologi-
cal evidence also showed that elevated lipoprotein TG, cholesterol, and triglyceride-
rich lipoprotein may be another reason of increased cardiac death and all-cause
mortality. Values of more than 150 mg/dL are considered elevated (Expert Panel on
Detection 2001), and values below that level are associated with reduced cardio-
vascular risk even after major reduction of the LDL-C (Miller et al. 2008). TG are
not directly affect the formation of atherosclerosis due to the large size of VLDL
particles and chylomicrons, thus limiting their inability to penetrate the arterial wall
and cause foam cell formation (Talayero and Sacks 2011). Elevated TG and low
HDL-C levels are believed to directly increase cardiovascular risk. But there is a
debate about whether triglyceride is an independent risk factor for cardiovascular
disease. A study of more than 300,000 participants did not find an independent asso-
ciation between TG levels and CVD after adjustment for confounders (Emerging
Risk Factors et al. 2009). These studies confuse the relationship between TG and
cardiovascular disease.
Effective and reasonable lipid regulation can significantly reduce and delay the inci-
dence and progression of atherosclerosis, which is involved in hyperlipidemia, and
effectively reduce the incidence and mortality of cardiovascular events. In clinical
practice, the lipids modifying therapy should follow the principles of comprehen-
sive, individualized medication, long-term stability, and safety monitoring. Treatment
measures should be diversified to effectively regulate the metabolism of blood lipids
and improve the status of other related diseases in order to achieve a better therapeu-
tic effect. According to the level of risk assessment of patients with dyslipidemia,
different treatment methods and drugs should be chosen. And the lipid-regulating
process should be long-term adherence and moderate intensity. Safety monitoring
is to strengthen the awareness of safe medication and timely monitor of relevant
indicators, to find and evaluate the safety of medication. Possible drug interactions
138 R.-X. Xu and Y.-J. Wu
should be reviewed when other treatment adjustments are made, especially with
the introduction of drugs that interfere with catabolic pathways such as cytochrome
P450.
5.4.1 Statins
Statins are the first-line treatment for hypercholesterolemia because of their relatively
few side effects and predictable benefits for treating LDL-C. They decrease hepatic
cholesterol synthesis by inhibiting HMG-CoA reductase, which is the rate-limiting
step in cholesterol biosynthesis, resulting in increased LDL receptor activity with
enhanced clearance of LDL particles and precursors. Statins reduce LDL-C con-
centration by up to 60% with more modest increases in HDL-C and decreases in
triglyceride levels. They are highly effective in lowering lipids, and long-term safety
and efficacy are now established.
The Scandinavian Simvastatin Survival Study (4S) clinical trials have shown for
the first time that statins reduce the mortality and overall mortality of coronary
heart disease (Scandinavian Simvastatin Survival Study Group 1994). The Choles-
terol and Recurrent Events (CARE), the Long-Term Intervention with Pravastatin
in Ischaemic Disease (LIPID), and the Lescol Intervention Prevention Study (LIPS)
trials have confirmed the important role of these drugs in the secondary prevention
of coronary heart disease (Sacks et al. 1996; Long-Term Intervention with Pravas-
tatin in Ischaemic Disease Study Group 1998; Serruys et al. 2002). The West of
Scotland Coronary Prevention Study (WOSCOPS), the Air Force/Texas Coronary
Atherosclerosis Prevention Study (AFCAPS/TexCAPS), the Collaborative Atorvas-
tatin Diabetes Study (CARDS), the Justification for the Use of Statins in Prevention:
An Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Heart Protection
Study (HPS) trials have extended statin use from ASCVD patients to primary pre-
vention and a wider population (Shepherd et al. 1995; Downs et al. 1998; Colhoun
et al. 2004; Ridker et al. 2008; Heart Protection Study Collaborative G 2002). Stud-
ies of the pleiotropic effects of statins have suggested that they may also improve
endothelial function, have antioxidant and anti-inflammatory effects, and stabilize
atherosclerotic plaque. Statins can reduce the levels of cytokines and chemokines,
5 Lipid-Modifying Drugs: Pharmacology and Perspectives 139
and decrease the expression of leukocyte adhesion molecules. Statins can also reduce
the expression of interstitial collagenase, increase the level of interstitial collagen,
decrease the level of ox-LDL, reduce the production of reactive oxygen species,
inhibit thrombosis, and increase the fibrinolytic capacity.
Statins are the most widely prescribed agents for treatment of dyslipidemia and
are the most effective medicines to reduce LDL-C and lower the risk of cardiovascu-
lar and cerebrovascular events. Statins are generally thought to be well tolerated, and
their use is infrequently the cause of major complications in contemporary practice.
However, statin dose dependently elevated aminotransferase levels, which incidence
rate was about 0.5–3.0%, resulting in an abnormal liver function in patients (McKen-
ney et al. 2006). Muscle complaints represent the most frequent adverse reports
among patients treated with statins (Rosenson et al. 2014b). Preclinical studies show
that statins decrease mitochondrial function, attenuate energy production, and alter
muscle protein degradation, thereby providing a potential link between statins and
muscle symptoms; controlled mechanistic and genetic studies in humans are nec-
essary to further understanding (Stroes et al. 2015). And the problems are usually
reversible when the dose of statin is decreased or the medication is discontinued or
using a different statin. Among statins, pravastatin, fluvastatin, and rosuvastatin are
hydrophilic and may be associated with fewer side effects of the muscle. Clinical trial
data have suggested a modest, but statistically significant, increase in the incidence
of new-onset type 2 diabetes mellitus with statin use (Maki et al. 2014). Multiple
case reports and data from randomized trials have suggested a potential association
between statins and cognitive impairment in some individuals (Rojas-Fernandez et al.
2014).
Ezetimibe is currently the only available drug in the class of cholesterol absorption
inhibitors. Plasma cholesterol is derived from intestinal absorption and endogenous
synthesis. Ezetimibe is a potent cholesterol absorption inhibitor, and it is able to
selectively block the intestinal absorption of cholesterol and related phytosterols
(Sudhop et al. 2002). Ezetimibe localizes at the brush border of the small intestine,
and it inhibits the absorption of cholesterol, leading to a reduction in cholesterol
from the small intestine to the liver. And this can reduce the hepatic cholesterol
stores and increase the clearance of blood cholesterol. Monotherapy is primarily
effective in reducing total cholesterol, LDL-C, and apo B, but its effects of reduc-
ing triglycerides or lowering HDL-C are not obvious and even increase the level of
HDL-C. Ezetimibe lowers serum cholesterol concentrations by selectively inhibiting
the absorption of cholesterol and related phytosterols by the small intestine (Sud-
hop and von Bergmann 2002). Ezetimibe has a mechanism of action that is com-
plementary to that of the HMG-CoA reductase inhibitors, resulting in synergistic
cholesterol-lowering effects when these drugs are used in combination (Sudhop and
140 R.-X. Xu and Y.-J. Wu
von Bergmann 2002). Combining ezetimibe with statins therapy results in syner-
gistic cholesterol-lowering effects and may lower LDL-C levels by an additional
15–20% than statin monotherapy (Gagne et al. 2002). Similarly, in a double-blind,
randomized trial, when added to statin, ezetimibe resulted in incremental lowering of
LDL cholesterol levels and improved cardiovascular outcomes (Cannon et al. 2015).
The ENHANCE trial (Effect of combination Ezetimibe and High-Dose Simvastatin
vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous
Familial Hypercholesterolemia) showed that coadministration of ezetimibe with sim-
vastatin was safe, well tolerated, and provided higher LDL-C reduction compared
with simvastatin alone in adolescents with HeFH (van der Graaf et al. 2008). Gener-
ally speaking, ezetimibe monotherapy is an option for patients with statin intolerance,
and combination therapy with statins is effective in those requiring large LDL-C
reductions. However, its clinical benefit in primary and secondary prevention has yet
to be established.
The adverse effect profile for combined ezetimibe/statin therapy is similar to statin
monotherapy, except for an increase in the incidence of hepatic enzyme elevations.
In IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International
Trial), 10 mg ezetimibe combine high-dose statin therapy further reduced LDL-C
and decreased adverse cardiovascular outcomes without adverse effects in patients
who were stable after an acute coronary syndrome (Spinar and Spinarova 2014). And
pharmacokinetic differences for ezetimibe have been identified in patients with mild
hepatic impairment; however, no dosage adjustments for ezetimibe are indicated.
Statins are the most effective therapy currently available for reducing the LDL-C level
and preventing cardiovascular events. However, additional therapies are necessary
for patients who cannot reach the target LDL-C level when taking the maximum-
tolerated dose of a statin. Proprotein convertase subtilisin/kexin type 9 (PCSK9)
is a secreted protease that promotes the degradation of the LDLR, but its catalytic
activity is not required for receptor degradation. The discovery of PCSK9 represents
a major milestone in the understanding of LDL metabolism. The PCSK9 protein
can control the number of LDL receptors. When it binds to the LDLR, the latter is
destroyed with the LDL particle. Interference with PCSK9’s LDL receptor-binding
capacity or silencing the gene for PCSK9 allows the LDLR to recycle to the cell sur-
face to remove more circulating plasma LDL. Over a decade ago, individuals with
gain-of-function mutations of the PCSK9 gene were found to underlie a rare form
of autosomal dominant hypercholesterolemia. Human loss-of-function mutations in
PCSK9 are associated with low levels of LDL and decreased risk of vascular disease
(Kathiresan 2008; Cohen et al. 2006). These discoveries led to the development of
monoclonal antibodies directed against PCSK9 as a novel cholesterol-lowering agent
5 Lipid-Modifying Drugs: Pharmacology and Perspectives 141
(Stein and Raal 2014). Animal, genetic, and human modeling support PCSK9 inhi-
bition strategies. Human mAbs bind to PCSK9 in the extracellular space preventing
the binding of PCSK9 to the LDL/LDLR complex. PCSK9 inhibitor is able to reduce
LDL cholesterol levels by at least 50%, whether or not they received diet therapy,
statin therapy, or combined statin plus ezetimibe (Blom et al. 2014). In randomized
trials, the use of monoclonal antibodies that inhibits PCSK9 significantly reduced
LDL cholesterol levels and reduced the incidence of cardiovascular events (Sabatine
et al. 2015; Robinson et al. 2015).
Among possible adverse effects, neurocognitive adverse events were uncommon,
though the slight excess occurrence was not related to LDL cholesterol level. Com-
pared to placebo, myalgia was slightly more common in alirocumab but not dif-
ferent in evolocumab groups. Common side effects include injection site reactions,
nasopharyngitis, upper respiratory tract infection, influenza, and back pain. The risk-
benefit ratio will become better defined as long-term and larger clinical trials are being
completed. As a result, PCSK9 inhibition has implications for clinicians who man-
age patients with dyslipidemia or severe hypercholesterolemia through reduction of
LDL-C levels and potential reduction of the risk of ASCVD events.
5.4.4 Niacin
In clinical medicine, nicotinic acid was the first hypolipidemic agent shown to
decrease the incidence of secondary myocardial infarction (MI), and it is able to
reduce total mortality in MI patients. Niacin, as a lipid-regulating drug, reduces TC,
LDL, VLDL, and TG, and increases HDL cholesterol, making it a useful medica-
tion for monotherapy or in combination with statins or fibrates. It decreases hepatic
production of VLDLs and apo B-100, inhibits free fatty acid release from adipose
tissue, and stabilizes apo A-I from HDL-C, maintaining the structure and function of
HDL-C. Nicotinic acid is effective at increasing HDL level even in patients whose
only lipid abnormality is a low HDL value. But niacin has no affect on the fecal
excretion of fats, sterols, or bile acids.
Clinical trials of niacin, alone or combined with other lipid-altering therapy, show
that niacin use was associated with a significant reduction in the composite endpoints
of any CVD event and major coronary heart disease event (Lavigne and Karas 2013).
However, there are different perspectives; some studies have demonstrated that the
combined use of niacin and statins did not have an incremental benefit on cardiovas-
cular morbidity and mortality. In addition, the combination of niacin and simvastatin
did not result in a greater reduction in the incidence of cardiovascular events than
simvastatin alone in the AIM-HIGH trial, which randomized patients with stable
cardiovascular disease (Investigators et al. 2011).
Furthermore, there was an increased risk of serious adverse events when niacin
used in antilipemic doses, including an increased incidence of disturbances in dia-
betes control, as well as serious gastrointestinal, musculoskeletal, dermatological,
142 R.-X. Xu and Y.-J. Wu
infectious, and bleeding adverse events. Some sustained-release nicotinic acid for-
mulations have a lower incidence of flushing but a higher incidence of hepatotoxicity
when compared to immediate-release forms.
5.4.6 PUFA
Combination therapy is now increasingly used to achieve goal lipid levels. The prin-
ciple is to combine two different classes of agents with different mechanisms of
action, such as a statin and a fibrate or nicotinic acid. Most sources warn against
144 R.-X. Xu and Y.-J. Wu
Dyslipidemia is one of the major risk factors for atherosclerosis and CAD. A large
number of epidemiological data and large-scale clinical trials show that correcting
dyslipidemia is conducive to the prevention and treatment of arteriosclerotic car-
diovascular disease. It is important to achieve greater understanding of treatment
patterns in real-world patients by evaluating pharmacologic treatment of mixed dys-
lipidemia patients with CVD risk factors. Lifestyle and dietary interventions are
integral parts of primary and secondary cardiovascular prevention and are recom-
mended for all patients. Statin medications are the most effective and widely used
agents for cholesterol lowering and have the most robust clinical trial data to support
their use in lowering cardiovascular risk. Statins are generally well tolerated but the
use may be limited by hepatotoxicity or muscle side effects. Combination with less
dose statins and PCSK9 inhibitor, ezetimibe, or other lipid-lowering drugs as well
as minimizing the side effects may achieve a recommended target LDL-C of lower
than 100 mg/dL, and optimally lower than 70 mg/dL in patients with CHD or CHD
risk equivalents or multiple CHD risk factors conferring an estimated 10-year risk
for a cardiovascular event higher than 20%.
References
Aarsland A, Chinkes D, Wolfe RR (1996) Contributions of de novo synthesis of fatty acids to total
vldl-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J
Clin Invest 98:2008–2017
Averna M, Stroes E (2017) Lipid alterations beyond LDLewg. how to assess and manage
cardiovascular risk associated with lipid alterations beyond ldl. Atheroscler Suppl 26:16–24
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R,
Collins R, Simes R, Cholesterol Treatment Trialists C (2005) Efficacy and safety of cholesterol-
lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised
trials of statins. Lancet 366:1267–1278
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ,
Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA, Inves-
tigators D (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl
J Med 370:1809–1819
Brown MS, Goldstein JL (1979) Receptor-mediated endocytosis: insights from the lipoprotein
receptor system. Proc Natl Acad Sci USA 76:3330–3337
5 Lipid-Modifying Drugs: Pharmacology and Perspectives 145
Calder PC, Grimble RF (2002) Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin
Nutr 56(Suppl 3):S14–S19
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS,
Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C,
Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I (2015)
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–2397
Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart
JC, Tedgui A, Najib-Fruchart J, Staels B (2000) ClA-1/SR-BI is expressed in atherosclerotic
lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.
Circulation 101:2411–2417
Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M,
Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B (2001) Ppar-alpha and ppar-gamma
activators induce cholesterol removal from human macrophage foam cells through stimulation
of the ABCA1 pathway. Nat Med 7:53–58
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low ldl,
and protection against coronary heart disease. N Engl J Med 354:1264–1272
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason
MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004) Investigators C. primary prevention
of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin
diabetes study (cards): Multicentre randomised placebo-controlled trial. Lancet 364:685–696
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA,
Kruyer W, Gotto AM, Jr (1998) Primary prevention of acute coronary events with lovastatin in
men and women with average cholesterol levels: results of AFCAPS/TexCAPS. air force/texas
coronary atherosclerosis prevention study. JAMA 279:1615–1622
Emerging Risk Factors C, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson
A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J (2009)
Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000
Expert Panel on Detection E (2001) Treatment of High Blood Cholesterol in A. Executive summary
of the third report of the national cholesterol education program (ncep) expert panel on detection,
evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA
285:2486–2497
Gagne C, Gaudet D, Bruckert E, Ezetimibe Study G (2002) Efficacy and safety of ezetim-
ibe coadministered with atorvastatin or simvastatin in patients with homozygous familial
hypercholesterolemia. Circulation 105:2469–2475
Gotto AM Jr, Brinton EA (2004) Assessing low levels of high-density lipoprotein cholesterol as
a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol
43:717–724
Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN (2004) Activation of nuclear hormone
receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth.
Nat Med 10:245–247
Gursky O (2005) Apolipoprotein structure and dynamics. Curr Opin Lipidol 16:287–294
Harris WS (1997) N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65:1645S–
1654S
Heart Protection Study Collaborative G (2002) Mrc/bhf heart protection study of cholesterol low-
ering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial.
Lancet 360:7–22
Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P,
Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low hdl cholesterol
levels receiving intensive statin therapy. N Engl J Med 365:2255–2267
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM,
Gill EA, Wild RA, Wilson DP, Brown WV (2015) National lipid association recommendations
for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 9:129–169
146 R.-X. Xu and Y.-J. Wu
Kathiresan S (2008) Myocardial infarction genetics C. A PCSK9 missense variant associated with
a reduced risk of early-onset myocardial infarction. N Engl J Med 358:2299–2300
Krauss RM (1995) Dense low density lipoproteins and coronary artery disease. Am J Cardiol
75:53B–57B
Kromhout D, Giltay EJ, Geleijnse JM (2010) Alpha Omega trial G. N-3 fatty acids and
cardiovascular events after myocardial infarction. N Engl J Med 363:2015–2026
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein
JJ, Shepherd J, Wenger NK (2005) Treating to new targets I. intensive lipid lowering with
atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435
Lavigne PM, Karas RH (2013) The current state of niacin in cardiovascular disease prevention: a
systematic review and meta-regression. J Am Coll Cardiol 61:440–446
Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group (1998) Prevention of
cardiovascular events and death with pravastatin in patients with coronary heart disease and a
broad range of initial cholesterol levels. N Engl J Med 339:1349–1357
Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N (2014) The diabetes subpanel of the
national lipid association expert P. An assessment by the statin diabetes safety task force: 2014
update. J Clin Lipidol 8:S17–S29
McKenney JM, Davidson MH, Jacobson TA, Guyton JR (2006) National lipid association statin
safety assessment task F. Final conclusions and recommendations of the national lipid association
statin safety assessment task force. Am J Cardiol 97:89C–94C
Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E (2008) Investigators PI-T. impact
of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome
in the prove it-timi 22 trial J Am Coll Cardiol 51:724–730
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ,
Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S (2011) American
Heart Association Clinical Lipidology T, Prevention Committee of the Council on Nutrition PA,
Metabolism, Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular N, Council on
the Kidney in Cardiovascular D. Triglycerides and cardiovascular disease: A scientific statement
from the american heart association. Circulation. 123:2292–2333
Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, Liu J, Cheng J, Bibbins-Domingo K, Shen
YM, He J, Goldman L (2010) Future cardiovascular disease in china: Markov model and risk
factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc
Qual Outcomes 3:243–252
Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S,
Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, Group MS (2006) Primary prevention of car-
diovascular disease with pravastatin in japan (mega study): a prospective randomised controlled
trial. Lancet 368:1155–1163
Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar
DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson
TM (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse
cholesterol transport. Proc Natl Acad Sci USA 98:5306–5311
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen
FS, Lindahl C, Szarek M, Tsai J (2005) Incremental decrease in end points through aggressive lipid
lowering study G. high-dose atorvastatin versus usual-dose simvastatin for secondary prevention
after myocardial infarction: The ideal study: a randomized controlled trial. JAMA. 294:2437–2445
Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner
TD, Bishop-Bailey D (2007) Activation of pparbeta/delta induces endothelial cell proliferation
and angiogenesis. Arterioscler Thromb Vasc Biol 27:63–69
Reiffel JA, McDonald A (2006) Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol
98:50i–60i
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, Koenig W, Libby P,
Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group
5 Lipid-Modifying Drugs: Pharmacology and Perspectives 147
JS (2008) Rosuvastatin to prevent vascular events in men and women with elevated c-reactive
protein. N Engl J Med 359:2195–2207
Risk, Prevention Study Collaborative G, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi
V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R (2013) N-3 fatty acids
in patients with multiple cardiovascular risk factors. N Engl J Med 368:1800–1808
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal
FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ,
Investigators OLT (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular
events. N Engl J Med 372:1489–1499
Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of
diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269–278
Rojas-Fernandez CH, Goldstein LB, Levey AI, Taylor BA, Bittner V (2014) The national lipid
association’s safety task F. An assessment by the statin cognitive safety task force: 2014 update.
J Clin Lipidol 8:S5–S16
Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M,
Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L (2012)
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.
Circulation 125:1905–1919
Rosenson RS, Brewer HB, Rader DJ (2014a) Lipoproteins as biomarkers and therapeutic targets in
the setting of acute coronary syndrome. Circ Res 114:1880–1889
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA (2014b) The national lipid associa-
tion’s muscle safety expert P. An assessment by the statin muscle safety task force: 2014 update.
J Clin Lipidol 8:S58–S71
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne
R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA (2015) Open-label study of long-
term evaluation against LDLCI. Efficacy and safety of evolocumab in reducing lipids and
cardiovascular events. N Engl J Med 372:1500–1509
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW,
Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events
after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent
events trial investigators. N Engl J Med 335:1001–1009
Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering
in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S).
Lancet. 344:1383–1389
Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson
G, Strauss B, Meier B (2002) Lescol intervention prevention study I. Fluvastatin for prevention
of cardiac events following successful first percutaneous coronary intervention: a randomized
controlled trial. JAMA. 287:3215–3222
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ
(1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
West of scotland coronary prevention study group. N Engl J Med 333:1301–1307
Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF
Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL (2003) Association of nitrotyrosine levels with
cardiovascular disease and modulation by statin therapy. JAMA 289:1675–1680
Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy
SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL,
Spertus J, Stein JH, Taubert KA, World Heart F (2011) The preventive cardiovascular nurses A.
AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other
atherosclerotic vascular disease: 2011 update: a guideline from the american heart association
and american college of cardiology foundation. Circulation 124:2458–2473
Spinar J, Spinarova L (2014) Vitovec J [improved reduction of outcomes: Vytorin efficacy
international trial (studie improve-it)]. Vnitr Lek 60:1095–1101
148 R.-X. Xu and Y.-J. Wu
Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N,
Patterson SD, Lobe DC, Johnson TG (2007) Triglyceride:High-density lipoprotein cholesterol
effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.
Arterioscler Thromb Vasc Biol 27:359–365
Staels B, Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor
agonists. Diabetes 54:2460–2470
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (1998) Mechanism
of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088–2093
Stein EA, Raal F (2014) Reduction of low-density lipoprotein cholesterol by monoclonal antibody
inhibition of PCSK9. Annu Rev Med 65:417–431
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgo-
zoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele
RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Cat-
apano AL, Chapman MJ, Ginsberg HN (2015) European atherosclerosis society consensus P.
Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society
consensus panel statement on assessment, aetiology and management. Eur Heart J 36:1012–1022
Sudhop T, von Bergmann K (2002) Cholesterol absorption inhibitors for the treatment of
hypercholesterolaemia. Drugs 62:2333–2347
Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann
K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation
106:1943–1948
Talayero BG, Sacks FM (2011) The role of triglycerides in atherosclerosis. Curr Cardiol Rep
13:544–552
Tamura S, Shimomura I (2005) Contribution of adipose tissue and de novo lipogenesis to
nonalcoholic fatty liver disease. J Clin Invest. 115:1139–1142
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S (2011) Statins for
the primary prevention of cardiovascular disease. Cochrane Database Syst Rev CD004816
van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ,
Kastelein JJ (2008) Efficacy and safety of coadministration of ezetimibe and simvastatin in
adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 52:1421–1429
Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H, Akinbami MA, Wang Q, Chen YE (2002)
Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation
and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem
277:11505–11512
Chapter 6
Hypertension Drug Therapy
Rutai Hui
Abstract Hypertension is still the number one global killer. No matter what causes
are, lowering blood pressure can significantly reduce cardiovascular complications,
cardiovascular death, and total death. Unfortunately, some hypertensive individu-
als simply do not know having hypertension. Some knew it but either not being
treated or treated but blood pressure does not achieve goal. The reasons for inade-
quate control of blood pressure are many. One important reason is that we are not
very familiar with antihypertensive agents and less attention has been paid to comor-
bidities, complications as well as the hypertension-modified target organ damage in
patients with hypertension. The right antihypertensive drug was not given to the right
hypertensive patients at right time. This reviewer studied comprehensively the lit-
erature, hopefully that the review will help improve antihypertensive drug selection
and antihypertensive therapy.
Abbreviations
R. Hui (B)
Chinese Academy of Medical Sciences FUWAI Hospital Hypertension Division, 167 Beilishilu
West City District, 100037 Beijing People’s Republic of China, China
e-mail: [email protected]
Introduction
Hypertension: Even though sustained increases in blood pressure (BP) above
115/75 mm Hg can increase cardiovascular disease morbidity and mortality (Sacks
and Campos 2010), the average adult BP < 120/ < 80 mmHg is defined as normal
BP as measured with a sphygmomanometer by using BP cuff around the upper arm
while sitting according to ACC/AHA (American College of Cardiology/American
Heart Association) guideline 2017 (Whelton et al. 2017). The European Society of
Hypertension (ESH)/The European Society of Cardiology (ESC) guideline (2018)
for the management of arterial hypertension (Williams et al. 2018) defined “a prehy-
pertension status in two categories: (1) normal BP of 120–129 mm Hg or diastolic
BP of 80–84 mm Hg; and (2) high-normal BP with systolic BP of 130–139 mm Hg
or diastolic BP of 85–89 mm Hg.” The definition of high-normal BP is not accepted
widely because this may confuse patients that they are still at normal BP range,
reluctant to take non-pharmacological or pharmacological management to control
their BP. In adults, hypertension is generally defined as a sustained systolic BP ≥
140 mm Hg and/or a sustained diastolic BP ≥ 90 mm Hg at office measurement,
which is equivalent to a 24-h ambulatory blood pressure monitoring (ABPM) average
6 Hypertension Drug Therapy 151
Heart disease: The high BP load is placed on the left ventricle, resulting in left
ventricular hypertrophy. With pressure load being longer, the heart enlarges and
dilates, and hypertrophy is more marked than dilation, until the left heart begins to
fail, particularly when the heart reaches 500 g in size. Congestive heart failure and
cardiac arrhythmias may result from the failing heart (Shenasa and Shenasa 2017;
Olivetti et al. 2000).
Heart failure: In the Framingham Heart Study, comparing the highest BP with
the lowest BP, the age-adjusted risk of congestive heart failure was 2.3 times higher
in men and 3 times higher in women (Patrick et al. 1971).
Coronary artery disease: Data from multiple risk factor intervention trial showed
that the relative risk for coronary artery disease mortality was 2.3 to 6.9 times higher
in persons with mild to severe hypertension than in those with normal BP (Winkleby
et al. 1997; Multiple Risk Factor Intervention Trial Group 1976; Stamler et al. 2012;
Multiple risk factor intervention trial 1982; Culleton et al. 1999). The relative risk for
stroke ranged from 3.6 to 19.2 times. The population-attributable risk for coronary
artery disease varied from 2.3 to 25.6%, whereas ranged from 6.8 to 40% for stroke
(Winkleby et al. 1997; Multiple Risk Factor Intervention Trial Group 1976; Stamler
et al. 2012; Multiple Risk factor Changes and Mortality Results 1982; Culleton et al.
1999).
Central nerve systems: The effect of hypertension on small arteries and arterioles
in the brain leads to thickening and loss of resilience. This hypertensive hyalinization
may produce occlusion with resultant small lacunar infarcts. This arteriolar sclerosis
also results in vessels that are more prone to rupture. The so-called hypertensive
hemorrhage is one of the causes of a stroke.
Stroke risk: Huang et al. (2013) reported that compared with an optimal BP
(<120/80 mm Hg), prehypertension was also associated with a 66% increased risk in
stroke after adjustment for multiple cardiovascular risk factors in a meta-analysis of
pooled data from 19 prospective cohort studies involving 762,393 patients (Huang
et al. 2014). In subjects with low range of prehypertension (120–129/80–84 mm
Hg), the risk of stroke increases 44%; in subjects with high range of prehypertension
(130–139/85–89 mm Hg), the risk of stroke increases to 95%.
Renal complications: The renal vasculature shows changes with hypertension,
including, but not limited to, hyaline arteriolosclerosis (thickening of small renal
arteries and arterioles, so-called nephrosclerosis) and small cortical scars with a
reduction in renal size. The changes seen in arterioles may include fibrinoid necrosis
as a consequence of hypertensive emergency (malignant hypertension) when systolic
BP is ≥180 mm Hg and/or diastolic BP ≥ 120 mm Hg along with signs of acute
or ongoing end-organ damage. Nephrosclerosis is one of the possible complications
of long-standing hypertension. The risk of hypertension-induced end-stage kidney
disease (ESKD) is higher in black patients, even when BP is under well control.
Furthermore, patients with diabetic nephropathy who are hypertensive also have a
high risk for developing ESKD (Whelton et al. 2017; Williams et al. 2018).
Hypertension is the most important modifiable risk factor for coronary heart dis-
ease (the leading cause of death in North America), stroke (the third leading cause
of death), congestive heart failure, ESKD, and peripheral vascular disease (Whelton
6 Hypertension Drug Therapy 153
et al. 2017; Williams et al. 2018). The Framingham Heart Study found a 72% increase
in the risk of all-cause death and a 57% increase in the risk of any cardiovascular
events in patients with hypertension who were also diagnosed with diabetes mellitus
(Chen et al. 2011).
Lowering BP can low cardiovascular disease risk. Since hypertension is the lead-
ing risk factor for cardiovascular disease morbidity and mortality worldwide, greater
efforts should be devoted to improving hypertension control. Despite our tremendous
scientific understanding of the cardiovascular risk factors that predispose to adverse
health outcomes, pinpointing the BP for optimal risk reduction continues to evolve
and be debated. Even we know for a long time that systolic BP over 110–115 mmHg
increases cardiovascular risk in every age group. Most BP management guidelines
remained focused on BP-lowering treatment in those patients meeting conventional
hypertension definitions. The recent landmark clinical trial SPRINT (Systolic Blood
Pressure Intervention Trial) provided strong evidence that high BP patients with high
cardiovascular disease risk (SPRINT Research Group 2015). Achieving systolic BP
between 120 and 124 mm Hg results in lower cardiovascular events and mortality than
systolic BP between 125 and 129 mm Hg (Tajeu et al. 2017). It has been reported that
with more than 7 years of follow-up, 63.0% incident cardiovascular events occurred
in individuals with BP < 140/90 mm Hg (Ziaeian and Fonarow 2017).
These findings held for individuals either younger or older than 65 years of age,
men or women, and across all race and ethnic groups studied. The conventional
standard for controlled BP < 140/90 mm Hg is not enough in terms of cardiovascular
disease prevention. The conventional definitions of hypertension may not adequately
encompass the population having events, indicating that under-treatment of BP is a
significant public health burden; a much larger population is at risk, with BP <
140/90 mm Hg but above optimal. Under this circumstance, adherence to guidelines
must be improved and expanded for patients with unquestionable elevations in BP and
lowering BP targets to SPRINT-defined levels is reasonable for selected populations
along with the use of other effective cardiovascular risk reductions strategies.
It is well known that antihypertensive therapy reduces cardiovascular disease
risk. It has been noticed that the cardiovascular disease event rate was nearly 3 times
greater in patients not taking any antihypertensive medication than in those taking
antihypertensive treatment (Gabriel et al. 2017).
The fundamental goal of treatment should be the prevention of the important
endpoints of hypertension, such as heart attack, stroke, and heart failure. Although
traditionally we reassured patients that they do not have hypertension at BP levels <
140/90 mm Hg or their hypertension was adequately controlled if BP < 140/90 mm
Hg, more and more evidences support that the vast majority of cardiovascular events
in the modern era occurred among individuals below that BP threshold. Identifying
patients that would benefit from SPRINT targeted BP levels could effectively reduce
event rates further.
Why should we actively lower BP? Most individuals diagnosed with hypertension
will have increased BP as they age. Clinical trials demonstrated that antihypertensive
therapy will benefit patients with lowering stroke risk 35–40%, myocardial infarction
risk 20–25%, and heart failure risk more than 50%. It is estimated that one death can be
154 R. Hui
Take two BP readings one to two minutes apart and average the readings (pre-
ferred). BP should be measured in both arms at initial evaluation. Consider checking
standing readings after one and three minutes to screen for postural hypotension,
especially in the elderly.
Hypertension is defined as office systolic BP at least 140 mmHg and/or diastolic
BP at least 90 mmHg, which is equivalent to a 24 h ABPM average of at least
130/80 mmHg, or an HBPM average at least 135/85 mmHg. When hypertension is
suspected because of an elevated screening BP, the diagnosis of hypertension should
be confirmed either by repeated office BP measurements over a number of visits or
6 Hypertension Drug Therapy 155
Systolic BP Diastolic BP
Normal BP <120 mm Hg, and <80 mm Hg
Elevated BP 120–129 mm Hg, and <80 mm Hg
Hypertension
The presence of HMOD further increases the risk of cardiovascular morbidity and
mortality, and cardiovascular target organ damage should be screened as part of risk
assessment in hypertensive patients.
Two classes of HMOD are subclinical and established cardiovascular and renal
disease.
(1) Arterial stiffening (pulse pressure wide): In older people, pulse pressure ≥
60 mm Hg; carotid–femoral PWV (pulse wave velocity) > 10 m/s;
(2) Left ventricular hypertrophy by using electrocardiogram: Sokolow–Lyon index
> 35 mm, or RavL ≥ 11 mm, Cornell voltage duration product > 2440 mm *
ms, or Cornell voltage > 28 mm in men or > 20 mm in women.
(3) Echocardiographic left ventricular hypertrophy: Left ventricular mass index >
50 g/m2.7 (men) > 47 g/m2.7 (hight in m2.7 ) (women); BSA (body surface area)
normalization may be used in normal-weight patients: left ventricular mass
index = left ventricular mass/BSA (g/m2 ), men > 115 g/m2 , women > 95 g/m2 .
(4) Microalbuminuria: 30–300 mg/24-h urine collection, or elevated albu-
min/creatinine ratio 30–300 mg/g, or 3.4–34 mg/mmol (preferred on morning
spot urine).
(5) Moderate chronic kidney disease with estimated glomerular filtration rate
(eGFR) 30–59 ml/min/1.73 m2 .
6 Hypertension Drug Therapy 157
High BP is the single biggest risk factor for cardiovascular disease. Hypertension
can cause the following diseases:
(1) Cerebrovascular disease: Ischemic stroke, hemorrhage, TIA (transient ischemic
attack).
(2) Coronary artery disease: Angina pectoris, myocardial infarction, and myocardial
revascularization; and the presence of atheromatous plaque on imaging.
(3) Heart failure, including HFpEF.
158 R. Hui
Sex (men > women), age, smoking (current or past), total cholesterol, HDL-C (high-
density lipoprotein cholesterol), serum uric acid, overweight or obesity, family his-
tory of premature cardiovascular disease (men < 55 years and women < 65 years);
family or parental history of early-onset hypertension, early-onset menopause, seden-
tary lifestyle, psychosocial and socioeconomic factors, and heart rate: rest > 80
beats/min.
Insufficiency Cohort study (Denker et al. 2002), 86% of recruited participants had
hypertension.
A meta-analysis from 18 cohort studies involving 257,384 patients identified a
lifetime risk of cardiovascular death, nonfatal myocardial infarction, and fatal or
nonfatal stroke, which was substantially higher in adults with ≥2 cardiovascular risk
factors than in those with only one risk factor (Berry et al. 2012). Treating some of the
modifiable risk factors may reduce BP and cardiovascular risk through modification
of shared pathology.
Cardiovascular and renal complications are the most important outcomes of chronic
hypertension. For individuals at age 40–70 years, each increment of 20 mmHg in
systolic BP or 10 mmHg in diastolic BP across the entire BP range from 115/75
to 185/115 mmHg doubles the risk of cardiovascular disease (James et al. 2014).
Treatment of hypertension should focus not only on BP readings.
ACC/AHA have published an online tool to calculate patients’ 10-year and life-
time ASCVD risk [ACC: ASCVD Risk Estimator Plus]. ESH/ESC 2018 guideline
(Williams et al. 2018) recommended to apply SCORE system to assess cardiovascu-
lar risk for patients with hypertension, but unfortunately, the SCORE system alone
may underestimate the risk, such as when HMOD present, especially left ventricular
hypertrophy, chronic kidney disease, and advanced retinopathy. HMOD further raises
the risk of cardiovascular morbidity and mortality. Therefore, in all patients with
hypertension, HMOD detection should be included in stratification of cardiovascular
risk to improve diagnostic, prognostic, and therapeutic processes.
It has long been known that treating cardiovascular risk factors such as obesity, dia-
betes, hypercholesterolemia, and smoking are as important as managing hypertension
in lowering overall cardiovascular risk. Meta-analysis has confirmed that lowering
BP reduces cardiovascular disease and death in people with baseline systolic BP of
140 mmHg or higher (Brunström and Carlberg 2018). However, primary preven-
tive BP lowering does not benefit people with lower baseline BP (except those with
preexisting cardiovascular disease) (Brunström and Carlberg 2018). One Cochrane
review found insufficient evidence to justify lower BP targets (≤135/85 mmHg) in
people with hypertension and cardiovascular disease (Saiz et al. 2018).
Cardiovascular Risk in Patients with Hypertension
160 R. Hui
SCORE is suitable for those who are not already at high or very high risk due to
established cardiovascular disease, renal disease, or diabetes, a markedly elevated
single factor (e.g., cholesterol) or hypertensive left ventricular hypertrophy.
The risk calculators are usually calibrated according to global risk factors, includ-
ing office BP readings. Cardiovascular risk in patients with hypertension can’t be
completely reversed by BP lowering alone even BP goal was well achieved. If anti-
hypertensive treatment has been long-standing, then the treated BP value will be
used to calculate the risk which will be lower than the patient’s actual risk. How to
impute out-of-office BP values into risk calculators becomes another conundrum.
In the estimation of cardiovascular risk, these various limitations should be kept in
mind in clinical practice.
To screen major cardiovascular risk factors to provide rationale for optimizing
lifestyle and to track risk factor progression to provide needed treatment.
Low risk: Hypertension disease stage 1: No other risk factors, high-normal systolic
BP 130–139 mm Hg and/or diastolic BP 85–89 mm Hg, or grade 1 systolic BP
140–159 mm Hg and/or diastolic BP 90–99 mm Hg.
Moderate risk: Stage 1 hypertension: No other risk factors, grade 2 systolic BP
160–179 mm Hg and/or diastolic BP 100–109 mm Hg.
High risk: Stage 1 hypertension: No other risk factors, grade 3 systolic BP 180 mm
Hg and/or diastolic BP 110 mm Hg.
(2) Hypertension stage 1, uncomplicated, having 1 or 2 risk factors:
Low risk: High-normal systolic BP 130–139 mmHg and/or diastolic BP 85–89 mm
Hg.
Moderate: Grade 1 systolic BP 140–159 mm Hg and/or diastolic BP 90–99 mm
Hg.
Moderate to high risk: Grade 2 systolic BP 160–179 mm Hg and/or diastolic BP
100–109 mm Hg.
High risk: Grade 3 systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg.
(3) Stage 1 hypertension (uncomplicated): Having ≥3 risk factors.
Low to moderate risk: High-normal systolic BP 130–139 mmHg and/or diastolic BP
85–89 mm Hg.
Moderate to high risk: Grade 1 systolic BP 140–159 mm Hg, diastolic BP 90–
99 mm Hg.
High risk: Grade 2 systolic BP 160–179 mm Hg and/or diastolic BP 100–109 mm
Hg. Grade 3 systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg.
b. Stage 2 (asymptomatic disease): Presence of HMOD, chronic kidney disease
grade 3, or diabetes mellitus without organ damage.
(1) Ascertained clinical cardiovascular diseases, including but not limited to acute
coronary syndrome, acute myocardial infarction, other arterial revasculariza-
tion; stroke, transient ischemic attack; aortic aneurysm and dissection as well
as peripheral artery disease.
(2) Confirmed cardiovascular disease on imaging (angiography or ultrasound),
including atherosclerotic plaques (e.g., >50% of stenosis, not including only
increase in the carotid intima-media thickness).
(3) Diabetes mellitus with target organ damage (i.e., proteinuria) or with a major
risk factor (grade 3 hypertension or hypercholesterolemia).
(4) Severe chronic kidney disease (eGFR < 30 ml/min/1.73 m2 ).
(5) Calculated 10-year ASCVD risk score >10% using the ASCVD algorithm
(Arnett et al. 2019).
Marked elevation of a single risk factor, particularly cholesterol, e.g., familial hyperc-
holesterolemia, or Grade 3 hypertension (SBP ≥ 180 mm Hg and/or DBP ≥ 110 mm
Hg); with diabetes, hypertensive left ventricular hypertrophy, moderate chronic
kidney disease (eGFR 30–59 ml/min/1.73 m2 ), a calculated 10-year risk score of
5–10%.
apoB ≥ 130 mg/dl (corresponds to low-density lipoprotein-C, LDL-C > 160 mg/dL);
ankle-brachial index <0.9. The available evidence suggests that many patients with
hypertension would benefit from statin therapy, blood glucose-lowering therapy,
antiplatelet therapy, and anticoagulant therapy (Williams et al. 2018; Arnett et al.
2019).
ACE inhibitors suppress the activity of ACE; an enzyme is responsible for the con-
version of angiotensin I into angiotensin II. At least 13 ACE inhibitors are available in
clinical practice at present, including captopril, enalapril, fosinopril, lisinopril, moex-
ipril, perindopril, quinapril, ramipril, trandolapril, benazepril, cilazapril, imidapril,
and zofenopril.
Mechanisms of action (Messerli et al. 2018): Under normal conditions,
angiotensin II binds to angiotensin receptor Type 1 and has the following effects:
(1) Vasoconstriction and vascular smooth muscle hypertrophy, which lead to BP
elevation and hypertension. Further, constriction of the efferent arterioles of the
kidney leads to increased perfusion pressure in the glomeruli.
(2) Ventricular remodeling and ventricular hypertrophy of the heart by stimulat-
ing the proto-oncogenes c-fos, c-jun, c-myc, transforming growth factor beta
through fibrogenesis and apoptosis.
(3) Stimulation of the adrenal cortex to release aldosterone, which acts on kid-
ney tubules, causes sodium and chloride ions retention and potassium excre-
tion. Sodium is a “water-holding” ion, so water is also retained, which leads to
increased blood volume, hence an increase in BP.
(4) Stimulation of the posterior pituitary releases vasopressin (antidiuretic hor-
mone), which acts on the kidneys to increase water retention. If antidiuretic
hormone production is excessive in heart failure, Na+ level in the plasma may
fall (hyponatremia), and this is a sign of increased risk of death in heart failure
patients.
ACE is located in the endothelial cells of large and small vessels, capillaries,
and venules, and in pulmonary endothelial cells. ACE inhibitors target ACE, which
catalyzes the conversion of angiotensin I to angiotensin II, leading to vasodilation of
small resistance arteries, reduction in total peripheral resistance, and reduction of BP.
Because cardiac output remains unchanged, despite BP lowering, heart rate remains
unchanged, and no postural hypotension occurs, likely because ACE inhibitors reset
baroreceptor function (Messerli et al. 2018).
164 R. Hui
(Hon-Yen et al. 2013; Sica 2003). As such, ACE inhibitors should be the drug treat-
ment of choice for patients with chronic kidney disease regardless of race or dia-
betic status. ACE inhibitors (and ARB) should not be a first-line treatment for black
hypertensives without chronic kidney disease (James et al. 2014). Results from the
ALLHAT trial showed that thiazide-like diuretics and CCBs were both more effective
as monotherapy in improving cardiovascular outcomes compared to ACE inhibitors
for this subgroup (Davis et al. 2002; Wright et al. 2002).
ACE inhibitors have been shown to reduce the prevalence of malignant cardiac
arrhythmias and the reduction in sudden cardiac death reported in large clinical trials
(Binkley et al. 1993).
The BP-lowering effect of ACE inhibitors is supposed to maintain for months and
years, because ACE inhibitors fail to suppress production of angiotensin II by alterna-
tive enzymatic pathways to ACE. The enzymatic pathway, such as chymase, trypsin,
and cathepsin, can also convert angiotensin I to angiotensin II. On the long term,
this alternative enzymatic pathway could up-regulate the production of angiotensin
II, particularly in the vasculature and the myocardium, resulting in attenuation of the
BP-lowering effect of ACE inhibitors (Kramkowski et al. 2007).
Since ACE is also responsible for the degradation of angiotensin (1–7), which
is formed in the endothelial layer of human blood vessels, and angiotensin (1–7)
acts as vasodilator and antiproliferative agent. Blocking ACE by ACE inhibitors
suppresses the degradation of angiotensin (1–7), and accumulation of angiotensin
(1–7) provides additional favored effect, protecting target organs. Indeed, long-term
administration of ACE inhibitors is associated with a reduction of left ventricular
hypertrophy, an improvement of endothelial function, a de-stiffening of large arteries,
and a remodeling of large and small arteries (Russ et al. 2018).
Side effects: Compared with ARBs, ACE inhibitors have several-fold higher
incidence of side effects at most doses (Law et al. 2003).
(1) The most common side effect of ACE inhibitors is a dry and irritating cough
(5–35%). This is a class effect which can occur in patients taking any one of the
ACE inhibitors and not dose-dependent. The exact mechanism of ACE inhibitor-
induced cough is not known. It is likely multifactorial event, and most likely
related to the inhibition of bradykinin and substance P breakdown that results
in accumulation of these protrusive mediators in respiratory tract. Bradykinin
also stimulates the production of prostaglandins which may contribute to cough
as well (prostaglandin E2 via the EP3 Receptor) (Arnett et al. 2019). Cessation
of ACE inhibitor use is the only way to stop the cough (Messerli et al. 2018).
(2) The other reported adverse effects are hepatotoxicity and effect on the fetus
(Sidorenkov and Navis 2014).
(3) Potentially life-threatening side effect is angioneurotic edema, a rare (0.55%
of white patients and 1.62% of black patients), but greater risk for African-
Americans, should pay extra-attention to the adverse effect because 20% of
them may be fatal (Agostoni et al. 1999). Angioneurotic edema is explained
by an increased in bradykinin concentrations, and/or increased concentration
of other peptides such as substance P as well. In 26 trials with 74,857 patients,
166 R. Hui
0.30% of weighted incidence of angioedema with ACE inhibitors has been iden-
tified (95% CI: 0.28–0.32%) (Makani et al. 2012). The incidence of angioneu-
rotic edema has been reported at about 1/2500 within the first week of taking
ACE inhibitors (Israili and Hall 1992; Brown et al. 1997; Messerli and Nuss-
berger 2000). However, it can first occur from a few hours to 8 years after
an ACE inhibitor is initiated (Yusuf et al. 2008). The subsequent incidence of
angioedema with ACE inhibitors is around 1 in 500 patients/year (Messerli and
Nussberger 2000; Slater et al. 1988; Grossman et al. 2000).
(4) A moderate reduction in renal function: Angiotensin II constricts the efferent
arteriole to a greater extent than the afferent one, blockade of ACE results in low
production of angiotensin II, a fall in glomerular afferent arteriolar flow, and the
vasodilatation of the glomerular efferent arteriole, such that GFR is maintained
despite low perfusion. If patients with severe renal artery stenosis or solitary
kidney, in case of dehydration, use of NSAIDs (non-steroidal anti-inflammatory
drugs), heart failure, and microvascular disease, functional renal insufficiency
occurs when using ACE inhibitors (Messerli et al. 2018).
Patients starting with an ACE inhibitor usually have a modest reduction
in GFR which is stabilized after several days. Serum creatinine could be tem-
porarily raised but not greater than 30% of the level before using ACE inhibitors,
and then stabilized after a week of treatment. This change represents a hemo-
dynamic (not a toxic) effect and is not a contraindication to continue ACE
inhibitor. Indeed, ACE inhibitor treatment has been shown in some, but not all
studies, to delay ESKD. Renal failure becomes especially problems when the
patient is concomitantly taking ACE inhibitor with an NSAID and a diuretic;
the risk of developing renal failure is significantly increased (Thomas 2000). In
patients with decreased renal perfusion significantly, such as congestive heart
failure, volume depletion, polycystic kidney disease, and renal artery steno-
sis, angiotensin II-dependent efferent vasomotor tone plays very important role
in maintenance of GFR. In these patients, initiation of ACE inhibitor therapy
blocks the production of angiotensin II and then could lead to a decrease in
renal perfusion and may result in renal function deterioration. Therefore, it is
necessary to monitor serum creatinine and electrolyte levels before and again
1 week after therapy (Messerli et al. 2018).
(5) Hyperkalemia: An ACE inhibitors suppress angiotensin II production and
reduce plasma aldosterone levels. Since aldosterone is responsible for increasing
the excretion of potassium, ACE inhibitors can cause retention of potassium and
hyperkalemia. Hyperkalemia can slow the impulse conduction velocity in both
nerves and muscle systems. Abnormal impulse conduction velocity may lead
to arrhythmia and cardiac dysfunction in cardiac tissue and muscle weakness,
paresthesia, nausea, diarrhea, and others in neuromuscular systems. In patients
receiving ACE inhibitors, serum potassium level should be closely monitored in
case of hyperkalemia (Sidorenkov and Navis 2014). ACE inhibitors usually do
not lead to significant biochemical changes in patients with normal kidney func-
tion. In those with impaired kidney function, ACE inhibitors can raise the serum
potassium concentration to the levels dangerous and requiring either a change
6 Hypertension Drug Therapy 167
Recommended ACE inhibitor dose for hypertension treatment (Aram et al. 2003)
(JNC-7)
Benazepril, equivalent daily dose 10 mg, starting from 10 mg, usually 30–40 mg,
maximum daily 80 mg.
Captopril, equivalent daily dose 25 mg twice a day, starting from 12.5 to 25 mg twice
a day, usually 25–50 mg twice a day, maximum daily 450 mg.
Enalapril, equivalent daily dose 5 mg, starting from 5 mg, usually 10–40 mg,
maximum daily 40 mg.
Fosinopril, equivalent daily dose 10 mg, starting from 10 mg, usually 20–40 mg,
maximum daily 80 mg once a day. Unlike most ACE inhibitors that are primarily
excreted by the kidneys, fosinopril is eliminated by both renal and hepatic pathways,
making it a safer choice in patients with renal failure and heart failure.
Lisinopril, equivalent daily dose 10 mg, starting from 10 mg, usually 10–40 mg,
maximum daily 80 mg.
Moexipril, equivalent daily dose 7.5 mg, starting from 7.5 mg, usually 7.5–30 mg,
maximum daily 30 mg.
Perindopril, equivalent daily dose 4 mg, starting from 4 mg, usually 4–8 mg,
maximum daily 16 mg.
Quinapril, equivalent daily dose 10 mg, starting from 10 mg, usually 20–80 mg,
maximum daily 80 mg.
Ramipril has been demonstrated to reduce mortality and to slow heart failure develop-
ment in patients with myocardial infarction. The cardiovascular beneficial effects can
also be observed in subjects regularly using ramipril without hypertension. Currently,
ramipril is the only ACE inhibitors for which such effects are actually evidence-based
(AIRE Study Investigators 1993).
Trandolapril, equivalent daily dose 2 mg, starting from 1 mg, usually 2–4 mg,
maximum daily 8 mg.
168 R. Hui
Use in combination: There are warnings about the combination of ACE inhibitors
with ARBs (Shelley 2014). Patients with heart failure may benefit from the com-
bination in terms of reducing morbidity and ventricular remodeling (Krum et al.
2004; Solomon et al. 2005). In the treatment of nephropathy, this combination of
ACE inhibitor with ARB therapy partially reversed the proteinuria and also exhib-
ited a reno-protective effect in patients afflicted with diabetic nephropathy, and
pediatric IgA nephropathy (Yang et al. 2012).
Nine types of ARBs are available in clinical practice, including losartan, candesartan
irbesartan, olmesartan, telmisartan, valsartan, fimasartan, azilsartan, and eprosartan.
Mechanisms of action: ARBs antagonize the effects of angiotensin II at the level
of the angiotensin II receptor type 1. All ARBs have high affinity for the receptor,
which are found in high concentration in various tissues, particularly in smooth
muscle cells, heart, kidney, and aorta (Messerli et al. 2018).
Because angiotensin II is a potent vasoconstrictor peptide, the blockade of its
action at angiotensin II receptor type 1, thereby reducing effects of angiotensin
II-induced vasoconstriction, sodium retention, and aldosterone release, leading to
vasodilation of small resistance arteries and reduction in total peripheral resistance
and BP. Cardiac output remains unchanged and no postural hypotension (Messerli
et al. 2018).
It has long been noticed that chronic using ARBs had some favorable effects on
cardiovascular system, including a reverse of hypertension-induced left ventricular
hypertrophy, endothelial function improvement, and a de-stiffening of large arteries.
These effects result in large artery relaxation and less pressure wave reflection when
cardiac contracting; the wave propagation along the aorta is slowed; both the central
systolic pressure and pulse pressure fall. The hemodynamic effects help reverse and
slow down the remodeling of large as well as small arteries. Reno-protection of
ARBs has been also observed in early type 2 diabetic nephropathy and proteinuria,
independent of BP lowering (Messerli et al. 2018).
ARBs are generally used for patients who are unable to tolerate ACE inhibitors
such as dry cough. But ARBs have nothing to do with ACE, so they don’t dis-
turb the metabolism of bradykinin; theoretically, no cough occurs. However, some
cases of ARB-induced cough are reported especially with losartan which respond
to discontinuation of losartan. Mechanism may be due to overexpressing unopposed
angiotensin II receptor type 2 in central nervous system and some degree of ACE
inhibitor-like property of losartan.
ARBs can be used alone to treat hypertension. If ARB monotherapy is insuffi-
cient to achieve BP goal, usually adding an antihypertensive diuretic. ARBs, like
ACE inhibitors, can cause injury or even death to a developing fetus; therefore, they
are prohibited for a childbearing woman who is planning to pregnancy or already
becomes pregnant. A study by Harel et al. found that ARBs had a trend to cause
6 Hypertension Drug Therapy 169
age, starting from 80 to 160 mg once a day in patients who are not volume depleted. If
BP is not controlled well, valsartan is either titrated up to 320 mg daily or combined
with an antihypertensive diuretic. It has been shown that valsartan combined with
diuretics is better than dose increasing over 80 mg.
Olmesartan: Olmesartan can be used alone or combined with other antihyper-
tensive agents such as diuretics. Starting from 20 mg daily, it can be titrated to 40 mg
daily if BP was not well controlled. Dose greater than 40 mg once a day has not been
shown greater effects.
Eprosartan: 400–800 mg once daily or twice daily in the treatment of patients
with hypertension and not volume depleted, combined with other antihypertensive
agents such as diuretics or CCBs if BP was not well controlled.
Azilsartan: 80 mg oral daily, used alone or combined with other antihypertensive
drugs. In patients receiving high-dose diuretics, starting from 40 mg daily.
Aliskiren is the only direct renin inhibitor product available in clinical practice. It
blocks transformation of angiotensinogen to angiotensin I. Aliskiren reduces circu-
lating angiotensin I as well as angiotensin II, producing a reduction in systolic and
diastolic BP. It is contraindicated in patients with bilateral renal stenosis and dur-
ing pregnancy. Compared with other blockers of RAAS, aliskiren has no dry cough
side effect, but it can cause angioedema and small increase in creatinine as ACE
inhibitors, and dose-dependent diarrhea.
Indications: Aliskiren has been approved as monotherapy or in combination
therapy for hypertension. No outcome data are available in terms of reducing
hypertension-related cardiovascular events. At present, it is often used as add-on
drug, not as the first-line antihypertensive agent. One trial showed that aliskiren may
have a potential reno-protection effect since the trial found that aliskiren combined
with losartan reduces proteinuria compared with losartan alone in patients with type
2 diabetes (Parving et al. 2008).
ALTITUDE trial evaluated the combination of aliskiren with RAAS blocker on
a primary endpoint consisting of combined cardiovascular and renal endpoints in
diabetic patients with cardiovascular disease, chronic kidney disease, or both with
a mean eGFR in the low 40s. The study was stopped prematurely because of a
significantly higher risk of adverse effects and no decrease in primary endpoint
among those taking aliskiren in combination with another RAAS blocker (Parving
et al. 2012).
6 Hypertension Drug Therapy 171
including high cholesterol and high triglyceride but do not have any clinically mean-
ingful lipid change (Ernst et al. 2009; Durate and Cooper-Dehoff 2010; Carter et al.
2008).
Caution:
Breastfeeding: Thiazides pass into breast milk and can decrease the flow of breast
milk. So, these drugs are classed as “drugs that have been associated with significant
effects on some nursing infants and should be given to nursing mothers with caution”
by the American Academy of Pediatrics Committee on Drugs (American Academy
of Pediatrics Committee on Drugs 2001).
Pregnancy: It can be used in pregnant hypertension women but not a first-line
choice (Gestational Hypertension and Preeclampsia 2019).
Athletes: Hydrochlorothiazide is prohibited in sports according to the regulations
of the World Anti-Doping Agency (Helmlin et al. 2016) because of its ability to mask
the use of performance-enhancing drugs.
Thiazide-type diuretics are associated with significant but small adverse glycemic
effects. Treatment with a lower dose thiazide might reduce or avoid glycemic changes
(Zhang et al. 2016; Scheen 2018).
ARIC (the Atherosclerosis Risk in Communities) study investigated the incidence
of new-onset diabetes in 12,550 adults who did not have diabetes mellitus at the study
beginning. After 3 years and 6 years of following up, new-onset diabetes risk was not
significantly higher in patients receiving thiazide diuretic therapy than the subjects
not receiving any antihypertensive therapy. The study only identified that new-onset
diabetes risk was 28% greater in the individuals who were taking beta-blockers for
hypertension for 6 years than in those with other antihypertensive agents. Low-dose
thiazide-type diuretics (i.e., hydrochlorothiazide < 12.5 mg once a day) or thiazide-
like diuretics (chlorthalidone or indapamide) can make these metabolic disturbances
less marked. The data from subgroups of patients with hypertension and type 2
diabetes supported that the cardiovascular benefits from thiazides lowering BP were
much greater than harm (Gress et al. 2000).
It is highly likely that the using an ACE inhibitor with diuretics could minimize
or avoid the adverse glucose metabolism caused by thiazide diuretics (Kenneth et al.
2008; Shamiss et al. 1995). The negative effect on glucose metabolism of diuretics
is dose-related, and it may also be related to hypokalemia. SHEP (The Systolic
Hypertension in the Elderly Program) study indicated that each decrease of 0.5 mEq/L
in serum potassium level during the first year of diuretics therapy was associated
with an increase in adjusted diabetes risk 45% (SHEP Study 1991). This diuretic-
induced diabetes risk can be prevented by either supplementation of potassium or
by combination with ACE inhibitors or potassium-sparing agents (Jeunemaitre et al.
1988). If thiazide diuretics were combined with aldosterone antagonist, not only
new-onset diabetes can be prevented by avoiding diuretic-induced hypokalemia, but
also BP control will be improved greatly (Sharabi et al. 2006). Indapamide may not
have a deleterious effect on glucose tolerance (Leonetti et al. 1990).
Diuretic-induced glucose changes may underline lesser prognostic significance.
ALLHAT study showed that no significant association of fast serum glucose change
6 Hypertension Drug Therapy 173
attack, stroke as well as congestive heart failure in patients with hypertension (Olde
Engberink et al. 2015).
Compared to the most prescribed thiazide-type diuretics such as hydrochloroth-
iazide, thiazide-like diuretics, indapamide, metolazone, and chlorthalidone, have an
advantage in lowering both systolic BP and diastolic BP without significantly increas-
ing the risks of hypokalemia and hyponatremia, or making a significant change of
BP and serum total cholesterol. Antihypertensive effect of thiazide-related diuretics
can be reduced by concomitant administration of NSAID, which block vasodila-
tory prostaglandin synthesis and therein negatively impact renal sodium handling.
Even though indapamide is considered as a thiazide-like diuretics, but it does not
necessarily have the same mechanism as other thiazide-like diuretics (James et al.
2014).
JNC-8 recommends both thiazide-type diuretics and thiazide-like diuretics as one
of the four classes of first-line antihypertensive drugs, either as monotherapy or in
combination with CCBs, ACE inhibitors, or ARBs (James et al. 2014). Fixed-dose
combination drugs are widely available as well, such as combinations of an ACE
inhibitor or an ARB with thiazide diuretics.
Recent meta-analysis results indicate that thiazide-type diuretics should be
replaced by the thiazide-like diuretics, which possess higher efficacy of BP reduction
and less risk of electrolyte disturbance and metabolic disorders (Liang et al. 2017).
Chlorthalidone is a longer acting thiazide with the duration of action for 24 to 72 h
and can be given orally once a day, useful when a lengthier period of natriuresis is
desired. Chlorthalidone can be used alone or combined with other antihypertensives.
Starting from 25 mg once a day, dose can be titrated to 50 mg or even 100 mg daily
if BP did not achieve goal. Usually, the dose of 100 mg or over 100 mg once a day
does not increase antihypertensive effects further but increase serum uric acid level
and hypokalemia risk over the range of 25–100 mg/day. So it may be better to add
second antihypertensive agents instead of increasing dose if additional BP control
is required (Madkour et al. 1996; Beckett et al. 2008). ALLHAT trial proved that
chlorthalidone with longer and stronger antihypertensive effect and less side effects
than thiazide diuretics, recommended chlorthalidone as favored choice of first-line
diuretics if available (Barzilay et al. 2006).
Besides its diuretic properties, chlorthalidone presents some protective effects on
vascular or organ damage in animal and human studies. In some clinical trials, it
was effective in reducing left ventricular mass index in hypertensive patients and
remarkably improving the renal function. In a recent clinical trial, use of a sustained-
release indapamide-based regimen as initial therapy led to relative reductions of 39%,
64%, and 21% in the rates of fatal stroke, heart failure, and death, respectively, in
patients older than 80 years of age (Madkour et al. 1996; Beckett et al. 2008).
Although much evidence demonstrated the effectiveness and advantages of inda-
pamide, there is no large-scale immediate clinical trial and meta-analysis to evaluate
the BP-lowering efficacy and safety between indapamide and hydrochlorothiazide
(Liang et al. 2017; Tamargo et al. 2014).
6 Hypertension Drug Therapy 175
Loop diuretics exert their effects in the nephron at the apical membrane in the thick
ascending limb of the loop of Henle and lower BP through reducing extracellular fluid
volume. Other major effects include a decrease in free water excretion during water
loading and reabsorption during dehydration, because of reduced osmotic gradient
in the medulla. An increased Ca2+ excretion is also observed in response to the
inhibition of the paracellular Ca2+ transport across renal epithelia (Whelton et al.
2017; Williams et al. 2018; James et al. 2014; Chobanian et al. 2003).
In the following situations, loop diuretics are preferred to thiazide-type and
thiazide-like diuretics in patients with acute coronary syndrome and heart failure or
in patients with chronic kidney disease and an eGFR less than 30 mL/min/1.73 m2 . If
persistent hypertension is not controlled with an ACE inhibitor (or ARB), CCB, and
beta-blocker, thiazide-type or thiazide-like diuretics, loop diuretics may be added
6 Hypertension Drug Therapy 179
accordingly, and then aldosterone antagonist (Whelton et al. 2017; Williams et al.
2018; James et al. 2014).
The most frequently used loop diuretics are furosemide, then bumetanide, and
torsemide. The onset of diuresis with furosemide is rapid, within 1 h, peaking at
3–6 h, with a smaller effect after 12 h. In order to prevent rebound, loop diuretics
should be given small dose, twice daily, or thrice daily in the treatment of hypertension
(Whelton et al. 2017; Williams et al. 2018).
Loop diuretics are not as effective as thiazides in lowering BP. They are usually
reserved for patients with renal insufficiency and remain benefit in case of chronic
kidney disease with serum creatinine > 1.5 mg/dL or eGFR < 30 ml/min/1.73 m2 (less
effect for thiazide diuretics) (Malha and Mann 2016). The use of loop diuretics was
not mentioned in JNC-8 guideline (James et al. 2014). Meanwhile, 2013 ESH/ESC
guideline recommended that a loop diuretic can only replace thiazide-type diuretics if
there is renal function impairment (serum creatinine of more than 1.5 mg/dL or eGFR
of less 30 ml/min/1.73 m2 ) since loop diuretics are lack of long-term cardiovascular
outcome data and appropriate dosing regimen of its use (Mancia et al. 2013). Unlike
thiazides, loop diuretics are still effective in lowering BP or in treating edema in
patients with poor kidney function (at stage 3 to 5, particularly with extracellular
fluid volume expansion) (Whelton et al. 2017; Williams et al. 2018).
6.5.6.1 Torsemide
Torsemide is a pyridine-sulfonyl urea type loop diuretic, mainly used in the manage-
ment of edema associated with congestive heart failure. As an antihypertensive agent,
torsemide is available as an oral tablet or injection solution, used alone or combined
with other antihypertensive agents. The dosage of torsemide can start from 5 mg once
a day and may be titrated to 10 mg once a day. When reached to a dose of 10 mg per
day, BP response is still not adequate, and additional antihypertensive drugs may be
added instead of increasing torsemide dose.
Torsemide has advantages being longer action duration and once daily dosing, and
more bioavailability (vs. furosemide). Torsemide and other loop diuretics appear to
have less side effects (such as less hyponatremia, hypokalemia and glucose intoler-
ance). Previous studies showed that high dose of thiazide diuretics (either thiazide-
type or thiazide-like) was more effective in lowering BP than loop diuretics (Whelton
et al. 2017; Williams et al. 2018; James et al. 2014; Chobanian et al. 2003).
The difference in efficacy among loop diuretics is probably related to the duration
of action. Commonly used loop diuretics, such as furosemide and bumetanide, have
a short duration of action (< 6 h); the antihypertensive efficacy of these medications
may be limited since the initial fluid loss can be counteracted by activation of RAAS,
leading to sodium retention during the period when the diuretic effect has worn off
(Whelton et al. 2017; Williams et al. 2018). They are less effective than thiazide-type
drugs in reducing BP in the non-edematous patient as has been shown in a recent
Cochrane analysis, reporting the systolic BP/diastolic BP reduction of several loop
diuretics in primary hypertension (Musini et al. 2015; Hermida et al. 2008).
180 R. Hui
Side effects of loop diuretics: Similar to thiazide diuretics, loop diuretics are
contraindicated in patients with gout (Whelton et al. 2017; Williams et al. 2018). No
evidence of torsemide-induced ototoxicity has been demonstrated in human. Low-
dose torsemide (2.5–5 mg) produces no detectable effects on electrolytes, glucose,
and lipids (and yet yields an antihypertensive effect comparable to thiazides) (Wargo
and Banta 2009; Roush et al. 2014).
Since a smaller fraction of filtered load of Na+ is reabsorbed at the distal tubular site
where thiazides act, Na+ excretion is associated with hypokalemia and mild metabolic
alkalosis due to both an increased K+ and H+ excretion in the collecting tubule in
response to the higher Na+ concentration at this site. In response to hypovolemia, a
significant secondary hyperaldosteronism can occur. Loop diuretics exert their effects
in the more proximal site than do thiazide diuretics. Therefore, the natriuretic effect
of loop is greater than that of thiazide diuretics. An increased Ca2+ excretion is also
observed in response to the inhibition of the paracellular Ca2+ transport across renal
epithelia (Whelton et al. 2017; Williams et al. 2018; James et al. 2014; Chobanian
et al. 2003).
6.5.6.2 Furosemide
Furosemide, like other loop diuretics, inhibits the luminal Na-K-Cl cotransporter in
the thick ascending limb of the loop of Henle, by binding to the chloride transport
channel, thus causing an increase in excretion of sodium, chloride, and potassium loss
in urine. Furosemide is primarily used for the treatment of hypertension and edema
when eGFR < 30 ml/min/1.73 m2 . Furosemide takes diuresis effect within 1 h and
completes within 6 h after oral administration, while intravenously administered
it typically begins working within five minutes, peak effect within 30 min, and
diuresis is complete within 2 h. It is excreted by tubular secretion; therefore, in severe
kidney function impairment (e.g., GFR 5–10 ml/min), lower doses are required due
to accumulation in the body. It also can cause further kidney damage and should be
administered with caution (Schaefer et al. 2018; Grams et al. 2019).
Side effects: Common side effects of furosemide are dehydration and elec-
trolyte imbalance, including loss of potassium, calcium, sodium, and magnesium.
Excessive use of furosemide will most likely lead to a metabolic alkalosis due
to hypochloremia and hypokalemia. Overdose may lead to dehydration, change in
drinking patterns and urination, seizures, gastrointestinal problems, kidney dam-
age, lethargy, collapse, and coma. Other side effects include ototoxic which usually
occurs with large intravenous doses and rapid administration and in renal impairment,
gout, caused by hyperuricemia and hyperglycemia (Schaefer et al. 2018; Grams et al.
2019).
Caution: Furosemide should be used with caution when combined with corticos-
teroids (as this increases the risk of electrolyte imbalance), aminoglycoside antibi-
otics (increases risk of kidney or ear damage), and trimethoprim sulfa (decrease
platelet count). Furosemide may increase the risk of digoxin toxicity due to
hypokalemia. The drug is best not used during pregnancy or in a lactating mother,
6 Hypertension Drug Therapy 181
since studies with other species have shown that the medication could pass through
the placenta and milk. Many studies have shown that the long-term use of furosemide
could cause varying degrees of thiamine deficiency. For this reason, thiamine needs
to be supplemented (Schaefer et al. 2018; Grams et al. 2019).
6.5.6.3 Bumetanide
Bumetanide is a loop diuretic of the sulfamoyl category. FDA approved for the
treatment of edema. Its off-label use is for the treatment of hypertension in patients in
whom high doses of furosemide or other diuretics are ineffective. The usual dosage
is 0.5–2 mg/day given once or twice daily. Bumetanide is 40 times more potent
than furosemide for patients with normal renal function. Bumetanide also masks
other drugs, including steroids, by diluting the contents of the user’s urine, yielding
a lower concentration of filtered substances, which makes them less likely to be
detected (Brunton et al. 2006).
collecting duct. The drugs act independently of aldosterone, including amiloride and
triamterene, block ENaC (epithelial sodium channel) in the luminal membrane of the
collecting duct (Dahal et al. 2015; Pelliccia et al. 2014). Only a modest natriuretic
effect can be expected, since a smaller fraction of filtered load of Na+ is reabsorbed
at this distal site of action, compared to the more proximal site of action of loop
diuretics and thiazide diuretics.
Amiloride blocks ENaC in the collecting tubule and thus blocks the reabsorption
of water. Like spironolactone, amiloride is often used to counteract potassium wasting
caused by other diuretics and also is the specific molecular target drug to treat Liddle’s
syndrome.
Side effects: The most common side effect is hyperkalemia with metabolic acido-
sis, particularly in patients with chronic kidney disease and heart failure or diabetes,
receiving potassium-sparing diuretics or potassium supplements, or taking concomi-
tantly an ACE inhibitor, an ARB, or an NSAID. Since spironolactone inhibits the
binding of dihydrotestosterone to androgen receptors and increases the clearance
of testosterone, the frequent complications are sexual side effects, including impo-
tence, decreased libido, bilateral gynecomastia, and mastodynia. Eplerenone is a
more selective aldosterone antagonist with much less sexual side effects (Pelliccia
et al. 2014).
Potassium-sparing diuretics, particularly mineralocorticoid receptor antagonists,
are contraindicated in patients with acute or severe renal failure (eGFR < 30 mL/min).
Although spironolactone did not show an appropriate evidence for reducing cardio-
vascular events in hypertensive patients, it reduced total mortality in patients with
advanced heart failure (Dahal et al. 2015). Moreover, its efficiency in resistant hyper-
tension is well established (Pelliccia et al. 2014). Similarly, eplerenone has been
shown to have greater impact on systolic BP and to improve endothelial function
in hypertensive patients with similar rates of hyperkalemia (Fujimura et al. 2012;
Hermida et al. 2008).
The following types of patients are at increased risk of developing hyperkalemia
and should be monitored closely when using potassium-sparing diuretics:
(1) Patients receiving RAAS inhibitors.
(2) Patients receiving other drugs that can cause hyperkalemia, e.g., trimethoprim,
sulfamethoxazole, amiloride, and triamterene.
(3) Patients with chronic kidney disease (eGFR < 60 mL/min/1.73 m2 ).
(4) Baseline serum potassium > 4.5 mmol/L.
6.5.7.1 Triamterene
throat, rash, and back pain. Triamterene can also cause kidney stones through direct
crystallization or by seeding calcium oxalate stones (Heran et al. 2012).
Caution with certain disease states: (Heran et al. 2012)
(1) Triamterene is best avoided in patients with chronic kidney disease due to the
possibility of hyperkalemia. Patients using triamterene take salt substitute cau-
tiously.
(2) The following situations, using triamterene, should be with caution: in patients
with prediabetes and diabetes, hepatic function impairment, and kidney stones.
(3) In patients with creatinine clearance less than 10 ml/min, triamterene should be
avoided.
(4) Kidney stones.
(5) Triamterene should be avoided if the creatinine clearance is less than 10 ml/min.
6.5.7.2 Amiloride
Amiloride has its principal antihypertensive effect by directly blocking ENaC (Qadri
et al. 2012) and inhibits sodium reabsorption in the late distal convoluted tubules,
connecting tubules, and collecting ducts in the nephron (Loffing et al. 2003). Onset
of action is about two hours and lasts for about one day (Formulary 2008).
The drug is often used in conjunction with a thiazide diuretic to counteract the
potassium-losing effect. Due to its potassium-sparing capacities, hyperkalemia may
occur. The risk of developing hyperkalemia is increased in patients who are also
taking ACE inhibitors, ARBs, other potassium-sparing diuretics, or any potassium-
containing supplements.
Amiloride should be stopped using for more than 3 days prior to laboratory test
in case of fatal hyperkalemia.
Indication:
(1) Amiloride is a second-line antihypertensive agent, and often used with a thi-
azide or other loop diuretic (e.g., furosemide), especially useful in patients with
hypertension having potential hypokalemia or in patients for which maintain-
ing a normal level of potassium is critically important, e.g., those taking digi-
talis (i.e., digoxin) are at higher risk for cardiac arrhythmia if their potassium
levels get too low (Heran et al. 2012).
(2) For people with resistant hypertension, already taking a thiazide diuretic,
an ACE inhibitor or an ARB, or a CCB, the addition of amiloride (or spironolac-
tone) was better at reducing BP than adding a beta-blocker or an alpha-1 blocker
(Han and Hee 2017). When combined with hydrochlorothiazide, amiloride had
positive effects on BP and blood sugar tolerance, to prevent the metabolic
side effects of thiazide diuretics, allowing for the use of higher thiazide doses
(O’Riordan et al. 2018).
184 R. Hui
(3) Amiloride is also a specific agent for the treatment of Liddle’s syndrome.
Because Liddle syndrome usually involves an upregulation of ENaC channels,
leading to hypokalemia, amiloride is useful as an ENaC channel inhibitor due
to its potassium-sparing effects, restoring BP and potassium to normal levels
(Tetti et al. 2018).
Side effects: Amiloride is generally well tolerated. Common side effects
include hyperkalemia, vomiting, loss of appetite, mild skin rash, and headache and
gastrointestinal side effects (nausea, vomiting, diarrhea, decreased appetite, flatu-
lence, and abdominal pain). Mild symptoms of hypokalemia include unusual skin
sensations, muscle weakness, or fatigue, but more severe symptoms such as flaccid
paralysis of the limbs, bradycardia, and even shock can occur (Heran et al. 2012).
Caution: Paying extra-attention to the following commodities: (Heran et al. 2012)
(1) Diabetes: Patients with diabetes are at higher risk for kidney functional insuffi-
ciency, which increases their risk for hyperkalemia. So, when patients with dia-
betes use amiloride, their potassium and kidney function should be closely mon-
itored. If performing glucose tolerance testing, amiloride must be discontinued
for at least 3 days prior to the test, due to the risk for fatal hyperkalemia.
(2) Kidney function insufficiency: Patients with kidney function insufficiency
(e.g., blood urea nitrogen > 30 mg/dL, or serum creatinine > 1.5 mg/dL) are at
high risk for hyperkalemia.
(3) Lactation: No data are available on the use of amiloride in women who are
breastfeeding. While diuretics can make lactation difficult, it is unlikely that
amiloride would induce this effect in the absence of other diuretics.
(4) Pregnancy: Data from animal studies suggest that it does not pose a risk to
the developing fetus. Limited human data from use during pregnancy suggest
an association with a specific congenital penis abnormality if taken during the
first trimester, as well as a risk for mild intrauterine growth restriction if taken
throughout pregnancy.
Contraindication: Amiloride is contraindicated for the following people:
(1) In patients with kidney function insufficiency, such as anuria, acute or chronic
renal insufficiency, or diabetic nephropathy. The situations are at increased risk
for serum hyperkalemia, such as blood urea nitrogen more than 30 mg/dl, or
serum creatinine level more than 1.5 mg/dl.
(2) In patients with plasma hyperkalemia (serum potassium concentration ≥
5.5 mEq/L).
(3) In patients who are hypersensitivity to amiloride or any ingredients within the
specific formulation.
(4) In patients who are already taking potassium-sparing drugs (e.g., spirono-
lactone and triamterene) or taking potassium supplements (e.g., potassium
chloride) in most circumstances.
6 Hypertension Drug Therapy 185
CCBs block the entry of calcium ion into muscle cells in artery walls as well as in
cardiac myocytes. There are two classes of CCBs in the treatment of hypertension,
particularly effective against large vessel stiffness, one of the common causes of
elevated systolic BP in elderly patients (Nelson 2010). CCBs are often less likely to
cause side effects in people over the age of 65 years. CCBs are principally used to
treat hypertension, arrhythmias, and chest pain related to angina. Certain groups of
people may especially benefit from CCBs in combination with other medications,
including African-Americans, individuals with kidney disease, the elderly, people
with diabetes (Chen et al. 2010; Hockerman et al. 1997).
5 mg once daily in the treatment of hypertension (Chen et al. 2010; Hockerman et al.
1997).
Felodipine: Felodipine inhibits the influx of extracellular calcium across the
myocardial and VSMC membranes. These effects elicit an increased oxygen delivery
to the myocardial tissue, a decreased total peripheral resistance, a decreased systemic
BP, and a decreased afterload. Recommended dosage is oral 5 mg once daily in the
treatment of hypertension (Chen et al. 2010; Hockerman et al. 1997).
Clevidipine: Clevidipine butyrate is a novel, ultra-short-acting DHP, rapidly
metabolized in blood and tissues and does not accumulate in the body. It is indi-
cated for the reduction of BP. Initial dose: 1 mg to 2 mg/h intravenous infusion
(0.5 mg/1 mL) Dose titration: At hypertension emergency, dose can be doubled
within 90 s. If BP goal was not achieved. After BP achieved goal, the drug dose titra-
tion should be less doubling and interval between dose adjustment can be increased
to 5 min to 10 min. Every increase in dose of 1–2 mg per hour usually lowers systolic
BP 2–4 mm Hg (Drugs.com, Clevidipine).
Maintenance dose: At the dose of 4 mg to 6 mg, most patients can have the desired
therapeutic BP response. Patients with severe hypertension may require doses up to
32 mg/h (Drugs.com, Clevidipine).
Maximum dose: 16 mg per hour, not much experience with dose up to 32 mg per
hour. Liquid should be restricted to less than 1000 ml per 24-hour period during drug
therapy (Drugs com, Clevidipine).
Duration of therapy: There is little experience with infusion durations beyond
72 h at any dose (Drugs.com, Clevidipine).
Transition to an oral antihypertensive agent: To discontinue this drug or to titrate
downward is established while appropriate oral treatment. Reduction of BP when
oral treatment is not feasible or not desirable (Drugs.com, Clevidipine).
DHP-CCBs lowers BP with increased heart rate or even tachycardia but in the
reduction of myocardial oxygen consumption, DHP-CCBs are less effective than
non-DHP-CCBs such as verapamil and diltiazem which decrease heart rate. DHP-
CCBs-induced tachycardia is caused by that baroreflex activation outweighs the
direct effects on the sinus node. Chronic administration would lead to baroreflex that
is less marked and heart rate can even be normalized (Chen et al. 2010; Hockerman
et al. 1997).
Potent vasodilator DHP-CCBs usually have less cardio-depressant activity than
non-DHPs-CCBs. Neither type of CCBs has direct effects on venous system and
does not modify preload.
It is still inconsistent in the CCB effects on the progression of renal disease in
patients with primary hypertension. Renal efferent arterioles do not express L-type
channels, CCBs preferentially dilate renal afferent arterioles which can lead to an
increase in glomerular pressure and accelerate glomerulosclerosis. On the other hand,
CCBs may have renal protection effects, including retardation of the renal growth,
dilating both afferent and efferent arterioles with new CCBs which block L-type and
T-type channels, resulting in improving glomerular hypertension (Chen et al. 2010;
Hockerman et al. 1997).
188 R. Hui
Caution: CCBs should not be taken with grapefruit products, neither whole fruit
nor juice because grapefruit products interfere with the normal excretion of CCBs.
It may be dangerous when a large amount of CCBs accumulated in body. Drinking
grapefruit juice or eating grapefruit should be waiting at least 4 h after taking CCBs
(Chen et al. 2010; Hockerman et al. 1997).
arteries, and vasodilatation of small arteries (Ripley and Saseen 2014; Cruickshank
2017; Wright 2016).
Non-vasodilating beta-blockers may exert deleterious or at least neutral effects
on the arterial system. For instance, it has been noticed that despite less deleterious
effects of catecholamine on the heart, atenolol did not significantly decrease total
peripheral resistance and sympathetic drive. Atenolol has also been found fewer
protective effects on HMOD than RAAS blockers, including left ventricular hyper-
trophy and carotid intima-media thickness (Ripley and Saseen 2014; Cruickshank
2017; Wright 2016)
Non-vasodilating beta-blockers can even stiffen large arteries through a direct
“profibrotic” effect, when the lowering of BP is not large enough to unload the
stiff components of the arterial wall. This deleterious effect can be due to several
mechanisms (Ripley and Saseen 2014; Cruickshank 2017; Wright 2016).
Beta-blockers lower BP and prevent heart attacks in people who have already
had a heart attack but they do not have a positive benefit on endpoints as some
other antihypertensives (James et al. 2014). In the United Kingdom, Management of
Hypertension in Adults in Primary Care guideline of the National Institute for Health
and Clinical Excellence (NICE 2006), first downgraded the role of beta-blockers due
to their risk of provoking type 2 diabetes (NICE 2006). In addition, beta-blockers
have been shown a less protective effect on stroke risk than other classes of antihyper-
tensive agents (Nelson 2010). A systematic review of 63 clinical trial data covered
35,000 participants and showed that beta-blockers increased mortality compared
with other antihypertensive agents (Wu et al. 2013). Therefore, beta-blockers are not
first-line therapy for hypertension except for patients with coronary heart disease,
heart failure, or tachycardia by European and US guidelines (Whelton et al. 2017;
Williams et al. 2018; James et al. 2014; Chobanian et al. 2003).
Beta-blocker contraindications: (1) Moderate-to-severe asthma (adrenergic
bronchodilatation requires intact beta-2 receptor function); (2) unstable systolic heart
failure; (3) second- or third-degree atrioventricular block; and (4) sick sinus syndrome
(with no pacemaker).
Used with caution: Diabetes milieus. Beta-blocker may worsen glucose intoler-
ance and mask hypoglycemic symptoms.
Side effects: Vivid dream, insomnia, hallucination, and depression. These side
effects are more often observed with the highly lipid-soluble beta-blockers such as
propranolol, metoprolol, and pindolol. These lipid-soluble beta-blockers can pen-
etrate the central nervous system easier than non-lipid-soluble ones, important but
less frequently observed with vasodilating beta-blockers (Ripley and Saseen 2014;
Cruickshank 2017).
Although beta-blockers are generally not recommended as first-line agents for
the treatment of hypertension by NICE (2006) and JNC8 guidelines (James et al.
2014), however, they are suitable alternatives when a compelling cardiac indication
is present. Nearly, all beta-receptor blockers can be nonselective at higher doses.
Caution should be taken when using beta-blockers in situations such as asthma
or severe obstructive pulmonary disease regardless of beta-receptor selectivity pro-
file. Abrupt discontinuance of beta-blocker may worsen angina or even myocardial
6 Hypertension Drug Therapy 191
Beta-1 receptor blockers may still be the first-line antihypertensive agent for patients
less than 60 years age or with other indications such as coronary heart disease and
sympathetic activity increase (heart rate over 85 beats/min) (Ripley and Saseen 2014;
Cruickshank 2017; Wright 2016).
Atenolol: Used as a conditional antihypertensive agent either used alone or with
other antihypertensive drugs, starting from 50 mg once a day. If the desired BP
response was not obtained, it can be titrated to 100 mg daily. It has been shown that
atenolol lacks specific potential for stroke prevention.
Metoprolol: Presently considered as conditional antihypertensive agent, either
used alone or with other antihypertensive drugs, starting from 50 mg immediate-
release formulation twice daily, maximum of 450 mg per day and extended-release
formulation, started from 47.5 mg once daily, maximum of 400 mg per day.
Propranolol: At present, propranolol is considered as a conditional antihyperten-
sive agent, either used alone or combined with other antihypertensive drugs (such as
diuretics), starting from 40 mg twice daily. Maintenance dose: 120–240 mg per day;
maximum of 640 mg per day. If planning to reduce the dose, reduced gradually over
a few weeks because exacerbation of angina and even myocardial infarction have
been reported following abrupt discontinuing propranolol therapy.
Bisoprolol: Except nebivolol, bisoprolol has more specific beta-1 blocking effect
than any other beta-blockers available in clinical practice right now. Start with 5 mg
once a day in the treatment of hypertension. The dose should be reduced to 2.5 mg
for hypertensive patients with bronchospastic disease. Maximum dose: 20 mg per
day if necessary.
Timolol: Used alone or combined with other antihypertensive agents such as
diuretics in treatment of hypertension. Starting with 10 mg twice daily, maximum of
30 mg daily. Abrupt discontinuing may lead to the exacerbation of ischemic heart
disease.
Lowering BP: Recommended starting dose is 5 mg once daily, with or without food,
as monotherapy or in combination with other antihypertensive agents. For patients
requiring further BP reduction, the dose can be increased up to 40 mg at 2-week
intervals. A more frequent dosing regimen is unlikely to be beneficial. In patients
with severe renal impairment (eGFR < 30 mL/min/1.73 m2 ), the recommended initial
dose is 2.5 mg once daily; titrate up slowly if needed.
In patients with moderate hepatic impairment, the recommended initial dose is
2.5 mg once daily; titrate up slowly if needed. Nebivolol has not been studied in
patients with severe hepatic impairment, and therefore it is not recommended in that
population.
Nebivolol has not been studied in patients receiving dialysis.
Nebivolol is not approved for use in children under 18 years of age.
It was not studied in patients with angina pectoris or who had a recent myocardial
infarction. There are no randomized controlled trials to study whether it can reduce
cardiovascular morbidity and mortality, demonstrating risk reduction with nebivolol.
Geriatric patients: Not necessary to adjust the dose (Gielen et al. 2006; Baldwin
and Keam 2009; Pessina 2001; Weber 2005; Poirier et al. 2001).
Nebivolol proved to be the most beta 1-selective beta-blockers tested so far, being
approximately 3.5 times more beta 1-selective than bisoprolol. The drug is highly
cardio-selective at 5 mg. In addition, at doses above 10 mg, nebivolol loses its car-
dioselectivity and blocks both beta-1 and beta-2 receptors (Bundkirchen et al. 2003;
Prescribing Information 2009; Nuttall et al. 2003).
Nebivolol is unique as a beta-blocker. Unlike carvedilol, it has NO potentiating,
vasodilatory effect via stimulation of beta-3 receptors. Along with labetalol, celipro-
lol, and carvedilol, it is one of four beta-blockers to cause dilation of blood vessels
in addition to effects on the heart (Agabiti and Rizzoni 2007; Galougahi 2016; Weiss
2006; Bakris 2009).
Nebivolol lowers BP by inhibiting peripheral vascular resistance with significant
increase in cardiac stroke volume. The net hemodynamic effects of nebivolol are the
balance of beta-blockade and maintaining cardiac output. Its antihypertensive effects
have been proved in various groups of patients including black patients (Rosei and
Rizzoni 2007; Galougahi 2016; Weiss 2006; Bakris 2009).
Common side effects include dizziness, feeling tired, nausea, and headaches.
Serious side effects are heart failure and bronchospasm (Nebivolol Side Effects
Site 2019; Nebivolol Hydrochloride Monograph for Professionals 2019; Nebivolol
Pregnancy 2019).
6 Hypertension Drug Therapy 193
Cautions: Like most other beta-blockers, abrupt stopping use of nebivolol may
cause severe adverse effects such as severe exacerbation of angina pectoris, myocar-
dial infarction, and ventricular arrhythmia in patients with or without coronary heart
disease. When planned to stop nebivolol, dose is recommended to reduce over one
to two weeks gradually; carefully monitor patients’ clinical presentations and advise
patient to minimize physical activity during the specific period of time. If angina
worsens or coronary insufficiency occurs, restart nebivolol promptly (Nebivolol
Side Effects Site 2019; Nebivolol Hydrochloride Monograph for Professionals 2019;
Nebivolol Pregnancy 2019).
Contraindications: Severe bradycardia, heart block greater than first degree, car-
diogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a per-
manent pacemaker is in place), severe hepatic impairment (Child-Pugh class B), and
hypersensitive to any component of this product (Nebivolol Side Effects Site 2019;
Nebivolol Hydrochloride Monograph for Professionals 2019; Nebivolol Pregnancy
2019).
the treatment of hypertension. However, they may be useful for some men with symp-
toms of prostate disease and for patients with pheochromocytoma and for resistant
hypertension as add-on therapy (Whelton et al. 2017; Williams et al. 2018).
Most frequently used for treatment of hypertension are prazosin, terazosin, and
doxazosin. They are particularly useful in BP lowering when BP is measured with
standing position or during exercise. These drugs can significantly lower BP but
with little or no change in cardiac output, heart rate, and cardiac index. The first-dose
phenomenon limited their use as antihypertensive agents. The phenomenon often
occurred during the first 90 min following the first dose, or the dose increased rapidly,
presented as sudden severe symptomatic orthostatic hypotension. The incidence of
syncope can be reduced by giving the drugs at bedtime or using gastrointestinal
therapeutic system which provides a true 24-hour delivery (Whelton et al. 2017;
Williams et al. 2018).
6.5.11.1 Spironolactone
only a weak diuretic because it primarily targets the distal nephron (collecting
tubule), where only small amounts of sodium are reabsorbed at collecting tubule.
Spironolactone needs to be combined with other diuretics to increase efficacy.
The clinical benefits of spironolactone as a diuretic can be typically observed
after 2–3 days from dosing beginning. Spironolactone is also commonly used to
treat symptoms of hyperandrogenism in polycystic ovary syndrome (Goodman
et al. 2015).
Side effects and cautions:
(1) Hyperkalemia: therefore, potassium supplementation should not
be given concurrently. Spironolactone together with trimetho-
prim/sulfamethoxazole increases the likelihood of hyperkalemia, especially in
the elderly. The trimethoprim portion acts to prevent potassium excretion in
the distal tubule of the nephron (Velázquez et al. 1993).
(2) Spironolactone directly blocks androgen signaling and also acts as
an inhibitor of androgen production. Higher doses of spironolactone are
not recommended in males due to the high risk of feminization and other
side effects. Impotence can occur because spironolactone blocks the effects
of the hormones aldosterone and testosterone and has some estrogen-like
effects. This is the reason why often reluctant to give it to younger men.
Spironolactone has not been well studied in pregnancy and should not be used
to treat pregnant-related hypertension.
Breast change: Spironolactone frequently causes breast pain and breast enlarge-
ment in women (Kenneth 2001; Tsioufis et al. 2016) and in men. This is probably
because of estrogenic effects on target tissue. At high doses, breast tenderness is
reported to occur in up to 40% of women (Conn et al. 1998). Spironolactone also
commonly produces gynecomastia (breast development) as a side effect in men,
dose-dependently (Tsioufis et al. 2016; Seldin and Giebisch 1997; Side Effects of
Drugs Annual 2014; McInnes 2008) with 5–10% at low dose and exceeding 50%
at high dose (Tsioufis et al. 2016; Seldin and Gerhard 1997; Side Effects of Drugs
Annual 2014; McInnes 2008; Ménard 2004; Thompson and Carter 1993; Eckman
and Dobs 2008; Mathur and Braunstein 1997). The spironolactone-induced gyneco-
mastia occurred at 27 ± 20 months after using the medication at low dose and at 9
± 12 months at high dose (Rosenberg et al. 2005) and regressed within a few weeks
after discontinuing the medication (van Blijderveen et al. 2014). Spironolactone-
induced gynecomastia may become irreversible after a sufficient duration (e.g., 1
year) because hyalinization and fibrosis of tissue occurred (Eckman and Dobs 2008;
Mathur and Braunstein 1997).
Menstrual disturbances: Spironolactone produces an irregular, anovulatory pat-
tern of menstrual cycles. It is also associated with metrorrhagia and menorrha-
gia (or menometrorrhagia) in a large percentage of women. In any case, regardless
of their mechanism, the menstrual disturbances associated with spironolactone can
usually be controlled well by concomitant treatment with a birth control pill, due to
its progestin component.
196 R. Hui
If GFR is below 30 mL/min or with a serum potassium of greater than 5.0 mEq/L,
spironolactone doses should be adjusted according to the degree of kidney function
as well (Pitt et al. 2014).
Pregnancy and breastfeeding: Spironolactone is able to cross the placenta and
considered pregnancy Category C, meaning that it is unclear if it is safe for use during
pregnancy. Likewise, it has been found to be present in the breast milk of lactating
mothers. It is generally recommended that women may not take the medication
while nursing.
Interaction with digoxin: Licorice, which has indirect mineralocorticoid activ-
ity by inhibiting mineralocorticoid metabolism, has been found to inhibit the anti-
mineralocorticoid effects of spironolactone (Armanini et al. 2016; Armanini et al.
2007; Salassa et al. 1962). Licorice may be used to reduce these side effects in
women treated with spironolactone as an antiandrogen who are bothered by them
(Armanini et al. 2016; Armanini et al. 2007). Spironolactone can reverse licorice-
induced hypokalemia. Spironolactone-mediated diuresis and natriuresis can be atten-
uated by aspirin and other non-steroidal anti-inflammatory drugs (Omar et al. 2012;
Lin et al. 2003; Parthasarathy and MacDonald 2007). Spironolactone may interfere
with the antidepressant drug effects, but the data are still inconsistent (Holsboer 1999;
Otte et al. 2010; Mostalac-Preciado 2011).
Contraindications: Hyperkalemia. When spironolactone was given in a typi-
cal dose in patients with heart disease, 10–15% of the patients will develop some
degree of hyperkalemia, and 6% of them were severe hyperkalemia (fatal). In a
higher than typical dose, the hyperkalemia rate increased to 24%, resulting in 0.2%
to 11% of hospitalization, and 0.3/1000 to 2.0/1000 death between early 1994 and
late 2001 (Lainscak et al. 2015; Juurlink et al. 2004). The risk of hyperkalemia is
greatest in the elderly, in people with renal impairment, e.g., due to chronic kid-
ney disease or diabetic nephropathy, in people taking certain other medications,
including ACE inhibitors, ARBs, NSAIDs, and potassium supplements, and at higher
dosage of spironolactone.
6.5.11.2 Eplerenone
Vasodilators act directly on the smooth muscle of arteries to relax their walls so blood
can move more easily through arteries; Direct-acting vasodilators are a heterogeneous
group of drugs, whose side effects are tachycardia and fluid retention. They are only
used in hypertensive emergencies or when other drugs failed, and even so are rarely
given alone. The most often prescribed in hypertension are minoxidil and hydralazine
(van den Born et al. 2019).
6.5.12.1 Minoxidil
retention which attenuate its BP-lowering effects (Whelton et al. 2017; Williams
et al. 2018; Pettinger 1980).
Minoxidil may produce serious adverse effects, such as peripheral edema, pericar-
dial effusion, occasionally progressing to tamponade, and exacerbation of angina pec-
toris, hypertrichosis which may require to discontinue minoxidil. Minoxidil should
be reserved only for hypertensive patients who do not respond adequately to maxi-
mum therapeutic doses of other antihypertensive agents, particularly in patients with
chronic kidney disease. It must be administered under close supervision, usually
concomitant use with therapeutic dose of beta-adrenergic blockers to prevent tachy-
cardia and increase myocardial workload and a diuretic acting in the ascending limb
of the loop of Henle to prevent serious fluid accumulation. BP response to minoxidil
is dose-dependent and proportional to the extent of hypertension. It is usually started
with 5 mg once daily and can be titrated to a maximum of 100 mg per day in a divided
dose (Whelton et al. 2017; Williams et al. 2018; van den Born et al. 2019).
6.5.12.2 Hydralazine
6.5.12.4 Nitroglycerine
It has been shown that daily glyceryl nitrate patch, a daily glyceryl nitrate patch,
could be safely used to lower BP for 7 days after acute stroke (Lancet ENOS trial)
(Bath et al. 2015).
6.5.12.5 Fenoldopam
Amiloride and Triamterene (Tetti et al. 2018; Rossier and Schild 2008).
ENaC is a membrane-bound ion channel, selectively permeable to the ions
of sodium (Na+) and assembled as a heterotrimer composed of three homologous sub-
units α or δ, β, and γ. These subunits are encoded by four genes: SCNN1A, SCNN1B,
SCNN1G, and SCNN1D. ENaC causes sodium to be reabsorbed in exchange for
potassium (lost in urine). ENaC inhibitors have a weak diuretic effect, and therefore
do not have a significant effect on BP. They are primarily used to counteract potassium
loss from thiazide and loop diuretics. In general, when ENaC inhibitors are combined
with thiazide diuretics, potassium increases in the range of 0.20–0.50 mEq/L can be
expected.
No studies were found that ENaC inhibitors were used by themselves to treat
hypertension. ENaC inhibitors are most commonly used for adjunct hypertension
treatment. Triamterene is the substrate of enzyme CYP1A2. Six studies showed
(4 with amiloride, 2 with triamterene) where ENaC inhibitors were added to
hydrochlorothiazide. The analysis found that ENaC inhibitors had no significant
effect on BP when added to hydrochlorothiazide. They are primarily used with thi-
azide diuretics to help prevent potassium loss. The highest doses were 5 mg for
amiloride, and 50 mg for triamterene in the studies. ENaC inhibitors are the targeted
drugs for Liddle’s syndrome (first-line drug) (Tetti et al. 2018).
Side effects: Hyperkalemia. When ENaC inhibitors are prescribed with thiazide or
loop diuretics, the combination can offset the hyperkalemia effect. When prescribing
ENaC inhibitors, one needs to pay attention to the factors that may increase the risk
of hyperkalemia, including kidney disease (GFR < 60 ml/min) or serum creatinine >
1.6 mg/dl, diabetes, dehydration (from diuretics, diarrhea, etc.), advanced age, and
6 Hypertension Drug Therapy 201
some medications that have potential increasing serum potassium level. High dietary
potassium salt substitutes, nuts, dried fruit, and potassium supplements may also
increase hyperkalemia risk in patient taking ENaC inhibitors. For patients at high
risk of hyperkalemia, taking ENaC inhibitors should have their potassium levels
monitored appropriately (Tetti et al. 2018; Rossier and Schild 2008).
Kidney stones (Triamterene): Deposits of triamterene and its metabolites in kid-
ney stone has raised concerns that triamterene may contribute to kidney stone for-
mation. No evidences support this concern. Triamterene is typically prescribed with
thiazide diuretics which are known to lower the risk of kidney stones (Tetti et al.
2018; Rossier and Schild 2008).
Uric acid/gout risk: Although the triamterene may elevate uric acid level, it does
not appear to have a significant effect on uric acid levels (Tetti et al. 2018; Rossier
and Schild 2008).
Magnesium retention: ENaC inhibitors appear to promote magnesium retention
by the kidneys (loop and thiazide diuretics promote magnesium loss).
Contraindications: Hyperkalemia (>5.5 mEq/L), concomitant spironolactone or
triamterene or amiloride, significant kidney disease (serum creatinine > 1.5 mg/dl),
known hypersensitivity, and severe liver disease (Tetti et al. 2018; Rossier and Schild
2008).
Folic acid deficiency (triamterene): Triamterene is a weak folic acid antagonist. It
may contribute to the appearance of megaloblastosis in cases where folic acid stores
have been depleted (Tetti et al. 2018; Rossier and Schild 2008).
Drug Interaction: Lithium—ENaC inhibitors may reduce the clearance of
lithium and should not be taken with lithium if possible. Lithium levels should be
monitored closely in patients taking ENaC inhibitors. Salt substitutes typically con-
tain a high amount of potassium. Cautions should be taken when consuming salt
substitutes. ENaC inhibitors have the potential to raise potassium levels. When taken
with other medications that raise potassium, the risk may be compounded. Medi-
cations have potential to cause hyperkalemia when concomitantly used with ENaC
inhibitors, including ACE inhibitors, ARBs, aldosterone antagonists (spironolac-
tone, eplerenone), aliskiren (renin inhibitor), cyclosporine, penicillin G potassium
injection (1 million units contains 1.68 mEq of potassium), potassium supplements,
tacrolimus, trimethoprim, and heparin. Heparin raises potassium secondary to inhibit-
ing aldosterone synthesis (low molecular weight heparin does not appear to have the
effect).
NSAIDs can block the therapeutic effect of ENaC inhibitors. Patients should be
monitored for decreased effectiveness of ENaC inhibitors when taking NSAIDs for
extended periods. Triamterene may potentiate the effect of muscle relaxants used
during anesthesia, including preanesthetic and anesthetic agents and skeletal muscle
relaxants (non-depolarizing) (Tetti et al. 2018; Rossier and Schild 2008).
202 R. Hui
6.5.14.1 Methyldopa
6.5.14.2 Clonidine
6.5.14.3 Guanfacine
6.5.14.4 Rilmenidine
Rilmenidine is the first example of a hypotensive drug which has more affinity for
imidazoline preferring receptors than for classical alpha 2-adrenoceptors. Rilmeni-
dine has two to three times higher selectivity than clonidine for the non-adrenergic
imidazoline receptors within the nucleus reticularis lateralis. Rilmenidine dose-
dependently decreases BP, Central side effects are significantly less frequent with
rilmenidine than with clonidine or methyldopa. In contrast to clonidine, no sodium
retention or weight gain is observed during chronic treatment with rilmenidine (Head
and Burke 2000; Cobos-Puc and Aguayo-Morales 2019; Bousquet et al. 1992).
Bosentan belongs to a new class of drug and works by blocking the receptors of the
hormone endothelin. It is specifically indicated only for the treatment of pulmonary
artery hypertension in patients with moderate-to-severe heart failure. It is a potential
drug for treatment of hypertension in the future (Chen et al. 2018).
inhibitors, and ARBs. Which type of medication to use initially for hypertension has
been the subject of several large studies and resulting national guidelines.
with hypertension had their BP to be lowered to the level <140/90 mm Hg, they were
told that their BPs were adequately controlled. This is not true.
In the modern era, hypertension is defined as office BP 130/80 or more (ACC/AHA
2017), and BP control goal is less than 130/80 (ACC/AHA 2017) or less than
140/90 mm Hg. Abundant epidemiological data have shown that the risk of cardio-
vascular disease rises with increasing BP, starting at ≥115/75 mm Hg, in a strong,
independent, graded, and continuous manner, indicating that lowering BP in patients
with BP more than 115/75 mm Hg but less than 140/90 mm Hg may further reduce
cardiovascular risk (Bundy et al. 2017).
6.6.4 Goal of BP
Lowering office systolic BP to <140 mmHg is beneficial for all patient groups,
including independent older patients. If tolerated, systolic BP may be targeted to
130 mm Hg or less, to reduce stroke risk further which can be potentially beneficial to
most patients. Systolic BP lowered to less than 120 mm Hg may not be recommended
concerning the balance between benefit and harm.
BP targets in old and very old patients. The desired systolic BP target range for all
patients aged more than 65 years is 130–139 mmHg, but any BP lowering toward this
target is likely to be beneficial, provided that the treatment is well tolerated. Achieving
systolic BP goal of <130 mm Hg is often impossible in some older people, such as
those with poor vascular compliance (i.e., pulse pressures more than 80 to 90 mm Hg,
who typically have dizziness and poor mentation when their systolic BP approaches
140 mm Hg (Williams et al. 2018). For older patients, treatment target may be BP <
140/90 mmHg and for those ≥80 years, BP < 160/90 mm Hg.
For patients with diabetes, systolic BP is targeted to less than 140 mm Hg. If
tolerated, to 130/80 mm Hg or less, but more than 120 mm Hg, this can reduce stroke
risk further, but not other major cardiovascular events. For patients with chronic
kidney disease, target BP range should be 130–139 mm Hg.
Target diastolic BP has not been very well studied. It is often recommended that
diastolic BP should be targeted to 80 mm Hg (ACC/AHA 2017). In some patients
with isolated systolic hypertension, their diastolic BP is already below the target.
These patients are still encouraged to control their systolic BP to target level and
well tolerated.
The optimal diastolic BP target has been less well defined, but less than 80 mm Hg
is recommended. Some patients with stiff arteries and isolated systolic hypertension
will already have diastolic BP levels below this target. These are high-risk patients,
and the low diastolic BP should not discourage treatment of their elevated systolic
BP to the recommended target, providing that treatment is well tolerated.
New definition of hypertension by the 2017 ACC/AHA Hypertension Guidelines
(Whelton et al. 2017) is BP > 130/80 mm Hg.
6 Hypertension Drug Therapy 207
Initial therapy for the majority of patients with hypertension should be a combination
of two drugs. The only exception would be in a limited number of patients with a
lower baseline BP close to their recommended target, who might achieve that target
with a single drug, or in some frailer old or very old patients (>80 years) in whom
more gentle reduction of BP may be desirable.
Single-pill combinations therapy has been shown to improve adherence to treat-
ment and is now the preferred strategy for initial two-drug combination treatment of
hypertension and for three-drug combination therapy when required.
Many guidelines exist for the management of hypertension. Most groups, including
the ESH/ESC, JNC, the American Diabetes Association, and the AHA/American
Stroke Association (ASA), recommend lifestyle modification as the first step in
208 R. Hui
Older people, especially after 60 years old, often have isolated systolic high BP with a
low diastolic BP (<90 mm Hg, even <60 mm Hg). This situation brings some concerns
about diastolic BP too low to meet coronary blood supply while lowering systolic
BP (so-called J-curve) and created a debate regarding the optimal treatment targets
for systolic hypertension in the elderly. SPRINT trial showed beneficial cardiovas-
cular effects of intensive systolic BP of <120 mmHg in older patients (Joshua et al.
2006). ACC/AHA/ASH guideline (2017) recommends a systolic BP reduction of
<130 mmHg (Whelton et al. 2017). JNC 8 recommends a systolic BP reduction
<150 mmHg for the same age of patients (James et al. 2014).
It has been found that on-treatment diastolic BP yielded no relationships with the
risk of cardiovascular disease or the risk of all-cause mortality. Systolic BP in the
range between 130 mm Hg and 144 mm Hg was associated with minimal adverse
outcomes but with a reduction in cardiovascular disease and in all-cause mortality
among Japanese older adults with isolated systolic hypertension (Yano et al. 2017).
Although recent data support that a systolic BP reduction of <140 mm Hg for
persons aged ≥60 years, with an attempt for systolic BP reduction to ≤130 mm Hg
in healthier subjects and those with cardiovascular disease, diabetes mellitus, and
chronic kidney disease, care should still be taken not to further reduce the systolic
BP in older subjects if their diastolic BP is ≤60 mmHg for the fear of J-curve effect
(Chrysant 2018).
Since sexual function is an important aspect of quality of life for the individuals and a
high prevalence of sexual dysfunction has been found in hypertensive men, attention
should be paid to the problem. Hypertension per se, regardless of drugs, has been
suggested to affect sexual function. Other cardiovascular risk factors, especially dia-
betes mellitus, have also been shown to correlate with impaired sexual function. It
has been proposed that sexual and especially erectile dysfunction may, at least in part,
represent just another manifestation of ASCVD or HMOD. The incidence of sex-
ual dysfunction is exacerbated by antihypertensive drug treatment, most frequently
occurred in using thiazide-class diuretics, β-blockers, and centrally acting sympa-
thoplegics. The third generation of β-blockers like nebivolol, thiazide-like diuretics,
and ARBs may improve erectile function, but this should be verified in large clinical
trials before written in the guideline. CCBs and ACE inhibitors have been considered
neutral with respect to this endpoint.
210 R. Hui
ACE inhibitors (cough can also be caused by ARBs), beta-blockers, and CCBs
have been associated with cough as a side effect. It is unknown what are the exact
mechanisms of cough. The level of evidence is strongest with ACE inhibitors. ACE
inhibitors are associated with a dry, persistent cough in 5–35% of patients who take
them. Chinese seem to have more this side effect (Coates 2010). The mechanism of
cough is likely multifactorial. This side effect is not dose-dependent and often pre-
cludes the use of all agents within the drug class. No one ACEI is any better or worse
than another in terms of causing coughing. It is known that the coughing may occur
within a week of starting ACE inhibitors or up to 1 year later. This cough is usually
worse at night and when the person is lying down. Stopping ACE inhibitors is the best
way to stop the cough. Cough will go away within 2 weeks to several months after
discontinuing ACE inhibitors. If switched to ARBs, cough risk becomes significantly
lower, but not for sure of completely gone (Messerli et al. 2018).
Beta-blockers: Blocking beta-2 receptors can cause bronchoconstriction (Whel-
ton et al. 2017). Many commercially available beta-1 selective blockers have a high
affinity for beta-2 receptors. Therefore, both selective and nonselective beta-blockers
may cause bronchoconstriction, especially at high dosage, which can lead some
patients to experience a cough reflex (Tiotiu et al. 2019; Morales et al. 2014).
CCBs: Although there are reported incidences of cough associated with CCBs, a
literature search for drug-induced cough associated with CCBs yielded no relevant
studies or case reports. The rates are low, estimated ranging from <1 to 6%. However,
the search yielded studies on the potential antitussive benefits of CCBs (Düsing 2005;
Khaja et al. 2016; Martínez-Salamanca et al. 2014; Angulo et al. 2010; Kamei and
Kasyya 1992).
other medications interfering with the laboratory test results should be stopped at
least 2 weeks before test (preferably 4 weeks). Under the circumstance, BP will
be controlled with medications which have less effects on renin-aldosterone mea-
surement such as verapamil slow-release (with or without hydralazine) or prazosin
(Whelton et al. 2017; Williams et al. 2018).
Acute onset, severe hypertension that is accurately measured using standard tech-
niques, persistent for 15 min or longer, is considered a hypertensive emergency.
Hypertensive emergency is defined as severe elevations in BP (> 180/120 mm Hg)
associated with evidence of new or worsening target organ damage. If left untreated,
1-year death rate is more than 79%, and the median survival is 10.4 months. With
BP control and medication compliance, the 10-year survival rate approaches 70%
(Whelton et al. 2017).
Hypertensive emergencies include the following conditions:
(1) Malignant hypertension, a typical presentation of a hypertension emergency, is
characterized by severe hypertension (usually grade 3) associated with fun-
duscopic changes (flame hemorrhages and/or papilloedema), microangiopa-
thy, and disseminated intravascular coagulation, and it can be associated with
encephalopathy (about 15% of cases), acute heart failure, and acute deteriora-
tion in renal function. The hallmark of this condition is small artery fibrinoid
necrosis in the kidney, retina, and brain. The term “malignant” reflects the very
poor prognosis for this condition if untreated.
(2) Patients with severe hypertension as well as other urgent clinical conditions
requiring immediate to bring BP to a safe level, for example, acute aortic
dissection, acute myocardial ischemia, or acute heart failure.
(3) Patients with pheochromocytoma present with severe hypertension or hyper-
tensive crisis.
(4) Pregnant women with severe hypertension or preeclampsia.
(5) In patients with hypertensive encephalopathy, the presence of somnolence,
lethargy, tonic seizures, and cortical blindness may precede a loss of conscious-
ness. However, focal neurological lesions are rare and should raise the suspicion
of stroke.
(6) Acute stroke, especially intracerebral hemorrhage, when associated with severe
hypertension, a more cautious approach is now recommended for acute BP
lowering in the emergency setting of acute stroke (Williams et al. 2018).
Target organ damage includes but is not limited to hypertensive encephalopathy,
intracerebral hemorrhage, acute ischemic stroke, acute myocardial infarction, acute
left ventricular failure with pulmonary edema, unstable angina pectoris, dissecting
aortic aneurysm, acute renal failure, and eclampsia (Whelton et al. 2017).
212 R. Hui
Symptoms are those of decompensated cardiac failure with shortness of breath, pul-
monary edema, lethargy, paroxysmal nocturnal dyspnea, and orthopnea. A cough
productive of frothy pink sputum may be reported. Left heart failure can lead to
biventricular failure, and there may be signs of peripheral edema and hepatomegaly.
An echocardiogram will usually be indicated, and imaging of the coronary arteries
may be helpful as reversible cardiac ischemia may improve symptoms and prognosis
(Whelton et al. 2017; Williams et al. 2018).
Typically presents with acute, severe chest pain with “ripping” or “tearing” charac-
teristics. It may radiate to the back or jaw. Syncope, altered cognition, and anxiety
are common neurologic symptoms. A BP difference of >20 mmHg is suggestive but
not diagnostic of an acute aortic dissection. Treatment will depend on the portion of
the aorta that is affected and may include surgical repair, endovascular stenting, or
medical therapy alone. All patients require close monitoring and intensive treatment
of BP and pulse, usually in a high-dependency or intensive care unit with appropriate
specialist input (Whelton et al. 2017; Williams et al. 2018).
6.9.4 Preeclampsia
ALLHAT trial showed that long-term use of diuretics induced more new-onset dia-
betes than CCBs, ARBs, and ACE inhibitors. Diuretics may increase plasma glucose
level and even new diabetes risk but did not worse clinical outcomes. The net effect
is beneficial to patients at least during the trial (Barzilay et al. 2012).
216 R. Hui
The prevalence of metabolic syndrome was 34.2% in the United States (Moore
et al. 2017). The metabolic syndrome is linked to several other disorders, including
nonalcoholic steatohepatitis, polycystic ovary syndrome, certain cancers, chronic
kidney disease, Alzheimer’s disease, Cushing’s syndrome, lipodystrophy, and
hyperalimentation.
No clinical proved therapy for metabolic syndrome is available now. Lifestyle
modification, with an emphasis on improving insulin sensitivity by means of dietary
modification, weight reduction, and exercise constitute the foundation of metabolic
syndrome treatment. It has not been clearly defined for the optimal antihypertensive
drug therapy for hypertensive patients with metabolic syndrome. No data are cur-
rently available that diuretics can worsen cardiovascular and renal outcomes even
there is risk for high plasm glucose and new-onset diabetes (Whelton et al. 2017).
ALLHAT trial showed that chlorthalidone was associated with only a small
increase in fasting glucose levels (1.5–4.0 mg/dL), and this increase did not translate
into increased cardiovascular risk. Similarly, high-dose ARB therapy reduces arte-
rial stiffness in patients with hypertension with the metabolic syndrome but did not
provide outcomes data (Barzilay et al. 2012).
Beta-blocker therapy increased diabetes risk by 33% compared with placebo and
22% compared with nondiuretic antihypertensive agents. In looking at specific beta-
blockers, the researchers found that atenolol and metoprolol increased diabetes risk
by 30% and 34%, respectively, compared with other antihypertensives (Bangalore
et al. 2007). The newer vasodilating beta-blockers, such as labetalol, carvedilol, and
nebivolol, have shown neutral or favorable effects on metabolic profiles compared
6 Hypertension Drug Therapy 217
with the traditional beta-blockers but no clinical trials showed that these vasodilating
beta-blockers improve cardiovascular outcomes (Zullo et al. 2018; Bell 2004).
It has been reported that patients with cerebral hemorrhage have a history of chronic
hypertension accounted for 89%, and these people’s systolic BP is generally in
160 mm Hg ~ 240 mm Hg, diastolic BP between 90 mm Hg ~ 160 mm Hg.
Observational studies showed that raised BP on ischemic stroke onset is prognos-
tically associated with excess risk for early adverse events and mortality. Benefit or
harm effects were still uncertain within the first 48–72 h to initiation or re-initiation
of antihypertensive treatment in ischemic stroke (Whelton et al. 2017).
ACC/AHA 2017 guideline (Whelton et al. 2017) recommended indications for
antihypertensive therapy in patients with ischemic stroke:
(1) The first antihypertensive therapy indication was when patient’s BP was >
220 mm Hg/120 mmHg and gradually to lower BP by 15% during the first
24 h after onset of stroke (Whelton et al. 2017).
(2) Those eligible for therapy with intravenous tissue plasminogen activator (tPA)
but their BP was > 185/110 mmHg. Before tPA, BP should be controlled to
less than 180/110 mm Hg. During tPA therapy, BP should be maintained at
<180/105 mm Hg at least for the first 24 h (Whelton et al. 2017).
Otherwise, acute and aggressive BP responses within 24-h of stroke onset should
be avoided, because the results from randomized controlled trials and recent meta-
analyses did not show that effectively controls elevated BP in the acute stage
of ischemic stroke could be translated into improvement in the risk of death or
dependency (Georgianou et al. 2018).
Maintenance of cerebral perfusion pressure provides physiologic support for the
safety of BP reduction in intracerebral hemorrhage (Tamm et al. 2016).
Antihypertensive indications: Only systolic BP > 220 mm Hg, or MAP > 150 mm
Hg, continuous intravenous infusion of antihypertensive agents is indicated. Sys-
tolic BP needs to be monitored closely not too lower every 5 min (Whelton et al.
2017). When elevated intracranial pressure is suspected and there are evidences
which support the diagnosis, monitor intracranial pressure and keep intracranial
pressure at 60–80 mm Hg by using intermittent or continuous intravenous infusion
of antihypertensive agents.
218 R. Hui
Recent data from some clinical trials support that intensive BP lowering to levels
< 140 mmHg for systolic BP is safe and lowers the risk of hematoma expansion
in patients with acute intracerebral hemorrhage (Verdecchia et al. 2016). Intensive
BP lowering in patients with acute cerebral hemorrhage is still controversial. The
treatment of participants with intracerebral hemorrhage to achieve a target systolic
BP of 110 mm Hg to 139 mm Hg did not result in a lower rate of death or dis-
ability than standard reduction to a target of 140 mm Hg to 179 mm Hg (Qureshi
et al. 2016). If systolic BP is >180 mm Hg or MAP is >130 mm Hg and there is
a possibility of elevated intracranial pressure, then consider monitoring intracranial
pressure and reducing BP using intermittent or continuous intravenous medications
while maintaining a cerebral perfusion pressure >60 mm Hg.
BP goal:
(1) Lowering BP 15–30%; first systolic BP achieved to 180 mm Hg and diastolic
BP to 105 mm Hg within first 6 h.
(2) Then BP lowered to the level before hemorrhage or systolic BP ≤ 160 mm Hg,
diastolic BP ≤ 90 mm Hg.
(3) When cerebral edema disappears and intracranial bleed is stopped completely,
clinical conditions are improved and stable, and BP can be lowered to 135/85 mm
Hg or even less to prevent hemorrhage recurrence.
(4) If the patient’s systolic BP was more than 180 mm Hg or MAP more than
130 mm Hg with no evidence of elevated intracranial pressure, MAP can be
lowered to 110 mm Hg, or target BP to 160/90 mm Hg by intravenous infusion
of antihypertensive drugs. The patients should be clinically monitored for every
15 min (Morgenstern et al. 2010).
Studies have shown that BP control in intracranial hemorrhage can be more aggres-
sive: Goal systolic BP was set to less than 160 mm Hg. It’s “probably” safe, even
systolic BP was lowered to less than 140 mm Hg. From onset of spontaneous intrac-
erebral hemorrhage to 6 h, patients have their systolic BP of 150–220 mm Hg, if
their systolic BPs were lowered to a level of less than 140 mm Hg, no reduction in
the rate of death or disability. Lowering BP to this level may be harmful (Anderson
et al. 2013).
For the patients with ischemic stroke and also tPA candidate: BP goal is
<185/110 mm Hg. Once tPA started, maintain BP ≤ 180/105 mm Hg (Anderson
et al. 2013).
Antihypertensive agents used intravenously in patients with hemorrhagic stroke:
Labetalol 5–20 mg, intravenous infusion (2 mg/min), repeated in every 15 min if
BP did not achieve to target level (maximum dose of 300 mg/24 h) or nicardipine:
intravenous infusion at rate 5–15 mg/h;
or Esmolol: intravenous loading dose 250 μg/kg; maintaining dose 25–
300 μg/kg/min.
or Enalapril: 0.625–5 mg by every 6 h, intravenous injection.
or Hydralazine: 5–20 mg intravenous injection by every 30 min; maintaining dose
1.5–5 μg/(kg/min).
6 Hypertension Drug Therapy 219
The presence of elevated BP increases the risk of recurrent stroke, and antihyperten-
sive drug treatment to lower BP has been linked to a reduction in 1-year recurrent
stroke risk by approximately 30%.
Specific antihypertensive agents that have shown benefit include diuretics, ACE
inhibitors, and ARBs. Reduction in BP appears to be more important than the choice
of specific agents used to achieve this goal. Thus, if diuretic and ACE inhibitor
or ARB treatment do not achieve BP target, other agents, such as CCB and/or
mineralocorticoid receptor antagonist, may be added (Whelton et al. 2017).
Achieving a systolic BP level <130 mm Hg was not associated with a lower stroke
risk, and systolic BP levels achieved <120 mm Hg did not show benefit. Patients with
a lacunar stroke treated to a systolic BP target of <130 mm Hg versus 130 mm Hg
to 140 mm Hg may be less likely to experience a future intracerebral hemorrhage
(Whelton et al. 2017).
as minimizing sodium intake and ensuring adequate sodium solute removal during
hemodialysis (Inrig et al. 2007; Agarwal et al. 2009).
Despite these interventions, pharmacologic therapy is usually required to control
BP to goal in hemodialysis patients. Most classes of antihypertensive agents are
appropriate, and a combination of agents is typically required.
First-line antihypertension agents: The preferred antihypertensive agents in
hemodialysis patients are RAAS inhibitors (either ACE inhibitors or ARBs), par-
ticularly those with diabetes mellitus or a history of heart failure (National Kidney
Foundation 2005).
RAAS inhibitors are both effective (their documented benefits on left ventricular
hypertrophy, pulse wave velocity, and potentially cardiovascular events) and safe.
The USRDS Wave 2 Study identified that the use of ACE inhibitors at baseline was
associated with a ~30% reduction of loss of residual renal function at 1 year (Moist
et al. 2000). Among ACE inhibitors, lisinopril has been proved to effectively lower
BP with no increase in intradialytic hypotension (Agarwal et al. 2001).
ARB—Clinical trials have also demonstrated ARBs to be safe and well toler-
ated in hemodialysis patients and relatively effective at lowering BP. Clinical trial
demonstrated that candesartan therapy significantly reduced cardiovascular events
and mortality rates in this trial (Takahashi et al. 2006; Suzuki et al. 2008). No single
ARB can be dialyzable and once daily. These make ARBs very attractive as first-line
antihypertensive drugs in patients with dialysis.
Atenolol is also reported as first-line therapy on the basis of the results of the
HDPAL Trial (Agarwal et al. 2014).
Second-line agents: Beta-blockers, particularly in patients with coronary artery
disease), combined alpha- and beta-blockers in patients with heart failure, CCBs,
and direct vasodilators. A long-acting DHP-CCB, such as amlodipine or felodipine,
is second-line therapy (Georgianos and Agarwal 2016). In patients with contraindi-
cations to ACE inhibitors or ARBs or cardiac conduction defects, these drugs are
sometimes used as first-line agents.
Nocturnal dosing: In order to minimize the risk of intradialytic hypotension,
and nocturnal hypertension in many patients with hemodialysis, nocturnal dosing of
antihypertensive drugs is recommended.
Monitoring serum potassium concentration: Clinical trials have also shown
ACE inhibitor therapy to be relatively safe in hemodialysis with no significant effect
on serum potassium and <3% incidence of symptomatic hypotension. Other stud-
ies suggest that RAAS inhibitors are associated with potential hyperkalemia due to
inhibiting extrarenal potassium loss (Armanini et al. 2007; Garthwaite and Bhan-
dari 2009). Thus, considering the effects of RAAS inhibitors on potassium han-
dling in patients with hemodialysis is uncertain, and monitoring of serum potassium
following initiation of RAAS inhibitors is suggested.
Except for fosinopril, most ACE inhibitors are dialyzable. To avoid intra-dialysis
hypertension, dialyzable ACE inhibitors should be replaced by un-dialyzable ARBs
or other un-dialyzable antihypertensive agents.
6 Hypertension Drug Therapy 221
in dialysis patients with resistant hypertension. The most frequent side effect is sig-
nificant fluid retention, including pleural and pericardial effusion. If fluid retention
cannot be controlled with hemodialysis, minoxidil may be discontinued.
Diuretics are not used frequently in patients with hemodialysis. It has been found
that diuretics use was associated with lower interdialytic weight gain and lower
relative risk of cardiac death in patients with higher residual renal function (Bragg-
Gresham et al. 2007). This study supports that diuretics can be helpful at controlling
interdialytic weight and BP in patients with higher residual renal function. If used
before dialysis, it is not necessary to stop diuretics upon initiation of hemodialysis
(Stirnadel-Farrant et al. 2019).
reduced proteinuria by 70% from baseline (Vogt et al. 2008). High salt intake dimin-
ishes nighttime dipping of BP in salt-sensitive hypertension. Importantly, obstructive
sleep apnea may contribute to nocturnal hypertension as well as BP non-dipping in
individuals with chronic kidney disease.
BP goal for hypertensive patients with chronic kidney disease: Expert consensus
recommended that a BP goal of less than 130/80 mm Hg for individuals with chronic
kidney disease and moderate-to-severe albuminuria (e.g., urine albumin-to-creatinine
ratio > 30 mg/g) either with or without diabetes mellitus. The available evidence is
inconclusive but does not prove that a BP target of less than 130/80 mm Hg improves
clinical outcomes more than a target of less than 140/90 mm Hg in adults with chronic
kidney disease (de Carvalho et al. 1977; Shah et al. 1978).
In a cohort of over 650,000 Veteran Americans with chronic kidney disease,
mortality was associated with two extreme BP groups (the lowest BP and the highest
BP), concluding that in patients with diastolic BP < 70 mm Hg, it may be harmful to
try to reduce systolic BP to <130 mm Hg (Kovesdy et al. 2013). Conversely, a high
salt diet offsets the antihypertensive efficacy of diuretics and blockers of RAAS as
well as their anti-proteinuria efficacy.
Diuretics use in advanced chronic kidney disease
Thiazide-type, thiazide-like diuretics, and loop diuretics: Guidelines recom-
mended switching from thiazides to loop diuretics when GFR falls below
30 ml/min/1.73 m2 . As a class, loop diuretics are relatively short-acting, limited
their widespread adoption to treat chronic hypertension compared with readily avail-
able thiazide diuretics (Chobanian et al. 2003; Hayashi et al. 2008). The doses of
furosemide as high as 250 mg intravenously have been found ineffective (Pitt et al.
1999). Thus, the role of the use of loop diuretics in end-stage kidney disease is
marginal at best, being limited to only those patients with significant residual kidney
function.
When using diuretics, chlorthalidone or torsemide is often selected due to their
long durations of action and greater potency, and chlorthalidone is preferred to
metolazone because of its lower cost.
The evidence against thiazide use is weak in advanced chronic kidney disease.
The JNC8 (James et al. 2014) and the AHA/ACC recommendations (Whelton et al.
2017) take no position on the use of thiazides versus loop diuretics in chronic kidney
disease. The position of the Kidney Disease Improving Global Outcomes guidelines
considered that although many clinicians switch from thiazides to loop diuretics, the
antihypertensive benefit of thiazides may still be preserved at low levels of GFR.
The short-acting effect of many loop diuretics hinders their efficacy in long-term
BP control. For all these reasons, clinicians may again turn to thiazide diuretics
as an alternative or loop diuretics as add-on in advanced chronic kidney disease
(estimated GFR < 30 mL/min/1.73 m2 ) where they traditionally have been thought
to be ineffective (Kramkowski et al. 2007). Clinical trial proved that the combination
of thiazide diuretics (such as Chlorthalidone) with a loop diuretic showed more
effective in lowering BP than using each alone in advanced chronic kidney disease
(stages 4 and 5), especially in patients with excess volume (Agarwal and Sinha 2012).
226 R. Hui
Patients in later stages of chronic kidney disease are likely to have resistant hyper-
tension. However, if chronic kidney disease was at stage 3, mineralocorticoid receptor
antagonist raised serum potassium by an average of 0.4 mEq/L and serum creatinine
levels from a mean 1.5 mg/dl to 1.8 mg/dl. Mineralocorticoid receptor antagonists
should not be used in advanced chronic kidney disease (such as chronic kidney
disease stage 4 or higher) (Pisoni et al. 2012).
In proteinuric chronic kidney disease and hypertension (Judd and Calhoun
2015): First-line antihypertensive drugs are ACE inhibitors or ARBs (Whelton et al.
2017). Second-line drugs are a DHP-CCB or a diuretic. Diuretics for the patient
have signs of volume overload or if we judge that a mineralocorticoid receptor
blocker will be urgently necessary to manage uncontrolled proteinuria and wish
to lower potassium before starting the mineralocorticoid receptor blocker. Third-line
antihypertensive drugs are ACE inhibitors or ARBs + CCBs + diuretics. On three
antihypertensive agents including one diuretic, BP remains not to achieve treatment
target; this is called resistant hypertension, and mineralocorticoid receptor blocker
should be added on. If the presence of chronic kidney disease and impaired renal
function pay more attention to plasma hyperkalemia, thiazide or loop diuretics may
be used to prevent hyperkalemia.
Spironolactone has been found to effectively lower BP as well as urinary pro-
tein. It should be cautioned in patients with baseline serum potassium greater than
4.6 mEq/L. It is contraindicated in acute kidney injury or in creatinine clearances
of less than 10 ml/min. Eplerenone is contraindicated when the creatinine clearance
falls to less than 30 ml/min. End-stage renal failure is defined as GFR declined to less
than 15 ml/min/1.73 m2 . Uncontrolled hypertension has been identified as the sec-
ond major cause of end-stage renal failure (National Kidney and Urologic Diseases
Information Clearinghouse 2010).
Although it is well known that lowering BP protect from cardiovascular disease,
the protective effect of BP reduction on kidney function can be less obvious and
only restricted to patients with diabetes or chronic kidney disease, in whom there
is a faster rate of disease progression (Velázquez et al. 1993). In most hypertensive
patients, BP reduction does not very often reduce the development of chronic kidney
disease, nor the slow rate of decline in renal function. On the other hand, some,
but not all RCTs (randomized clinical trials), have also shown a protective effect of
BP lowering on the progression of chronic kidney disease toward end-stage kidney
disease in both diabetic and nondiabetic nephropathy (Whelton et al. 2017). RCTs
based on clinical outcomes have limitations, such as that these trials largely limited to
older and high-risk patients, and over a relatively short duration of follow-up, rarely
beyond 5 years.
6 Hypertension Drug Therapy 227
are more likely to suffer from preeclampsia in those who have early hypertension pre-
sentation, previous miscarriage, and previous pregnancy having hypertension (Carey
et al. 2018; Chobanian et al. 2003). Although no evidences support that BP control
to target level can prevent preeclampsia, antihypertensive medications should still
be the choice to prevent the maternal consequence of severe hypertension.
Transient hypertension: Diagnosis made retrospectively. BP returns to normal
by 12 weeks’ postpartum. It may recur in subsequent pregnancies.
Female patients with hypertension who are at childbearing age can get pregnant.
Hypertension needs to be appropriately controlled by using antihypertensive agents
with no fetotoxic before conception. Goal of systolic BP 140 mm Hg to 159 mm
Hg/diastolic BP 90 mm Hg to 109 mm Hg is appropriate if there are no other com-
plications. Drugs are indicated for acute elevation of diastolic BP ≥ 105 mm Hg;
the diastolic BP goal is gradually reduced to 90 mm Hg to 100 mm Hg (Ameri-
can College of Obstetricians and Gynecologists 2013; Regitz-Zagrosek et al. 2011;
Committee on Obstetric Practice 2015).
Hypertension during pregnancy affects about 6–8% of pregnant women, who are
at a higher risk of stroke and complications during delivery. As in women with
chronic hypertension, antihypertensive medications should be prescribed with the
goal of preventing maternal consequences of severe hypertension, because there is
no evidence that targeted BP control prevents preeclampsia (Whelton et al. 2017;
Williams et al. 2018; American College of Obstetricians and Gynecologists 2013;
Regitz-Zagrosek et al. 2011; Committee on Obstetric Practice 2015).
Approximately, 15–45% of women initially diagnosed with gestational hyper-
tension will develop preeclampsia, and this is more likely with earlier presenta-
tion, previous miscarriage, and previous hypertensive pregnancy, as well as higher
BP. Preeclampsia can damage pregnant women’s organs and be very dangerous to
pregnant women’s healthy if it isn’t properly treated.
Besides high BP, preeclampsia can also cause proteinuria, which is a sign of kidney
damage, headaches, changes in vision, upper abdominal pain, and decreased urine
output. If a pregnant woman is suspected of having preeclampsia, antihypertensive
medicines must be prescribed to control BP and prevent complications. Controlling
high BP is an important part of the treatment for preeclampsia. Medications can
help treat it, but the only way to cure the disorder is to deliver a baby. Depending
6 Hypertension Drug Therapy 229
on the severity of symptoms and how near to term, the doctor may decide when
necessary to deliver a baby right away (Whelton et al. 2017; Williams et al. 2018;
American College of Obstetricians and Gynecologists 2013; Regitz-Zagrosek et al.
2011; Committee on Obstetric Practice 2015).
Additionally, much of the obstetric literature focuses on diastolic BP rather than
systolic BP in contrast to hypertension guidelines in adults which emphasizes the
importance of systolic BP.
During pregnancy, the challenge is to decide when to use antihypertensive medi-
cations and what level of BP to target. Untreated mild-to-moderate hypertension is
unlikely to lead to unfavorable long-term maternal outcomes during the 9 months
of pregnancy. In this setting, antihypertensive agents are mainly used to prevent
and treat severe hypertension; to prolong pregnancy safely for as long as possible,
thereby maximizing the gestational age of the infant; and to minimize fetal exposure
to medications that may have adverse effects (Whelton et al. 2017; Williams et al.
2018; Chobanian et al. 2003; American College of Obstetricians and Gynecologists
2013; Regitz-Zagrosek et al. 2011; Committee on Obstetric Practice 2015).
(1) Severe hypertension (defined as ≥160/110 mm Hg, rather than stages as most
guidelines).
(2) Preeclampsia.
(3) Eclampsia.
No antihypertensive has been proven safe for use during the first trimester. Drug
therapy was indicated for uncomplicated chronic hypertension when diastolic BP
was ≥100 mm Hg (Korotkoff V). Treatment at lower levels may be indicated for
patients with diabetes mellitus, renal disease, or target organ damage.
these patients who are at an increased risk of hypotension if aggressive lowering BP.
Antihypertensive medications such as parental labetalol, hydralazine, or oral nifedip-
ine should be started with a lower dose to minimize maternal and fetal adverse effects
(Whelton et al. 2017; Williams et al. 2018; American College of Obstetricians and
Gynecologists 2013; Regitz-Zagrosek et al. 2011; Committee on Obstetric Practice
2015).
In women with preeclampsia, consideration should be given to initiating agents
for the treatment of acute severe hypertension at lower doses, because these patients
may be intravascularly volume depleted and may be at increased risk for hypotension.
A recent meta-analysis of 24 trials (2949 women) in which different antihyperten-
sive drugs were compared for the treatment of severe hypertension in pregnancy
concluded that there is insufficient data to favor one agent over another, although
others have concluded that agents other than parenteral hydralazine (e.g., parenteral
labetalol or oral nifedipine) are preferable because of reduced maternal and fetal
adverse effects (Whelton et al. 2017; Williams et al. 2018; American College of
Obstetricians and Gynecologists 2013; Regitz-Zagrosek et al. 2011; Committee on
Obstetric Practice et al. 2015; Veerbeek et al. 2015).
6.18.6 BP Goals
Only a small proportion of currently available drugs have been adequately evaluated
in pregnant women, and many others are contraindicated.
First-line of antihypertensive agents used in pregnant-related hypertension:
methyldopa, labetalol, and long-acting nifedipine (Butalia et al. 2018). The com-
bination of nifedipine with magnesium sulfate may cause excessively low BP and
negative effects on the patient’s muscle and nerves. Hydralazine is another drug that
can be given orally or intravenously (very severe cases of hypertension) to control
hypertension in pregnancy. Its main side effect is tachycardia arrhythmia (Magee
et al. 2003).
The American College of Obstetricians and Gynecologists has issued a task force
report, including recommendations for prevention, taking aspirin in selected cases,
and treatment of severe hypertension with magnesium in patients with hypertension
in pregnancy (American College of Obstetricians and Gynecologists 2013). A report
detailing treatment of hypertensive emergencies during pregnancy and postpartum
has also been released (Regitz-Zagrosek et al. 2011; Committee on Obstetric Practice
2015).
Methyldopa, starting dosage: 750 mg orally loading dose, then 250–500 mg PO
twice a day; maximum dose: 2000 mg/day in up to 4 doses. Safety after the first
trimester has been well documented, including 7 years follow-up of offspring.
Labetalol, direct Vasodilators, starting dose: 100–200 mg orally bid; maximum
dose: 1200 mg/day in up to 4 doses. The medication may be associated with fetal
growth restriction. For intravenous infusion: 1–2 mg/min. Because of a lower inci-
dence of maternal hypotension and other adverse effects, labetalol is replacing
hydralazine. It is avoided in women with asthma or with congestive heart failure.
Hydralazine is a director vasodilator. Long experience of safety and efficacy is
in the treatment of pregnant-related hypertension. The greatest use is in the urgent
control of severe hypertension or as a third-line agent for multidrug control of refrac-
tory hypertension. It has been widely used for chronic hypertension in the second
and third trimesters, but its use has been supplanted by agents with more favorable
adverse effect profiles. A meta-analysis of the use of intravenous hydralazine in
severe hypertension in pregnancy concluded that parenteral labetalol or oral nifedip-
ine were preferable first-line agents, with hydralazine as a suitable second-line agent
(Butalia et al. 2018).
Hydralazine is effective orally, intramuscularly, or intravenously (bolus or infu-
sion). Parenteral administration is useful for rapid control of severe hypertension,
starting dose: 10 mg orally, 4 times a day; maximum dose: 200 mg/day in up to 4
doses. Few controlled trials and long experience with few adverse events are docu-
mented. It is useful in combination with sympatholytic agent. Hydralazine may cause
neonatal thrombocytopenia. Usually, 5 mg is given through intravenous or intramus-
cular injection, then 5–10 mg for every 20–40 min; once BP controlled, it is repeated
for every 3 h. For intravenous infusion: 0.5–10.0 mg/h; if not satisfied with BP goal,
20 mg intravenous injection or 30 mg orally taken, or consider another class drug
232 R. Hui
6.18.8 Contraindications
First-trimester use of ACE inhibitors and ARBs should be avoided since first-
trimester exposure to ACE inhibitors has been associated with a greater incidence of
malformations of the cardiovascular and central nervous systems. It may be best to
counsel women to switch to alternate agents while attempting to conceive, in other
terms, need to replace antihypertensive drugs with either methyldopa, or labetalol,
or hydralazine or long-acting nifedipine or combined for at least 3 months before
attempting to conceive (Regitz-Zagrosek et al. 2011; Committee on Obstetric Practice
2015; Butalia et al. 2018).
ACE inhibitors and ARBs lead to fetal loss in animals; human use associated
with cardiac defects, fetopathy, oligohydramnios, growth restriction, renal agenesis,
and neonatal anuric renal failure, which may be fatal. ACE inhibitors and ARBs are
fetotoxic and not approved for use before and during pregnancy. Both ACE inhibitors
and ARBs have been shown fetotoxic in the second and third trimesters of pregnancy.
For ARBs, case reports with effects have been published similar to ACE inhibitors
(Committee on Obstetric Practice 2015; Veerbeek et al. 2015).
Beta-receptor blockers, depending on specific agent, may decrease uteroplacental
blood flow; impair fetal response to hypoxic stress; risk of growth restriction when
started in the first or second trimester (atenolol); and may be associated with neona-
tal hypoglycemia at higher doses. Propranolol is a beta-blocker that lowers BP by
reducing heart rate and the amount of blood pumped by the heart. It’s been associated
with birth defects, such as fetal bradycardia, or slow heartbeat, slowed development,
and neonatal hypoglycemia (Committee on Obstetric Practice 2015; Veerbeek et al.
2015).
Generally, diuretics such as furosemide and hydrochlorothiazide should be
avoided during pregnancy.
6.18.10 Preeclampsia
The lowest postnatal hypertension risk of 33% was found in patients with ante-
natal preeclampsia (proteinuric hypertension), then severe antenatal hypertension
(>160/100 mm Hg), hypertension requiring antenatal treatment, to the highest risk of
>75% in patients with pre-termed delivery (before 37 weeks of gestation) triggered by
maternal hypertensive disease (American College of Obstetricians and Gynecologists
2013; Committee on Obstetric Practice 2015; ACOG 2018).
The perceived advantages of starting treatment in the early postnatal period are
that episodes of severe hypertension will be reduced and discharge to the community
will not be delayed unnecessarily.
Nice guidelines for postpartum care are recommended that BP should be measured
within 6 h of delivery. All maternal women should be aware of preeclampsia man-
ifestations and how to urgently contact an appropriate health professional (ACOG
2018; NICE guideline 2019). New patients should have a thorough history taken
and physical examination, full blood count, electrolytes, and liver function tested
to exclude impending eclampsia (American College of Obstetricians and Gynecol-
ogists 2013; Carty et al. 2010; Tong et al. 2017; Lewis 2003; National Institute for
Health and Clinical Excellence 2010).
Regardless of whether antihypertensive agents are prescribed immediately fol-
lowing delivery, all women should be closely monitored with regular recordings of
BP and fluid balance. It is anticipated that the introduction of modified obstetric early
warning system charts might facilitate the detection of women who require further
medical review (Lewis 2003).
Follow-up: Once discharged, BP should be measured on alternate days for the
first 2 weeks and refer for medical review if two measurements >150/100 mmHg
are obtained more than 20 min apart. If patients have preeclampsia symptoms or
if patient’s BP is more than 160/100 mm Hg, hospital review will be required. In
most postnatal hypertension women, antihypertensive therapy should continue for
at least 2 weeks and for some with early and severe hypertension, antihypertensive
therapy should continue beyond 6 weeks. These patients may need further medi-
cal review to investigate their underlying causes. When BP achieves the levels of
130–140/80–90 mm Hg, the dose of antihypertensive agents can be reduced. If med-
ication is required beyond 6 weeks, then further medical review should be arranged
to investigate the possibility of an underlying cause. The 6-week postnatal visit is
an opportunity to establish the diagnosis and to discuss implications for future preg-
nancies. All women who have had a diagnosis of preeclampsia should have their
blood pressure measured and the urine tested for proteinuria (American College of
Obstetricians and Gynecologists 2013; Committee on Obstetric Practice 2015).
236 R. Hui
To advise women with hypertension who wish to breastfeed that their treatment can
be adapted to accommodate breastfeeding and that the need to take antihypertensive
medication does not prevent them from breastfeeding (NICE guideline 2019).
Enalapril could be offered to treat hypertension in women during the postnatal
period (Hypertension et al. 2013), with appropriate monitoring of maternal renal
function and maternal serum potassium (NICE guideline 2019). For black African
women or Caribbean family origin with hypertension during the postnatal period,
antihypertensive treatment could start with nifedipine or amlodipine if the woman
previously used the medication to successfully control her BP. The NICE guideline
on hypertension in adults recommended (NICE guideline 2019), if BP did not achieve
the goal with a single medicine in the postnatal period in women with hypertension
and try the combination of nifedipine (or amlodipine) with enalapril. If the combina-
tion still did not achieve BP goal or not tolerated, labetalol or atenolol can be added
to the combination. Where possible, avoid using diuretics or ARBs to treat hyper-
tension in women with postnatal hypertension who are breastfeeding or expressing
milk (NICE guideline 2019).
When treating women with antihypertensive medication during the postnatal
period, drugs are taken once daily when possible. Diuretics or ARBs are better
to be avoided in women in the postnatal period who are breastfeeding or expressing
milk (NICE guideline 2019).
In the treatment of women with postnatal hypertension who are not breastfeeding
or not planning to breastfeed, NICE guideline for postpartum care recommended
that BP should be measured within 6 h of delivery, be aware of preeclampsia symp-
toms, and how to urgently contact an appropriate health professional for all postnatal
women.
NICE postnatal guidance (National Institute for Health and Clinical Excellence
2006) recommends medical review if diastolic BP is more than 90 mm Hg sustained
over 4 h, associated with any symptoms of preeclampsia. Any new patients should
have a thorough medical history taken and physical examination and laboratory tests
to exclude eclampsia or HELLP syndrome.
NICE guidance (National Institute for Health and Clinical Excellence 2010) rec-
ommends that the platelet count, transaminases, and serum creatinine are checked
48–72 h after birth, or step down from Level 2 care, and only repeated thereafter if
abnormal or clinically indicated.
Given that up to 44% of eclampsia fits occur in the postnatal period, usually within
first 48 h following delivery (Douglas and Redman 1994). Hospitalized women with
preeclampsia are better to delay discharge until the day when their BP is less than
150/100 mm Hg.
In situations where hypertension predates the pregnancy, it is advisable to discon-
tinue methyldopa following delivery and switch back to antihypertensive medications
and dose used at the pre-pregnant stage. If wishing to breastfeeding, or to taking any
new drugs, the best way is to get advice from a pharmacologist before delivery.
6 Hypertension Drug Therapy 237
Patients with refractory hypertension were identified after routine clinical follow-up
of ≥3 visits for ≥6 months, had uncontrolled BP in spite of being adherent to a reg-
imen of >5 classes of antihypertensive agents, including chlorthalidone 25 mg daily
and mineralocorticoid receptor antagonists (spironolactone, 25 mg daily, ≤50 mg
per day or eplerenone, 50 mg bid) without evidence of underlying secondary causes
of hypertension. Its prevalence is approximately 5% of patients with uncontrolled
resistant hypertension. This is a recently proposed phenotype of antihypertensive
treatment failure and an extreme subtype of resistant or difficult-to-treat hypertension
(Acelajado et al. 2019).
Mechanism: Refractory hypertension may be more likely attributable to height-
ened sympathetic output as opposed to inappropriate fluid retention (Acelajado et al.
2019).
Treatment: Effective sympathetic inhibition, either with medications or device-
based approaches (Acelajado et al. 2019). To first select chlorthalidone because
its superiority over hydrochlorothiazide to reduce BP, particularly nighttime high
BP, is likely related to its longer half-life. However, chlorthalidone use is more
frequently associated with adverse metabolic effects, particularly hypokalemia and
6 Hypertension Drug Therapy 239
All patients with new hypertension and resistant hypertension should be ruled out of
secondary hypertension.
Therapy: The purpose of therapy in patients with renal artery disease is to con-
trol blood pressure and preserve renal function. If hypertension control cannot be
achieved or a decline in renal function is evident, revascularization should be more
strongly considered (endovascular angioplasty and surgery) (Badila et al. 2014).
Angioplasty: Renal artery stenosis is a potentially reversible cause of hyperten-
sion. Randomized controlled trials comparing medical therapy with medical ther-
apy and renal artery stenting have failed to show a benefit for renal artery stenting.
Angioplasty is still the first-line treatment for renovascular stenosis secondary to
fibromuscular dysplasia. Renal artery stenting is presently very often used in the
treatment of atherosclerotic renal artery stenosis, but its clinical efficacy is inconsis-
tent. Renal denervation is promising in the treatment of drug-resistant hypertension,
and technical standard and clinical outcome need to be confirmed before it becomes
clinical routine (Minocha 2016; Gornik et al. 2019).
The renal percutaneous transluminal angioplasty is an accepted and durable treat-
ment strategy when the etiology of renovascular hypertension is fibromuscular dys-
plasia. Currently, correction of renal arterial inflow stenosis is reserved for patients
with renal artery stenosis of >80% with a significant trans-lesional pressure gradient;
difficult to control BP with more than three antihypertensives, especially in younger
patients; and those with truncal rather than ostial stenosis; patient with a rapid dete-
rioration of renal function; flash pulmonary edema; and post-transplant renal artery
stenosis (Mohan and Bourke 2015; Mousa et al. 2017).
The rate of restenosis has been reported in the range of 5–11% after 1 year (Safian
and Textor 2001). Interventional therapy is still controversial for atherosclerotic renal
artery stenosis. The angioplasty response was poorer in patients with ostial lesion,
sequential stenosis of single artery, or stenosis in multiple renal arteries on the same
side. Endovascular treatment of renal artery stenosis may be considered in patients
with impaired renal function (Safian and Textor 2001; Gray et al. 2002; Durros et al.
1068).
Surgical revascularization: A meta-analysis of 47 retrospective or nonrandom-
ized studies compared the outcomes in patients subjected to surgical revascular-
ization versus patients subjected to endovascular procedures. The results showed
similar technical success rates, and surgical revascularization had better long-term
BP control and renal function, but slightly higher perioperative mortality (attributed
to concomitant aortic surgery) (Abela et al. 2009).
Medical treatment: No matter whether patients with renovascular hyperten-
sion need revascularization management or not, antihypertensive medical therapy
is necessary either before or after surgery. Better control of BP before the operation
can improve surgical outcomes. Continued medical treatment after revasculariza-
tion can maintain improved BP results or help control refractory hypertension due
to irreversible target damage imposed by long-term hypertension. Preferred choice
of agents is adrenergic receptor blockers and diuretics. In patients with malignant
hypertension, arterial dilators can be added to the management. CCBs are not used
widely. Both ACE inhibitors and ARBs are contraindicated because of their renal
function unfavored effect. Medical therapy remains the cornerstone of treatment for
renal artery stenosis. The intensification of antihypertensive therapy and the control
242 R. Hui
References
A global brief on Hypertension, Silent killer, global public health crisis, World Health Day 2013.
www.who.int. Printed by WHO Document number: WHO/DCO/WHD/2013.2. Any queries
regarding this document should be addressed to: [email protected]
ABC-H Investigators, Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia
P, Eguchi K, Kario K, Hoshide S, Polonia J, de la Sierra A, Hermida RC, Dolan E, Zamalloa
H (2014) Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine
cohorts of 13,844 patients with hypertension. J Hypertens 32:2332–2340. https://doi.org/10.
1097/hjh.0000000000000355
ACOG (The American College of Obstetricians and Gynecologists) (2018) Committee opinion:
optimizing postpatum care. Obstetrics and Gyneology 131(5):e140–e150
ACOG Committee Opinion No. 767 Summary: Emergent Therapy for Acute-Onset, Severe Hyper-
tension During Pregnancy and the Postpartum Period. Obstet Gynecol 133(2):409–412. https://
doi.org/10.1097/aog.0000000000003082
ADA: Standards of Medical Care in Diabetes. Diabetes Care (2016) 39(Suppl. 1): S1–S2 https://
doi.org/10.2337/dc16-s001
AIRE Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of
acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril
Efficacy (AIRE) Study Investigators. Lancet 342 (8875):821–828
Abela R, Ivanova S, Lidder S, Morris R, Hamilton G (2009) An analysis comparing open surgical
and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc Endovasc Surg
38:666–675
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA (2019a) Treatment of resistant and refrac-
tory hypertension. Circ Res 124(7):1061–1070. https://doi.org/10.1161/circresaha.118.312156
PMID: 30920924
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA (2019) Treatment of resistant and refractory
hypertension. Circulat Res 124:1061–1070. Originally Published 28 Mar 2019. https://doi.org/
10.1161/CIRCRESAHA.118.312156
Agabiti Rosei E, Rizzoni D (2007) Metabolic profile of Nebivolol, a beta-adrenoceptor antag-
onist, with unique characteristics. Drugs 67(8): 1097–107. https://doi.org/10.2165/00003495-
200767080-00001. pmid 17521213
Agarwal R (1999) Supervised atenolol therapy in the management of hemodialysis hypertension.
Kidney Int 55:1528–1535
Agarwal R, Alborzi P, Satyan S, Light RP (2009) Dry-weight reduction in hypertensive hemodialysis
patients (DRIP): a randomized, controlled trial. Hypertension 53:500–507 [PubMed: 19153263]
Agarwal R, Lewis R, Davis JL, Becker B (2001) Lisinopril therapy for hemodialysis hypertension:
Hemodynamic and endocrine responses. Am J Kidney Dis 38:1245–1250 [PubMed: 11728957]
Agarwal R, Nissenson AR, Battle D, Coyne DW, Trout JR, Warnock DG (2003) Prevalence, treat-
ment, and control of hypertension in chronic hemodialysis patients in the United States. Am J
Med 115:291–297
Agarwal R, Sinha AD (2009) Cardiovascular protection with antihypertensive drugs in dialysis
patients: systematic review and meta-analysis. Hypertension 53:860–866 [PubMed: 19273737]
Agarwal R, Sinha AD (2012) Thiazide diuretics in advanced chronic kidney disease. J Am Soc
Hypertens 6(5):299–308 [PubMed: 22951101]
244 R. Hui
Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG (2014) Hypertension in hemodialysis
patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant
29:672–681
Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J (1999) Angioedema due
to angiotensin-converting enzyme inhibitors. Immunopharmacology 44:21–25
Ahmed ME, Walker JM, Beevers DG, Beevers M (1986) Lack of difference between malignant and
accelerated hypertension. Br Med J (Clin Res Ed) 292(6515):235–237
Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH (2016) Antihypertensive drugs and
male sexual dysfunction: a review of adult hypertension guideline recommendations. J Cardiovasc
Pharmacol Ther. 21(3):233–244. https://doi.org/10.1177/1074248415598321
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin
SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR (2012)
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative
Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated
hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack
trial. Hypertension 59:926–933
Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B
(2000) Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in
hemodialysis patients. Kidney Int 57:2485–2491 [PubMed: 10844617]
Ambale-Venkatesh B, Yang X, Wu CO, Liu K, Hundley WG, McClelland R, Gomes AS, Folsom
AR, Shea S, Guallar E, Bluemke DA, Lima JAC (2017) Cardiovascular event prediction by
machine learning: the multi-ethnic study of atherosclerosis. Circ Res 121(9):1092–1101. https://
doi.org/10.1161/circresaha.117.311312 Epub 2017 Aug 9
American Academy of Pediatrics Committee on Drugs (2001a) Transfer of drugs and other
chemicals into human milk. Pediatrics 108(3):776–789
American Academy of Pediatrics Committee on Drugs (2001b) Transfer of drugs and other
chemicals into human milk. Pediatrics. 108(3):776–89. September 2001. PMID 11533352
American College of Obstetricians and Gynecologists (2013) Task Force on Hypertension in Preg-
nancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on
Hypertension in Pregnancy. Obstet Gynecol 122:1122–1131
American Diabetes Associations (2013) Standards of medical care in diabetes—2013. Diabetes
Care 36(suppl 1):S11–S66 [PubMed: 23264422]
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C et al (2013a) INTERACT2 Inves-
tigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl
J Med 368:2355–2365
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P,
Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis
SM, Chalmers J (2013b) Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral
Hemorrhage. N Engl J Med 368(25):2355–2365. https://doi.org/10.1056/nejmoa121460
Angulo J, Wright HM, Cuevas P, González-Corrochano R, Fernández A, Cuevas B, La Fuente
JM, Gupta S, Sáenz de Tejada I. Nebivolol dilates human penile arteries and reverses erec-
tile dysfunction in diabetic rats through enhancement of nitric oxide signaling. J Sex Med. 2010
Aug;7(8):2681–97. https://doi.org/10.1111/j.1743-6109.2010.01710.x
Aram V. Chobanian, George L. Bakris, Henry R. Black, William C. Cushman, Lee A. Green, Joseph
L. Izzo, Daniel W. Jones, Barry J. Materson, Suzanne Oparil, Jackson T. Wright, Edward J. Roc-
cella, and the National High Blood Pressure Education Program Coordinating Committee. The
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289(19):2560–72. DOI: https://
doi.org/10.1001/jama.289.19.2560
Arjun D. Sinha and Rajiv Agarwal. Clinical Pharmacology of Antihypertensive Therapy for the
Treatment of Hypertension in CKD. CJASN May 2019, 14 (5) 757–764. https://doi.org/10.2215/
CJN.04330418
6 Hypertension Drug Therapy 245
van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Ver-
hamme KM (2014) Risk of hyponatremia with diuretics: chlorthalidone versus hydrochloroth-
iazide. Am J Med 127:763–771
Bobrie G, Frank M, Azizi M (2012) Sequential nephron blockade versus sequential renin–
angiotensin system blockade in resistant hypertension. J Hypertens 30:1656–1664
Booth JN 3rd, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O’Brien EC, Oparil
S, Ravenell J, Safford MM, Seals SR, Shimbo D2, Shea S, Spruill TM, Tanner RM2, Munt-
ner P (2017) Incident cardiovascular disease among adults with blood pressure < 140/90 mm Hg.
Circulation 136(9):798–812. https://doi.org/10.1161/circulationaha.117.027362. Epub 2017 Jun
20
Bousquet P, Feldman J, Tibirica E, Bricca G, Greney H, Dontenwill M, Stutzmann J, Belcourt A
(1992) Imidazoline receptors: a new concept in central regulation of the arterial blood pressure.
Am J Hypertens. 1992 Apr;5(4 Pt 2):47S–50S
Bowman BN, Nawarskas JJ, Anderson JR (2016) Treating diuretic resistance: an overview. Cardiol
Rev 24(5):256–260. https://doi.org/10.1097/crd.0000000000000116
Bozzo P, Einarson A (2009) Use of diuretics during pregnancy. Can Fam Physician. 55(1):44–45.
PMCID: PMC2628835. PMID: 19155365
Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba
T, Kurokawa K, Ramirez S, Young EW (2007) Diuretic use, residual renal function, and mortality
among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am
J Kidney Dis 49(3):426–431
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn
SM, Zhang Z, Shahinfar S (2001) RENAAL Study Investigators: Effects of losartan on renal
and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med
345:861–869
Brisco-Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, Wilson FP, Testani
JM (2018) Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop
Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis. J Am Heart Assoc.
7(18):e009149
Brown NJ (2003) Eplerenone: Cardiovascular Protection. Circulation 107(19):2512–2518
Brown NJ, Snowden M, Griffin MR (1997) Recurrent angiotensin-converting enzyme inhibitor–
associated angioedema. JAMA 278:232–233
Brown MJ, Williams B, Morant S, et al; for the PATHWAY Studies Group. Effect of amiloride, or
amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood
pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Dia-
betes Endocrinol 2015; published online Oct 19. http://dx.doi. org/https://doi.org/10.1016/s2213-
8587(15)00377-0
Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes
G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM. British Hypertension
Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY)
Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochloroth-
iazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind
randomised phase 4 trial. Lancet Diabetes Endocrinol 2016; 4:136–147
Brunstrom M, Carlberg B (2018) Association of blood pressure lowering with mortality and car-
diovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA
Intern Med 178:28–36
Brunström M, Carlberg B (2018) Association of blood pressure lowering with mortality and car-
diovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA
Intern Med. 178(1):28–36
Brunton, Laurence; Lazo, John S.; Parker, Keith L., eds. (2006). Goodman & Gilman’s The
Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. pp. 749–753
Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH (January 2003). Beta 1-
adrenoceptor selectivity of Nebivolol and bisoprolol. A comparison of [3 H]CGP 12.177 and
248 R. Hui
[125 I]iodocyanopindolol binding studies. Eur. J. Pharmacol. 460 (1): 19–26. https://doi.org/10.
1016/s0014-2999(02)02875-3. pmid 12535855
Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J (2017)
Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A System-
atic Review and Network Meta-analysis. JAMA Cardiol. 2(7):775–781. https://doi.org/10.1001/
jamacardio.2017.1421
Butalia S, Audibert F, Côté AM, Firoz T, Logan AG, Magee LA, Mundle W, Rey E,
Rabi DM, Daskalopoulou SS, Nerenberg KA (2018) Hypertension Canada. Hypertension
Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy. Can J Cardiol
34(5):526–531. https://doi.org/10.1016/j.cjca.2018.02.021. PMID: 29731014
Cai G, Zheng Y, Sun X, Chen X (2013) Prevalence, awareness, treatment, and control of hypertension
in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness,
and Treatment Rates in Chronic Kidney Disease Patients With Hypertension in China. J Am
Geriatr Soc 61(12):2160–2167 [PubMed: 24479145]
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W,
Sica D, Ferdinand K (2008) A Scientific Statement From the American Heart Association Profes-
sional Education Committee of the Council for High Blood Pressure Research. Carey. Resistant
Hypertension: Diagnosis, Evaluation, and Treatment. Circulation 117: e510–e526. Originally
Published 24 Jun 2008. https://doi.org/10.1161/CIRCULATIONAHA.108.189141
Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman
WC, Oparil S, Wright JT Jr; Working Group from the National Heart, Lung, and Blood Insti-
tute. Thiazide-induced dysglycemia: call for research from a working group from the national
heart, lung, and blood institute. Hypertension. 2008 Jul;52(1):30–6. https://doi.org/10.1161/
hypertensionaha.108.114389. Epub 2008 May 26
Carty DM, Delles C, Dominiczak AF (2010) pre-eclampsia and future maternal health. J Hypertens
28(7):1349–1355
de Carvalho JG, Dunn FG, Lohmöller G, Frohlich ED (1977) Hemodynamic correlates of prolonged
thiazide therapy: comparison of responders and nonresponders. Clin Pharmacol Ther 22:875–880
Catala-Lopez F, Macias Saint-Gerons D, Gonzalez-Bermejo D, Rosano GM, Davis BR, Ridao
M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos
R, Hutton B.Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult
patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med
2016;13: e1001971. https://doi.org/10.1371/journal.pmed.1001971. eCollection 2016 Mar
Caughey AB (2017) Apgar scores: two methodologic studies exploring their use in research. Paediatr
Perinat Epidemiol 31(4):346–347. https://doi.org/10.1111/ppe.12379 Epub 2017 Jul 3
Chen CW, Jaffe IZ, Karumanchi SA (2014) Pre-eclampsia and cardiovascular disease. Cardiovasc
Res 101(4):579–586
Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C. Bosentan therapy for pulmonary arterial
hypertension and chronic thromboembolic pulmonary hypertension: a systemic review and meta-
analysis. Clin Respir J. 2018. Jun;12(6):2065–2074. https://doi.org/10.1111/crj.12774
Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, Wang Y, Yang X, He L (2010). Calcium channel
blockers versus other classes of drugs for hypertension. Cochrane Database Systematic Rev 8(8):
CD003654. https://doi.org/10.1002/14651858.cd003654.pub4. pmid 20687074
Chrysant SG (2018) Aggressive systolic blood pressure control in older subjects: benefits and risks.
Postgrad Med 130(2):159–165. https://doi.org/10.1080/00325481.2018.1433434
Cobos-Puc L, Aguayo-Morales H (2019) cardiovascular effects mediated by imidazoline drugs:
an update. Cardiovasc Hematol Disord: Drug Targets 19(2):95–108. https://doi.org/10.2174/
1871529x18666180629170336
Committee on Obstetric Practice. Committee Opinion No. 623: Emergent therapy for acute-onset,
severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015;125:
521–5
6 Hypertension Drug Therapy 249
Conn, Jennifer J.; Jacobs, Howard S. (1998). Managing hirsutism in gynaecological practice. BJOG:
An International Journal of Obstetrics and Gynaecology. 105 (7): 687–696. https://doi.org/10.
1111/j.1471-0528.1998.tb10197.x issn 1470-0328
Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG (1992)
Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912–1918
Costas T (2016) Roland Schmieder; Giuseppe Mancia. Interventional Therapies for Secondary and
Essential Hypertension. Springer. p. 44. ISBN 978–3-319-34141-5
Cruickshank JM (2017) The Role of Beta-Blockers in the Treatment of Hypertension. Adv Exp
Med Biol 956:149–166. https://doi.org/10.1007/5584_2016_36
Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular
disease and death: the Framingham Heart Study. Ann Intern Med 131(1):7–13
Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP (2015) The effects of
aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized
and nonrandomized studies. Am J Hypertens 28:1376–1385. https://doi.org/10.1093/ajh/hpv031
Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M (2009) The pre-
ventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and
metabolic risk factors. PLoS Med. 6:e1000058. https://doi.org/10.1371/journal.pmed.1000058
David S.H Bell. Advantages of a third-generation β-blocker in patients with diabetes mellitus. The
American Journal of Cardiology 2004, 93 (9, Supplement 1): 49–52
David A. Warrell; Edward J. Benz; Timothy M. Cox; John D. Firth (2003). Oxford Textbook of
Medicine. Oxford University Press. pp. 1–. ISBN 978–0-19-262922-7
Davis B, Cutler JA, Gordon D. Major outcomes in high risk hypertensive patients randomized to
angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihyper-
tensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA: J Am
Med Assoc. 2002;288(23):2981–97. https://doi.org/10.1001/jama.288.23.2981. pmid 12479763
Delyani John A (2000) Mineralocorticoid receptor antagonists: The evolution of utility and
pharmacology. Kidney Int 57(4):1408–1411
Devlin JW, Seta ML, Kanji S, Somerville AL (2004) Fenoldopam versus nitroprusside for
the treatment of hypertensive emergency. Ann Pharmacother 38(5):755–759
Donald W. Seldin; Gerhard H. Giebisch (23 September 1997). Diuretic Agents: Clinical Physiology
and Pharmacology. Academic Press. pp. 630–632. ISBN 978–0-08-053046-8. Archived from the
original on 4 July 2014
Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, Andrew B. Buroker, Zachary D. Gold-
berger, Ellen J. Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J. William
McEvoy, Erin D. Michos, Michael D. Miedema, Daniel Muñoz, Sidney C. Smith Jr., Salim S.
Virani, Kim A. Williams Sr., Joseph Yeboah and Boback Ziaeian. 2019 ACC/AHA Guideline on
the Primary Prevention of Cardiovascular Disease. A Report of the American College of Car-
diology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the
American College of Cardiology. Volume 74, Issue 10, September 2019. DOI: https://doi.org/10.
1016/j.jacc.2019.03.010
Douglas KA, Redman CW (1994) Eclampsia in the United Kingdom. BMJ 309:1395–1400
Duarte, JD; Cooper-Dehoff, RM (2010). ”Mechanisms for blood pressure lowering and metabolic
effects of thiazide and thiazide-like diuretics”. Expert Review of Cardiovascular Ther-
apy. 8 (6): 793–802. https://doi.org/10.1586/erc.10.27. pmc 2904515 pmid 20528637. nihmsid:
NIHMS215063
Duley L (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33(3):130–137
Durros G, Jaff M, Mathiak L, Dorros G, He T (2002) Multicenter Registry Participants. Multicenter
Palmaz stent renal artery stenosis revascularization registry report: four-year follow–up of 1068
successful patients. Catheter Cardiovasc Interv 55:182–188
Dworkin LD, Cooper CJ (2009) Renal-artery stenosis. N Engl J Med 361:1972–1978
Düsing R (2005) Sexual dysfunction in male patients with hypertension: influence of antihyperten-
sive drugs. Drugs 65(6):773–786
250 R. Hui
Eckman A, Dobs A (November 2008). Drug-induced gynecomastia. Expert Opin Drug Saf. 7 (6):
691–702. https://doi.org/10.1517/14740330802442382. pmid 18983216
Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of
hypertension, 1988–2008. JAMA 303(20):2043–2050 [PubMed: 20501926]
Ehud Grossman. Blood Pressure: The Lower, the Better. The con side Diabetes Care. 2011 May;
34(Suppl 2): S308–S312. Published online 2011 Apr 22. doi: https://doi.org/10.2337/dc11-s245.
PMCID: PMC3632198. PMID: 21525474
Eirin A, Textor SC, Lerman LO (2019) Novel therapeutic strategies for renovascular disease. Curr
Opin Nephrol Hypertens 28(4):383–389. https://doi.org/10.1097/mnh.0000000000000513
Elisabeta Badila, Emma Tintea. How to manage renovascular hypertension. An article from the
e-journal of the ESC Council for Cardiology Practice. Vol. 13, N8 – 09 Dec 2014
Ernst ME1, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009 Nov
26;361(22):2153–64. https://doi.org/10.1056/nejmra0907219
F J Mackay, G L Pearce, and R D Mann. Cough and angiotensin II receptor antagonists: cause
or confounding? Br J Clin Pharmacol. 1999 Jan; 47(1): 111–114. doi: https://doi.org/10.1046/j.
1365-2125.1999.00855.x PMCID: PMC2014204. PMID: 10073748
Fellner RC, Cook AK, O’Connor PM, Zhang S, Pollock DM, Inscho EW (2014) High-salt diet
blunts renal autoregulation by a reactive oxygen species-dependent mechanism. Am J Physiol
Renal Physiol 307(1):F33–F40 [PubMed: 24872316]
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996) Impact of hypertension
on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379–1385
[PubMed: 8731103]
Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche
T, Durkan A, Hissaria P, Blombery P, Barbour TD (2018) Consensus opinion on diagnosis
and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med
J. 48(6):624–636. https://doi.org/10.1111/imj.13804
Freis ED (1989) Critique of the clinical importance of diurectic-induced hypokalemia and elevated
cholesterol level. Arch Intern Med 149(12):2640–2648
Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto
Y, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y; ROCK Study Group. Mineralocorticoid
receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase
activity in patients with hypertension. Clin Pharmacol Ther. 2012; 91:289–297. https://doi.org/
10.1038/clpt.2011.227
GBD 2016 Alcohol Collaborators. Collaborators (514). Alcohol use and burden for 195 countries
and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet. 2018 Sep 22; 392(10152):1015-1035. https://doi.org/10.1016/s0140-6736(18)31310-2.
Epub 2018 Aug 23
Galougahi, Keyvan (February 19, 2016). β3 Adrenergic Stimulation Restores Nitric Oxide/Redox
Balance and Enhances Endothelial Function in Hyperglycemia. JAHA. 5 (2): e002824 https://
doi.org/10.1161/jaha.115.002824. pmc 4802476. pmid 26896479
Garovic V, Textor S (2005) Renovascular Hypertension and Ischemic Nephropathy. Circulation
112:1362–1374
Garthwaite E, Bhandari S (2009) The effects of angiotensin converting enzyme inhibitors on potas-
sium homeostasis in dialysis patients with and without residual renal function. Artif Organs
33:641–647
Georgianos PI, Agarwal R (2016) Pharmacotherapy of hypertension in chronic dialysis patients.
Clin J Am Soc Nephrol 11:2062–2075
Georgianou E, Georgianos PI, Petidis K, Athyros VG, Sarafidis PA, Karagiannis A (2018)
Antihypertensive therapy in acute ischemic stroke: where do we stand? J Hum Hypertens
32(12):799–807. https://doi.org/10.1038/s41371-018-0105-7 Epub 2018 Sep 19
Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. Obstet Gynecol.
2019;133: e1–25; Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203. Obstet
Gynecol. 2019; 133: e26-50
6 Hypertension Drug Therapy 251
Gielen W, Cleophas TJ, Agrawal R (August 2006). Nebivolol: a review of its clinical and phar-
macological characteristics. Int J Clin Pharmacol Ther. 44 (8): 344–57. https://doi.org/10.5414/
cpp44344. pmid 16961165
Giorgio Olivetti, Elena Cigola, Roberta Maestri, Costanza Lagrasta, Demenico Corradi. Recent
advances in cardiac hypertrophy. Cardiovas Res, 45 (1):68–75, https://doi.org/10.1016/S0008-
6363(99)00298-9
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Asso-
ciation of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE);
Androgen Excess and PCOS Society (AES). AMERICAN ASSOCIATION OF CLINICAL
ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDRO-
GEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO
THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC
OVARY SYNDROME–PART 1. Endocr Pract. 2015 Nov;21(11):1291–300. https://doi.org/10.
4158/ep15748.dsc
Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M6, Boulanger M, Bruno RM, de Leeuw
P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeune-
maitre X, Kadian-Dodov D, Kim ES, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland
AM, Touzé E9 van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF. First Interna-
tional Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019
Apr;24(2):164–189. https://doi.org/10.1177/1358863x18821816. Epub 2019 Jan 16
Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh
J, Cushman M, Divers J, Gutiérrez OM (2019) APOL1 kidney risk variants and cardiovascular
disease: an individual participant data meta-analysis. J Am Soc Nephrol. pii: ASN.2019030240.
https://doi.org/10.1681/asn.2019030240
Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM (2002) Clinical benefit of renal
artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure.
Vasc Med. 7:275–279
Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive
therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N
Engl J Med 2000; 342:905–912, pmid:10738048
Grosskopf I, Rabinovitz M, Rosenfeld JB (1986) Combination of furosemide and metolazone in
the treatment of severe congestive heart failure. Isr J Med Sci 22(11):787–790
Grossman E, Messerli FH, Neutel JM (2000) Angiotensin II receptor blockers: equal or preferred
substitutes for ACE inhibitors? Arch Intern Med 160:1905–1911
Guanmin Chen, Finlay A McAlister, Robin Walker, Brenda R Hemmelgarn, Norm R C Campbell.
Cardiovascular Outcomes in Framingham Participants With Diabetes The Importance of Blood
Pressure. Hypertension 2011, 57(5):891–7, DOI: https://doi.org/10.1161/hypertensionaha.1https:
//doi.org/10.162446
Han, Da Hee (29 August 2017). Spironolactone and Amiloride Effective in Drug-Resistant
Hypertension. MPR. Haymarket Media, Inc. Retrieved 9 June 2018
Hans-Jörg Helmlin, André Mürner, Samuel Steiner, Christina Weber, Hans Geyer, Sven Guddat,
Deutsche Sporthochschule Köln, Wilhelm Schänzer, Mario Thevis. Detection of the diuretic
hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-
inflammatory drug (NSAID) tablet contamination. August 2016, Forensic science interna-
tional 267, DOI: https://doi.org/10.1016/j.forsciint.2016.08.029
Hansson L, Svensson A, Gudbrandsson T, Sivertsson R (1983) Treatment of hypertension with beta-
blockers with and without intrinsic sympathomimeticactivity. J Cardiovasc Pharmacol 5(Suppl
1):S26–S29
Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS (2012) The effect of com-
bination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalemia
and acute kidney injury: systematic review and meta-analysis. BMJ 344: e42
252 R. Hui
blood pressure among prevalent hemodialysis patients. Am J Kidney Dis 50:108–118 [PubMed:
17591530]
Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting
enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med
117:234–242
Jaillon P (1990) Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol
66(9):21C–23C
Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol. 1990
Sep 25;66(9):21C-23C. PMID:1977302, https://doi.org/10.1016/0002-9149(90)90758-s
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT,
LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR,
Wright JT, Narva AS, Ortiz E (2013) 2014 evidence-based guideline for the management of high
blood pressure in adults. JAMA 1097:1–14. https://doi.org/10.1001/jama.2013.284427
James D. Neaton, PhD; Richard H. Grimm Jr, MD, PhD; Ronald J. Prineas, MB, PhD; et alJeremiah
Stamler, MD; Greg A. Grandits, MS; Patricia J. Elmer, PhD; Jeffrey A. Cutler, MD; John M.
Flack, MD; James A. Schoenberger, MD; Robert McDonald, MD; Cora Elizabeth Lewis, MD,
MSPH; Philip R. Liebson, MD; Janet Raines, MS, RD; Isabelle Joffrion, RN, MAE; Ralph E.
Allen, PAC; Linda Jones, CRNP, MN; Deborah Parker; Jacqueline K. De Worth, MS, RD; Evelyn
Anzelone; Doris Gunn; Ann George; JoAnn Montgomery; Gilberto S. Neri, MD; Eleanor Betz,
RD; Barbara Mascitti, RD; Ellen Plank, RNNP; Brenda Peterson, RN; Tracy Remijas, MPH; Wal-
ter Washington; Irene Turner, MT; Laura Stefanie; Pamela Aye, MS, RD; Susan Madnek-Oxman,
MS, RD; Helen Jones; Stephen R. Mascioli, MD, MPH; Nancy Van Heel, MS, RD; Cindy Bjerk,
MS, RD; Fran Galle, RN; Patricia Laqua, RD; Margaret Miller, MT (ASCP); Liv Marit Bell,
RN, MPH; Mary Ellen Robinson, MS, RD; Carolyn Thorson; Raymond Townsend, MD; Arlene
Caggiula, PhD; Sinda Dianzumba, MD; Carole Ciak, RN, BSN; Marcella Link, MS, RD; Beth
Hall, RD; Mary Monske, RN, BSN; Therese M. Theobald, BS, RDCS; Michelle Berry, MS,
RD; Terry Coyne, MS, RD; Claire A. Bunker, PhD; Kaye Kramer, RN, BSN; Alain G. DuCh-
ene; Leslie A. Holland; Sylvia Tze, MS; Serena Sjolund; Cynthia A. Launer, MS; John Lagus,
MS; Cynthia M. Miller; Kenneth H. Svendsen, MS; Arthur Leon, MD; Brian Laing, MS; Marsha
McDonald, MA; Dean Surbey, MBA; Mary Kay Wiche, RD, MPH; Kimberly Kuiper; Richard
Remington, PhD; Thomas J. Coates, PhD; Richard Devereux, MD; Ray W. Gifford Jr, MD; Her-
bert Langford, MD; Laurence McCullough, PhD; Herman A. Tyroler, MD. Treatment of Mild
Hypertension Study Final Results.JAMA. 1993;270(6):713–724. https://doi.org/10.1001/jama.
1993.03510060059034
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT,
LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC (2014) Evidence-Based Guideline for the
Management of High Blood Pressure in Adults Report from the Panel Members Appointed to
the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520. https://doi.org/10.1001/
jama.2013.284427
Jennifer C (2004) Eplerenone. Proc (Bayl Univ Med Cent); Eplerenone (Inspra), a new aldos-
terone antagonist for the treatment of systemic hypertension and heart failure. Pub MedCen-
tral.2004, 17(2): 217–20. PMC 1200656. PMID 16200104
Jeunemaitre X, Charru A, Chatellier G, Degoulet P, Julien J, Plouin PF, Corvol P, Ménard J.. Long-
term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents
for treatment of essential hypertension. Am J Cardiol1988; 62:1072–1077. pmid:3189169
Jolobe O. Malignant hypertension in lgA nephropathy. Br J Hosp Med (Lond). 2015 Mar;76(3):177.
https://doi.org/10.12968/hmed.2015.76.3.177
Joseph G. Murphy, Margaret a. Lloyd (editors in chief). Associate Editors – Peter A. Brady, Lyle J.
Olson, Raymond C. Shields. Mayo Clinic Cardiology. Concise Textbook, Fourth Edition. Mayo
Clinic Scientific Press, Mayo Foundation for Medical Education and Research 2013; Ch 47, pg.
470–474
JosephMcGraw,MitchellCherney, KatherineBichler, ArminGerhardt, Mirielle Nauman..The Rela-
tive Role of CYP3A4 and CYP3A5 in Eplerenone Metabolism. Toxicology Letters. Available
254 R. Hui
A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Gio-
vannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek
HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn
GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khati-
bzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin
JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes
W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman
TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian
D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard
J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Peliz-
zari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess
EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room
R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sap-
kota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapel-
berg NJ, Steenland K, Stöckl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van
Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White
RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf
AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A com-
parative risk assessment of burden of disease and injury attributable to 67 risk factors and risk
factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012; 380: 2224–60. https://doi.org/10.1016/s0140-6736(12)61766-8
Lin SH, Yang SS, Chau T, Halperin ML (2003) An unusual cause hypokalemic paralysis: chronic
licorice ingestion. Am J Med Sci 325(3):153–156. https://doi.org/10.1097/00000441-200303000-
00008 pmid 12640291
Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA, Wang J (2009) Blood pressure reduction
for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature.
Hypertens Res 32:1032–1040. https://doi.org/10.1038/hr.2009.139
Loffing, Johannes; Kaissling, Brigitte (2003). Sodium and calcium transport pathways along the
mammalian distal nephron: from rabbit to human. Am J Physiol Renal Physiol. 284 (4): F628–
F643. https://doi.org/10.1152/ajprenal.00217.2002. pmid 12620920
London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar
ME (2001) Alterations of left ventricular hypertrophy in and survival of patients receiving
hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759–2767 [PubMed:
11729246]
Lévy BI (2004) Can angiotensin II type 2 receptors have deleterious effects in cardiovascular
disease? Implications for therapeutic blockade of the renin–angiotensin system. Circulation
109(1):8–13. https://doi.org/10.1161/01.cir.0000096609.73772.c5
MacCarthy EP, Bloomfield SS (1983) Labetalol: a review of its pharmacology, pharmacokinetics,
clinical uses and adverse effects. Pharmacotherapy 3(4):193–219
Madkour H, Gadallah M, Riveline B, Plante GE, Massry SG. Indapamide is superior to thiazide in
the preservation of renal function in patients with renal insufficiency and systemic hypertension.
Am J Cardiol. 1996; 77: 23b–5b
Magee LA, Cham C, Waterman EJ, Ohlsson A, Von Dadelszen P (2003) Hydralazine for treatment
of severe hypertension in pregnancy: meta-analysis. BMJ 327(7421):955–960. https://doi.org/10.
1136/bmj.327.7421.955. PMCID: PMC259162. PMID: 14576246
Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, Bangalore S (2012)
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system
inhibitors. Am J Cardiol 110:383–391. https://doi.org/10.1016/j.amjcard.2012.03.034 Epub 2012
Apr 20
Malha L, Mann SJ (2016) Loop diuretics in the treatment of hypertension. Curr Hypertens Rep
18(4):27. https://doi.org/10.1007/s11906-016-0636-7
Mancia G (2006) Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 24:S17–S24
6 Hypertension Drug Therapy 257
Muntner P, Gutiérrez OM, Zhao H, Fox CS4, Wright NC, Curtis JR5, McClellan W, Wang H, Kilgore
M, Warnock DG, Bowling CB.Validation study of medicare claims to identify older US adults with
CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am
J Kidney Dis. 2015 Feb;65(2):249–58. https://doi.org/10.1053/j.ajkd.2014.07.012. Epub 2014
Sep 19
Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton
PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-Visit Variability of Blood Pressure
and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern
Med. 2015 Sep 1;163(5):329–38. https://doi.org/10.7326/m14-2803
Murray CJ, Abraham J, Ali MK, Alvarado M, Atkinson C, Baddour LM, Bartels DH, Benjamin
EJ, Bhalla K, Birbeck G, Bolliger I, Burstein R, Carnahan E, Chen H, Chou D, Chugh SS,
Cohen A, Colson K, Cooper LT, Couser W, Criqui MH, Dabhadkar KC, Dahodwala N, Danaei
G, Dellavalle RP, Jarlais DC, Dicker D, Ding EL, Dorsey E, Duber H, Ebel BE, Engell RE, Ezzati
M, Felson DT, Finucane MM, Flaxman S, Flaxman AD, Fleming T, Forouzanfar MH, Freedman
G, Freeman MK, Gabriel SE, Gakidou E, Gillum RF, Gonzalez-Medina D, Gosselin R, Grant
B, Gutierrez HR, Hagan H, Havmoeller R, Hoffman H, Jacobsen KH, James SL, Jasrasaria R,
Jayaraman S, Johns N, Kassebaum N, Khatibzadeh S, Knowlton LM, Lan Q, Leasher JL, Lim S,
Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, MacIntyre MF, Mallinger L, McDermott MM,
Meltzer M, Mensah GA, Michaud C, Miller TR, Mock C, Moffitt TE, Mokdad AA, Mokdad
AH, Moran AE, Mozaffarian D, Murphy T, Naghavi M, Narayan K, Nelson RG, Olives C, Omer
SB, Ortblad K, Ostro B, Pelizzari PM, Phillips D, Pope C 3rd, Raju M, Ranganathan D, Razavi
H, Ritz B, Rivara FP, Roberts T, Sacco RL, Salomon JA, Sampson U, Sanman E, Sapkota A,
Schwebel DC, Shahraz S, Shibuya K, Shivakoti R, Silberberg D, Singh GM, Singh D, Singh JA,
Sleet DA, Steenland K, Tavakkoli M, Taylor JA, Thurston GD, Towbin JA, Vavilala MS, Vos
T, Wagner GR, Weinstock MA, Weisskopf MG, Wilkinson JD, Wulf S, Zabetian A, Lopez AD
(2013) The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA
310:591–608. https://doi.org/10.1001/jama.2013.13805
Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD, Blood pressure-lowering efficacy of
loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015; 5: CD003825
Ménard J (2004) The 45-year story of the development of an anti-aldosterone more specific than
spironolactone. Mol Cell Endocrinol 217(1–2):45–52. https://doi.org/10.1016/j.mce.2003.10.008
pmid 15134800
NICE guideline [NG133]: Hypertension in pregnancy: diagnosis and management. Published
date: June 2019
National Institute for Health and Clinical Excellence (NICE) 2006, Hypertension: management
of hypertension in adults in primary care. NICE clinical guideline 34 (Partial update of NICE
clinical guideline 18). www.nice.org.uk N1050 70 k 1p Jun 06, ISBN 1–84629-222-0
National Institute for Health and Clinical Excellence. Hypertension in Pregnancy. The Management
of Hypertensive Disorders in Pregnancy. London: NICE; 2010
National Institute for Health and Clinical Excellence. Routine Postnatal Care of Women and their
Babies. London: NICE; 2006
National Kidney Foundation. K/DOQI Clinical Practice Guidelines for cardiovascular disease in
dialysis patients. Am J Kidney Dis. 2005; 45 Suppl. 4: S49–S59. S69–S75
National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Am J Kidney Dis, 39 (Suppl 1) (2002), pp. S1-S266
National Kidney and Urologic Diseases Information Clearinghouse. Kidney and urology diseases
statistic for the United States. http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/. Accessed 14
Jan 2010]
Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth
D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor
Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med
1992; 152: 1490–1500
Nebivolol Pregnancy and Breastfeeding Warnings”. Drugs.com. Retrieved 3 March 2019
260 R. Hui
Patrick A. McKee. William P. Castelli, Patricia M. McNamara, and William B. Kannel. The Natural
History of Congestive Heart Failure: The Framingham Study. N Engl J Med 1971; 285:1441–
1446. https://doi.org/10.1056/nejm197112232852601
Paul Muntner, Barry R. Davis, William C. Cushman, Sripal Bangalore, David A. Calhoun, Sara L.
Pressel, Henry R. Black, John B. Kostis, Jeffrey L. Probstfield, Paul K. Whelton, and Mahboob
Rahman and for the ALLHAT Collaborative Research Group*Treatment-Resistant Hyperten-
sion and the Incidence of Cardiovascular Disease and End-Stage Renal Disease Results From
the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Hypertension. 2014; 64:1012–1021
Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C (2014) Efficacy and safety of eplerenone in the
management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int
J Cardiol 177:219–228
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen
G, Cifkova R, Deaton C. The Fifth Joint Task Force of the European Society of Cardiology
and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by
representatives of nine societies and by invited experts) Developed with the special contribution
of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) (2012)
Eur Heart J 33(17):1635–2170
Pessina AC (December 2001). Metabolic effects and safety profile of Nebivolol J. Cardiovasc.
Pharmacol. 38. Suppl 3: S33–5. PMID 11811391
Pettinger (1980) Minoxidil and the treatment of severe hypertension. N Engl J Med 303:922–926.
https://doi.org/10.1056/nejm198010163031607
Pisoni R, Acelajado MC, Cartmill FR et al (2012) Long-term effects of aldosterone blockade in
resistant hypertension associated with chronic kidney disease. J Hum Hypertens 26(8):502–506
[PubMed: 21677673]
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS,
Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E,
Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay
SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med
370(15):1383–1392
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) Ran-
domized Aldactone Evaluation Study Investigators: the effect of spironolactone on morbidity and
mortality in patients with severe heart failure. N Engl J Med 341:709–717
Plouin PF (2003) Stable patients with atherosclerotic renal artery stenosis should be treated first
with medical managemen. Am J Kidney Dis 42:851–857
Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika
M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA, African American Study of Kidney
Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension
control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease.
Hypertension. 2009; 53(1):20–27. [PubMed: 19047584]
Poirier L, Cléroux J, Nadeau A, Lacourcière Y (2001) Effects of Nebivolol and atenolol on insulin
sensitivity and haemodynamics in hypertensive patients. J Hypertens 19(8):1429–1435. https://
doi.org/10.1097/00004872-200108000-00011 pmid 11518851
Prescribing information for Bystolic (PDF). Retrieved 2009–06-11
Price, RS; Kasner, SE (2014). Hypertension and hypertensive encephalopathy Handbook of clinical
neurology. 2014,119: 161–7
Prince M, Tafur JD, White CJ (2019) When and How Should We Revascularize Patients With
Atherosclerotic Renal Artery Stenosis? JACC Cardiovasc Interv. 12(6):505–517. https://doi.org/
10.1016/j.jcin.2018.10.023
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003)
Health outcomes associated with various antihypertensive therapies used as first-line agents: a
network meta-analysis. JAMA 289:2534–2544. pmid:12759325
262 R. Hui
Punit S. Ramrakha; Punit Ramrakha; Jonathan Hill (23 February 2012). Oxford Handbook of
Cardiology. OUP Oxford. pp. 107–. ISBN 978–0-19-964321-9
Qadri, Yawar J.; Rooj, Arun K.; Fuller, Catherine M. (April 2012). ENaCs and ASICs as therapeutic
targets. American Journal of Physiology. Cell Physiology. 302 (7): C943–C965. https://doi.org/
10.1152/ajpcell.00019.2012
Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner
T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and
the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in
Patients with Acute Cerebral Hemorrhage. N Engl J Med 2016; 375:1033–1043. https://doi.org/
10.1056/nejmoa1603460
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs
JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M. European Society of Gynecology (ESG);
Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine
(DGesGM); ESC Committee for Practice Guidelines. ESC Guidelines on the management of
cardiovascular diseases during pregnancy: the task force on the Management of cardiovas-
cular diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J.
2;32(24):3147–3197. https://doi.org/10.1093/eurheartj/ehr21
Remonti LR, Dias S, Leitao CB, Kramer CK, Klassman LP, Welton NJ, Ades AE, Gross JL (2016)
Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes-
network meta-analysis of randomized trials. J Diabetes Complications 30:1192–1200. https://
doi.org/10.1016/j.jdiacomp.2016.04.020
Reudelhuber TL (2005) The continuing saga of the AT2 receptor: a case of the good, the bad,
and the innocuous. Hypertension 46(6):1261–1262. https://doi.org/10.1161/01.hyp.0000193498.
07087.83
Ripley TL, Saseen JJ (2014) β-blockers: a review of their pharmacological and physiolog-
ical diversity in hypertension. Ann Pharmacother 48(6):723–733. https://doi.org/10.1177/
1060028013519591 Epub 2014 Mar 31
Ripley TL1, Saseen JJ. β-blockers: a review of their pharmacological and physiological diver-
sity in hypertension. Ann Pharmacother. 2014 Jun;48(6):723–33. https://doi.org/10.1177/
1060028013519591. Epub 2014 Mar 31
Robert M. Carey, David A. Calhoun, George L. Bakris, Robert D. Brook, Stacie L. Daugherty, Cheryl
R. Dennison-Himmelfarb, Brent M. Egan, John M. Flack, Samuel S. Gidding, Eric Judd, Daniel T.
Lackland, Cheryl L. Laffer, Christopher Newton-Cheh, Steven M. Smith, Sandra J. Taler, Stephen
C. Textor, Tanya N. Turan, William B. White, and on behalf of the American Heart Association
Professional/Public Education and Publications Committee of the Council on Hypertension;
Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on
Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of
Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation,
and Management: A Scientific Statement From the American Heart Association. Hypertension.
2018;72: e53–e90
Rocha-Singh KJ, Eisenhauer AC, Textor SC, Cooper CJ, Tan WA, Matsumoto AH, Rosenfield
K (2008) American Heart Association Writing Group 8. Atherosclerotic Peripheral Vascular
Disease Symposium II: intervention for renal artery disease. Circulation 118(25):2873–2878.
https://doi.org/10.1161/circulationaha.108.191178
Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar
R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou
G, Tenenbaum-Gavish K, Meiri H, Gizurarson S1, Maclagan K, Nicolaides KH. Aspirin ver-
sus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug
17;377(7):613–622. https://doi.org/10.1056/nejmoa1704559
Rosemary Townsend, Patrick O’Brien, Asma Khalil. Current best practice in the management of
hypertensive disorders in pregnancy. Integrated Blood Pressure Control 2016:9 79–94
6 Hypertension Drug Therapy 263
Sturkenboom MCJM, Dieleman JP, Picelli G, Mazzaglia G, Mozaffari E, Filippi A, Cricelli C, van
der Lei J (2008) Prevalence and treatment of hypertensive patients with multiple concomitant
cardiovascular risk factors in The Netherlands and Italy. J Hum Hypertens 22:704–713
Sullivan TJ (1991) Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides.
JAMA 265(1):120–121
Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R (2008) Effect of
angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an
open-label randomized controlled trial. Am J Kidney Dis 52:501–506 [PubMed: 18653268]
Tajeu GS, Booth III JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O’Brien EC, Oparil
S, Ravenell J, Safford MM, Seals SR (2017) Incident cardiovascular disease among adults with
blood pressure. Circulation. 136:798–812. https://doi.org/10.1161/circulationaha.117.027362
Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y (2006) Candesar-
tan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on
chronic haemodialysis—a randomized study. Nephrol Dial Transplant 21:2507–2512 [PubMed:
16766543]
Takeda A, Toda T, Fujii T, Shinohara S, Sasaki S, Matsui N (2005) Discordance of influence of
hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis
45:112–118 [PubMed: 15696450]
Taler SJ, Textor SC, Canzanello VJ, Schwartz L (1999) Cyclosporin-induced hypertension:
incidence, pathogenesis and management. Drug Saf 20(5):437–449
Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thi-
azide and thiazide-like diuretics. Expert Opin Pharmacother. 2014 Mar;15(4):527–47. https://
doi.org/10.1517/14656566.2014.879118
Tamm AS, McCourt R, Gould B, Kate M, Kosior JC,Jeerakathil T, Gioia LC, Dowlatshahi D,
Hill MD, Coutts SB; Demchuk AM, Buck BH, Emery DJ, Shuaib A, Butcher KS. Cerebral
Perfusion Pressure is Maintained in Acute Intracerebral Hemorrhage: A CT Perfusion Study.
AJNR Am J Neuroradiol. 2016; 37(2):244–51 (ISSN: 1936-959X)
Taylor AL, Ziesche S, Yancy C, Carson P, DAgostino R, Jr, Ferdinand K, Taylor M, Adams K,
Sabolinski M, Worcel M, Cohn JN the African-American Heart Failure Trial Investigators. Com-
bination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;
351:2049–2057
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant Subjects with cardiovascular Dis-
ease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor
blocker j telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-
converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372:1174–83
Tetti M, Monticone S, Burrello J, Matarazzo P, Veglio F, Pasini B, Jeunemaitre X, Mulatero P.Liddle
Syndrome: Review of the Literature and Description of a New Case. Int J Mol Sci 19(3). pii:
E812. https://doi.org/10.3390/ijms19030812. Review
Tetti M, Monticone S, Burrello J, Matarazzo P, Veglio F, Pasini B, Jeunemaitre X, Mulatero P (2018)
Liddle syndrome: review of the literature and description of a new case. Int J Mol Sci 19(3). https://
doi.org/10.3390/ijms19030812. PMID 29534496
Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A (2002) Combined effects of
systolic blood pressure and serum cholesterol on cardiovascular mortality in young (55 years)
men and women. Eur Heart J 23:528–535
Thomas MC (2000) Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Aus-
tralia. 172(4):184–195. PMID 10772593
Thomopoulos C, Parati G, Zanchetti A (2017) Effects of blood-pressure lowering treatment on
outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive
patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J
Hypertens 35:922–944
Thompson DF, Carter JR (1993). Drug-induced gynecomastia. Pharmacotherapy. 13(1): 37–
45. https://doi.org/10.1002/j.1875-9114.1993.tb02688.x (inactive 2019-03-14). PMID 8094898
266 R. Hui
Abstract Heart failure (HF) is defined as a clinical syndrome resulting from struc-
tural or functional impairment of ventricular fillings or ejections of blood. Currently,
HF is divided into three groups which include HF with reduced ejection fraction
(HFrEF), HF with preserved ejection fraction (HFpEF) and HF with midrange EF
(HFmrEF). Even though major advances have been made in treating HFrEF during
the past decades, heart failure is a fatal disease. In this review, we briefly summa-
rize the current advances in pharmaceutical managements for heart failure, which
includes drugs used in acute heart failure as well as those that prevent heart failure
progression, in each category major clinical trials are also described. In addition,
information about some of potential new drugs are also mentioned. Traditional Chi-
nese medicine also shows its potential in treating HF, and we are still lack of medicine
to treat HFpEF.
The definition of heart failure (HF) varies with time. The current American College
of Cardiology (AHA) guidelines defines HF as a complex clinical syndrome that
results from structural or functional impairment of ventricular filling or ejection of
blood. According to this guideline, HF with reduced ejection fraction (HFrEF) is
defined as an ejection fraction 40%, whereas HF with preserved ejection fraction
(HFpEF) is defined as an ejection fraction 50%. (Yancy et al. 2013). ESC 2016
heart failure guideline advocates a new term for patients with HF and a left ventric-
ular ejection fraction (LVEF) that ranges from 40 to 49%—“HF with midrange EF
(HFmrEF),” this group of patients have better outcome and the underlying character-
istics, pathophysiology and treatments are worthy of further studying (Ponikowski
et al. 2016).
During the process of fighting this deadly disease, major advances have been
made in understanding the pathophysiology of HFrEF which lead to a sophisticated
system of life support, medications, and mechanical devices that reduce morbidity
and mortality and improve life quality of heart failure patients during the past four
decades; however, there are major unmet needs. Nowadays, HF is regarded as a
rising global epidemic (Bui et al. 2011; Vos et al. 2012). Over 1 million patients
are hospitalized for HF each year in the USA alone, and the prevalence of HF will
increase ≈50% between 2012 and 2030, resulting in >8 million people 18 years of
age with HF (Mozaffarian et al. 2015; Heidenreich et al. 2013). At the same time, HF
is still ranking one of the top reasons for death in middle-income and low-income
countries (Mortality GBD and Causes of Death C 2015; Dokainish et al. 2015).
Besides the great burden of HFrEF, our little understanding of pathophysiology of
HFpEF which account nearly 50% of HF syndrome prevents effective treatment to
HFpEF, up-to-now all of pharmaceutical treatment to HFpEF are neutral. There is
still a long way to go before we can effectively treat HFpEF.
In this review, we will briefly describe the clinical manifestations of heart failure,
focusing on the major pharmaceutical therapy of well-established medications as well
as some of promising new drugs to heart failure from clinical management views; the
device therapy and mechanical support of HF are referred to other comprehensive
reviews (Gustafsson and Rogers 2017; Mitter and Yancy 2017).
When a physician facing a patient suspected with HF, she/he might ask themselves
the following questions: Can the patient be diagnosed as heart failure? Is the HF
acute or chronic? What is the etiology of the HF? Can we find out and correct the
exacerbating factors? How can we treat the symptoms? How can we prolong the
patient’s survival?
When suspecting a patient with HF, a physician should collect complete medical his-
tory and perform careful physical examination that provide fundamental information
of etiology of HF and exacerbating factors.
7.2.1.1 Symptoms
Chest Radiography
Chest radiography could provide the information whether the patient has pulmonary
edema or other pulmonary diseases in emergency room. The classic chest radiograph
appearance of pulmonary edema of acute decompensated heart failure is a “butterfly”
pattern of interstitial and alveolar opacities bilaterally fanning out to the periphery
of the lungs. Many patients are also present with increased interstitial markings
including Kerley B lines (thin horizontal linear opacities extending to the pleural
surface caused by accumulation of fluid in the interstitial space), peribronchial cuff-
ing, and evidence of prominent upper lobe vasculature (indicating pulmonary venous
hypertension) (Mann et al. 2014; Gehlbach and Geppert 2004).
The Electrocardiogram
Most of ECG findings are nonspecific in HF patients, but some of ECG changes pro-
vide important information for clinical management. Arrhythmia could be the reason
for acute heart failure such as atrial arrhythmia with fast ventricular response, and
tachycardiomyopathy. Sinus tachycardia might indicate activating sympathetic nerve
which would be the management aim for long-term treatment. And also, evaluation
of the QRS complex has become a critical part to identify patients needing cardiac
resynchronization therapy (Writing Committee et al. 2013), as well as anticoagulation
for atrial fibrillation, or pacing for bradycardia.
272 X. Lin and L. Fang
Biomarkers
Natriuretic peptide biomarkers are useful biomarkers to assist the diagnosis of heart
failure, especially when the cause of dyspnea is unclear. B-type (i.e., brain) natriuretic
peptide (BNP) and its amino-terminal cleavage pro-peptide equivalent, N-terminal
pro–B-type natriuretic peptide (NT-proBNP) are most commonly measured natri-
uretic peptides; both of these two biomarkers are released from cardiomyocytes
in response to stretch (McQuade et al. 2017). While BNP, not NT-proBNP, is a
substrate for neprilysin. Angiotensin receptor–neprilysin inhibitor (ARNI) (valsar-
tan/sacubitril), a dual blockade of renin–angiotensin–aldosterone system (RAAS)
and the natriuretic peptide system to treat HFrEF (Jhund and McMurray 2016),
increases BNP levels (Packer et al. 2015), but not NT-proBNP levels (Zile et al.
2016), therefore only NT-proBNP should be tested when ARNI is used. BNP and
NT-proBNP might be in normal range in stable HF patients, and the changes of
their values with the symptoms can provide useful and instant information about the
change of the heart functions.
Even though not used clinically, circulating concentrations of soluble ST2 (a
member of the interleukin receptor family) and Galectin 3, as promising myocardial
fibrosis markers, have been shown to be strongly linked to progressive HF and death
in patients across the different stages of HF (Yancy et al. 2017; Santaguida et al.
2014). Combined with natriuretic peptide, these markers could provide valuable
information of heart function and tissue characteristics to assist HF management in
the near future.
The combination of symptoms, X-ray, and an elevated biomarker can assist the
diagnosis of HF, the pathway of diagnosing heart failure is shown in Fig. 7.2.
Fig. 7.2 Diagnostic algorithm for diagnosis of heart failure of non-acute onset. BNP: B-type
natriuretic peptide; CAD: coronary artery disease; HF: heart failure; MI: myocardial infarction;
NT-proBNP: N-terminal pro-B type natriuretic peptide. Adopted from 2016 ESC guidelines for the
diagnosis and treatment of acute and chronic heart failure (Ponikowski et al. 2016)
7 Pharmaceutical Treatment for Heart Failure 275
seen causes including nutritional, infiltrative, and other diseases (Ponikowski et al.
2016; Fonarow et al. 2008; Dickstein et al. 2008).
Most of HF patients could have stable heart function unless under stress. The
most common precipitating factors are pneumonia/respiratory diseases (15.3%),
ischemia/acute coronary syndrome (14.7%), arrhythmia (13.5%), and uncontrolled
hypertension (10.7%). Non-adherence to medications was identified in 8.9% and non-
adherence to diet in 5.2% of patients (Fonarow et al. 2008; Nieminen et al. 2005;
Mysliwiec and Bonita 2017). These exacerbating factors generally cause volume
overloading either in lung or in dependent organs leading to clinical manifestations
of heart failure.
The main goals of treatment for HF are to reduce symptoms, prolong survival,
improve the quality of life, and prevent disease progression.
Reducing the water retention is always the first step to improve symptoms as well
as to increase the heart contractility and blood vessels dilation. Therefore diuretics,
inotropes, and vasodilators are first-line medications to stabilize the decompensated
vital signs.
When symptoms are reduced, physicians would consider how to prolong the
survival of patients. The core compensation mechanisms of heart failure is con-
tinuous activating adrenergic nervous system and the renin–angiotensin system
(RAS), which secret biologically active molecules exerting on the heart and cir-
culation and ultimately result in heart remodeling (Mann et al. 2014). Consequently,
anti-neurohormonal system drugs such as angiotensin-converting enzyme inhibitors
(ACE inhibitor), beta blockers and aldosterone antagonists become the cornerstone
to treat HFrEF.
7.3.1.1 Diuretics
Diuretics are the first choice to reduce the symptoms of acute HF. Diuretics increase
the urine volume by enhancing the excretion of water, sodium chloride, and other
276 X. Lin and L. Fang
ions, leading to a decrease in plasma and extracellular fluid volume and a decrease
in peripheral congestion. The aim of diuretic therapy is to achieve and maintain
euvolaemia with the lowest achievable doses.
Loop Diuretics, potassium-sparing diuretics, and thiazide diuretics and metola-
zone are three classes of diuretics and newly appeared water diuresis (“aquaretics”)
are gaining more attention. Loop diuretics are the primary pharmacologic agents and
typically produce rapid symptom relief in most patients.
Loop Diuretics
Our bodies maintain the chemical balance and are cleansed by glomerular filtration,
tubular reabsorption and tubular secretion in kidney; among them, formation of the
medullary gradient by acting at the ascending limb of the nephron loop is a major step
to form the urine in reasbsorption process (Marieb and Hoehn 2007). Loop diuretics,
including furosemide, bumetanide, and torsemide, act by reversibly inhibiting the
action of the sodium-potassium-chloride cotransporter in the thick ascending limb
of the loop of Henle thereby preventing sodium reabsorption and the obligatory
water reabsorption that normally follows. Loop diuretics also induce the synthesis of
prostaglandins, resulting in renal and peripheral vascular smooth muscle relaxation
and vasodilatation increase in renal blood flow and redistribution of renal cortical
blood flow. Up to now, furosemide is still the most widely used loop diuretic orally
or intravenously, furosemide reduces right atrial and pulmonary capillary wedge
pressure within minutes when given intravenously (0.5–1.0 mg/kg) (Felker 2012;
Michael 2010).
Thiazide diuretics inhibit the sodium-chloride transporter in the distal tubule. This
transporter normally only reabsorbs about 5% of filtered sodium, therefore these
diuretics are less efficacious than loop diuretics, but they have synergistic effects
with loop diuretics. So it is very common that physicians use a loop diuretic and a
thiazide together. Thiazide diuretics’ effectiveness is limited in patients with reduced
glomerular filtration. Metolazone, an oral quinazoline diuretic, is much more potent
than hydrochlorothiazide and remains effective even when the glomerular filtration
rate is <30 mL/min, making it a useful adjunct to loop diuretics in patients with
diuretic resistance or severe renal insufficiency (Mann et al. 2014; Sica 2003).
Potassium-Sparing Diuretics
The most often used potassium-sparing diuretics are the aldosterone receptor antag-
onists spironolactone and eplerenone. Even though spironolactone and eplerenone
7 Pharmaceutical Treatment for Heart Failure 277
are classified as diuretics, their roles in HF are far beyond just diuretics, as impor-
tant medication to anti-remodeling, they will be discussed in the following part
PREVENTION OF DISEASE PROGRESSION Aldosterone Antagonists.
Vasopressin Antagonists
Diuresis is notoriously known for their side effects including electrolyte and
metabolic disturbances, volume depletion as well as azotemia. Potassium depletion
is the most common side effect when using loop diuresis, and physicians generally
advocate that the serum K+ should be maintained between 4.0 and 5.0 mEq/L. Oral
potassium supplements in the form of KCL extended-release tablets or liquid con-
centrate should be used whenever possible. The excessive use of diuretics can lead
to hypotensive symptoms and azotemia which usually resolve after a decrease in
the dosage or frequency of diuretics (Mann et al. 2014). Acceptable elevated blood
serum creatinine may be necessary to maintain control of heart failure symptoms in
some advanced patients.
One of the inherent limitations of diuretics is diuretic resistance, even though the
underlying mechanism is not fully clarified, some of clinical strategies might help
(Bowman et al. 2016). The major strategy in outpatient is to combine two classes of
diuretic concurrently. Adding a proximal tubule or a distal collecting tubule diuretic
to a loop diuretic is often effective. Alternative method is administration of short-
acting diuretics several times per day or continuous intravenous infusion of a loop
diuretic usually furosemide through a constant-infusion pump (Mann et al. 2014).
278 X. Lin and L. Fang
7.3.1.2 Vasodilators
Nitrates
The ability to dilate vessels of nitrates changes with the dosages: Vasodilation is
achieved in low dose and arteries and coronary arteries would dilate in higher dosage.
The starting dose of nitroglycerin usually is 20 μg/min with rapid uptitration every
5–15 min in either 20 μg/min increments or doubling of the dose (Mann et al. 2014;
den Uil and Brugts 2015).
Sodium Nitroprusside
Nesiritide
Nesiritide (recombinant human B-type [brain] natriuretic peptide) can cause potent
vasodilation in the venous and arterial vasculatures, resulting in significant reductions
in venous and ventricular filling pressures and mild increases in cardiac output (Mann
et al. 2014).
The effectiveness of Nesiritide in decompensated Heart Failure (ASCEND-HF)
was tested in 7,141 patients with either reduced or preserved ejection fraction. The
7 Pharmaceutical Treatment for Heart Failure 279
The inotropic drugs and inodilators (inotropic drugs with vasodilatory properties)
increase cardiac output through cyclic adenosine monophosphate (cAMP)-mediated
inotropy and reduce PCWP through vasodilation (Hasenfuss and Teerlink 2011).
However, even the short term use of intravenous inotropes (except for digoxin) is
associated with significant side effects such as hypotension, atrial or ventricular
arrhythmias, and an increase in in-hospital and possibly long-term mortality (Felker
et al. 2003). The use of these drugs should be limited to patients with dilated ven-
tricles and reduced ejection fraction who are present with low SBP (<90 mmHg) or
low measured cardiac output in the presence of signs of congestion and organ hypop-
erfusion. Additionally, intravenous inotropes may be used in cardiogenic shock as
a temporary therapy to prevent hemodynamic collapse or as a life-sustaining bridge
to more definitive therapy for those patients awaiting mechanical circulatory sup-
port, ventricular assist devices, or cardiac transplantation (Heart Failure Society of
A et al. 2010; Jessup et al. 2009). These agents should be used with close telemetry
monitoring and be stopped as soon as adequate organ perfusion is restored (Jaarsma
et al. 2009; Teerlink et al. 2009).
Dobutamine
Even though dobutamine might increase the mortality of heart failure, it is the most
commonly used positive inotrope (Tacon et al. 2012). Dobutamine has multiple
actions through an agonist of both beta1 and beta2 adrenergic receptors with vari-
able effects on the alpha receptors. Stimulation of Beta receptor results in increased
inotropy and chronotropy by increasing intracellular cAMP and calcium. At low
doses, stimulation of beta2 and alpha receptors causes vasodilation, resulting in
decreased systemic vascular resistance and indirect increases in cardiac output.
At higher doses, effects would include vasoconstriction, decreased venous capaci-
tance and increased right atrial pressure. Many patients will experience improved
renal perfusion with dobutamine doses of 1–2 μg/kg/min, while higher doses
(5–10 μg/kg/min) may be necessary for profound hypoperfusion (Mann et al. 2014).
280 X. Lin and L. Fang
Dopamine
Epinephrine
Phosphodiesterase Inhibitors
who have had prolonged administration of milrinone may experience delayed dete-
rioration, so they should be observed for at least 48 h after cessation (Mann et al.
2014).
Levosimendan
7.3.1.4 Vasopressors
Vasopressors could be used for patients with marked central organ hypoperfusion.
These agents will redistribute cardiac output centrally at the expense of peripheral
perfusion and increased afterload. Phenylephrine is a selective alpha1 receptor ago-
nist with potent direct arterial vasoconstrictor effects. Norepinephrine also is a potent
agonist of the beta1 and the alpha1 receptors but is a weaker agonist of beta2 recep-
tors. These agents may be used in case of severe hypotension, particularly when the
hypotension is related to systemic vasodilation, rather than to a decrease in cardiac
output. Both of these agents may induce end-organ hypoperfusion and tissue necrosis
(Mann et al. 2014).
Relaxin
vasodilatory action and effects on cardiac fibrosis and remodeling, cardiac precondi-
tioning and ischemia, inflammation. Chemically, it is a 6-kDa polypeptide produced
by the mammalian corpus luteum and placenta. These functions along with increased
GFR and cardiac output make relaxin a potential candidate for treatment of acute
heart failure. Serelaxin (recombinant human relaxin-2) mediates vasodilatation by
multiple NO-mediated mechanisms, in addition to VEGF and endothelin pathway.
The efficacy and safety of serelaxin were proved by a large, international, double-
blinded, placebo-controlled Phase III trial: the RELAXin in Acute Heart Failure
(RELAX-AHF) Trial 1161 patients presented with dyspnea, congestion, mild to
moderate renal insufficiency were randomized to a 48 h infusion of either sere-
laxin (30 μg/kg/day) or placebo in addition to standard of care. Relax significantly
improved VAS AUC (less dyspnea) over 5 days, but dyspnea which was evaluated by
Likert scale, was not different for the first 24 h. The 60 day survival, death or readmis-
sion rates was no different with placebo, but 180 day mortality was lower in serelaxin
group. The improvement in renal function in patients receiving serelaxin suggested
potential benefits in cardiorenal syndrome (Teerlink et al. 2013; Ponikowski et al.
2014).
The RELAX-AHF trial exclude high-risk patients with low blood pressure, there-
fore further clinical trials with sufficient statistical power and a diverse, hetero-
geneous patient base are needed to evaluate outcome in heart failure treated with
serelaxin.
Endothelin receptor antagonists block the actions of endothelin-1 (ET-1), the most
powerful endogenous vasoconstrictor that is produced by the vascular endothelial
cells. It exerts its effects by binding to two receptors, ETA and ETB which are
located on the vascular smooth muscle cells, resulting in significant systemic arte-
rial vasoconstriction. Even though bearing the hope of improving AHF symptom,
Tezosentan, a nonselective ETA-B antagonist, did not show significant difference
in 24 h dyspnea and 7 day clinical end points between the tezosentan-treated and
placebo-treated groups in a pivotal phase III clinical trial: The Value of Endothe-
lin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
(McMurray et al. 2007).
Istaroxime
Stresscopin
Nicorandil
Nicorandil is a balanced vasodilator that acts as both NO donor and arterial K(+)
ATP channel opener. Nicorandil might also exhibit cardioprotective properties via
mitochondrial ischemic preconditioning.
In a prospective, randomized controlled trial, 106 AHF patients were randomized
within one hour of arrival to receive either standard therapy or standard therapy plus
simultaneous intravenous nicorandil (0.2 mg/kg bolus followed by 0.2 mg/kg/h for
24 h; nicorandil group, n = 50). Patients in the nicorandil group exhibited greater
improvement of dyspnea as measured by change in a five-point Likert scale com-
pared to those in the control group, also improved left ventricular filling pressure
measured by E/e but it did not reduce all-cause mortality and readmission rates at
60 days. Intravenous nicorandil therapy was safe and did not cause side effects such
as excessive hypotension or reflex tachycardia (Harada et al. 2017).
Most of the large clinical trials of new therapies for acute heart failure (AHF)
have yielded negative results in terms of long-term outcomes. In view of the diverse
pathophysiology of AHF, it would be unrealistic to expect that a single drug would
exert beneficial effects in all patients with AHF. There remain areas of significant
unmet need including vasodilators with proven clinical benefits, agents that optimize
myocardial performance without significant adverse effects, and agents that improve
or protect renal function (Vaduganathan et al. 2013).
Drugs that reverse cardiac remodeling such as those interfere with the excessive
activation of the renin-angiotensin-aldosterone system and the adrenergic nervous
system can prevent heart failure progression. For clinicians, Angiotensin-Converting
Enzyme Inhibitors/Angiotensin Receptor Blockers/ARNI, Beta Blockers and Aldos-
terone Antagonists are must be used medicine to prolong patients’ lives unless there
are contraindications for use.
The side effects of ACE inhibitors include worsening of renal function, hyper-
kalaemia, symptomatic hypotension, cough, and, rarely, angioedema. An ACE
inhibitor should not be used in patients with creatinine 221 mmol/L or 2.5 mg/dL
or eGFR 30 mL/min/1.73 m2 or hyperkalaemia.
Angiotensin Receptor Blockers (ARBs) are recommended for patients who cannot
tolerate ACE inhibitors because of cough or angioedema. While patients intolerant to
ACE inhibitors are likely to have the same side effects with ARBs. In these situations,
the combination of hydralazine and an oral nitrate should be considered.
ARBs are well tolerated in patients who are intolerant of ACE inhibitors because
of cough, skin rash, and angioedema and should therefore be used in symptomatic
and asymptomatic patients with an EF below 40%. ACE inhibitors and ARBs inhibit
the renin-angiotensin system by a different mechanism: ACE inhibitors block the
enzyme responsible for converting angiotensin I to angiotensin II, ARBs block the
effects of angiotensin II on the angiotensin type 1 receptor, the receptor subtype that
is responsible for all of the adverse biologic effects. Multiple ARBs are approved for
286 X. Lin and L. Fang
Beta blocker therapy represents a major advance in the treatment of patients with
HFrEF. Beta blockers interfere with the harmful effects of sustained activation of the
central nervous system by competitively antagonizing one or more adrenergic recep-
tors (alpha1, beta1, and beta2), especially beta1 adrenergic receptor. Beta blockers
can reverse the process of LV remodeling of HF patients, relief patient symptoms,
prevent hospitalization, and prolong life. Therefore beta blockers are indicated for
patients with EF below 40%.
7 Pharmaceutical Treatment for Heart Failure 287
Beta blocker therapy is well tolerated by the great majority of patients with HF
(>85%), including those with diabetes mellitus, chronic obstructive lung disease,
and peripheral vascular disease. Nonetheless, a subset of patients (10–15%) might
be intolerant to beta blockers because of worsening fluid retention or symptomatic
hypotension (McMurray et al. 2012).
The dose titration of beta blockers should proceed no sooner than 2-week intervals,
because the initiation and/or increased dosing of these agents may lead to worsening
fluid retention. Therefore it is important to optimize the dose of diuretic and patients
should be in their dry weight before starting beta blockers.
Patients might have feelings of general fatigue or weakness when starting a beta
blocker treatment. In most instances, the increased fatigue spontaneously resolves
within several weeks or months; however, sometimes it may be severe enough to
limit the dose or withdrawal the treatment. Therapy with beta blockers can lead to
bradycardia and/or exacerbate heart block. Therefore the dose of beta blockers should
be decreased if the heart rate decreases to less than 50 beats/min and/or if second-
or third-degree heart block or symptomatic hypotension develops, beta blockers are
not recommended for patients with asthma with active bronchospasm (Mann et al.
2014).
standard therapy including diuretics, ACE inhibitors, and beta blockers (Jessup et al.
2009).
Spironolactone is a synthetic steroid that competes for cytoplasmic aldosterone
receptor. It does not produce hypokalemia because it inhibits aldosterone-sensitive
sodium reabsorption, less potassium and hydrogen ion are exchanged for sodium
by this transporter and therefore less potassium and hydrogen are lost to the urine.
Spironolactone is generally relatively weak diuretics (Michael 2010).
The first evidence that aldosterone antagonists could produce a major clinical
benefit in HF was demonstrated by the Randomized Aldactone Evaluation Study
(RALES) trial (Uchida et al. 2005), which evaluated spironolactone (25 mg/day ini-
tially, titrated to 50 mg/day for signs of worsening HF) versus placebo in NYHA
class III or IV HF patients with an LVEF below 35%. Administration of spirono-
lactone led to a 30% reduction in total mortality when compared with placebo (P =
0.001). The frequency of hospitalization for worsening HF also was 35% lower in
the spironolactone group than in the placebo group.
Eplerenone was developed by replacing the 17-alpha-thioacetyl group of spirono-
lactone with a carbomethoxy group. The Eplerenone in Mild Patients Hospitalization
and Survival Study in Heart Failure (EMPHASIS-HF) trial (Zannad et al. 2011),
which was performed in patients with NYHA class II HF with an EF below 30%
(or 35% if the QRS width was more than 130 ms), demonstrated that eplerenone
(titrated to 50 mg/day) led to a significant 27% decrease in cardiovascular death or
HF hospitalization (HR, 0.63 [95% CI, 0.54–0.74]; P < 0.001). Significant decreases
were also observed in all-cause death (24%), cardiovascular death (24%), all-cause
hospitalization (23%), and HF hospitalizations (43%). Of importance, the effect of
eplerenone was consistent across all prespecified subgroups.
Spironolactone should be initiated at a dose of 12.5–25 mg daily and uptitrated to
25–50 mg daily, whereas eplerenone should be initiated at doses of 25 mg/day and
increased to 50 mg/day.
The major side effects with the use of aldosterone antagonists are the development
of life-threatening hyperkalemia, especially in patients who are receiving potassium
supplements or with underlying renal insufficiency. Aldosterone antagonists are not
recommended when the serum creatinine is greater than 2.5 mg/dL (or creatinine
clearance is below 30 mL/min) or the serum potassium is greater than 5.5 mmol/l.
Painful gynecomastia may develop in 10–15% of patients who use spironolactone,
in which case eplerenone may be substituted (Mann et al. 2014).
7 Pharmaceutical Treatment for Heart Failure 289
Ivabradine
Ivabradine is a heart rate lowering agent that acts by selectively blocking the cardiac
pacemaker If current that controls the spontaneous diastolic depolarization of the
sinoatrial node. Ivabradine blocks If channels in a concentration-dependent manner
by entering the channel pore from the intracellular side and thus can only block the
channel when it is open. The magnitude of If inhibition is directly related to the
frequency of channel opening and would therefore be expected to be most effective
at higher heart rates.
Ivabradine also was shown to improve outcomes in the Systolic Heart Failure
Treatment with the If Inhibitor Ivabradine Trial (SHIFT) (Swedberg et al. 2012),
which enrolled symptomatic patients with an LVEF of 35% or less who were in
sinus rhythm with heart rate of 70 beats/min or higher and on standard medical
therapy for HF (including beta blockers).
Cardiac Glycosides
TCM has a history of more than 2,000 years with unique theories and rich experience,
even though TCM is considered as an alternative medicine in most western countries,
nearly 70% patients in China preferred the use of both western medicine and TCM
(Hao et al. 2017). Recently TCM proved their effects in improving hard and/or
surrogate endpoints in heart failure patients by a series of high quality random control
trials. The efficacy and safety of Qiliqiangxin capsule were compared with placebo
in a RCT enrolling 512 chronic heart failure for 12 weeks, the medicine significantly
reduced N-terminal pro-B-type natriuretic peptide and improve LVEF and quality
of life as well as composite cardiac events (Li et al. 2013). Nuanxin capsule and
placebo were randomly assigned to 5150 chronic heart failure patients for 24 weeks,
and the TCM reduced hospitalization rate and incidence of acute heart failure (Zuo
et al. 2010). The ability to increase LVEF of Shencaotongmai was also proved in
a multicenter RCT enrolling 280 patients (Hao et al. 2017). And all of these TCM
show good safe profiles. Even though the effect of TCM medications on long-term
outcomes is still unclear, they would play an active role in heart failure treatment.
References
McMurray JJ, Teerlink JR, Cotter G et al (2007) Effects of tezosentan on symptoms and clinical
outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA
298:2009–2019
McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment
of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute
and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration
with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869
McMurray JJ, Packer M, Desai AS et al (2014) PARADIGM-HF investigators and committees.
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004.
https://doi.org/10.1056/nejmoa1409077
McQuade CN, Mizus M, Wald JW et al (2017) Brain-Type Natriuretic Peptide and Amino-Terminal
Pro-Brain-Type Natriuretic Peptide discharge thresholds for acute decompensated heart failure:
a systematic review. Ann Intern Med 166:180–190
Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with
acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297:1883–1891
Metra M, Teerlink JR, Voors AA et al (2009) Vasodilators in the treatment of acute heart failure:
what we know, what we don’t. Heart Fail Rev 14:299–307
Michael Felker G (2010) Diuretic management in heart failure. Congest Heart Fail 16(Suppl 1):S68–
S72
Micheletti R, Palazzo F, Barassi P et al (2007) Istaroxime, a stimulator of sarcoplasmic reticulum
calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart
failure. Am J Cardiol 99:24A–32A
Mitter SS, Yancy CW (2017) Contemporary approaches to patients with heart failure. Cardiol Clin
35:261–271
Mortality GBD and Causes of Death C (2015) Global, regional, and national age-sex specific all-
cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for
the Global Burden of Disease Study 2013. Lancet 385:117–171
Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics–2015 update:
a report from the American Heart Association. Circulation 131:e29–322
Mysliwiec M, Bonita RE (2017) Outpatient emergencies: acute heart failure. Med Clin North Am
101:507–519
Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ven-
tricular diastolic function by echocardiography: an update from the American society of echocar-
diography and the European association of cardiovascular imaging. J Am Soc Echocardiogr
29:277–314
Nauman D, Greenberg B (1993) Studies of Left Ventricular Dysfunction (SOLVD). Am J Geriatr
Cardiol 2:28–36
Nieminen MS, Bohm M, Cowie MR et al (2005) Executive summary of the guidelines on the
diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European
society of cardiology. Eur Heart J 26:384–416
O’Connor CM, Starling RC, Hernandez AF et al (2011) Effect of nesiritide in patients with acute
decompensated heart failure. N Engl J Med 365:32–43
Packer M, Coats AJ, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart
failure. N Engl J Med 344:1651–1658
Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients
with severe chronic heart failure: results of the carvedilol prospective randomized cumulative
survival (COPERNICUS) study. Circulation 106:2194–2199
Packer M, McMurray JJ, Desai AS et al (2015) Angiotensin receptor neprilysin inhibition compared
with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation
131:54–61
Pfeffer MA (1993) The Survival and Ventricular Enlargement (SAVE) study: rationale and
perspective. Herz 18(Suppl 1):430–435
294 X. Lin and L. Fang
Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management
of heart failure: a report of the American college of cardiology foundation/American heart
association task force on practice guidelines. J Am Coll Cardiol 62:e147–e239
Yancy CW, Jessup M, Bozkurt B et al (2017) ACC/AHA/HFSA focused update of the 2013
ACCF/AHA guideline for the management of heart failure: a report of the American college
of cardiology/American heart association task force on clinical practice guidelines and the heart
failure society of America. J Card Fail
Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and
mild symptoms. N Engl J Med 364:11–21
Zile MR, Claggett BL, Prescott MF et al (2016) Prognostic implications of changes in N-Terminal
Pro-B-Type Natriuretic Peptide in patients with heart failure. J Am Coll Cardiol 68:2425–2436
Zou Xu, Pan GM, Sheng XG et al (2010) Double blinded randomized and controlled study on
treatment of chronic heart failure by nuanxin capsul. Chin J Integr Trad West Med 31(1):19–22
Chapter 8
Drug Discovery for Coronary Artery
Disease
Qing Wan, Siyuan Qian, Yonghu Huang, Yuze Zhang, Zekun Peng,
Qiaoling Li, Bingyan Shu, Liyuan Zhu and Miao Wang
Abstract Cardiovascular disease is the number one cause of human morbidity and
mortality worldwide. Although cholesterol-lowering drugs, including statins and
recently approved PCSK9 inhibitors, together with antithrombotic drugs have been
historically successful in reducing the occurrence of coronary artery disease (CAD),
the high incidence of CAD remains imposing the largest disease burden on our
healthcare systems. We reviewed cardiovascular drugs recently approved or under
clinical development, with a particular focus on their pharmacology and limita-
tions. New agents targeting cholesterol/triglyceride lowering bear promise of further
cardiovascular risk reduction. Some new antidiabetic agents show cardiovascular
benefit in patients with diabetes. Improved antithrombotic agents with diminished
bleeding risk are in clinical development. The recent clinical success of the IL-1β
antibody in reducing atherothrombosis opens a new era of therapeutic discovery that
targets inflammation. Chinese traditional medicine and cardiac regeneration are also
discussed. Human genetics studies of CAD and further delineation of key determi-
nants/pathways underlying the residual risk of CAD under current standard therapy
will continue to fuel the pipeline of cardiovascular drug discovery.
The discovery that statins reduce cholesterol levels and CAD has promoted searching
for new targets to lower cholesterol. This has yielded new drugs, such as PCSK9
inhibitors and cholesterol-absorption blockers, as well as drug candidates.
Low-density lipoprotein (LDL) particles receptor (LDLR) binds and initiates the
ingestion of LDL-particles, which contains lipid molecules (including cholesterol),
from the circulation, thus reducing plasma cholesterol concentrations. Proprotein
convertase subtilisin/kexin type 9 (PCSK9) interacts with LDLR and mediates
its intracellular degradation. When PCSK9 is blocked, more LDLRs are recycled
to remove LDL-particles from the circulation. Thus, PCSK9 inhibition promotes
LDLR-mediated liver uptake of circulating LDL, lowering plasma cholesterol lev-
els. A link between PCSK9 and hypercholesterolemia was initially published in 2003,
and PCSK9 monoclonal antibodies were approved as a new therapeutic strategy to
reduce LDL-C in 2015. The progress from PCSK9 discovery to targeted treatment
is unprecedented in terms of scale and speed.
Monoclonal Antibodies
Treatment of patients at high risk for cardiovascular events with antibodies blocking
PCSK9 allows further cholesterol lowering by ~60% on top of standard therapy,
including statin (Sabatine et al. 2015; Robinson et al. 2015). The first two PCSK9
inhibitors, alirocumab (Praluent, Sanofi/Regeneron) and evolocumab (Repatha,
Amgen), were approved as biweekly subcutaneous injections, by the U.S. Food
and Drug Administration (FDA) for lowering LDL cholesterol when statins and
8 Drug Discovery for Coronary Artery Disease 299
other drugs are not sufficiently effective or poorly tolerated. The GLAGOV (Global
Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravas-
cular Ultrasound) trial (Nicholls et al. 2016) showed that adding evolocumab to
statin therapy produced significant atheroma regression and a continuous benefit
with LDL-C levels down to as low as 20 mg/dL. The FOURIER (Further Cardiovas-
cular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)
trial showed that in patients with atherosclerotic cardiovascular disease who were
receiving statin therapy, subcutaneous injection of evolocumab (either 140 mg every
2 weeks or 420 mg monthly) reduced LDL cholesterol by 59%, from a median base-
line value of 92 mg per deciliter (2.4 mmol/L) to 30 mg per deciliter (0.78 mmol/L),
and decreased cardiovascular risk (the primary composite endpoint of cardiovascular
death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary
revascularization) by 15% (Sabatine et al. 2017). There was no significant difference
between the study groups with regard to adverse events (including new-onset diabetes
and neurocognitive events), with the exception of injection-site reactions, which were
more common with evolocumab. No difference in cognitive function was observed
between evolocumab and placebo over a median of 19 months (Giugliano et al.
2017). Recent ODYSSEY OUTCOMES trial shows that among patients who had a
previous acute coronary syndrome and who were receiving high-intensity statin ther-
apy, alirocumab treatment with a target level of LDL cholesterol level of 25–50 mg
per deciliter (0.6–1.3 mmol/L) reduces the risk of recurrent ischemic cardiovascular
events (Schwartz et al. 2018).
Future use of these PCSK9 antibodies may rely on compliance with injection delivery,
safety of prolonged exposure to very low levels of LDL cholesterol and on possibili-
ties of developing anti-drug antibodies, which may curtail cholesterol-lowering effi-
cacy. Cost-effectiveness analysis indicates limitations on the general use of PCSK9
antibody drugs (about $14,000 per year) (Hlatky and Kazi 2017). Their use may
particularly be appropriate for those with genetic defects for whom statins are not
sufficiently effective, or intolerable (Nissen et al. 2016).
Antisense Oligonucleotide
Suppression of PCSK9 expression by antisense oligonucleotide has been explored
for functional inhibition of PCSK9. Inclisiran is a synthetic small interference RNA
(siRNA) molecule, inhibits intracellular PCSK9 synthesis by suppressing mRNA
translation in hepatocytes. In phase I and II clinical trials (Fitzgerald et al. 2017;
Ray et al. 2017), subcutaneous injection of inclisiran results in a dose-dependent,
long-term, sustained reduction in LDL-C, with a single or double doses of 300 mg
(at a 90 days interval) achieved ~50% reduction at day 180. Inclisiran provides
advantages over monoclonal antibodies with an infrequent dosing interval of twice
a year to reduce LDL-C by over 50%, similar to that achieved with biweekly or
monthly administered antibodies. Inclisiran has been well tolerated and safe, without
severe adverse events so far. Serious adverse events (myalgia, headache, fatigue,
nasopharyngitis, back pain, hypertension, diarrhea, and dizziness) occurred similarly
between inclisiran group and placebo group (11% vs. 8%) (Ray et al. 2017). Ongoing
studies will establish the long-term safety of inclisiran, which is also important to
RNA based therapy in general.
300 Q. Wan et al.
Vaccination
A vaccine that targets PCSK9 has been developed to treat high LDL-particle concen-
trations. The vaccine uses a virus-like particle (VLP) as an immunogenic carrier of
an antigenic PCSK9 peptide. VLP’s are viruses that have had their DNA removed so
that they retain their external structure for antigen display and can induce an immune
response but are unable to cause infection. Mice and macaques vaccinated with bac-
teriophage VLPs displaying PCSK9-derived peptides developed high-titer IgG anti-
bodies that bound to circulating PCSK9. Vaccination was associated with signifi-
cant reductions in total cholesterol, free cholesterol, phospholipids, and triglycerides
(Crossey et al. 2015).
Small Molecules
Development of small molecular inhibitor for PCSK9 is challenging. This may reflect
general difficulty to use small molecules to directly block protein-protein interac-
tion. The plant alkaloid berberine inhibits the transcription of the PCSK9 gene in
immortalized human hepatocytes in vitro, and lowers serum PCSK9 in mice and
hamsters in vivo (Dong et al. 2015). Given the low bioavailability of berberine, its
action on intestinal microbiota has recently emerged as a new mechanism underlying
its hypolipidemic effect (See also in the section of Traditional Chinese Medicine).
Cholesterol-lowering drugs with differential mechanisms of action may have com-
plementary clinical applications. For example, PCSK9 inhibitors may be appropri-
ate for patients with statin intolerance, such as those with statin-associated muscle
symptoms.
Blocking the absorption of cholesterol from the small intestine decreases the amount
of cholesterol normally available to liver cells, leading them to absorb more from
circulation and thus lowering levels of circulating cholesterol. Ezetimibe targets the
critical mediator of cholesterol absorption, the Niemann-Pick C1-like 1 (NPC1L1)
protein on the gastrointestinal tract epithelial cells and in hepatocytes, thereby reduc-
ing the absorption of cholesterol from the intestine. The IMPROVE-IT (Improved
Reduction of Outcomes: Vytorin Efficacy International Trial) (Cannon et al. 2015)
reports that, in stable patients who had had an acute coronary syndrome within the
preceding 10 days, Ezetimibe, when added to statin therapy, resulted in incremental
lowering of LDL cholesterol levels (1.4 mM vs. 1.8 mM) and improved cardiovas-
cular outcomes—32.7% versus 34.7% on composite rate of cardiovascular death,
nonfatal MI, unstable angina requiring rehospitalization, coronary revascularization,
or nonfatal stroke, over an median follow-up of 6 years.
8 Drug Discovery for Coronary Artery Disease 301
Cholesteryl ester transfer protein (CETP) mediates the transfer of HDL cholesteryl
esters for triglyceride (TG) in VLDL/LDL (Millar et al. 2017; Krauss et al. 2015).
CETP inhibition increases high-density lipoprotein (HDL) cholesterol (traditionally
regarded as good cholesterol) levels and decreases low-density lipoprotein (LDL)
cholesterol (traditionally regarded as bad cholesterol) levels. It once bears promise
to reduce the risk of atherosclerosis and other cardiovascular diseases by improving
blood lipid levels. However, four drugs of this class failed in clinical trials for high-
risk patients. Torcetrapib failed due to excess deaths in Phase III clinical trials, likely
owing to the off-target effects of the drug. Lacking clinical efficacy, Dalcetrapib,
Evacetrapib, and Obicetrapib halted, respectively, in 2012, 2015, and 2017. REVEAL
(Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification)
trial evaluated Anacetrapib, a novel CETP inhibitor, in patients with atherosclerotic
vascular disease who were receiving intensive statin therapy (Group et al. 2017).
The mean level of HDL cholesterol was higher by 1.12 mM in the anacetrapib
group than in the placebo group (a relative difference of 104%), and the mean level
of non-HDL cholesterol was lower by 0.44 mM, a relative difference of −18%.
The major coronary event occurred in 10.8% of patients in the anacetrapib group
versus 11.8% of patients in the placebo group (9% relative risk difference), after
4.1 years of follow-up (Group et al. 2017). Anacetrapib treatment was associated
with a slightly higher systolic blood pressure level (0.7 mm/Hg) and an elevated risk
for a diminished estimated glomerular filtration rate, with no significant between-
group differences in the risk of death, cancer, or other serious adverse events. It is
unclear whether the reduction in cardiovascular risk is the consequence of effects
on the HDL raising or on CETP inhibitor-mediated reductions in LDL cholesterol,
which has been validated with statins. Anacetrapib accumulates in adipose tissue
with prolonged administration, and only minimally decline 1 year after cessation
of treatment. Merck halted the development of anacetrapib, likely due to relatively
modest benefit and safety concerns. It remains unknown whether CETP inhibitors
may work better as monotherapy (intensive statin use in the patients of REVEAL
trial may actually attenuate the efficacy), and whether certain subgroups with certain
genotype may respond better to CETP inhibition in terms of HDL particles taking
up cholesterol from the vessel wall. It is necessary to gain insights into the relation
between HDL-particle content and beneficial function and to identify alternative
targets and drug candidates.
However, this notion has been challenged. Niacin lowers the LDL cholesterol level
and raises the HDL cholesterol level. Among participants with atherosclerotic vas-
cular disease, the addition of extended-release niacin–laropiprant(a drug itself has no
cholesterol-lowering effect, but reduces facial flushes induced by niacin) to statin-
based LDL cholesterol-lowering therapy did not significantly reduce the risk of major
vascular events but did increase the risk of serious adverse events (HPS2-THRIVE
trial).
Artificial HDL-like apolipoprotein A1 complexes (apoA1-Milano) once held
promise in mediating regression of atherosclerosis. The failure to show benefits with
MDCO-216 in the MILANO-PILOT trial further challenges the idea of raising HDL
for cardiovascular benefit. There are other forms of HDL that continue to undergo
clinical trials, as these trials progress we will see how the HDL story ultimately plays
out.
pemafibrate administered 0.2 mg tablet twice daily will delay the time to first occur-
rence of any component of the clinical composite endpoint of nonfatal MI, nonfa-
tal ischemic stroke, hospitalization for unstable angina requiring unplanned coro-
nary revascularization, or cardiovascular death, in patients with type 2 diabetes and
dyslipidemia. This trial is estimated to complete in 2022.
Eicosapentaenoic Acid
Eicosapentaenoic acid (EPA) is the main component of fish oil. EPA belongs to
the omega-3 series of polyunsaturated fatty acids (PUFA). It is an indispensable
essential nutrient that cannot be synthesized by the human body. Therefore, it is
called an essential fatty acid. Although linolenic acid can be converted into EPA
in the human body, this reaction is very slow in the human body and the amount
of conversion is very small, far from meeting the human body’s need for EPA, and
therefore must be supplemented directly from food. Clinical trials have demonstrated
that omega-3 series fatty acids not only can lower cholesterol and triglyceride levels,
but inhibit platelet aggregation and inflammatory responses. Its mechanism of action
may be that omega-3 PUFA competes with the storage of arachidonic acid to replace
it and block the production of pro-inflammatory eicosanoids (Davinelli et al. 2018).
Extensive research shows marine-derived omega-3 fatty acids decrease triglycerides
with a potential reduction in cardiovascular disease in certain populations.
AMR101 (icosapent ethyl) is ethyl eicosapentaenoic acid, an ethyl ester of eicos-
apentaenoic acid (EPA, an omega-3 fatty acid). AMR101 is a highly purified ethyl
ester of EPA, and is approved by the FDA in 2012 for severe hypertriglyceridemia.
REDUCE-IT (Bhatt et al. 2019) (Reduction of Cardiovascular Events With EPA—
Intervention Trial) evaluated the cardiovascular effect of 2 g of icosapent ethyl twice
daily in patients with established cardiovascular disease or with diabetes and other
risk factors, who had been receiving statin therapy and who had a fasting triglyceride
level of 135–499 mg per deciliter (1.52–5.63 mmol/L) and a low-density lipoprotein
cholesterol level of 41–100 mg per deciliter (1.06–2.59 mmol/L). Compared with
placebo, 4 g/Day AMR101 reduced long-term cardiovascular events (Composite
endpoint of CV death, nonfatal MI, nonfatal stroke, coronary revascularization, and
hospitalization for unstable angina) (17.2% vs. 22.0%, hazard ratio, 0.75; 95% [CI],
0.68–0.83; P < 0.001) in high-risk patients with elevated triglyceride levels despite
the use of statins. A larger percentage of patients in the icosapent ethyl group than in
the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%,
P = 0.004).
The cardiovascular benefit of n–3 fatty acids appears to relate to disease condition
and/or dose. In general, populations at usual risk (VITAL trial, a primary prevention
trial among men 50 years of age or older and women 55 years of age or older),
marine n–3 fatty acids (at a dose of 1 g per day) did not result in a lower inci-
dence of major cardiovascular events (primary endpoint, a composite of myocardial
infarction, stroke, or death from cardiovascular causes) (hazard ratio, 0.92; 95% con-
fidence interval [CI], 0.80–1.06; P = 0.24), but reduced a key secondary endpoint,
total myocardial infarction, 0.72 (95% CI, 0.59–0.90) (Manson et al. 2019). Among
patients with diabetes without atherosclerotic cardiovascular disease (ASCEND trial)
304 Q. Wan et al.
(Group et al. 2018) 1 g n – 3 fatty acids daily did not reduce the risk of serious vascular
events compared with placebo (olive oil).
Epanova (omega-3 carboxylic acids) is a concentrate of omega-3 free fatty acids,
developed from fish oils. STRENGTH (STatin Residual Risk Reduction With
EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia) trial is a long-
term cardiovascular outcome study to assess Epanova, taken once daily on top of
statin, in patients with hypertriglyceridemia and low HDL and high risk for CVD.
This phase 3 trial is started in 2014 and estimated to complete in late 2019.
Apolipoprotein C-III Inhibition
Apolipoprotein C-III (APOC3) is a component of TG-rich lipoproteins, known to
inhibit lipoprotein lipase-mediated hydrolysis of TG-rich lipoproteins and to nega-
tively affect receptor-mediated hepatic uptake of remnants of TG-rich lipoproteins,
thereby regulating plasma TG levels. Elevated APOC3 levels result in accumula-
tion of atherogenic very-low-density lipoproteins (VLDL) and chylomicron rem-
nants, as a consequence of impaired lipolysis and disturbed clearance of TG-rich
lipoproteins. Elevated APOC3 levels, especially when present on apolipoprotein E-
containing lipoproteins, are an independent risk factor for CVD. Rare mutations that
disrupt APOC3 function were associated with lower levels of plasma triglycerides
and APOC3 and with a reduced risk of CAD (Tg et al. 2014). People with homozy-
gous loss of function of APOC3 show marked blunting of the usual postprandial rise
in plasma triglycerides (Saleheen et al. 2017). Although fibrates, statins and omega-3
fatty acids modestly decrease triglyceride levels (and apoC-III concentrations), there
are many patients who still have severe hypertriglyceridemia and are at increased
risk for pancreatitis and potentially for CVD.
ISIS 304801 is an antisense oligonucleotide that specifically binds to APOC3 mRNA
and induces its degradation. It robustly decreases both, apoC-III production and
triglyceride concentrations. In a phase 2 trial in patients with severe or uncontrolled
hypertriglyceridaemia, weekly subcutaneous injections of 100, 200, or 300 mg of
ISIS 304801 for 13 weeks ISIS 304801 as monotherapy produced a dose-dependent,
prolonged reduction in TG levels (largest decrease with 300 mg: 70.9% vs. 20.1%
increase on placebo) and increase in HDL levels (300 mg: 45.7% vs. 0.7% with
placebo). A similar effect was observed when the drug was used as an add-on to
stable doses of fibrate therapy (Gaudet et al. 2015). It is being currently evaluated
in phase 3 trials (Schmitz and Gouni-Berthold 2018). An outcome trial is needed to
establish clinical proof-of-concept with therapeutics that inhibit APOC3.
Angiopoietin-Like 3 Inhibition
Angiopoietin-like 3 (ANGPTL3) is a protein that inhibits lipoprotein lipase (LPL)
and endothelial lipase (EL), thereby increasing plasma triglyceride, LDL cholesterol,
and HDL cholesterol. LPL is a rate-limiting enzyme for the hydrolysis of circulat-
ing triglycerides (TG) into free fatty acids that are absorbed by peripheral tissues
(Zhang 2016). ANGPTL3 is a novel target to reduce triglyceride-rich lipoproteins
(Olkkonen et al. 2018). Evinacumab is an antibody from Regeneron, which blocks the
actions of ANGPTL3. An antisense oligonucleotide from Ionis Pharmaceuticals also
blocks ANGPTL3 activity. Animal studies, as well as early clinical studies, show that
8 Drug Discovery for Coronary Artery Disease 305
Historical success of statins, together with the recent approval of PCSK9 inhibitors,
has firmly established the therapeutic principle of lowering LDL-C for treating CAD.
However, residual cardiovascular risk following successful LDL-C lowering therapy
remains substantial. Inflammation is thought of as an essential pathology for CAD and
its acute manifestation, myocardial infarction (MI), which involves cytokines, such as
interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α, and C-reactive protein
(CRP, a marker of inflammation) production. In addition to innate immunity, adaptive
immunity is also associated with atherosclerosis through antigen-presenting cells, T
and B lymphocytes. Statin is known to have anti-inflammatory activity besides LDL-
C lowering effects, which may also contribute to its cardiovascular efficacy. Indeed,
aggressive lipid lowering by high-dose atorvastatin decreases high-sensitivity CRP
(hsCRP) serum levels and entails regression of atheromas. The clinical benefit is
extended to primary prevention in patients with LDL-C levels < 130 mg/dl but ele-
vated hsCRP, where rosuvastatin significantly reduces major cardiovascular event
rates, with reductions in both LDL-C and hsCRP. In acute coronary syndrome (ACS),
aggressive statin therapy also lowered the incidence of primary endpoints including
MI, with the most substantial benefit in patients with declines in both LDL-C and
CRP. Recent FOURIER Trial reveals that LDL-C and hsCRP are independently asso-
ciated with the cardiovascular outcome (Bohula et al. 2018). Nevertheless, teasing
out the anti-inflammatory effect of statin from its LDL cholesterol-lowering effect
in cardiovascular prevention appears practically impossible.
Previous trials exploring treatment that specifically targets inflammation failed
to show clinical benefits in CAD patients. The targets involved include p38 MAP
306 Q. Wan et al.
kinase, CRP, secretory phospholipase A2 (sPLA2, an enzyme catalyzes the first step
of the arachidonic acid pathway of inflammation), lipoprotein-associated phospho-
lipase A2 (Lp-PLA2, a secreted acetylhydrolase that catalyzes the degradation of
platelet-activating factor), IL-1R, the IL-6 receptor, CC2 chemokine receptor, and
some immunomodulatory or immunosuppressive therapies, such as cyclosporine and
colchicine, CD20 blocker. Recently, the CANTOS (Canakinumab Anti-inflammatory
Thrombosis Outcome Study) trial provides first clinical evidence that an IL-1β
antibody that leads to marked reductions in IL-6 and CRP reduces cardiovascular
risk.
• IL-1β inhibition
IL-1, a pro-inflammatory cytokine, promotes the development of atherosclerosis and
contributes to adverse remodeling and left ventricular dysfunction after acute myocar-
dial infarction (AMI). In phase II studies, IL-1 blockade suppressed the inflamma-
tory response associated with ST-segment elevation AMI and prevented heart failure
(HF). Other phase II studies show improved exercise capacity with IL-1 blockade in
patients with HF. Several IL-1 blockers are available for clinical use, which differ in
mechanism of action, and potentially also efficacy and safety.
Canakinumab (trade name Ilaris) is a human monoclonal antibody that specif-
ically inhibits IL-1β function. IL-1β is synthesized as a precursor form protein
only after stimulation, in contrast to IL-1α. Canakinumab was approved for the
treatment of cryopyrin-associated periodic syndromes (CAPS) in 2009. CAPS is a
spectrum of auto-inflammatory syndromes including familial cold autoinflammatory
syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory
disease. In September 2016, FDA approved the use of canakinumab on 3 addi-
tional rare and serious auto-inflammatory diseases: TNF receptor-associated peri-
odic syndrome, hyper immunoglobulin D syndrome/mevalonate kinase deficiency
and Familial Mediterranean fever.
CANTOS trial shows that, in patients with previous myocardial infarction and per-
sistently elevated hsCRP (> = 2 mg/L), subcutaneous administration of canakinumab
every 3 months at 150 mg led to a significantly lower rate of recurrent cardiovascular
events (nonfatal MI, nonfatal stroke, or cardiovascular death) than placebo with a
hazard ratio (HR) of 0.85 (95% CI, 0.74–0.98), independent of lipid-level lowering
(Ridker et al. 2017). Baseline clinical characteristics did not define patient groups
with greater or lesser cardiovascular benefits when treated with canakinumab. How-
ever, trial participants allocated to canakinumab who achieved hsCRP concentrations
less than 2 mg/L had a 25% reduction in major adverse cardiovascular events (HR
= 0.75, 95% CI 0.66–0.85), whereas no significant benefit was observed among
those with on-treatment hsCRP concentrations of 2 mg/L or above (HR = 0.90,
0.79–1.02, p = 0.11). These data further suggest that lower is better for inflamma-
tion reduction with canakinumab (Ridker et al. 2018). This phase 3 trial provides
the first clinical proof-of-principle for anti-inflammatory therapy for atherosclerosis.
Interestingly, the CANTOS trial also showed a significant reduction in lung cancer
incidence and mortality in the canakinumab treated group compared to the placebo.
A higher incidence of fatal infection was observed in the canakinumab group than in
8 Drug Discovery for Coronary Artery Disease 307
the placebo, which is likely due to a blunting of the inflammatory signs of infection
leading to delayed presentation and diagnosis. IL-1 blockade was not associated with
opportunistic infections and there was no difference in all-cause mortality with the
canakinumab treatment. Cost-effectiveness and potential risk of immune suppres-
sion determine whether and who might benefit from the use of canakinumab for
cardiovascular prevention.
• Methotrexate and lessons learned
Methotrexate inhibits dihydrofolate reductase that is essential for DNA synthesis
and it also inhibits lymphocyte activation. It is on the World Health Organization’s
List of Essential Medicines being used as a chemotherapy agent and immune system
suppressant. Low-dose methotrexate is an effective anti-inflammatory therapy widely
used to treat rheumatoid arthritis. The CIRT (Cardiovascular Inflammation Reduction
Trial) evaluates effects of low-dose (15–20 mg per week) methotrexate on rates of
MI, stroke, and cardiovascular death among patients with previous MI or multivessel
coronary disease who additionally had either type 2 diabetes or metabolic syndrome,
conditions associated with an enhanced pro-inflammatory response. However, low-
dose methotrexate did not reduce levels of IL-1β, IL-6, or CRP and did not result in
fewer cardiovascular events than placebo in these patients with stable atherosclerosis
(Ridker et al. 2018), raising questions on the dose and population selected.
Clinical data on inflammatory biomarkers, biological data and recent Mendelian
randomization data suggest that inflammatory mediators of atherosclerosis may con-
verge on the central IL-1, tumor necrosis factor (TNF-a), IL-6 signaling pathway.
On this basis, emerging anti-inflammatory approaches to vascular protection can be
categorized into two broad groups, those that target the central IL-6 inflammatory
signaling pathway and those that do not. Both approaches have the potential to benefit
patients and reduce vascular events, but may not concord each other. The inflamma-
tory system is redundant, compensatory, and crucial for survival, evaluation of risks,
as well as benefits, must drive the development of agents in this class.
Thrombosis that occludes blood vessels is the direct cause of acute manifestations
of CAD. Antiplatelet drugs reduce thrombotic risk by inhibiting platelet activa-
tion and aggregation. Thromboxane and ADP activate their corresponding platelet
receptors TP and P2Y12, respectively, and result in platelet inside-out signaling and
integrin αIIbβ3 (glycoprotein IIb/IIIa) conformation change allowing its binding to
fibrinogen to aggregate platelets. Drugs targeting the above pathways have been suc-
cessfully used in the clinic. Aspirin suppresses thromboxane production and inhibits
platelet aggregation. It is a cornerstone therapy for secondary cardiovascular preven-
tion in ACS, a benefit further enhanced by additional P2Y12 antagonism through
clopidogrel, or, more recently developed prasugrel or ticagrelor. Platelet integrin
αIIbβ3 inhibitors are potent antithrombotic drugs that are used intravenously to treat
308 Q. Wan et al.
ACS, but they also have the life-threatening adverse effect of causing bleeding. Dis-
covery of antiplatelet drugs that can effectively prevent thrombosis while sparing
bleeding side effects remains an unmet medical need.
• Proteinase-activated receptors
Thrombin activates platelets by cleaving/activating a G–protein-coupled family of
proteinase-activated receptors (PARs). The signaling mechanism involves the prote-
olytic unmasking of an N-terminal receptor sequence that acts as a tethered receptor-
activating ligand. The recognized targets of thrombin cleavage and activation for
signaling are PAR1 and PAR4, in which thrombin cleaves at a conserved target
arginine to reveal a tethered ligand. Unlike anticoagulants, PAR1 inhibitors block
downstream of PAR1 without directly impacting thrombin-induced fibrin polymer-
ization. Vorapaxar (Zontivity), a competitive PAR1 antagonist, is effective in treating
ACS, however, the severe bleeding associated with this drug has limited its use in
the clinic. Due to the efficacy of thrombin acting via PAR1, strategies to selectively
inhibit specific PAR1-mediated G protein signaling pathways or to target the sec-
ond thrombin platelet receptor, PAR4, are being devised (Wong et al. 2017). The
rationale behind these alternative approaches is to bias downstream thrombin activ-
ity via PARs to allow for inhibition of pro-thrombotic pathways but maintain other
pathways that may preserve hemostatic balance and improve bleeding profiles for
widespread clinical use.
• Platelet integrin outside-in signaling
Activated platelets facilitate coagulation (platelet procoagulant activity, PPA) mainly
by exposing the procoagulant phospholipid phosphatidylserine (PS) on the outer
membrane surfaces and releasing PS-expressed microvesicles (MVs). Recent studies
indicate that selective targeting of integrin outside-in signaling as a new antithrom-
botic strategy that has the advantage of potently inhibiting occlusive platelet throm-
bus expansion without causing excessive bleeding (Shen et al. 2013). β3 integrins
serve as a shear sensor activating the Gα13-dependent outside-in signaling pathway
to facilitate platelet procoagulant function. An inhibitor of outside-in signaling that
targets Gα13-integrin interaction was discovered to prevent occlusive thrombosis
in vivo by inhibiting both coagulation and platelet thrombus formation (Pang et al.
2018). It is known that partial inhibition of platelet thrombus formation by platelet
activation inhibitors or by integrin inhibitors are not effective in inhibiting fibrin clot
formation, whereas complete inhibition of integrin ligand-binding function is likely
to cause excessive bleeding. Thus, by targeting integrin outside-in signaling without
blocking platelet adhesion and primary aggregation, it is possible to diminish platelet-
dependent intravascular fibrin clot without causing excessive bleeding. Because the
intravascular fibrin clot around the platelet thrombus is associated with thrombus
expansion and stabilization, this novel effect of outside-in signaling inhibitors is
likely to contribute to the potency and anticlotting effect of these new drugs, and
is advantageous over the current antiplatelet drugs. Pharmacological targeting of
Gα13-integrin interaction is under preclinical development.
8 Drug Discovery for Coronary Artery Disease 309
Fig. 8.1 Coagulation pathway and anticoagulant targets. Coagulation cascade is a series of sequen-
tial reactions in which zymogens are converted to active serine proteases ultimately resulting in the
formation of covalently cross-linked fibrin. Blood coagulation can be triggered via the extrinsic
pathway that is initiated by tissue factor following tissue trauma or via an intrinsic pathway that is
driven by FXII activation. Anticoagulants targeting FXII, FXI and FIX are in development
310 Q. Wan et al.
Epidemiologic studies show a clear correlation between lower blood sugars and bet-
ter health outcomes in patients with diabetes mellitus. Every 1% increase in the
8 Drug Discovery for Coronary Artery Disease 313
hemoglobin A1c was associated with an 18% increase in the risk of cardiovascular
(CV) events, 12–14% increase risk of death and a 37% increased risk of eye dis-
ease or kidney disease. Most diabetic patients die of cardiovascular disease (CVD).
Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart
failure (HF) in these patients. Treating blood glucose to current guidelines is safe and
very important for reducing microvascular complications like nerve, kidney and eye
disease. However, most glucose-lowering drugs studied, as in trials of ADVANCE,
ACCORD, VADT, etc., failed to reduce cardiovascular adverse events despite the
proven ability to lower blood glucose, especially in patients with a long duration of
type 2 diabetes mellitus (T2D) and prevalent CVD. Such drugs include metformin,
sulfonylureas, PPAR agonists thiazolidinediones and dipeptidyl peptidase-4 (DPP-4)
inhibitors. No significant long-term efficacy of insulin on any clinical outcome in
T2D was observed. Actually, some diabetes drugs, in particular, rosiglitazone, even
increase adverse cardiovascular events. As such, regulatory guidance specifies the
need to establish cardiovascular safety of new diabetes therapies in patients with T2D
in order to rule out excess cardiovascular risk. There is evidence suggesting that ear-
lier treatment in prediabetic patients before disease onset may be effective although
its effects are delayed (UKPDS trial). Recent trials show that diabetes drugs targeting
SGLT2 or GLP1 may improve cardiovascular outcome in patients with established
T2D.
• Sodium-glucose linked transporter 2 inhibition
Sodium-glucose linked transporter (SGLT) is a family of glucose transporter, with
SGLT1 and SGLT2 being the two most well-known members. SGLT1 is found in the
enterocytes of the small intestine and in the proximal straight tubule. SGLT2 is mainly
expressed in the proximal convoluted tubule of the nephron. They contribute to renal
glucose reabsorption. In a healthy nephron, the filtered glucose in the glomerulus is
all reabsorbed along the nephron (at least 90% in the proximal convoluted tubule,
via SGLT2). In hyperglycemic condition, glucose is excreted in urine because SGLT
is saturated with the filtered glucose. SGLT2 inhibitors increase urinary glucose
excretion, thus improving glycemic control independent of insulin.
Empagliflozin (trade name Jardiance) is an SGLT2 inhibitor, approved for the
treatment of T2D in adults in 2014. EMPA-REG OUTCOME trial (Zinman et al.
2015) reports that in a population of patients with T2D and established cardiovascular
disease on a background of standard care, empagliflozin reduces the combined CV
endpoint of CV death, nonfatal MI, and nonfatal stroke compared to placebo (10.5%
vs. 12.1%, HR = 0.86). Empagliflozin also significantly and robustly reduced the
individual endpoints of CV death (3.7%, vs. 5.9%; 38% relative risk reduction), any
cause mortality (5.7% and 8.3%, respectively; 32% relative risk reduction), and hos-
pitalization for HF (2.7% and 4.1%, respectively; 35% relative risk reduction) in this
high-risk population. These cardiovascular beneficial effects of empagliflozin may
result from an interplay of various factors beyond glucose control such as weight loss,
blood pressure lowering and sodium depletion, renal hemodynamic effects, effects
on myocardial energetics, and/or neurohormonal effects, etc. Future studies are war-
ranted to clarify the underlying mechanisms, and importantly to assess whether such
314 Q. Wan et al.
stroke (13.0% vs. 14.9%, HR, 0.87; 95% CI, 0.78–0.97). The rate of death from
cardiovascular cause (4.7% vs. 6.0%, HR, 0.78, 95% CI, 0.66–0.93) and from any
cause (8.2% vs. 9.6%, HR, 0.85; 95% CI, 0.74–0.97) was lower in the liraglutide
group. The most common adverse events leading to the discontinuation of liraglutide
were gastrointestinal events (Alvarez-Villalobos et al. 2016).
Semaglutide (Ozempic, Novo Nordisk) is a GLP-1 analogue with an extended
half-life of approximately 1 week. In a trial (SUSTAIN-6) of 3297 patients with T2D
who were at high cardiovascular risk, semaglutide treatment significantly lowered
the combined risk for CV death, nonfatal MI or nonfatal stroke compared to placebo
(6.6% vs. 8.9%, HR, 0.74). The rates of nonfatal MI and nonfatal stroke, for the
semaglutide group as compared to placebo group, were 2.9% versus 3.9% (HR,
0.74; P = 0.12) and 1.6% versus 2.7% (HR, 0.61; P = 0.04), respectively. Rates of
death from cardiovascular causes were similar in the two groups. Rates of new or
worsening nephropathy were lower in the semaglutide group, but rates of retinopathy
complications were significantly higher (HR, 1.76; 95% CI, 1.11–2.78; P = 0.02).
Fewer serious adverse events occurred in the semaglutide group, although more
patients discontinued treatment because of adverse events, mainly gastrointestinal
(Marso et al. 2016).
The cardiovascular beneficial effects of empagliflozin and liraglutide may attribute
to effects other than their glucose-lowering effect, since both drugs only modestly
reduced blood glucose (0.4% in HbA1c). Understanding the underlying mechanism
may provide new therapeutic targets for patients with atherosclerotic disease or at
risk.
Coronary artery disease (CAD), also known as coronary heart diseases or ischemic
heart disease, refers to a series of diseases such as stable angina, unstable angina,
myocardial infarction and sudden cardiac death that are mainly attributable to coro-
nary artery stenosis due to atherosclerotic plaque. The development of atherosclerosis
leads to a decrease or even cessation (in the case of atherothrombosis) of the coronary
artery flow, resulting in cardiomyocyte damage and functional loss. Some traditional
Chinese medicine (TCM) has been used for CAD, to relieve symptoms. However,
there is a lack of clinical outcome trials for most if not all TCM that are already in
practice for CAD treatment. Because TCM is an impure natural product, potential
multiple active ingredients and their interactions make it challenging to precisely
delineate their molecular pharmacology or therapeutic target. Nevertheless, with a
modern pharmacological approach, researchers have identified some bioactive com-
ponents in TCM extractions. Further studies may lead to the discovery of new drugs
that demonstrate clear pharmacology, clinical efficacy as well as toxic profile. Listed
below are some bioactive ingredients derived from TCM extractions that have pub-
lished evidence on their potential mechanism of action. It’s worth to note that purified
ingredients from TCM do not necessarily have a similar profile of efficacy or safety
compared with the TCM from which they are isolated.
• Berberine
Berberine is a quaternary ammonium salt from the protoberberine group of benzyliso-
quinoline alkaloids found in such plants as Berberis. This first recorded use of berber-
ine is described in the ancient Chinese medical book The Divine Farmer’s Herb-Root
Classic. Berberine is considered an antibiotic and has been used to treat gastroen-
teritis, bacillary dysentery, ocular conjunctivitis, suppurative otitis media. Whether
berberine may be used for treating diabetes, hyperlipidemia is under investigation.
Berberine might also possess antiaging (gero-suppressive) properties. The bioavail-
ability of berberine is low (Liu et al. 2016). Berberine is reported to inhibit the
intestinal absorption of cholesterol and promote the excretion of cholesterol from
the liver to the bile in hyperlipidemic hamsters (Li et al. 2015). Berberine may influ-
ence microbiota in the intestine, which contributes to the reduced plasma cholesterol
levels, a novel mechanism different from statin (Zhu et al. 2018; Feng et al. 2018).
Phase II clinical trial of berberine is ongoing.
• Danshensu
Radix Salviae miltiorrhizae, danshen root (danshen), is one of the widely used Chi-
nese herbal medicines in clinics, containing rich phenolic compounds. Danshensu
(DSS) is the main active compound responsible for the pharmacologic effects of dan-
shen. DSS has various various cardiovascular protective effects, which include coro-
nary artery dilation, platelet inhibition, microcirculation improvement, cardiomy-
ocyte protection from myocardial ischemia-reperfusion injury (Yu et al. 2017). DSS
appears to act on mTOR signaling (Fan et al. 2016) and involve in ROS scaveng-
ing and boosting endogenous antioxidants, including SOD, CAT, MDA, GSH-PX
8 Drug Discovery for Coronary Artery Disease 317
and HO-1, via activating nuclear factor erythroid-2-related factor 2 (Nrf2) signaling
pathway (Yu et al. 2015).
Dantonic® (T89-07-CAESA) is a botanical drug that consists of extracts of dan-
shen (Radix Salviae Miltiorrhizae) and sanqi (Radix Notoginseng) with borneol in
a capsule form. The drug is currently approved in 26 countries outside the USA for
the treatment and prevention of chronic stable angina pectoris and other cardiovas-
cular disease related conditions. A Phase III clinical trial (https://clinicaltrials.gov/
ct2/show/NCT01659580) is to confirm the efficacy and safety of the drug at 150
and 225 mg doses in the prevention and treatment of angina pectoris in patients
with Chronic Stable Angina. The trial was completed in late 2016, with no results
published.
• Tanshione IIA
Lipid-soluble extractions of Danshen consist of tanshinone I, IIA, B, cryptotanshi-
none, dihydrotanshinone I, methylenetanshinone, and isotanshinone IIA. Among the
tanshinone, tanshinone IIA is widely used in treatment of various cardiovascular dis-
eases. Tanshinone IIA decreases expression of TLR4, NF-Kb-p65, MyD88, IL-2,
IL-6, IL-8, PICP, and PIINP, as well as alleviates macrophage infiltration, cardiomy-
ocyte apoptosis, which might result from inhibition of TLR4/MyD88/NF-KB signal-
ing pathway (Wu et al. 2018). In addition, the cardioprotective effect of tanshinone
IIA may also partially mediated via blocking alternative complement pathway (Wang
et al. 2011) and by repressing miR-1 level in ischemic and hypoxic cardiomyocytes,
which subsequently restored its target Cx43 protein (Zhang et al. 2010).
• Ligustrazine
Ligustrazine (4-methyl-pyrazine[tetramethylpyrazine]), a crude herbal drug isolated
from the dried root or rhizome of Rhizoma Chuanxiong, has been long used in China
to treat CVDs including coronary heart disease, hypertension, arrhythmia, heart fail-
ure, dilated cardiomyopathy, dyslipidemia, and myocarditis (Lv et al. 2012; Kwan
et al. 1990). Ligustrazine suppresses the development of atherosclerosis and hepatic
lipid accumulation via the alleviation of oxidative stress and dyslipidemia (Jiang
et al. 2011). Ligustrazine has a protective function on the endothelium via inhibition
of immunological reactions, underscores its role in atherosclerotic prevention (Wu
et al. 2012).
• Ginkgolide B
Ginkgolide B (GB) is the major terpenoid component extracted from G. Biloba
leaves. GB exerts an antagonistic activity against the platelet-activating factor (PAF)
and thus inhibits PAF-induced inflammatory reactions (Yang et al. 2004; Mahmoud
et al. 2000). PAF antagonist GB has a protective effect against IR-induced myocardial
dysfunction likely via protecting membrane phospholipids (Pei et al. 2015).
• Astragaloside
Astragalus membranaceus is a commonly used traditional Chinese herb that contains
flavonoids, saponins, and other active ingredients that have wide pharmacological
318 Q. Wan et al.
of the RhoA signaling pathway, and restores the production of ATP during cardiac
I/R (Cui 2017).
Use of TCM mainly relies on empirical experience. Confirming the efficacy of
TCM with placebo-controlled and randomized clinical trial, and clarification of their
molecular pharmacology, will allow identification of new therapy/targets for treating
CAD. In this regard, TCM is an enriched resource for new drug discovery.
target for promoting neovascularization and driving heart regeneration after injury
(MI) (He et al. 2017).
In the past 2 decades, several strategies to repair the injured heart and improve
heart function have been pursued, including cellular and noncellular therapies. Cell
therapy is a central issue of regenerative medicine and is raising a growing interest
in the scientific community, but its full therapeutic potential in CAD has not been
reached yet. Different strategies for the production of cardiomyocytes from human
embryonic stem cells or human-induced pluripotent stem cells, by direct reprogram-
ming and induction of cardiomyocyte proliferation have been tried. Transplanta-
tion of induced pluripotent stem cell-derived cardiomyocytes for cardiac repair has
encountered problems related to safety and low engraftment rates. Cell-free-based
approaches for heart repair and regeneration involve cardioprotective secretory fac-
tors or direct reprogramming of resident cardiac fibroblasts to cardiomyocyte-like
cells. Endogenous cardiomyocyte proliferation can be evoked by modulating cell
cycle regulators, the Hippo signaling pathway, and the cardiac microenvironment.
Hippo-Yap signaling pathway controls heart regeneration and size in adult mice.
Agrin, a component of the extracellular matrix, has been identified to promote car-
diomyocyte regeneration by interrupting the interaction between dystrophin glyco-
protein complex and YAP (Bassat et al. 2017; Morikawa et al. 2017). In particular,
treatment with Agrin after MI promoted cardiac regeneration in adult mice, raising
a possibility of its clinical use of Agrin with a novel promising approach. Genome
editing can correct underlying mutations causing heart disease in animals and offers
a state-of-the-art therapeutic approach for cardiac repair. The therapeutic potential of
cardiac regeneration approaches can be improved by optimizing the delivery method
of therapeutic factors. Significant clinical efforts have been put forward following the
explosion of preclinical research showing the efficacy of stem/progenitor cell ther-
apy in failing heart. However, preclinical outcomes of cardiac regenerative therapy
approaches have not translated effectively to clinical trials. A reproducible cell-based
therapy or regenerative medicine remains to come.
electrocardiographic changes of
myocardial ischemia and electrical
regeneration of the heart in
subjects with coronary artery
diseases
BI10773 (empagliflozin) HF A small molecule that inhibits Phase 3 Eli Lilly and
SGLT 2 Boehringer Ingelheim
AMG 986 HF A small-molecule agonist of the Phase 1 AMGEN
Apelin receptor (APJ)
Omecamtiv mecarbil Chronic HF A small-molecule activator of Phase 3 AMGEN
cardiac myosin.
(continued)
325
Table 8.1 (continued)
326
for obesity
OPC-269 CVD NA Phase 1 Ligand
Pharmarceuticals, Inc.
Nitroxyl Donor CVD A small molecule inhibits Phase 2 Bristol-Myers Squibb
inflammatory by reducing cytokine
production and activating the
cGMP/PKG/ATP-sensitive K+
channel
CS-3150/Esaxerenone CVD A novel nonsteroidal Phase 3 Ligand
mineralocorticoid receptor Pharmarceuticals, Inc.
antagonist
CXL-1427 CVD A nitric oxide donor and prodrug Phase 2 Ligand
of CXL-1020 Pharmarceuticals, Inc.
(continued)
329
Table 8.1 (continued)
330
MRA/RG1569 (RO4877533, Large-vessel vasculitis, Giant cell Humanized antihuman IL-6 Phase 3 Chugai Pharma USA,
tocilizumab, Actemra® ) arteritis and Systemic sclerosis receptor monoclonal antibody Inc.
DP9 Pectoris DP9 provides transdermal skin Phase 2 Dimera
cream progesterone in unit-dose
packages that allow reliable
achievement of effective exposure
levels with optimized
pharmacokinetics; DP9 provides
transdermal skin cream
progesterone in unit-dose packages
that allow reliable achievement of
effective exposure levels with
optimized pharmacokinetics
(continued)
331
Table 8.1 (continued)
332
current standard therapy remain largely unknown. The atherogenic process as a con-
sequence of hypercholesterolemia, and inflammation has been considerably refined
by the appreciation of endothelial injury, the role of myeloid cells, T/B lymphocytes,
and dendritic cells in innate and acquired immunity, subendothelial apoB-lipoprotein
retention, and the identification of signals, such as chemotactic cytokines, regulating
the lesional recruitment and homeostasis of inflammatory cells. Further understand-
ing the mechanistic links among lipid metabolism disorder, inflammation, hyperten-
sion, and thrombosis continue to emerge as the pathogenic interface that fuels the
therapeutic options for CAD.
Just like the Scandinavian Simvastatin Survival Study in 1994 marked the begin-
ning of the statin era, the Canakinumab Anti-inflammatory Thrombosis Outcome
Study in 2017 opens a new era for atherosclerosis prevention focused on inflam-
mation inhibition. Canakinumab is currently the only agent specifically targeting
inflammation that is proven to reduce cardiovascular event rates at clinical levels.
Inhibition of IL-6 and modulation of upstream determinants of IL-1 activation, such
as NLRP3 inflammasome, might be an alternative therapeutic option that is under
investigation. Inhibition of other inflammatory pathways might also benefit from
vascular disease patients. Future studies are needed for an in-depth understanding
of cardiovascular inflammation, delineation of candidate target from the perspec-
tive of systems biology, appropriate selection of patients or timing of intervention
that allows maximal benefit. New agents with improved safety profiles and favored
cost-effectiveness are still in need.
Antihypertensive beta-blockers lower mortality from MI and delay atheroprogres-
sion (IVUS trials) (Sipahi et al. 2007). Intensive blood pressure lowering (Group et al.
2015; Chobanian et al. 2003) reduces major adverse cardiovascular events in patient
population at high risk. In a population of intermediate-risk (HOPE-3 trial), choles-
terol lowering (Yusuf et al. 2016), or combination of cholesterol lowering and blood
pressure lowering (Yusuf et al. 2016), but not blood pressure lowering alone (Lonn
et al. 2016), reduced the risk of cardiovascular events. Interference with the renin–
angiotensin system improves endothelial function and reduces coronary event rates
disproportionately to lower blood pressure, supporting direct atheroprotective effects
(Investigators et al. 2008). Dyslipidemia and hypertension might contribute to the
occurrence of cardiovascular events at different stages of atherosclerosis. Elucidation
of the underlying mechanisms may allow new therapeutic intervention.
Human genome-wide association study, transcriptional, proteomic and metabolic
profiling of CAD, complemented with animal studies of established and unstable
atherosclerosis that faithfully recapitulate human biology, will further delineate
molecular mechanism of CAD and pave the way toward discovery of new thera-
peutic targets and drugs. New strategies are emerging, such as anti-inflammation,
triglyceride lowering, chemokine signaling modulation and vaccination against
oxidized/pro-inflammatory phospholipids (Que et al. 2018). These strategies will
have to overcome translational challenges before further reducing CAD, the main
disease burden to mankind.
334 Q. Wan et al.
Sources of Funding This work was supported by the National Natural Science Foundation of
China (81570269), Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
(2017-I2M-1-008, 2016-I2M-1-003/006), Peking Union Medical College and Chinese Academy of
Medical Sciences.
References
Davinelli S et al (2018) Cardioprotection by cocoa polyphenols and omega-3 fatty acids: a disease-
prevention perspective on aging-associated cardiovascular risk. J Med Food. https://doi.org/10.
1089/jmf.2018.0002
Delaney MK et al (2016) Differential roles of the NADPH-Oxidase 1 and 2 in platelet activation
and thrombosis. Arterioscler Thromb Vasc Biol 36:846–854. https://doi.org/10.1161/ATVBAHA.
116.307308
Dong B, Li H, Singh AB, Cao A, Liu J (2015) Inhibition of PCSK9 transcription by berber-
ine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-
proteasome degradation pathway. J Biol Chem 290:4047–4058. https://doi.org/10.1074/jbc.
M114.597229
Dong Z et al (2017) Astragaloside IV alleviates heart failure via activating PPARalpha to switch
glycolysis to fatty acid beta-oxidation. Sci Rep 7:017–02360
Erlinge D et al (2017) Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J
Med 377:1132–1142. https://doi.org/10.1056/NEJMoa1706443
Fan G et al (2016) Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting
autophagy and apoptosis via activation of mTOR signalling. J Cell Mol Med 20:1908–1919.
https://doi.org/10.1111/jcmm.12883
Feng R et al (2018) Gut microbiota-regulated pharmacokinetics of berberine and active metabolites
in beagle dogs after oral administration. Front Pharmacol 9:214. https://doi.org/10.3389/fphar.
2018.00214
Fitzgerald K et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med
376:41–51. https://doi.org/10.1056/NEJMoa1609243
Forstermann U (2008) Oxidative stress in vascular disease: causes, defense mechanisms and poten-
tial therapies. Nat Clin Pract Cardiovasc Med 5:338–349. https://doi.org/10.1038/ncpcardio1211
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an
SGLT2 inhibitor. N Engl J Med 376:2300–2302. https://doi.org/10.1056/NEJMc1701990
Fruchart JC (2017) Pemafibrate (K-877), a novel selective peroxisome proliferator-activated recep-
tor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 16:124.
https://doi.org/10.1186/s12933-017-0602-y
Gaudet D et al (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyc-
eridemia. N Engl J Med 373:438–447. https://doi.org/10.1056/NEJMoa1400283
Giugliano RP et al (2017) Cognitive function in a randomized trial of evolocumab. N Engl J Med
377:633–643. https://doi.org/10.1056/NEJMoa1701131
Group SR et al (2015) A Randomized trial of intensive versus standard blood-pressure control. N
Engl J Med 373:2103–2116. https://doi.org/10.1056/nejmoa1511939 (2015)
Group HTRC et al (2017) Effects of anacetrapib in patients with atherosclerotic vascular disease.
N Engl J Med 377:1217–1227. https://doi.org/10.1056/nejmoa1706444
Group ASC et al (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med
379:1540–1550. https://doi.org/10.1056/nejmoa1804989 (2018)
Gutierrez MJ et al (2014) Efficacy and safety of ETC-1002, a novel investigational low-density
lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia
and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 34:676–683. https://doi.org/10.1161/
atvbaha.113.302677
Hao H et al (2017) Loss of endothelial CXCR7 impairs vascular homeostasis and cardiac remod-
eling after myocardial infarction: implications for cardiovascular drug discovery. Circulation
135:1253–1264. https://doi.org/10.1161/CIRCULATIONAHA.116.023027
He L et al (2017) Preexisting endothelial cells mediate cardiac neovascularization after injury. J
Clin Investig 127:2968–2981. https://doi.org/10.1172/JCI93868
Hennuyer N et al (2016) The novel selective PPARalpha modulator (SPPARMalpha) pemafi-
brate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflamma-
tion and atherosclerosis. Atherosclerosis 249:200–208. https://doi.org/10.1016/j.atherosclerosis.
2016.03.003
336 Q. Wan et al.
Hlatky MA, Kazi DS (2017) PCSK9 inhibitors: economics and policy. J Am Coll Cardiol 70:2677–
2687. https://doi.org/10.1016/j.jacc.2017.10.001
Huang H, Lai S, Wan Q, Qi W, Liu J (2016) Astragaloside IV protects cardiomyocytes from
anoxia/reoxygenation injury by upregulating the expression of Hes1 protein. Can J Physiol
Pharmacol 94:542–553
Investigators O et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events.
N Engl J Med 358:1547–1559. https://doi.org/10.1056/NEJMoa0801317
Jiang F, Qian J, Chen S, Zhang W, Liu C (2011) Ligustrazine improves atherosclerosis in rat via
attenuation of oxidative stress. Pharm Biol 49:856–863
Key NS (2014) Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hema-
tology Am Soc Hematology Educ Program 2014:66–70. https://doi.org/10.1182/asheducation-
2014.1.66 (2014)
Kimura W et al (2015) Hypoxia fate mapping identifies cycling cardiomyocytes in the adult heart.
Nature 523:226–230. https://doi.org/10.1038/nature14582
Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM (2015) Changes in LDL particle
concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib
alone or in combination with atorvastatin. J Clin Lipidol 9:93–102. https://doi.org/10.1016/j.jacl.
2014.09.013
Kwan CY, Daniel EE, Chen MC (1990) Inhibition of vasoconstriction by tetramethylpyrazine: does
it act by blocking the voltage-dependent Ca channel? J Cardiovasc Pharmacol 15:157–162
Kwok HH, Chan LS, Poon PY, Yue PY, Wong RN (2015) Ginsenoside-Rg1 induces angiogenesis
by the inverse regulation of MET tyrosine kinase receptor expression through miR-23a. Toxicol
Appl Pharmacol 287:276–283
Larsson M et al (2014) A factor XIIa inhibitory antibody provides thromboprotection in extracor-
poreal circulation without increasing bleeding risk. Sci Transl Med 6:222ra217. https://doi.org/
10.1126/scitranslmed.3006804
Li L et al (2018) Ginsenoside Rg1 ameliorates rat myocardial ischemia-reperfusion injury by
modulating energy metabolism pathways. Front Physiol 9
Li XY et al (2015) Effect of berberine on promoting the excretion of cholesterol in high-fat diet-
induced hyperlipidemic hamsters. J Transl Med 13:015–0629
Li L, Hou X, Xu R, Liu C, Tu M (2017) Research review on the pharmacological effects of
astragaloside IV. Fundam Clin Pharmacol 31:17–36
Liu CS, Zheng YR, Zhang YF, Long XY (2016) Research progress on berberine with a special
focus on its oral bioavailability. Fitoterapia 109:274–282
Lonn EM et al (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular
disease. N Engl J Med 374:2009–2020. https://doi.org/10.1056/NEJMoa1600175
Lu JM, Yao Q, Chen C (2009) Ginseng compounds: an update on their molecular mechanisms and
medical applications. Curr Vasc Pharmacol 7:293–302
Lv L, Jiang SS, Xu J, Gong JB, Cheng Y (2012) Protective effect of ligustrazine against myocardial
ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase. Clin Exp Pharmacol
Physiol 39:20–27
Mahaffey KW et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular
events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study).
Circulation 137:323–334. https://doi.org/10.1161/CIRCULATIONAHA.117.032038
Mahmoud F et al (2000) In vitro effects of Ginkgolide B on lymphocyte activation in atopic asthma:
comparison with cyclosporin A. Jpn J Pharmacol 83:241–245
Manson JE et al (2019) Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.
N Engl J Med 380:23–32. https://doi.org/10.1056/NEJMoa1811403
Marso SP et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141
Matafonov A et al (2014) Factor XII inhibition reduces thrombus formation in a primate thrombosis
model. Blood 123:1739–1746. https://doi.org/10.1182/blood-2013-04-499111
8 Drug Discovery for Coronary Artery Disease 337
Millar JS et al (2017) Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and
plasma apolipoproteins C-II, C-III, and E. J Lipid Res 58:1214–1220. https://doi.org/10.1194/jlr.
M074880
Morikawa Y, Heallen T, Leach J, Xiao Y, Martin JF (2017) Dystrophin-glycoprotein complex
sequesters Yap to inhibit cardiomyocyte proliferation. Nature 547:227–231. https://doi.org/10.
1038/nature22979
Neal B et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J
Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
Neuen BL et al (2018) Cardiovascular and renal outcomes with canagliflozin according to base-
line kidney function: data from the CANVAS program. Circulation. https://doi.org/10.1161/
CIRCULATIONAHA.118.035901
Nicholls SJ et al (2016) Effect of Evolocumab on progression of coronary disease in statin-treated
patients: the GLAGOV randomized clinical trial. JAMA 316:2373–2384. https://doi.org/10.1001/
jama.2016.16951
Nickel KF, Long AT, Fuchs TA, Butler LM, Renne T (2017) Factor XII as a therapeutic target in
thromboembolic and inflammatory diseases. Arterioscler Thromb Vasc Biol 37:13–20. https://
doi.org/10.1161/ATVBAHA.116.308595
Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M (2014) ETC-1002: a future option
for lipid disorders? Atherosclerosis 237:705–710. https://doi.org/10.1016/j.atherosclerosis.2014.
10.099
Nissen SE et al (2016) Efficacy and tolerability of evolocumab versus ezetimibe in patients with
muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315:1580–1590.
https://doi.org/10.1001/jama.2016.3608
Olkkonen VM, Sinisalo J, Jauhiainen M (2018) New medications targeting triglyceride-rich
lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Atherosclerosis 272:27–32. https://doi.org/10.1016/j.atherosclerosis.2018.03.019
Pang A et al (2018) Shear-induced integrin signaling in platelet phosphatidylserine exposure,
microvesicle release, and coagulation. Blood 132:533–543. https://doi.org/10.1182/blood-2017-
05-785253
Pei HX, Hua R, Guan CX, Fang X (2015) Ginkgolide B reduces the degradation of membrane
phospholipids to prevent ischemia/reperfusion myocardial injury in rats. Pharmacology 96:233–
239
Perez-Sanchez C et al (2017) Ubiquinol effects on antiphospholipid syndrome prothrombotic pro-
file: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 37:1923–1932. https://
doi.org/10.1161/atvbaha.117.309225
Pietraforte D et al (2014) Redox control of platelet functions in physiology and pathophysiology.
Antioxid Redox Signal 21:177–193. https://doi.org/10.1089/ars.2013.5532
Porrello ER et al (2011) Transient regenerative potential of the neonatal mouse heart. Science
331:1078–1080. https://doi.org/10.1126/science.1200708
Preis M et al (2017) Factor XI deficiency is associated with lower risk for cardiovascular and
venous thromboembolism events. Blood 129:1210–1215. https://doi.org/10.1182/blood-2016-
09-742262
Que X et al (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hyperc-
holesterolaemic mice. Nature 558:301–306. https://doi.org/10.1038/s41586-018-0198-8
Radholm K et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the
CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. https://doi.
org/10.1161/CIRCULATIONAHA.118.034222
Ray KK et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
N Engl J Med 376:1430–1440. https://doi.org/10.1056/NEJMoa1615758
Revenko AS et al (2011) Selective depletion of plasma prekallikrein or coagulation factor XII
inhibits thrombosis in mice without increased risk of bleeding. Blood 118:5302–5311. https://
doi.org/10.1182/blood-2011-05-355248
338 Q. Wan et al.
Wu DM et al (2018) Tanshinone IIA prevents left ventricular remodelling via the TLR4/MyD88/NF-
kappaB signalling pathway in rats with myocardial infarction. J Cell Mol Med 22:3058–3072
Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR (2004) Increased hepatic platelet
activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut
53:877–883
Yao C et al (2018) Genome-wide mapping of plasma protein QTLs identifies putatively causal genes
and pathways for cardiovascular disease. Nat Commun 9:3268. https://doi.org/10.1038/s41467-
018-05512-x
Yau JW et al (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides
attenuates catheter thrombosis in rabbits. Blood 123:2102–2107. https://doi.org/10.1182/blood-
2013-12-540872
Yin H et al (2011) Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling
in a rat model of myocardial infarction. J Mol Med 89:363–375
Yu J et al (2015) Danshensu protects isolated heart against ischemia reperfusion injury through
activation of Akt/ERK1/2/Nrf2 signaling. Int J Clin Exp Med 8:14793–14804
Yu LJ et al (2017) Salvianolic acid exerts cardioprotection through promoting angiogenesis in
animal models of acute myocardial infarction: preclinical evidence. Oxidative Med Cell Longev
2017:8192383. https://doi.org/10.1155/2017/8192383
Yusuf S et al (2016a) Cholesterol lowering in intermediate-risk persons without cardiovascular
disease. N Engl J Med 374:2021–2031. https://doi.org/10.1056/NEJMoa1600176
Yusuf S et al (2016b) Blood-pressure and cholesterol lowering in persons without cardiovascular
disease. N Engl J Med 374:2032–2043. https://doi.org/10.1056/NEJMoa1600177
Zhang S et al (2015) Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy
by regulating NF-kappaB/PGC-1alpha signaling mediated energy biosynthesis. PloS one 10
Zhang R (2016) The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking.
Open Biol 6:150272. https://doi.org/10.1098/rsob.150272
Zhang Y et al (2010) Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway
in post-infarction rat cardiomyocytes. Cell Physiol Biochem 26:991–998
Zheng X et al (2017) Ginsenoside Rb1 improves cardiac function and remodeling in heart failure.
Exp Anim 66:217–228
Zhou MX, Fu JH, Zhang Q, Wang JQ (2015) Effect of hydroxy safflower yellow A on myocardial
apoptosis after acute myocardial infarction in rats. Genet Mol Res 14:3133–3141. https://doi.org/
10.4238/2015
Zhu L et al (2018) Berberine treatment increases Akkermansia in the gut and improves high-fat
diet-induced atherosclerosis in Apoe(-/-) mice. Atherosclerosis 268:117–126. https://doi.org/10.
1016/j.atherosclerosis.2017.11.023
Zinman B et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720